

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/00		A2	(11) International Publication Number: WO 00/20450 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/23519		(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 7 October 1999 (07.10.99)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 60/103,322 7 October 1998 (07.10.98) US 60/106,473 30 October 1998 (30.10.98) US 60/114,088 29 December 1998 (29.12.98) US			
(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): JOHNS, Margaret, Ann [US/US]; 2800 Deake Avenue, Ann Arbor, MI 48108 (US). MOLDOVER, Brian [US/US]; 4893 S. Ridgeside Circle, Ann Arbor, MI 48105 (US). OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US).			
(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			
(54) Title: ALPHA-2/DELTA GENE			
(57) Abstract			
<p>The present invention relates to three novel genes and polypeptides derived therefrom encoding "$\alpha 2\delta$-C" and/or "$\alpha 2\delta$-D" proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

-1-

ALPHA-2/DELTA GENE

FIELD OF THE INVENTION

The present invention relates to novel genes and polypeptides derived and identified therefrom encoding polypeptides related to the alpha-2-delta (" $\alpha 2\delta$ ") protein that is a subunit of the voltage-sensitive calcium channel. In particular, three human novel genes and polypeptides derived and identified therefrom encoding three human polypeptides related to the $\alpha 2\delta$ protein are disclosed. The invention also describes vectors and host cells comprising the novel genes. The invention also describes methods for using the novel genes, polypeptides, and antibodies specifically targeting the polypeptides in the detection of genetic alterations of the gene, subcellular localization of the polypeptide, gene therapy applications, diagnostics for syndromes associated with altered $\alpha 2\delta$ expression, such as neurological diseases and disorders, diabetes, cancer, and other diseases associated with $\alpha 2\delta$ expression, and binding assays in connection with chemical databases, specifically, development of proprietary screening strategies for molecules which modify $\alpha 2\delta$ protein activity.

BACKGROUND OF THE INVENTION

The voltage activated calcium channels ("VSCCs") of vertebrates have been shown to be involved in a variety of different physiological processes including muscle contraction, insulin release from the pancreas, and neurotransmitter release in the nervous system (Greenberg D. Annals of Neurology, 1997;42:275-82; Catterall W.A., Trends in Neurosciences, 1993;16:500-506; Catterall W., Epstein P.N., Diabetologia, 35(Suppl 2:S23-33) 1992; Birnbaumer L., et al., Neuron, 1994:13; Rorsman P., et al., Diabete Metab., 1994;20:138-145).

VSCCs are most highly expressed in excitable tissues including brain, skeletal muscle, and heart. They are multiprotein complexes composed of a

-2-

central $\alpha 1$ pore-forming subunit variably associated with beta, gamma, and/or an $\alpha 2\delta$ subunit. Nine different functional classes of VSCCs have been described, based on biophysical and pharmacological studies. These functional classes are mainly determined by the $\alpha 1$ subunit composition. The beta, gamma, and $\alpha 2\delta$ subunits modulate channel function, affecting the kinetics of activation and inactivation, voltage-dependence, peak amplitude, and ligand binding. Walker N., De Waard M., Trends in Neurosciences, 1998;21(4):148-154.

A number of compounds useful in treating various diseases in animals, including humans, are thought to exert their beneficial effects by modulating functions of voltage-dependent calcium channels. Many of these compounds bind to calcium channels and alter cellular calcium flux in response to a depolarizing signal. However, a lack of understanding of the structure of channel subunits and the genes that code for them has hampered scientists both in discerning the pharmacology of compounds that interact with calcium channels and in the ability to rationally design compounds that will interact with calcium channels to have desired therapeutic effects. The lack of understanding is due in part to the fact that it has not been possible to obtain the large amounts of highly purified channel subunits that are required to understand, at the molecular level, the nature of the subunits and their interactions with one another, with the cell membranes across which the channels allow calcium ions to pass, with calcium and other ions, and with low molecular weight compounds that affect channel function.

Further, the lack of information on genes that code for calcium channel subunits has prevented the understanding of the molecular properties of the mature calcium channel subunits and their precursor proteins (i.e., the mature subunits with signal peptides appended to the amino-terminus) and the regulation of expression of calcium channel subunits. An understanding of these properties, and of how expression of calcium channel subunits genes is regulated, may provide the basis for designing therapeutic agents which have beneficial effects through affecting calcium channel function or concentration. Furthermore, the availability of sequences of genes coding for calcium channel subunits would make possible the diagnosis of defects, which might underlie a number of diseases, in genes coding for such subunits.

-3-

5 Expression experiments in *Xenopus* oocytes have demonstrated that in order to produce fully functional calcium channels, the $\alpha 1$ and $\alpha 2\delta$ subunits must both be expressed. Absence of the $\alpha 2\delta$ subunit results in a nonfunctional channel, even though the $\alpha 1$ subunit, through which ions flow, is fully expressed. Indeed, not only the ion flux through these channels, but the pharmacological properties of the $\alpha 1$ are different in the absence of the $\alpha 2\delta$ subunit. The $\alpha 2\delta$ subunit, therefore, is a critical component of VSCCs and one that must be studied if one is to better characterize VSCC function.

10 A detailed understanding of VSCC operation is beginning to reveal some mechanisms for interceding in the progression of diseases associated with abnormal VSCC functions. US Patent No. 5,618,720, which issued April 8, 1997, references $\alpha 1$ and $\alpha 2\delta$ subunits and the polynucleotide sequences that encode the subunits. The publication, however, does not disclose any additional $\alpha 2\delta$ subunits and in light of the importance of the $\alpha 2\delta$ subunit, it can be understood that the 15 identification and characterization of new $\alpha 2\delta$ subunits and the genes encoding these subunits would advance molecular genetic and pharmacological studies to understand the relations between the structure and the function of VSCCs.

20 Also, a further understanding of the biochemical mechanisms behind these subunits and their effect on mammals may lead to new opportunities for treating and diagnosing diseases related to abnormal (high or low) VSCC operation. Stated another way, a better understanding of the molecular mechanisms of VSCC operation will allow improved design of therapeutic drugs that treat diseases 25 related to abnormal VSCC expression, and specifically abnormal $\alpha 2\delta$ expression.

25 The cDNAs, oligonucleotides, peptides, antibodies for the $\alpha 2\delta$ proteins, which are the subject of this invention, provide a plurality of tools for studying VSCC operations in various cells and tissues and for diagnosing and selecting inhibitors or drugs with the potential to intervene in various disorders or diseases in which altered $\alpha 2\delta$ expression is implicated. Such disease states affected 30 include epilepsy and other seizure-related syndromes, migraine, ataxia and other vestibular defects (for review, Terwindt, GM et. Al., Eur J Hum Genet 1998 Jul-Aug; 6(4):297-307), chronic pain (Backonja M, JAMA 1998 Dec 2;280(21):1831-6), mood, sleep interference (Rowbotham M, JAMA 1998 Dec

-4-

2;280(21):1837-42), anxiety (Singh et al., Psychopharmacology 1996 Sep. 5 127(1): 1-9), ALS (Mazzini L et. Al., J Neurol Sci 1998 Oct, 160 Suppl 1:S57-63), multiple sclerosis (Metz L, Semin Neurol 1998;18(3):389-95), mania (Erfurth A, et al., J Psychiatr Res 1998 Sep-Oct;32(5):261-4), tremor (Evidente VG, et al., Mov Disord 1998 Sep;13(5):829-31), parkinsonism (Olson WL, et al., Am J Med 10 1997 Jan;102(1):60-6) substance abuse/addiction syndromes (Watson, WP et al., Neuropharmacology 1997 Oct;36(10):1369-75), depression, and cancer, since at least one $\alpha 2\delta$ gene is located in a region of the genome which is thought to harbor an important tumor suppressor gene (Kok K., et al., Adv Cancer Res 1997;71:27-92).

The $\alpha 2\delta$ gene is also thought to play a part in proliferative diseases other than cancer, such as inflammation. Treatment with compounds which bind to $\alpha 2\delta$ lead to changes in the signal transduction mechanism of certain proteins. This includes altered levels of MEK (eg, MEK1 and MEK2) which activates the 15 MAP kinase. Inhibitors of MEK appear to mimic the analgesic activities associated with the binding of gabapentin to $\alpha 2\delta$. Activation of MAP kinase by mitogens appears to be essential for proliferation, and constitutive activation of this kinase is sufficient to induce cellular transformation.

20

SUMMARY OF THE INVENTION

While the $\alpha 1$ subunit is known to be coded for by 9 genes, the beta subunit by 4 genes, and the gamma subunit by 2 genes, previously only two human $\alpha 2\delta$ genes were known: " $\alpha 2\delta$ -A (cDNA Accession No. M76559.1 and protein Accession No. P54289.1) and $\alpha 2\delta$ -B (cDNA SEQ ID NO 1 and protein SEQ ID 25 NO 2). The $\alpha 2\delta$ -A gene codes for at least five different splice variants which show tissue-specific expression (Angelotti T., Hoffman F., FEBS, 1996;397:331-337). Translation of the $\alpha 2\delta$ -A gene produces a polypeptide which is post-translationally cleaved into the $\alpha 2$ and the δ subunits. $\alpha 2$ and δ are then joined by disulfide bonds (De Jongh K., JBC, 1990;265(25):14738-14741; Jay S., JBC, 30 1991;266(5):3287-3293). $\alpha 2$ is thought to be completely extracellular and is heavily glycosylated, while δ probably forms a single transmembrane domain with five intracellular amino acids at its c-terminus (Brickley K., FEBS,

-5-

1995;364:129-133). This transmembrane domain anchors the protein to the membrane. A_{2δ}-B is related to α_{2δ}-A and is available in the public database, GENBANK.

The inventors, however, have discovered the existence of two new human α_{2δ} genes, hereinafter referred to as “α_{2δ}-C”, and “α_{2δ}-D” genes (gene names CACNA2C and CACNA2D). The present invention, therefore, relates to the isolation of polynucleotide sequences which identify and encode novel α_{2δ}-related proteins (preferably α_{2δ}-C and α_{2δ}-D proteins) that are expressed in various cells and tissues, both the polynucleotide sequences for the full length genes and any splice variants and their encoded proteins. The polynucleotide sequences are identified in SEQ ID NOS 3-4 and the amino acid sequences of the α_{2δ} proteins encoded by the three novel genes are set forth in SEQ ID NOS 5-6.

The invention also concerns a purified or isolated nucleic acid comprising at least 20 consecutive nucleotides of the nucleotide sequences SEQ ID NOS 3-4, or a nucleotide sequence complementary thereto.

A_{2δ}-C protein of SEQ ID NO 5 is 28% identical and 48% similar at the protein level to α_{2δ}-A protein. A_{2δ}-C protein is 28% identical and 47% similar to α_{2δ}-B. A_{2δ}-C gene of SEQ ID NO 3 contains a mapped marker (known as an STS) within its nucleotide sequence which has been mapped to human chromosome 3p21.1. This region of the human genome is thought to harbor an important tumor suppressor gene, thus α_{2δ}-C gene is a candidate tumor suppressor gene (Kersemaekers AM, et al., Br J Cancer 1998;77(2); 192-200).

A_{2δ}-D protein of SEQ ID NO 6 is 28% identical and 47% similar at the protein level to α_{2δ}-A protein. A_{2δ}-D protein is 28% identical and 46% similar to α_{2δ}-B protein. A_{2δ}-D gene of SEQ ID 4 maps to a previously published cosmid contig on human chromosome 12p13.3.

The unique full length polynucleotides of the present invention were initially discovered by mining the genbank database for sequences with homology to α_{2δ}, by utilizing known nucleotide sequences and various methods known in the art, including tools provided by Compugen Systems Ltd. See Sequence Analysis Primer by Michael Gribskov, John Devereux, Oxford University Press, 1994. After identification of expressed sequenced tags (ESTs) and full-length

-6-

sequences related to $\alpha 2\delta$ -A, cloning methods were used to obtain, in hand, full-length sequences for $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, see Examples 1, 2 and 3. In short, an arrayed human, kidney cDNA library obtained from Origene, was screened by PCR, using oligonucleotide primers derived from the database sequences. Clones identified from the library screen were sequenced by standard methods for verification. A summary of the sequencing information is provided in Example 3.

Analysis of the cloned sequences for $\alpha 2\delta$ -B, $\alpha 2\delta$ -C, and $\alpha 2\delta$ -D led to the identification of a conserved domain and of a number of splice variants. The conserved domain is known as a vonWillebrand factor A3 domain (Huizinga, EG, et. al., Structure 1997, Sept 15;5(9):1147-56). This domain has been described in a large number of proteins and is thought to mediate cell adhesion. Interesting splice-variants of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D were also identified. These variants result in a c-terminal truncation of the respective protein sequences. Truncation of the c-terminus may lead to the production of a soluble, secreted $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein with new functions beyond that previously described for $\alpha 2\delta$.

The $\alpha 2\delta$ proteins are of interest because they play an important role in many disease states. In one example, $\alpha 2\delta$ -A has been shown to be a high-affinity binding target of the anti-convulsant drug gabapentin (NEURONTIN) (Gee N., JBC 1996;271:5768-5776). This property of the $\alpha 2\delta$ -A protein has the potential to have profound physiological effects. Thus, by regulating the levels or activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, or by modulating their function, desirable physiological effects may be obtained. Such effects may be used to treat a variety of diseases involving abnormal expression of $\alpha 2\delta$ or the abnormal expression of VSCCs (i.e., disease states include, but are not limited to epilepsy, chronic pain, anxiety, diabetes, ALS, mania, cancer, tremor, parkinsonism, migraine, ataxia, mood, sleep interference, depression, multiple sclerosis, inflammation).

The rationale for the therapeutic use of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins to design or discover treatment for these diseases is based upon the fact that gabapentin has been successfully used for treating epilepsy, chronic pain, and ALS, and has implications for use in the treatment of mania, tremor, parkinsonism, migraine, ataxia, mood, inflammation, sleep interference, and/or multiple sclerosis). Gabapentin is known to bind to $\alpha 2\delta$ -A with high affinity and

this binding is thought to represent the mechanism of action of gabapentin. Therefore, gabapentin and/or other compounds which bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may have similar, or related, therapeutic effects to the effects seen with gabapentin. Also, compounds which are known to have therapeutic effects on calcium channels are regulated in their affinity by the presence of $\alpha 2\delta$. Thus, pharmacological or genetic approaches to alleviating this deficiency will have a major impact on the diseases described above.

5

One aspect of the invention is to provide purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The purified proteins may be obtained from either recombinant cells or naturally occurring cells. The purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention may be mammalian in origin. Primate, including human-derived $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, are examples of the various proteins specifically provided for. The invention also provides allelic variants and biologically active derivatives of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

10

Another aspect of the invention is to provide polynucleotides encoding the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention and to provide polynucleotides complementary to polynucleotide coding strand. The polynucleotides of the invention may be used to provide for the recombinant expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may also be used for

20

genetic therapy purposes so as to 1) treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 2) test for presence of a disease, or susceptibility to a disease, due to alterations or deletions in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 3) analyze or alter the subcellular localization of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide, 4) clone or isolate discrete classes of RNA similar to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, 5) express discrete classes of RNA in order to alter the levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes.

25

30

The invention also relates to oligonucleotide molecules useful as probes or primers, wherein said oligonucleotide molecules hybridize specifically with any nucleotide sequence comprising or related to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, particularly the sequences of SEQ ID NOS 3-4. These oligonucleotides are useful

-8-

either as primers for use in various processes such as DNA amplification and microsequencing or as probes for DNA recognition in hybridization analyses.

A nucleic acid probe or primer according to the invention comprises at least 8 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3-4, preferably from 8 to 200 consecutive nucleotides, more particularly from 10, 15, 20 or 30 to 100 consecutive nucleotides, more preferably from 10 to 90 nucleotides, and most preferably from 20 to 80 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3 or 4. Preferred probes or primers of the invention comprise the oligonucleotides selected from the group consisting of the oligonucleotides set forth in the examples below.

The invention also concerns a method for the amplification of a region of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes. The method comprises the step of: contacting a test sample suspected of containing the desired $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D sequence or portion thereof with amplification reaction reagents, comprising a pair of amplification primers such as those described above, the primers being located on either side of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D nucleotide region to be amplified. The method may further comprise the step of detecting the amplification product. For example, the amplification product may be detected using a detection probe that can hybridize with an internal region of the amplified sequences. Alternatively, the amplification product may be detected with any of the primers used for the amplification reaction themselves, optionally in a labeled form.

The invention also concerns diagnostic kits for detecting the presence of at least one copy of a $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D DNA in a test sample, said kits containing a primer, a pair of primers or a probe according to the invention.

In a first embodiment, the kit comprises primers such as those described above, preferably forward and reverse primers which are used to amplify the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene or a fragment thereof.

In a second embodiment, the kit comprises a hybridization DNA probe, that is or eventually becomes immobilized on a solid support, which is capable of hybridizing with the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene or a fragment thereof. The

-9-

techniques for immobilizing a nucleotide primer or probe on a solid support are well-known to the skilled person.

The kits of the present invention can also comprise optional elements including appropriate amplification reagents such as DNA polymerases when the kit comprises primers, reagents useful in hybridization reactions and reagents useful to reveal the presence of a hybridization reaction between a labeled hybridization probe and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene.

Another aspect of the invention is to provide antibodies capable of binding to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention. The antibodies may be polyclonal or monoclonal. The invention also provides methods of using the subject antibodies to detect and measure expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins either *in vitro* or *in vivo*, or for detecting proteins that interact with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or molecules that regulate any of the activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

Another aspect of the invention is to provide assays for the detection of proteins that interact with $\alpha 2\delta$ -C or $\alpha 2\delta$ -D using genetic approaches. A preferred embodiment involves the use of yeast two-hybrid approaches for this screening. (Bartel and Fields, *The Yeast Two-Hybrid System*, Oxford University Press, 1997)

Another aspect of the invention is to provide assays for the detection or screening of therapeutic compounds that interfere with, or mimic in any way, the interaction between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins and ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

In a first embodiment, such a method for the screening of a candidate substance comprises the following steps :

- a) providing a polypeptide comprising the amino acid sequence of SEQ ID NO 5 and/or 6, or a peptide fragment or a variant thereof;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance; and
- d) detecting the complexes formed between said polypeptide and said candidate substance.

-10-

In one embodiment of the screening method defined above, the complexes formed between the polypeptide and the candidate substance are further incubated in the presence of a polyclonal or a monoclonal antibody that specifically binds to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention or to the peptide fragment or variant thereof.

The candidate substance or molecule to be assayed for interacting with the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide may be of diverse nature, including, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides.

In another embodiment of the present screening method, increasing concentrations of a substance competing for binding to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein with the considered candidate substance is added, simultaneously or prior to the addition of the candidate substance or molecule, when performing step c) of said method. By this technique, the detection and optionally the quantification of the complexes formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof and the candidate substance or molecule to be screened allows the one skilled in the art to determine the affinity value of said substance or molecule for said $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof.

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein having the amino acid sequence of SEQ ID NO 5 and/or 6 or a peptide fragment or a variant thereof, and optionally means useful to detect the complex formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or its peptide fragment or variant and the candidate substance. In a preferred embodiment the detection means consist in monoclonal or polyclonal antibodies directed against the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a peptide fragment or a variant thereof.

The assays of the invention therefore comprise the step of measuring the effect of a compound of interest on binding between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and the ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. Binding may be measured in a variety of ways, including the use of labeled $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or labeled ligands. These ligands may include, but are not limited to,

-11-

neutral alpha-amino acids, which have been shown to bind to $\alpha 2\delta$ -A, or therapeutic compounds such as gabapentin or related analogues.

Another aspect of the invention is to provide assays for the discovery of proteins that interact directly or indirectly with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The assays of the invention comprise a method for detecting such interactions in cells, or in biochemical assays. These interactions may be detected in a variety of ways, including the use of the cDNA encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins themselves, or fragments or modifications thereof. The assays may also comprise a method for detecting the interaction between $\alpha 2\delta$ subunits and other subunits of the calcium channel, such as $\alpha 1$ subunits. These assays may involve measuring the interaction between the proteins directly, or assaying the activity of a fully assembled calcium channel.

Before the present sequences, polypeptides, methods for making and using the invention are described, it is to be understood that the invention is not to be limited only to the particular sequences, polypeptides and methods described. The sequences, polypeptides and methodologies may vary, and the terminology used herein is for the purpose of describing particular embodiments. The foregoing is not intended and should not be construed as limiting the invention in any way since the scope of protection will ultimately depend upon the claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto.

BRIEF DESCRIPTION OF THE INVENTION

Figure 1: Fine-mapping of $\alpha 2\delta$ -B to mouse chromosome 9

Figure 2: Human $\alpha 2\delta$ -B tissue distribution

Figure 3: [3 H] gabapentin binding activity by human $\alpha 2\delta$ -B in transiently transfected COS7

Figure 4: Human $\alpha 2\delta$ -C tissue distribution

-12-

DETAILED DESCRIPTION OF THE INVENTION

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutshcer, ed., (1990) Academic Press, Inc.); *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), and *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, N.J.) *Sequence Analysis Primer* (Gribskov, et al., 1994, Oxford University Press).

In one aspect, the present invention provides novel isolated and purified polynucleotides, hereinafter referred to as alpha-2-delta-C and alpha-2-delta-D ("α2δ-C", "α2δ-D") genes, encoding α2δ-C and α2δ-D proteins, wherein the polynucleotide sequences are substantially similar to those shown in SEQ ID NOS 3-4 and the polypeptide sequences are substantially similar to those shown in SEQ ID NOS 5-6. The terms "α2δ-C" and "α2δ-D" are used broadly herein. Unless noted otherwise, the terms "α2δ-C" and "α2δ-D" include any natural mammalian-derived form of α2δ-C and α2δ-D and the like. It is preferred that the terms α2δ-C and α2δ-D include all mammals, including but not limited to primates and humans.

The polynucleotides provided for may encode complete α2δ-C and/or α2δ-D proteins or portions thereof. The polynucleotides of the invention may be produced by a variety of methods including *in vitro* chemical synthesis using well known solid phase synthesis technique, by cloning or combinations thereof. The polynucleotide of the invention may be derived from cDNA or genomic libraries. Persons of ordinary skill in the art are familiar with the degeneracy of the genetic code and may readily design polynucleotides that encode α2δ-C and/or α2δ-D proteins that have either partial or polynucleotide sequence homology to naturally

-13-

occurring polynucleotide sequences encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may be single stranded or double stranded.

Polynucleotide complementary to polynucleotides encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are also provided.

5 Polynucleotides encoding an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein can be obtained from cDNA libraries prepared from tissue believed to possess $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or mRNA and to express it at a detectable level. For example, a cDNA library can be constructed by obtaining polyadenylated mRNA from a cell line known to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, and using the mRNA as a template to synthesize double stranded cDNA.

10 Libraries, either cDNA or genomic, are screened with probes designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include monoclonal and polyclonal antibodies that recognize and specifically bind to an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein. For cDNA 15 libraries, suitable probes include carefully selected oligonucleotide probes (usually of about 20-80 bases in length) that encode known or suspected portions of an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the same or different species, and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene, and/or homologous genomic DNAs or fragments thereof.

20 Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in Chapters 10-12 of Sambrook et al., Molecular Cloning: A Laboratory Manual, New York, Cold Spring Harbor Laboratory Press, 1989).

25 A preferred method of practicing this invention is to use carefully selected oligonucleotide sequences to screen cDNA libraries from various tissues. The oligonucleotide sequences selected as probes should be sufficient in length and sufficiently unambiguous that false positives are minimized. The actual nucleotide sequence(s) is/are usually designed based on regions of an $\alpha 2\delta$ protein that have the least codon redundancy. The oligonucleotides may be degenerate at 30 one or more positions. The use of degenerate oligonucleotides is of particular importance where a library is screened from a species in which preferential codon usage is not known.

-14-

The oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use ATP (e.g., T32P) and polynucleotide kinase to radiolabel the 5' end of the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

cDNAs encoding α 2 δ proteins can also be identified and isolated by other known techniques of recombinant DNA technology, such as by direct expression cloning or by using the polymerase chain reaction (PCR) as described in U.S. Patent No. 4,683,195, in section 14 of Sambrook, et al . , Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, New York, 1989, or in Chapter 15 of Current Protocols in Molecular Biology, Ausubel et al. eds., Green Publishing Associates and Wiley-Interscience 1991. This method requires the use of oligonucleotide probes that will hybridize to DNA encoding an α 2 δ -C and/or α 2 δ -D protein.

As defined herein, "substantially similar" includes identical sequences, as well as deletions, substitutions or additions to a DNA, RNA or protein sequence that maintain any biologically active portion thereof of the protein product and possess any of the conserved motifs. This includes, but is not limited to, any splice variants of α 2 δ -C and/or α 2 δ -D which are found to exist. Preferably, the DNA sequences according to the invention consist essentially of the DNA sequence of SEQ ID NOS 3-4. These novel purified and isolated DNA sequences can be used to direct expression of the α 2 δ -C and/or α 2 δ -D protein and for mutational analysis of α 2 δ -C and/or α 2 δ -D protein function.

Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein, and techniques well known in the art.

In a preferred embodiment, the present invention comprises a nucleotide sequence that hybridizes to the nucleotide sequence shown in SEQ ID NOS 3-4 under high stringency hybridization conditions. As used herein, the term "high stringency hybridization conditions" refers to hybridization on a filter support at 65°C in a low salt hybridization buffer to the probe of interest at 2×10^8 cpm/ μ g for between about 8 hours to 24 hours, followed by washing in 1% SDS, 20 mM

-15-

phosphate buffer and 1 mM EDTA at 65°C, for between about 30 minutes to 4 hours. In a preferred embodiment, the low salt hybridization buffer comprises between, 0.5-10% SDS, and 0.05M and 0.5 M sodium phosphate. In a most preferred embodiment, the low salt hybridization buffer comprises, 7% SDS, and 0.125M sodium phosphate.

5

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

10

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about Tm-5°C (5°C below the melting temperature (Tm) of the probe) to about 20°C to 25°C below Tm. As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

15

The polynucleotides of the invention have a variety of uses, some of which have been indicated or will be addressed in greater detail, *infra*. The particular uses for a given polynucleotide depend, in part, on the specific polynucleotide embodiment of interest. The polynucleotides of the invention may be used as hybridization probes to recover α 2 δ -C and/or α 2 δ -D proteins from genetic libraries. The polynucleotides of the invention may also be used as primers for the amplification of α 2 δ -C and/or α 2 δ -D protein encoding polynucleotides or a portion thereof through the polymerase chain reaction (PCR) and other similar amplification procedures. The polynucleotides of the invention may also be used as probes and amplification primers to detect mutations in α 2 δ -C and/or α 2 δ -D protein encoding genes that have been correlated with diseases, particularly diseases related to an altered function for α 2 δ -A protein. Including, but not limited to, those diseases stated above.

20

25

30

-16-

The invention also provides a variety of polynucleotide expression vectors, comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or a sequence substantially similar to it subcloned into an extra-chromosomal vector. This aspect of the invention allows for *in vitro* expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene, thus permitting an analysis of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene regulation and $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein structure and function. As used herein, the term "extra-chromosomal vector" includes, but is not limited to, plasmids, bacteriophages, cosmids, retroviruses and artificial chromosomes. In a preferred embodiment, the extra-chromosomal vector comprises an expression vector that allows for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein production when the recombinant DNA molecule is inserted into a host cell. Such vectors are well known in the art and include, but are not limited to, those with the T3 or T7 polymerase promoters, the SV40 promoter, the CMV promoter, or any promoter that either can direct gene expression, or that one wishes to test for the ability to direct gene expression.

In a preferred embodiment, the subject expression vectors comprise a polynucleotide sequence encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in functional combination with one or more promoter sequences so as to provide for the expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (or an anti-sense copy of the sequence suitable for inhibition of expression of an endogenous gene). The vectors may comprise additional polynucleotide sequences for gene expression, regulation, or the convenient manipulation of the vector, such additional sequences include terminators, reporters, enhancers, selective markers, packaging sites, and the like. Detailed description of polynucleotide expression vectors and their use can be found in, among other places Gene Expression Technology: Methods in Enzymology Volume 185 Goeddel ed, Academic Press Inc., San Diego, CA (1991), Protein Expression in Animal Cells Roth ea., Academic Press, San Diego, CA (1994).

The polynucleotide expression vectors of the invention have a variety of uses. Such uses include the genetic engineering of host cells to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. In a further aspect, the present invention provides recombinant host cells that are stably transfected with a recombinant DNA molecule comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D subcloned into an extra-chromosomal

-17-

vector. The host cells of the present invention may be of any type, including, but not limited to, bacterial, yeast, mammalian cells, and *Xenopus* oocytes.

Transfection of host cells with recombinant DNA molecules is well known in the art (Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, 1989) and, as used herein, includes, but is not limited to calcium phosphate transfection, dextran sulfate transfection, electroporation, lipofection and viral infection. This aspect of the invention allows for *in vitro* and *in vivo* expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D and its gene product, thus enabling high-level expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. In a further aspect of the invention the RNA molecules containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D can be injected into *Xenopus* oocytes along with other calcium channel subunit clones and calcium flux across the oocyte membrane can be measured using standard electrophysiological techniques.

In another aspect of the invention transgenic animals can be constructed by injection of the nucleotide sequence for $\alpha 2\delta$ -C or $\alpha 2\delta$ -D cloned in suitable expression vectors into germ cells.

Other uses of the polynucleotide expression vectors, discussed in greater detail, *infra*, include, their use for genetic therapy for diseases and conditions in which it may be desirable to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins at levels greater than naturally occurring expression levels. Alternatively, it may be desirable to use the subject vectors for anti-sense expression to reduce the naturally occurring levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

$\alpha 2\delta$ -C and $\alpha 2\delta$ -D share amino acid homology to $\alpha 2\delta$ -A, thus it is very likely that they share some structural and functional characteristics with $\alpha 2\delta$ -A. $\alpha 2\delta$ -A is known to interact with other subunits of voltage-sensitive calcium channels, such as $\alpha 1$ and beta. When calcium channels are expressed in oocytes, a functional channel is only produced when an $\alpha 2\delta$ subunit is present. Therefore, $\alpha 2\delta$ is required for calcium channel function. In addition, $\alpha 2\delta$ -A has been shown to bind to gabapentin, a drug used to treat epilepsy, chronic pain, ALS, and potentially other neurological diseases. The mechanism of action of gabapentin is thought to be through its interaction with $\alpha 2\delta$. Given the homology between the $\alpha 2\delta$ proteins, it is likely that $\alpha 2\delta$ -C and $\alpha 2\delta$ -D also share these functions.

-18-

The polynucleotide sequences of SEQ ID NOS 3-4 were mapped to human chromosomes using the nucleotide sequences for the cDNA from library sources (See Examples 2-3) to generate probes. The sequences were mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include *in situ* hybridization to chromosomal spreads, and PCR-based mapping by amplifying DNA from standard radiation hybrid cell lines. (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, NYC. A₂δ-C of SEQ ID NO 3 maps to human chromosome 3p21.1. A₂δ-D of SEQ ID NO 4 maps to a previously published cosmid contig on human chromosome 12p13.3.

In another aspect, the present invention provides a substantially purified recombinant protein comprising a polypeptide substantially similar to the α₂δ-C and/or α₂δ-D polypeptides shown in SEQ ID NOS 5-6. Furthermore, this aspect of the invention enables the use of α₂δ protein in several *in vitro* assays described below. As used herein, the term "substantially similar" includes deletions, substitutions and additions to the sequences of SEQ ID NOS 5-6 introduced by any *in vitro* means, or any genetic alterations naturally seen *in vivo*. As used herein, the term "substantially purified" means that the protein should be free from detectable contaminating protein, but the α₂δ-C and/or α₂δ-D protein may be co-purified with an interacting protein, or as an oligomer. In a most preferred embodiment, the protein sequence according to the invention comprises an amino acid sequence of SEQ ID NOS 5-6. Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein and techniques well known in the art. This aspect of the invention provides a novel purified protein that can be used for *in vitro* assays, and as a component of a pharmaceutical composition.

A₂δ-C and/or α₂δ-D proteins may be used to discover molecules that interfere with its activities. For example, molecules that prevent the binding of α₂δ-C and/or α₂δ-D to ligands such as neutral alpha-amino acids (for example (L)-leucine), or to other molecules such as other subunits of the voltage-sensitive calcium channels.. Additionally, α₂δ-C and/or α₂δ-D proteins may be used to

-19-

find other proteins with which it directly interacts, and potentially representing additional important regulators of VSCC transport.

The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the present invention have a putative biological activity of modulating the cellular flux of calcium, potentially including both intracellular and extracellular calcium stores. The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention may be isolated from a variety of mammalian animal species. Preferred mammalian species for isolation are primates and humans. The invention also contemplates allelic variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. A 2δ -C and/or $\alpha 2\delta$ -D proteins may be prepared from a variety of mammalian tissues. Preferably, $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are obtained from recombinant host cells genetically engineered to express significant quantities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. A 2δ -C and/or $\alpha 2\delta$ -D proteins may be isolated from non-recombinant or recombinant cells in a variety of ways well known to a person of ordinary skill in the art.

The terms “ $\alpha 2\delta$ -C protein” and “ $\alpha 2\delta$ -D protein” as used herein refers not only to proteins having the amino acid residue sequence of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, but also refers to functional derivatives and variants of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. A “functional derivative” of a native polypeptide is a compound having a qualitative biological activity in common with the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Thus, a functional derivative of a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein is a compound that has a qualitative biological activity in common with a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, e.g., binding to other calcium channel subunits and modulating the flux of calcium in cells, or binding to neutral alpha-amino acids and other cognate ligands. “Functional derivatives” include, but are not limited to, fragments of native polypeptides from any animal species (including human), and derivatives of native (human and non-human) polypeptides and their fragments, provided that they have a biological activity in common with a respective native polypeptide. “Fragments” comprise regions within the sequence of a mature native polypeptide. The term “derivative” is used to define amino acid sequence and glycosylation variants, and covalent modifications of a native polypeptide, whereas the term “variant” refers to amino acid sequence and glycosylation

-20-

variants within this definition. Preferably, the functional derivatives are polypeptides which have at least about 70% amino acid sequence similarity, more preferably about 80% amino acid sequence similarity, even more preferably at least 90% amino acid sequence similarity, most preferably at least about 99% 5 amino acid sequence similarity with the sequence of a corresponding native polypeptide. Most preferably, the functional derivatives of a native α 2 δ -C and/or α 2 δ -D protein retain or mimic the region or regions within the native polypeptide sequence that directly participate in ligand binding. The phrase "functional derivative" specifically includes peptides and small organic molecules having a 10 qualitative biological activity in common with a native α 2 δ -C and/or α 2 δ -D protein.

"Identity" or "homology" with respect to a native polypeptide and its 15 functional derivative is defined herein as the percentage of amino acid residues in the candidate sequence that are similar to residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Neither N- or C-terminal extensions nor insertions, nor alternatively-spliced variants, shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known in the art.

20 Amino acid sequence variants of native α 2 δ -C and/or α 2 δ -D proteins and α 2 δ -C and/or α 2 δ -D protein fragments are prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant α 2 δ -C and/or α 2 δ -D protein encoding DNA, or by *in vitro* synthesis of the desired 25 polypeptide. There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. With the exception of naturally-occurring alleles, which do not require the manipulation of the DNA sequence encoding the α 2 δ -C and/or α 2 δ -D protein, the amino acid sequence variants of α 2 δ -C and/or α 2 δ -D protein are preferably 30 constructed by mutating the DNA, either to arrive at an allele or an amino acid sequence variant that does not occur in nature.

-21-

Alternatively or in addition, amino acid alterations can be made at sites that differ in α 2 δ -C and/or α 2 δ -D proteins from various species, or in highly conserved regions, depending on the goal to be achieved.

Sites at such locations will typically be modified in series, e.g. by

- 5 (1) substituting first with conservative choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue or residues, or (3) inserting residues of the same or different class adjacent to the located site, or combinations of options 1-3.

One helpful technique is called "alanine scanning" Cunningham and
10 Wells, Science 244, 1081-1085 (1989). Here, a residue or group of target residues is identified and substituted by alanine or polyalanine. Those domains demonstrating functional sensitivity to the alanine substitutions are then refined by introducing further or other substituents at or for the sites of alanine substitution.

15 After identifying the desired mutation(s), the gene encoding an α 2 δ -C and/or α 2 δ -D protein variant can, for example, be obtained by chemical synthesis.

More preferably, DNA encoding an α 2 δ -C and/or α 2 δ -D protein amino acid sequence variant is prepared by site-directed mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the α 2 δ -C and/or α 2 δ -D protein. Site-directed (site-specific) mutagenesis allows the production of
20 α 2 δ -C and/or α 2 δ -D protein variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 20 to 25
25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered. In general, the techniques of site-specific mutagenesis are well known in the art, as exemplified by publications such as, Edelman et al., DNA 2:183 (1983). As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a
30 single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. This and other phage vectors are commercially available and their use is well known to those skilled in the art.

-22-

A versatile and efficient procedure for the construction of oligodeoxyribonucleotide directed site-specific mutations in DNA fragments using M13-derived vectors was published by Zoller, M.J. and Smith, M., Nucleic Acids Res. 10, 6487-6500 [1982]). Also, plasmid vectors that contain a single-stranded phage origin of replication, Veira et al., Meth. Enzymol. 153:3 (1987)] may be employed to obtain single-stranded DNA. Alternatively, nucleotide substitutions are introduced by synthesizing the appropriate DNA fragment in vitro, and amplifying it by PCR procedures known in the art.

In general, site-specific mutagenesis may be performed by obtaining either a double-stranded or a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant protein. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea et al., Proc. Natl. Acad. Sci. USA 75, 5765 (1978). This primer is then annealed with the single-stranded protein sequence-containing vector, and subjected to DNA-polymerizing enzymes such as, E. coli polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate host cells such as HB101 cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement. Thereafter, the mutated region may be removed and placed in an appropriate expression vector for protein production.

The PCR technique may also be used in creating amino acid sequence variants of an α 2 δ -C and/or α 2 δ -D protein. When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the

-23-

opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 500-5000 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primes can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

Further details of the foregoing and similar mutagenesis techniques are found in general textbooks, such as, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd edition, Cold Spring Harbor Press, Cold Spring Harbor (1989), and Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley and Sons (1995).

Naturally-occurring amino acids are divided into groups based on common side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophobic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gin, his, lys, erg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Conservative substitutions involve exchanging a member within one group for another member within the same group, whereas non-conservative substitutions will entail exchanging a member of one of these classes for another. Variants obtained by non-conservative substitutions are expected to result in significant changes in the biological properties/function of the obtained variant, and may result in α 2 δ -C and/or α 2 δ -D protein variants which block α 2 δ -C and/or α 2 δ -D protein biological activities, i.e., modulation of calcium flux, or binding to neutral, alpha-amino acids. Amino acid positions that are conserved among

-24-

various species are generally substituted in a relatively conservative manner if the goal is to retain biological function.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous.

5 Deletions may be introduced into regions not directly involved in ligand binding.

Amino acid insertions include amino- and/or carboxyl terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e. insertions within the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein amino acid sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5 residues, more preferably 1 to 3 residues. Examples of terminal insertions include the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins with an N-terminal methionyl residue, a naturally-occurring N-terminal signal sequence, an artifact of direct expression in bacterial recombinant cell culture, and fusion of a

10 heterologous N-terminal signal sequence to the N-terminus of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to facilitate the secretion of the mature $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein from recombinant host cells. Such signal sequences will generally be obtained from, and thus homologous to, the intended host cell species. Suitable sequences include STII or Ipp for E. coli, alpha factor for yeast, and viral signals

15 such as herpes gD for mammalian cells. Other insertional variants of the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein molecules include the fusion of the N- or C-terminus of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to immunogenic polypeptides, e.g. bacterial polypeptides such as betalactamase or an enzyme encoded by the E. coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long

20 half-life such as immunoglobulin regions (preferably immunoglobulin constant regions), albumin, or ferritin, as described in PCT published application WO 89/02922.

25 Since it is often difficult to predict in advance the characteristics of a variant $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, it will be appreciated that screening will be needed to select the optimum variant. For this purpose biochemical screening assays, such as those described herein below, will be readily available.

30 In a further aspect, the present invention provides antibodies and methods

-25-

for detecting antibodies that selectively bind polypeptides with an amino acid sequence substantially similar to the amino acid sequence of SEQ ID NOS 5-6. As discussed in greater detail, *infra*, the antibody of the present invention can be a polyclonal or a monoclonal antibody, prepared by using all or part of the sequence of SEQ ID NOS 5-6, or modified portions thereof, to elicit an immune response in a host animal according to standard techniques (Harlow and Lane (1988), eds. Antibody: A Laboratory Manual, Cold Spring Harbor Press). In a preferred embodiment, the entire polypeptide sequence of SEQ ID NOS 5-6 is used to elicit the production of polyclonal antibodies in a host animal.

The method of detecting α 2 δ -C and/or α 2 δ -D antibodies comprises contacting cells with an antibody that recognizes α 2 δ -C and/or α 2 δ -D protein and incubating the cells in a manner that allows for detection of the α 2 δ -C and/or α 2 δ -D protein-antibody complex. Standard conditions for antibody detection of antigen can be used to accomplish this aspect of the invention (Harlow and Lane, 1988). This aspect of the invention permits the detection of α 2 δ -C and/or α 2 δ -D protein both *in vitro* and *in vivo*.

The subject invention provides methods for the treatment of a variety of diseases characterized by undesirably abnormal cellular levels of α 2 δ -C and/or α 2 δ -D. Diseases may be treated through either *in vivo* or *in vitro* genetic therapy. Protocols for genetic therapy through the use of viral vectors can be found, among other places, in Viral Vector Gene Therapy and Neuroscience Applications, Kaplit and Lowry, Academic Press, San Diego (1995). Gene therapy applications typically involve identifying target host cells or tissues in need of the therapy, designing vector constructs capable of expressing a desired gene product in the identified cells, and delivering the constructs to the cells in a manner that results in efficient transduction of the target cells. The cells or tissues targeted by gene therapy are typically those that are affected by the disease that the vector construct is designed to treat. For example, in the case of cancer, the targeted tissues are malignant tumors.

The genetic therapy methods of the present invention comprise the step of introducing a vector for the expression of α 2 δ -C and/or α 2 δ -D protein (or inhibitory anti-sense RNA) into a patient cell. The patient cell may be either in

-26-

the patient, i.e., *in vivo* genetic therapy, or external to the patient and subsequently reintroduced into the patient, i.e., *in vitro* genetic therapy. Diseases that may be treated by the subject genetic therapy methods include, but are not limited to epilepsy, chronic pain, ALS, mania, cancer, anxiety, diabetes, tremor, 5 parkinsonism, migraine, ataxia, mood, sleep interference, multiple sclerosis and inflammation).

In a preferred aspect of the invention, a method is provided for protecting mammalian cells from abnormal levels of α 2 δ -C and/or α 2 δ -D in cells, comprising introducing into mammalian cells an expression vector comprising a 10 DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4, that is operatively linked to a DNA sequence that promotes the expression of the DNA sequence and incubating the cells under conditions wherein the DNA sequence of SEQ ID NOS 3 or 4 will be expressed at high levels in the mammalian cells. Suitable expression vectors are as described above. In a 15 preferred embodiment, the coding region of the human α 2 δ -C and/or α 2 δ -D gene is subcloned into an expression vector under the transcriptional control of the cytomegalovirus (CMV) promoter to allow for constitutive α 2 δ -C and/or α 2 δ -D gene expression.

In another preferred aspect of the present invention, a method is provided 20 for treating or preventing abnormal levels of α 2 δ -C and/or α 2 δ -D in VSCCs, comprising introducing into mammalian tumor cells an expression vector comprising a DNA that is antisense to a sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4 that is operatively linked to a DNA sequence that promotes the expression of the antisense DNA sequence. The cells 25 are then grown under conditions wherein the antisense DNA sequence of SEQ ID NOS 3 or 4 will be expressed at high levels in the mammalian cells.

In a most preferred embodiment, the DNA sequence consists essentially of 30 SEQ ID NOS 3 or 4. In a further preferred embodiment, the expression vector comprises an adenoviral vector wherein α 2 δ -C and/or α 2 δ -D cDNA is operatively linked in an antisense orientation to a cytomegalovirus (CMV) promoter to allow for constitutive expression of the α 2 δ -C and/or α 2 δ -D antisense cDNA in a host

-27-

cell. In a preferred embodiment, the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D adenoviral expression vector is introduced into cells by injection into a mammal.

Another aspect of the invention is to provide assays useful for determining if a compound of interest can bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. This binding

5 may interfere with, or mimic, the binding of ligands to the VSCCs, or this binding may affect the function of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in modulating calcium flux. The assay comprises the steps of measuring the binding of a compound of interest to an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Either the $\alpha 2\delta$ -C and/or the $\alpha 2\delta$ -D protein or the compound of interest to be assayed may be labeled with a detectable label, e.g., a

10 radioactive or fluorescent label, so as to provide for the detection of complex formation between the compound of interest and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

In another embodiment of the subject assays, the assays involve measuring the interference, i.e., competitive binding, of a compound of interest with the binding interaction between an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and a ligand already known to bind to $\alpha 2\delta$ -A protein. For example, the effect of increasing quantities of a

15 compound of interest on the formation of complexes between radioactivity labeled ligand and an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein may be measured by quantifying the formation of labeled ligand- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein complex formation. In another embodiment of the subject assays, the assays involve measuring the

20 alteration, i.e., non-competitive inhibition, of a compound of interest with the activity of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (compounds which bind to a different region of $\alpha 2\delta$ and inhibit $\alpha 2\delta$ activity, but don't prevent binding of ligands such as gabapentin).

25 Polyclonal antibodies to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins generally are raised in animals by multiple subcutaneous (se) or intraperitoneal (ip) injections of an $\alpha 2\delta$ protein and an adjuvant. It may be useful to conjugate the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g. keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues),

-28-

N-hydroxysuccinimide (through lysine resides), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}_1\sim\text{N}=\text{C}=\text{NR}$, where R and R_1 are different alkyl groups.

5 Animals are immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 fig of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein antibody titer.

10 Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, but also may be conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

15 Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. For example, the anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein monoclonal antibodies of the invention may be made using the hybridoma method first described by Kohler & Milstein, Nature 256:495 (1975), or may be made by recombinant DNA methods [Cabilly, et al, U.S. Pat. No. 4,816,567].

20 Antibodies can also be generated using phage display. In this approach libraries of peptides of random sequence are generated in antibody genes cloned into phage. These phage libraries are screened for antibodies by screening against the immobilized protein. (Hoogenboom-HR, Trends-Biotechnol. 1997 Feb; 15(2): 62-70)

25 In the hybridoma method, a mouse or other appropriate host animal, such a hamster is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*.

-29-

Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Coding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (academic Press, 1986)].

5 The anti- α 2 δ -C and/or α 2 δ -D protein specific antibodies of the invention have a number of uses. The antibodies may be used to purify α 2 δ -C and/or α 2 δ -D proteins from either recombinant or non-recombinant cells. The subject antibodies may be used to detect and/or quantify the presence of α 2 δ -C and/or α 2 δ -D proteins in tissue samples, e.g., from blood, skin, and the like.

10 Quantitation of α 2 δ -C and/or α 2 δ -D proteins may be used diagnostically for those diseases and physiological or genetic conditions that have been correlated with particular levels of α 2 δ -C and/or α 2 δ -D protein expression levels.

15 In a further aspect, the present invention provides a diagnostic assay for detecting cells containing α 2 δ -C and/or α 2 δ -D deletions, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4.

20 This aspect of the invention enables the detection of α 2 δ -C and/or α 2 δ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool. The PCR primers can be chosen in any manner that allows the amplification of an α 2 δ -C and/or α 2 δ -D gene fragment large enough to be detected by gel electrophoresis. Detection can be by any method, including, but not limited to ethidium bromide staining of agarose or polyacrylamide gels, autoradiographic detection of radio-labeled α 2 δ -C and/or α 2 δ -D gene fragments, Southern blot hybridization, and DNA sequence analysis. In a preferred embodiment, detection is accomplished by polyacrylamide gel electrophoresis, followed by DNA sequence analysis to verify the identity of the deletions. PCR conditions are routinely determined based on the length and base-content of the primers selected according to techniques well known in the art (Sambrook et al., 1989).

25 An additional aspect of the present invention provides a diagnostic assay for detecting cells containing α 2 δ -C and/or α 2 δ -D deletions, comprising isolating total cell RNA and subjecting the RNA to reverse transcription-PCR amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4. This

-30-

aspect of the invention enables the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool.

Reverse transcription is routinely accomplished via standards techniques (Ausubel et al., in Current Protocols in Molecular Biology, ed. John Wiley and Sons, Inc., 1994) and PCR is accomplished as described above.

The present invention may be better understood with reference to the accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

10

Examples

Example 1

The sequence for human $\alpha 2\delta$ -A, c-DNA Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). Four full-length RNA sequences were identified (c-DNA Accession Nos. AF040709.1, AF042792.1, AF042793.1, and AB011130.1) which were highly homologous to $\alpha 2\delta$ -A. The DNA sequence of $\alpha 2\delta$ -B is provided by SEQ ID NO 1 and the amino acid sequence of $\alpha 2\delta$ -B is provided by SEQ ID NO 2. Using standard alignment tools, these four sequences were found to represent 4 different variants of the same gene. This gene was named $\alpha 2\delta$ -B. Further searches of the sequence databases, and analysis of proprietary clustered sequences generated using Compugen software, led to the identification of additional sequences related to $\alpha 2\delta$ -B. This includes human ESTs (Accession Nos. T80372.1, AA360556.1, AI563965.1, N53512.1, a mouse EST (Accession No. AA000341.1), and a sequence from C.elegans (Accession No. CAA90091.1). Since the initial identification of $\alpha 2\delta$ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (
human: AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1,

-31-

AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1,
AA435601.1, AI094263.1; **mouse:** AA008996.1; **rat:** AI105056.1,
AI502878.1).

A2δ-B is 53 % identical and 69% similar at the amino acid level to α2δ-A.

5 The α2δ-B mRNA is 5482 bp long, and codes for a protein of 1145 amino acids.
The three splice-variants of α2δ-B which were identified differ only in the 5'
untranslated region, and do not alter the amino acid sequence. A2δ-B aligns to
genomic sequence from a previously published cosmid contig on human
chromosome 3p21.3. This DNA contig covers more than 600kb of sequence. The
10 Accession Nos. for these genomic sequences are Z84493.1, Z84494.1, Z75743.1,
Z75742.1, and Z84492.1. Analysis of the DNA sequences flanking α2δ-B led to
the identification of genes flanking α2δ-B on human chromosome 3p21.3 which
had been mapped in both human and mouse. These flanking genes include CIS,
HyaL1, GNAI-2, and GNAT-1. In mouse, all of the flanking genes were localized
15 to mouse chromosome 9, 60cM. Analysis of mapping data stored in the Mouse
Genome Database, by Jackson Laboratory, led to the identification of three mouse
neurological phenotypes that had been genetically mapped to the same mouse
chromosome 9, 60cM region. These phenotypes include epilepsy1, ducky and
tippy. Epilepsy1 and ducky both have spike-wave activity consistent with
epilepsy. This tentatively maps α2δ-B to the chromosome 9, 60cM region in
20 mouse, and identifies α2δ-B as a candidate gene for the mouse mutants ducky,
tippy, and El1 (for overview of mapping data see Figure 1).

25 Northern and RT-PCR analysis of RNA expression levels of human α2δ-B
were performed to analyze the expression pattern of α2δ-B. For Northern
analysis, multiple tissue Northern blots and brain blots were obtained from
Clontech. Non-isotopic DNA probes for α2δ-B were generated by PCR using
SEQ ID NOS 7-8 and SEQ ID NO 1 as a template. Hybridization and washing
conditions were in accordance with the manufacturer's instructions (Boehringer
Mannheim). A2δ-B was found to have highest expression in lung, and was also
30 detected in brain, heart, skeletal muscle, and at lower levels in all tissues tested
(Figure 2). For the Northern blot surveying different areas of human brain, α2δ-B
had the highest level of expression in the cerebral cortex, but was detected in all

-32-

areas of the human brain (Figure 2). RT-PCR expression analysis of human $\alpha_2\delta$ -B was also performed. RT-PCR analysis, using a cDNA tissue panel obtained from Clontech and SEQ ID NOS 7-8 for PCR-based gene amplification (cycles: 1X at 94 C 1', 35X at 94 C 0.5', 55 C 1', 72 C 2'; 1X at 72 C 10'), produced an expression pattern for $\alpha_2\delta$ -B consistent with results from Northern analysis.
Overall, the expression pattern of $\alpha_2\delta$ -B is consistent with a proposed role of $\alpha_2\delta$ -B in epilepsy.

In order to determine if $\alpha_2\delta$ -B has functional properties comparable to $\alpha_2\delta$ -A, the ability of $\alpha_2\delta$ -B to bind to amino acids and gabapentin was measured.
For this analysis, COS-7 cells were transiently transfected with the full-length porcine $\alpha_2\delta$ -A, and human $\alpha_2\delta$ -B genes each in the vector pcDNA3 (Invitrogen)(pcDNA3.1 for $\alpha_2\delta$ -B) by the lipofectamine mediated transfection method. The cells were transfected and membranes harvested by the generic methods outlined below. The K_D for binding of [3 H] gabapentin to $\alpha_2\delta$ -B, as compared to $\alpha_2\delta$ -A, can be found in Table 1. Additional binding studies were performed using techniques similar to those outlined below. Alterations to the protocol are listed below under the subheading "Alternative Method for Measuring [3 H] Gabapentin binding". The data for these binding studies are in figure 3. Overall, the binding and Western data demonstrated that the porcine $\alpha_2\delta$ -A and human $\alpha_2\delta$ -B full-length gene-products expressed transiently in the COS-7 system bind [3 H]gabapentin with high affinity.

Table 1: Saturation binding data for $\alpha_2\delta$ -B

Porcine $\alpha_2\delta$ -A (n=2)	Human $\alpha_2\delta$ -B (n=2)
K_D , 23.1 nM	K_D , 32.6 nM
K_D , 21.2 nM	K_D , 87.2 nM
<i>Mean = 22.2 nM</i>	<i>Mean = 59.9 nM</i>

-33-

Transient Transfection method (150mm plate)

1: Seed 3.9×10^6 COS-7 cells/150mm plate in 42ml DMEM + 10% FBS +

5u/ml Penicillin / 5 μ g/ml Streptomycin on 150mm plate. Grow O/N.

2: Setup

Tube A – 30ug DNA in 300ul TE + 1.8ml Optimem (5u/ml Penicillin / 5 μ g/ml Streptomycin)

Tube B – 150ul Lipofectamine + 1.95ml Optimem (5u/ml Penicillin / 5 μ g/ml Streptomycin)

3: At time=0 mix tubes A and B and leave at RT for 45 minutes.

4: Wash cells with 30ml Optimem (5u/ml Penicillin / 5 μ g/ml Streptomycin) twice then add 16.8ml Optimem (5u/ml Penicillin / 5 μ g/ml Streptomycin) to the plates. At t=45 minutes add A/B mix to plates.

5: At t=6 hours add 21ml of Optimem (5u/ml Penicillin / 5 μ g/ml Streptomycin).

6: At t=24 hours replace medium with 42ml Optimem (5u/ml Penicillin / 5 μ g/ml Streptomycin)

7: At t=48 hours rinse the cells twice with 20ml of PBS then harvest.

20

Membrane preparation (perform at 4°C)

1 Harvest cells into a 2ml eppendorf in 1.5ml 1mM EDTA/1mM EGTA/0.1mM PMSF (added immediately prior to use from a 1000x stock)/20% Glycerol/10mM HEPES pH7.4 @ 4°C using a cell scraper.

2 Mix cells end-over-end for 30 minutes at 4°C then centrifuge at 20,000 x g for 5 minutes.

3 Resuspend pellet in 1.5ml 1mM EDTA/1mM EGTA/20% Glycerol/10mM HEPES pH7.4 @ 4°C then immediately re-centrifuge at 20,000 x g for 5 minutes.

-34-

4 Resuspend pellet to ~1mg/ml (protein concentration as determined by the Bradford protein assay) in 1mM EDTA/1mM EGTA/20% Glycerol/10mM HEPES pH7.4 @ 4°C

5 For total [³H] binding, cells were sonicated for 30-40 seconds, centrifuged for 10' at 750-1000Xg, and the supernatant was centrifuged for 30' at 50,000Xg. The resulting pellet was resuspended in 5mM

[³H]Gabapentin saturation binding assay methodology and data analysis

10 Assays were carried out at 21°C in a final volume of 250µl in 96-well deep-well plates. Duplicate wells were set up for both 'total' and 'non-specific' binding. Specific binding was defined as that remaining after subtraction of the 'non-specific binding' values from the 'total' binding values. Assay components were added in the following order (all reagents were diluted in

15 10mM HEPES (pH 7.4 at 21°C)):

Total binding 200µl 10mM HEPES pH 7.4

Non-specific binding 175µl 10mM HEPES pH 7.4 and 25µl 100µM
(S+)-3-isobutyl GABA

25µl Appropriate COS membrane sample

20 25µl [³H]gabapentin

The reaction was incubated at 21°C for 45 minutes then filtered through GF/B filters soaked in 50 mM Tris-Cl pH 7.4 @4°C (wash buffer), filters were washed three times with wash buffer.

25

The filters were then counted in a scintillation counter.

Saturation experiments were performed with 12 duplicate data points ('Total' and 'Non-Specific' binding determined in duplicate for each concentration of [³H]gabapentin tested) and a [³H]gabapentin concentration range from ~1 to 400nM. Data was analyzed using KEL-RADLIG for Windows.

-35-

Alternative Method for Measuring [³H] Gabapentin binding

The method described above was followed with the following exceptions:

5 1) **COS7 transfection:** 20ug of α 2 δ -A or α 2 δ -B plasmid DNA were incubated with 30ul of lipofectamine. The mixture was overlaid onto the cells in 1.5ml of serum-free medium and incubated for 5 hours. Then FBS was added to the dishes to bring the final concentration to 10%. The medium was changed the next morning. Forty-eight hours after transfection the cells were harvested for membrane preparation.

10 2) **Membrane preparation:** Cells were washed twice with cold PBS and then scraped off the tissue culture plates in cold 5mM of Tris/5mM EDTA (pH7.4) containing PMSF (0.1mM), leupeptin (0.02mM), and pepstatin (0.02mM). The cells were incubated on ice for 30 minutes and then sonicated for 30-40 seconds. The homogenate was centrifuged for 10 minutes at 750-1000xg, and then the supernatent was centrifuged for 30 minutes at 50,000xg. The resulting pellet was resuspended in the same buffer as described above.

15 3) **Binding Assays:** The radioligand binding assay was done using 0.05 mg of membrane protein incubated in the presence of 20 nM of [³H] gabapentin. The membranes were incubated in 10 mM Hepes (pH 7.4) for 40-50 minutes at room temperature, and then filtered onto pre-wetted GF/C membranes and quickly washed five times with 3ml of ice cold 50mM tris buffer pH7.4. The filters were dried and counted in a liquid scintillation counter. To determine background binding, 10 uM of isobutyl GABA was used and the resulting counts subtracted from the total counts of each sample.

Detection of α 2 δ -A and α 2 δ -B expression with anti- α_2 polyclonal antibodies

30 Using affinity purified anti- α_2 polyclonal antibodies (antigen derived from porcine α 2 δ -A; See Brown and Gee (1998) *JBC* 273 25458-25465 for pAb

-36-

generation details) the expression of the porcine $\alpha_2\delta$ -A and human $\alpha_2\delta$ -B proteins (over and above control levels - COS cells transfected with the parent pcDNA3 vector) was confirmed. N.B. Cross reaction of the pAb's with $\alpha_2\delta$ -B was not unexpected given the ~50% amino acid sequence identity. Furthermore, and with reference to Example 2, expression of $\alpha_2\delta$ -C was not detected using this antibody (sequence identity with $\alpha_2\delta$ -A ~30%).

Example 2

The sequence for human $\alpha_2\delta$ -A, Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession Nos. AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1) corresponding to a new gene, with similarity to $\alpha_2\delta$ -A, named $\alpha_2\delta$ -C. Additional searches of the sequence databases led to the identification of other sequences related to $\alpha_2\delta$ -C. This includes a mouse EST (Accession No. AU022914.1, AI843362.1), and an STS (Accession No. G36524.1) which maps to human chromosome 3p21.1. Since the initial identification of $\alpha_2\delta$ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (human ESTs: AA459804.1, AI696320.1, AI051759.1, AI696214.1; human genomic sequence: AC010180.1; mouse EST: AA445859.1, mouse RNA: AJ010949.1).

In order to clone a full-length $\alpha_2\delta$ -C, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 9-10) based on sequence derived from EST clone accession number AA190607.1 which were designed to amplify a 273 bp fragment. A positive clone was identified in a kidney library. After sequencing, this clone was identified as a novel 3' splice variant (SEQ ID NO 43). The protein sequence, which can be derived from SEQ ID NO 43, of this novel splice variant is a truncated, potentially secreted soluble form of $\alpha_2\delta$ -C. PCR was performed, using primers (SEQ ID NOS 9 and 11) and a human adult

-37-

brain library from LTI as a template, and the resulting fragment of 248 bp was cloned in pBS and sequence verified. A SacI-NcoI fragment from the kidney clone, a NcoI-KpnI fragment from the PCR center clone, and a KpnI-NotI fragment from a clone obtained from the IMAGE consortium (corresponding to Accession No. R43629.1) were ligated together, using methods standard to the art, to create a full-length clone. Each individual clone, and the full-length clone (SEQ ID NO 3), were sequence verified. A number of other EST clones from the IMAGE consortium were also obtained and sequenced. One of these clones (corresponding to Accession No. AI051759.1) contained two novel splice-variants which result in a truncated, potentially soluble $\alpha_2\delta$ -C (SEQ ID NO 44).

Full-length $\alpha_2\delta$ -C is 28 % identical and 48% similar at the amino acid level to $\alpha_2\delta$ -A. The $\alpha_2\delta$ -C mRNA sequence (SEQ ID NO 3) is 3770 bp long, and codes for a protein of 1085 amino acids (SEQ ID NO 5). In addition, three splice variants of $\alpha_2\delta$ -C were identified . Two of the variants contain deletions of internal exons. The third variant contains a novel 3' end. Two of these splice-variants produce a truncated protein which is devoid of the membrane anchoring delta subunit. These variants may represent a secreted alpha2 protein which could have additional functions beyond regulation of voltage-sensitive calcium channels.

In order to identify sequences for $\alpha_2\delta$ -C from other species, human and mouse specific primers (SEQ ID NOS 9-10 and 12-13, respectively) were used to amplify $\alpha_2\delta$ -C RT-PCR products. RNA from human brain was purchased from Invitrogen, Carlsbad, CA (catalog #D6030-15). RNA from rat and mouse brain was isolated using standard in-house protocols. First-strand cDNA synthesis was completed using Superscript Choice System (LTI, Bethesda, MD, catalog #18090-019). Ethanol precipitated cDNA was added to PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ High Fidelity (LTI, Bethesda, MD). Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. Products

-38-

were purified using Millipore Ultrafree-MC PCR purification filter units (catalog # UFC3LTKOO) prior to DNA sequence analyses. Using this approach, three sets of primers (SEQ ID NO 36, 37; SEQ ID NO 12, 13, SEQ ID NO 38, 39) where used for PCR amplification of rat $\alpha_2\delta$ -C. Three partial rat sequences for $\alpha_2\delta$ -C were identified (SEQ ID NOS 40, SEQ ID NO 14, SEQ ID NO 41).

RT-PCR analysis of RNA expression levels were performed to analyze the expression pattern of $\alpha_2\delta$ -C. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes.

PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. The primers used for this amplification from the human template correspond to SEQ ID NOS 9-10, and from the mouse template correspond to SEQ ID NOS 12-13. By RT-PCR, $\alpha_2\delta$ -C was found to be expressed in a wide variety of tissues (Table 2). The highest levels of $\alpha_2\delta$ -C were detected in human brain, and also in human testis and kidney. In addition to RT-PCR, the cDNA sequence for this gene has been detected in a human, adult brain library and also libraries from: infant brain, hNT neural cell line, testis, total fetus, alveolar rhabdomyosarcoma, adenocarcinoma, and a pooled germ cell library.

Northern blot analysis was performed using $\alpha_2\delta$ -C as a probe. Human total RNA was obtained from Invitrogen (Carlsbad, CA) (brain. total RNA(Cat #D6030-01), kidney total RNA (Cat #D6070-01), testis total RNA(Cat #D6121-01), liver total RNA(Cat # D6080-015)) or Ambion Inc(Austin, TX)(placenta total RNA Cat#7950, heart total RNA Cat #7966), lung total RNA(Cat #7968)) RNA was electrophoresed in formaldehyde agarose gels then transferred to charged nylon membranes(Ambion Inc. (Austin TX) Cat #10104. The EST clone (SEQ ID NO 47) was digested with BamHI and used as template in an RNA synthesis

-39-

reaction that yielded 32P labeled probe. The nylon membranes containing the RNA were prehybridized for 2 hours in ExpressHyb hybridization solution (Clontech Inc. (Palo Alto, CA)(Cat # 8015-1). After the prehybridization 4X106 cpm of RNA probe labeled with 32P were added to the solution and the hybridization was performed in the same solution for 2 hours. After hybridization the nylon filter was washed for 1 hour with 4 changes of 2X SSC, 0.5% SDS at room temperature. The nylon filter was transferred to a solution of 0.2X SSC, 0.5% SDS at 68°C and washed with 4 changes of solution. The nylon filters were then exposed to phosphorimager screens Molecular Dynamics(Sunnyvale, CA)and read on a Storm phosphorimager.Molecular Dynamics(Sunnyvale, CA). Results from Northern analysis (Figure 4) indicate that $\alpha_2\delta$ -C has highest levels of expression in human brain, kidney, and testis.

Since $\alpha_2\delta$ -C has sequence homology to $\alpha_2\delta$ -A, and $\alpha_2\delta$ -A functions as a subunit of VSCCs, experiments were undertaken to determine if $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A and produce functional VSCCs. Xenopus oocytes were isolated using standard techniques and injected with cRNA for α_{1B} , β_{1C} and $\alpha_2\delta$ -C subunits of voltage-gated Ca²⁺ channels. Four days to 1 week following injection of cRNA, Ca²⁺ channel currents were measured using two-electrode voltage clamp with 5 mM Ba²⁺ as the charge carrier. Test pulses to +10 mV from a holding membrane potential of -80 mV were applied to evoke Ca²⁺ channel currents. Peak inward currents evoked during the test pulse were measured. The amplitude of inward currents is proportional to the expression level of voltage-gated Ca²⁺ channels.

Expression of α_{1B} , β_{1C} without $\alpha_2\delta$ subunits produced currents with an average amplitude of 105 ± 13 nA (n=20). Co-injection of $\alpha_2\delta_c$ with α_{1B} and β_{1C} subunits produced a significant increase in current amplitude to 213 ± 12 nA (n=20, p < 0.01 compared to no $\alpha_2\delta$ subunits). These data suggest that $\alpha_2\delta_c$ has an effect on Ca²⁺ channels similar to $\alpha_2\delta_A$, enhancing the level of channel expression. However, $\alpha_2\delta_c$ did not produce as large of an effect on channel expression as $\alpha_2\delta_A$, producing a 2-fold increase in current compared to a 20-fold increase observed with the co-injection of $\alpha_2\delta_A$. Overall, these initial functional

-40-

studies indicate that $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A in voltage-sensitive calcium channels after co-injection into Xenopus oocytes with the $\alpha 1$ and beta subunits.

Table 2: RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA C

	Tissue	Human <i>a2d-C</i>	Mouse <i>a2d-C</i>
5	Brain	+++	+
	Heart	++++	-
10	Kidney	++	++
	Liver	-	-
	Colon	+	not assayed
15	Lung	+	++
	Small Intestine	++	+
	Muscle	++++	++
	Stomach	++	-
	Testis	+++	++
	Placenta	++	not assayed
20	Salivary Gland	++	not assayed
	Thyroid Gland	++	not assayed
	Adrenal Gland	++	-
	Pancreas	++	not assayed
	Ovary	++	-
25	Uterus	++	-
	Prostrate	++	++
	Skin	++	-
	PBL	-	not assayed
	Bone Marrow	-	not assayed
	Fetal Brain	++	not assayed
30	Fetal Liver	++	not assayed

Example 3

The sequence for human $\alpha 2\delta$ -A, Accession No. M76559.1, was used to perform BLASTP searches against the Genbank non-redundant protein database

-41-

and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession No. T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1) corresponding to 5 a new gene, with similarity to α 2 δ -A, named α 2 δ -D. Additional searches of the sequence databases led to the identification of other sequences related to α 2 δ -D. This includes genomic sequence derived from human chromosome 12p13.3 10 (Accession No. AC005342.1, AC005343.1). Since the initial identification of α 2 δ -D, additional related sequences have been deposited into the Genbank database. These sequences correspond to Accession Nos. (human ESTs: T96900.1, AI457823.1, AI377638.1, and AI433691.1).

To isolate a full-length α 2 δ -D clone, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 18-19) based on sequence derived from EST clone Accession No. AA001473.1 which were 15 designed to amplify a 372 bp fragment. A positive clone was identified in a placental library, and was confirmed using a nested internal primer (SEQ ID NO 20). This clone was fully sequenced. The sequence extended 350 bp 5' of the sequence obtained from the EST sequences, but did not include the 5' end.

To obtain the 5' end, two approaches were undertaken. One approach 20 utilized 5' RACE (Rapid Amplification of cDNA Ends). For 5' RACE, placenta poly A+ RNA from Clontech was used to construct a RACE-ready cDNA library using a Marathon cDNA Amplification kit purchased from Clontech. The 5'-end sequence of α 2 δ -D was obtained by 5' RACE PCR using first set of primers: Marathon cDNA adapter primer 1 (SEQ ID NO 45) and gene specific primer I 25 (SEQ ID NO 21). The PCR product was re-amplified using a set of nested primers: adapter primer 2 (SEQ ID NO 46) and gene specific primer II (SEQ ID NO 22). A resulting 1 kb PCR product was cloned into a TA vector (Invitrogen) and sequenced. Sequence analysis revealed that it contains the 5' sequence of α 2 δ -D.

A second method undertaken to identify the 5' end of α 2 δ -D was a PCR-based library screen performed by Edge, using the 5' most sequence known for 30 α 2 δ -D. Nine clones were PCR amplified by the methods indicated above, for

-42-

verification using primers with SEQ ID NOS 48 and 49. These nine positive clones were then sequenced for verification by standard methods. All nine clones were identical to each other, and all were short of the 5' end by approximately 500 bp. However, these clones contained novel splice-variants of $\alpha 2\delta$ -D, with 5 insertions of novel nucleotide sequences (SEQ ID NO 16).

The full-length sequence of $\alpha 2\delta$ -D is 28 % identical and 47% similar at the amino acid level to $\alpha 2\delta$ -A. The $\alpha 2\delta$ -D mRNA is 5,073 bp long (SEQ ID NO 4), and codes for a protein of 1120 amino acids (SEQ ID NO 6) . In addition, two splice variants of $\alpha 2\delta$ -D were identified. One of the variants contains a 72 bp 10 deletion of an internal exon (SEQ ID NO 15). The amino acid sequence of this variant can be found in SEQ ID NO 17. The second variant contains two novel insertions, one of 338 bp and one of 305 bp (SEQ ID NO 16). These insertions appear to result in a truncated protein (SEQ ID NO 42), comparable to the truncated protein sequence identified for $\alpha 2\delta$ -C in Example 2.

RT-PCR analysis of RNA expression levels of human $\alpha 2\delta$ -D were performed in order to analyze the tissue distribution of $\alpha 2\delta$ -D. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X 20 PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. In the case of the $\alpha 2\delta$ -D human panels two separate sets of primers were used to 25 distinguish splice variants and wild type species (SEQ ID NOS 18 & 20, SEQ ID NOS 23 & 19, respectively).

Analysis of the results from RT-PCR of $\alpha 2\delta$ -D (see Table 3) indicate that 30 $\alpha 2\delta$ -D is expressed in a wide variety of tissues, with highest levels in placenta, adrenal gland and pancreas, but also detected in all tissues other than colon. Of note, $\alpha 2\delta$ -D was detected in human brain, consistent with a potential role in

-43-

neurological disease. In addition, based on the tissue distribution of EST sequences, the cDNA sequence for $\alpha_2\delta$ -D has been detected in human libraries from: adult brain, retina, fetal liver/spleen, fetal heart, pineal gland, and testis.

5 Table 3. RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA D

	Tissue	Human $\alpha 2\delta$ -D **	Human $\alpha 2\delta$ -D
	Brain	+++	+++
	Heart	+++	-
10	Kidney	+++"*	-
	Liver	++	-
	Colon	-	-
	Lung	++	-
	Small Intestine	+"*	-
15	Muscle	++	-
	Stomach	++	-
	Testis	+++	-
	Placenta	++++*	-
	Salivary Gland	++	++++
20	Thyroid Gland	+++	++++
	Adrenal Gland	++++	+++
	Pancreas	++++*	++
	Ovary	+"*	++
	Uterus	+"*	++
25	Prostrate	+"*	+
	Skin	+	-

-44-

PBL	+++	-
Bone Marrow	+++	-
Fetal Brain	+++	-
Fetal Liver	++	-

10 Example 4. Knockout of $\alpha 2\delta$ -B

In order to create a mouse knockout of α 2 δ -B, Genome Systems (Catalog: BAC 4922 Mouse ES 129SvJ PCR based Library Screen) performed a PCR-based screen of a mouse BAC library using primers SEQ ID NOS 25-26, which were predicted to amplify an 650 bp cDNA or genomic fragment. One positive BAC clone (Genome Systems DNA control number: BAC-22401) from this screen was received. The same primers were used to generate a human DNA probe. This probe was used on a Southern blot to identify a ~10kb HindIII mouse genomic fragment from the BAC, which was subcloned into the HindII site of plasmid vector pRS416 (Stratagene). Two separate subclones were sequenced by standard techniques, using the T3 and T7 primers and SEQ ID NOS (25-32). Two 500 bp regions of sequence from the 5' and 3' ends of the 10kb genomic fragment (SEQ ID NOS 33 and 34, respectively), plus a 1.8kb sequence contig (SEQ ID NO 35) were identified. This genomic sequence can be used to identify the intron/exon structure of a portion of mouse α 2 δ -B gene, and may contain regulatory elements important for α 2 δ -B gene expression.

Example 5. Identification of amino acids encoded by $\alpha 2\delta$ gene

The amino acid sequences of α 2 δ -C and α 2 δ -D, indicated in SEQ ID NOS 5 and 6, were determined by translating the nucleotide sequences described in SEQ ID NOS 3 and 4, and aligning the amino acid sequences of α 2 δ -A, α 2 δ -B, α 2 δ -C, and α 2 δ -D. The correct open reading frame for each amino acid sequence was determined based on homology of the amino acid sequences to other α 2 δ -A

-45-

homologs. At the amino acid level, $\alpha 2\delta$ -C is 28% identical and 48% similar to $\alpha 2\delta$ -A and is 28% identical and 47% similar to $\alpha 2\delta$ -B, and $\alpha 2\delta$ -D is 28% identical and 47% similar to $\alpha 2\delta$ -A and is 28% identical and 46% similar to $\alpha 2\delta$ -B. Although $\alpha 2\delta$ -C and $\alpha 2\delta$ -D are related to $\alpha 2\delta$ -A, they are distinctly new and different genes.

5

Example 6. Proposed method of detecting the $\alpha 2\delta$ -C and $\alpha 2\delta$ -D proteins by using an $\alpha 2\delta$ -C and $\alpha 2\delta$ -D antibody

10 Antibodies could be developed which specifically detect epitopes unique to $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, or which detect all $\alpha 2\delta$ proteins. These antibodies could be developed by either synthesizing a peptide which is identical to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or by bacterially-expressing a fusion protein containing either $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and then injecting these peptides into a research animal in order to stimulate an immunogenic response. Antibodies generated in such a manner could be used to detect levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in cells. This could be done by immunocytochemistry, where whole cells are fixed and then the antibody is used on the whole cells to detect expression of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and to detect the subcellular localization of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D. Or, cells may be lysed and protein extracts generated and analyzed for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D expression.

15

20

Example 7. Isolation of RNA for cDNA Library

In order to isolate $\alpha 2\delta$ -C or $\alpha 2\delta$ -D from cells, RNA could be isolated by lysing cells from any tissue of interest using standard methods known in the field. After isolation, RNA is reverse-transcribed into cDNA using the enzyme reverse transcriptase and a poly(T) primer or a mix of random primers. A mix of cDNA is produced, representing a large number of the genes which are expressed in the beginning cell population at a particular point in time. Once the cDNA pool has been created, it can be restricted and then ligated into a cloning vector using methods standard in the field. This results in a cDNA library.

25

30

-46-

Example 8. cDNA Cloning Procedure

A₂ δ -C or α 2 δ -D could be cloned from a cDNA library, created as above, by using primers specific for α 2 δ -C or α 2 δ -D nucleotide sequences in a polymerase chain reaction, with the cDNA used as a template. Alternatively, 5 α 2 δ -C or α 2 δ -D sequences could be used as a probe in order to screen the cDNA library by hybridization. Using either technique, single clones are ultimately isolated from the library and sequenced using standard techniques. By sequencing multiple clones from a library, one could look for the existence of alternatively-spliced variants of α 2 δ -C or α 2 δ -D, or for the existence of single nucleotide polymorphisms, or for mutations/alterations in α 2 δ -C or α 2 δ -D.

Example 9. Screening cDNA Library with Antibody

A cDNA library could also be screened by using an antibody to α 2 δ -C or α 2 δ -D. The cDNA library is cloned into a vector which allows induction of protein expression of the cloned inserts. The complete cDNA library is induced to express a protein representing the cloned insert, then single clones which contain an insert that codes for α 2 δ -C or α 2 δ -D are identified if they hybridize to an antibody generated against α 2 δ -C or α 2 δ -D. Positive clones are isolated, and then sequenced using standard methods.

It is to be understood that the invention is not to be limited to the exact details of operation, or to the exact compounds, compositions, methods, procedures or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art, and the invention is therefore 25 to be limited only by the full scope of the appended claims.

-47-

We claim

1. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4.
2. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS 3 or 4 under high stringency hybridization conditions.
3. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS 3 or 4.
4. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS 5 or 6.
5. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS 3 or 4.
6. A recombinant DNA molecule comprising the isolated and purified DNA sequence of Claim 3 or 4 subcloned into an extra-chromosomal vector.
- 15 7. A recombinant host cell comprising a host cell transfected with the recombinant DNA molecule of Claim 6.
8. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 5 or 6.
- 20 9. A substantially purified recombinant polypeptide of Claim 8, wherein the polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 5 or 6.
10. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially 25 of the amino acid sequence shown in SEQ ID NOS 5 or 6.

-48-

11. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 8.

12. A method of detecting α 2 δ -C or α 2 δ -D protein in cells, comprising contacting cells with the antibody of Claim 11 and incubating the cells in a manner that allows for detection of the α 2 δ -C or α 2 δ -D protein-antibody complex.

5 13. A diagnostic assay for detecting cells containing α 2 δ -C or α 2 δ -D mutations, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 or by analyzing the genomic DNA directly by a hybridization method and determining whether the resulting PCR product contains a mutation.

10 14. A diagnostic assay for detecting cells containing α 2 δ -C or α 2 δ -D mutations, comprising isolating total cell RNA, subjecting the RNA to reverse transcription-PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 and determining whether the resulting PCR product contains a mutation.

15 15. A method for the amplification of a region of the DNA sequence of Claim 1, 2, or 3, the method comprising the step of: contacting a test sample suspected of containing the desired sequence of Claim 1, 2, or 3 or portion thereof with amplification reaction reagents.

20 16. A diagnostic kit for detecting the presence of at least one copy of the DNA sequence of Claim 1, 2, or 3 in a test sample, said kits containing a primer, a pair of primers or a probe, and optionally amplification reagents .

-49-

17. An assay for the detection or screening of therapeutic compounds that interfere with or mimic the interaction between the polypeptide of Claim 8, 9, or 10 and ligands that bind to the polypeptide of Claim 8, 9, or 10.

18. The assay of Claim 17, herein the assay comprises the steps of:

- 5 a) providing a polypeptide of Claim 8, 9, or 10;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance;
 and
- d) detecting the complexes formed between said polypeptide and said candidate substance.

10 19. A method for protecting mammalian cells from abnormal calcium flux, comprising introducing into mammalian cells an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the isolated and purified DNA sequence in mammalian cells.

15 20. A method for treating or preventing epilepsy, comprising introducing into a mammal an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the antisense strand of the isolated and purified DNA sequence in mammalian cells.

20 21. A method for purifying α 2 δ -C or α 2 δ -D protein from cells, comprising:

- a) transfecting a host cell with a vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3 operatively linked to a promoter capable of directing gene expression in a host cell;

-50-

- b) inducing expression of the isolated and purified DNA sequence in the cells;
 - c) lysing the cells;
 - d) isolating α 2 δ -C or α 2 δ -D protein from the cells ; and
 - e) purifying α 2 δ -C or α 2 δ -D protein from the isolate.
- 5 22. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
- 10 23. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49 under high stringency hybridization conditions.
- 15 24. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
- 20 25. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
26. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
27. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 17 or 42.
28. A substantially purified recombinant polypeptide of Claim 26, wherein the

-51-

polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 17 or 42.

29. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID NOS 17 or 42.

5 30. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 26.

10 31. A method of using polynucleotide sequences to treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, 15 Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, 20 AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.

30 32. The method of claim 31 wherein the disease is selected from the group consisting essentially of: seizure-related syndromes, migraine, ataxia, vestibular defects, chronic pain, mood, sleep interference, anxiety, ALS, multiple sclerosis,

-52-

mania, tremor, parkinsonism, substance abuse/addiction syndromes, mood, depression, and cancer.

33. A method of using polynucleotide sequences to test for presence of a
5 disease, or susceptibility to a disease, due to alterations or deletions in α 2 δ -C and/or α 2 δ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1,
10 AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1,
15 AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1,
20 AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.


34. A method of using polynucleotide sequences to identify the binding
25 potential of the polynucleotide sequences to gabapentin, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1,

-53-

AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1,
AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1,
AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1,
AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1,
5 AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1,
T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1,
AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1,
H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and
AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID
10 NOS 1-16, 18-41, or 43-49.

1/4
FIGURE #1

Fine Mapping of Alpha2/delta to mouse chromosome 9




Human $\alpha 2\delta 2$ Tissue Distribution

Figure 3. [^3H] Gabapentin binding activity by human $\alpha 2\alpha 1$ in transiently transfected Cos 7 cells





FIGURE #4

1 2 3 4 5 6 7



Lane 1-Brain RNA

Lane 2-Kidney RNA

Lane 3-Testis RNA

Lane 4-Lung RNA

Lane 5-Heart RNA

Lane 6-Placenta RNA

Lane 7-Liver RNA

WO 00/20450

-1-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT:
 (A) NAME: Margaret Ann Johns
 (B) STREET:
 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 10 APPLICANT:
 (A) NAME: Brian Jay Moldover
 (B) STREET:
 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 15 APPLICANT:
 (A) NAME: James David Offord
 (B) STREET:
 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 20 APPLICANT:
 (A) NAME: James David Offord
 (B) STREET:
 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 25 APPLICANT:
 (A) NAME: James David Offord
 (B) STREET:
 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 30 APPLICANT:
 (A) NAME: James David Offord
 (B) STREET:
 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 35 (ii) TITLE OF INVENTION: Alpha-2/Delta Gene
 (iii) NUMBER OF SEQUENCES: 49
- 40 (iv) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- 45 (2) INFORMATION FOR SEQ ID NO: 1:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 50 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: α2δ-B
- 55 (iii) MOLECULE TYPE: cDNA

-2-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CGGGCAGCGCAGCCCCAGAGGGCGTGCAGCCCGAGGCCCTCGCGGAGAAGGCG
CGGGCGGAGGAGAGGCCGAGTTACCGCCCGGCCGCCCAACCCGCCGCCGCCGC
5 CGCCGCCACTGCCCGCCCTCCCGCGCCGCATCTGAATGAAACATGGCGGTGCCGGCTCGG
ACCTGCAGGCCCTCTCGGCCCGCCAGCGCGACTGCAGCCCTGGCCCGCTGCCGCCAC
CCTGGCCCGGCACCCGGCGCCGACGTCCGGCCCGCTGTGGCTGCTGCCGCTT
CTACCGCTGCTCGCCGCCCTCGCTACAGCTCCCCCAGCAGCACACGATGCAGCAC
10 TGGGCCCGGTCTGGAGCAGGAGTCAGCGCTGATGCGGATTGGAGGCGTCCAGCAGCTC
CGTGAGATTACAAGGACAACCGAACCTGTTGAGGGTACAGGAGAATGAGCCTCAGAAGTTGGT
GAGAAGGGTGGCAGGGGACATTGAGAGCCTCTGGACAGGAAGGGTGCAGGCCCTGAAGAGACTGGCT
GATGCTGCAGAGAACTCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGT
15 TACTATGACGCCAACGGCTGACGCTGAGCTGGACGACCTGAGAGTGAGGATGTGAAAGGGGGTCT
AAGGCCAGCACCTAACGGCTGGACTTCATCGAGGACCAAACCTCAAGAACAAAGGTCAACTATTCA
TACGGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTCATCCTCAATGAGCTAAC
TGGACAGAGGCCCTGGAGAATGTGTTCATGGAAAACCGCAGACAAGACCCACACTGCTGTGGCAG
20 GTCTTCGGCAGGCCACAGGAGTCACTCGTACTACCCGGCCACCCCGTGGCAGGCCAACAGAAC
ATCGACCTGTACGATGTCCGAAGGAGACCTGGTATATCCAGGGGGCTCGTACCCAAAGACATG
GTCATCATCGTGGATGTGAGTGGCAGTGTGAGCGGCTGACCTGAAGCTGATGAAGACATCTGTC
TGCAGAGATGCTGGACACGCTGTCAGTGAATGACTATGTGAATGTGGCTCGTTAACGAGAAGGCA
25 CAGCCTGTCATGCTTCACACACCTGGTGCAGGCCATGTGCGAACAAAGAAGGTGTTAACAGGAA
GCTGTCAGGGCATGGTGGCCAAGGGCACACAGGCTACAAGGCCGGCTTGAGTATGCCCTTGAC
CAGCTGCAGAACCTAACATCCTCGGCCAACGCAACAAAGATGATCATGATGTTAACGGATGGT
GGTAGGAGCCGCGTGCAGGACGCTTTGAGAAGTACAATTGCCAACCGGACGGTGCCTGTT
30 ACTTTCTCCGTGGGGCAGCATAACTATGACGTCACACCGCTGCACTGGGATGGCTGTTAACAGGAA
GGCTACTATTTGAGATCCCTTCATCGGAGCCATCCGATCAACACACAGGAATATCTAGATGTG
TTGGCAGGCCCATGGTGGCTGCCAGGCAAGGAGGCAAGCAGGTTCACTGGACCTGTAATGACATC
GATGCACTGGGACTGGGTTGGTGGTAACAGGGACCCCTCCCTGTTAACCTGACACAGGATGGC
35 CCTGGGGAAAAGAAGAACCAAGCTGATCCTGGCGTGTGGGATTGACGTGGCTGTAATGACATC
AAGAGGCTGACCCCAACTACACGCTTGGAGCCAACGGCTATGTGTTGCCATTGACCTGAACGGC
TACGTGTTGTCACCCCAATCTAACGCCCCAGACCACCAACTTCCGGAGCCTGACTCTGGAC
TTCCCTGGATGCGGAGCTAGAGGATGAGAACAAAGGAAGAGATCCGTCGGAGCATGATTGATGGCAAC
AAGGGCCACAAGCAGATCAGAACGTTGGTCAAGTCCTGGATGAGAGGTACATAGATGAGGTGACA
40 CGGAACATACACCTGGGTGCCTATAAGGAGCAACTAACGCTGGGGCTGGTGTCCCACCCCTAC
AGCACCTCTACCTCCAAGCCAACTCAGTGACCAAGATCCTGCAGGTCAAGTATTTGAGTTCTG
CTCCCCAGCAGCTTGAGTCTGAAGGACACGTTTATTGCTCCAGAGAGACTGCAAGGACCTG
AATCCCTCAGACAACAACACCGAGTTCTGAAAAACTTATTGAGCTCATGGAGAAAGTGA
45 GACTCCAAGCAGTGCACAAACTCCTCTGCACAAACCTGATCTGGACACGGGCATCACGCAGCAG
CTGGTAGAGCGTGTGGAGGGACCAGGATCTAACACAGTACAGCTACTGGCGTGTGCTGCC
ACAGACGGTGGCATACCCGAGTCTTCCCAACAAGGCAGCTGAGGACTGGACAGAGAACCTGAG
CCCTTCAATGCCAGCTCTACCGCCGAGCCTGGATAACCAAGGTTATGCTTCAAGCCCCCACAC
CAGGATGCCCTGTTAAGGCCGCTGGAGCTGGAGAACATGACACTGTGGGATCCTCGTACAGCT
50 GTGGAGCTCAGCTAGGCAGGCCACACTGAGGCCAGCAGTGGTGGCGTCAAGCTGGACCTAGAG
GCTTGGGTGAGAAGTCAAGGTCTAGGCCAGCAACCGTACCCACCAAGACCAGCCTCAGAAGTGC
GGCCCAACAGCCACTGTGAGATGGACTGCGAGGTTAACAAATGAGGACTTA
55 GATGATGGAGGATTCTGGTGTCAAACCAAGAACATCAGTGGACCGAGGTGGCAGGGTCTTC
ACTGAGGTGGATGCCAACCTGATGCTGGCACTCTACAAATAACTCCTCTACACCCGCAAGGAGTCC
TATGACTATCAGGCCCTGTGCCCCCTCAGCCCCCTGGCAACCTGGGTGCTGCACCCGGGGTGT
TTTGTGCCACCGTGTGAGATTCTTACCTGGCTGGACCTCTGCTGCCCTGGTCCCTG
TTCCAGCAGCTCTACGGCTCATCTACACAGCTGGTCCAAGCAGACCCGGAGGCGAG
GGGAGCCCCGAGACGCCGAGAGGAGCAGCTGCGTCAAGAACAGACCCAGTACTACTTCGGCTCG
AACGCCCTCTACAAACGCCATCATGACTGCGAACACTGCTCCAGGCTGTTCCACGGCAGAGACTG
ACCAACACCAATCTCTCTTGTGGTGGCCGAGAACGCCGCTGTGAGCCAGTGCAGGCTGGCG
CTGCTGCAGAAGGAGACGCACTGCCAGGGACGCCGGAGCAGTGTGAGCTAGTGCAGAGACCG
CGATACCCGAGAGGGCCGACATCTGCTCGACTACAACGCCAGAGAACATCTCAGACTGTGGC
CGCGGGGCTCTTCCGCCGCTGGCGTCTGGTCTCCCTGCAACTGCTGCTGCCCTGG
CTGCCGCCGCCGCCAGCCTCAAGTCCTCGTCCAGCCTCTGCCGCTCTGAGCACCCTGCC
ACCCACCTCCACTCCACCTCACCCGGCTCTCGCCTTCCCACCCCTCTGCC
GCCTTAGAGCCTCGTCCCTCCCTCACTGAAGGACCTGAGCTGCCAGGCC
GCAGAGTCTGGTCTG

-3-

CGCTTGGGATGGGGAGTCCTAAAGCAGGACGCCGAGGTGTTGGCACCCAAATCACATCTCACC
TCCGAACTGTTCAAGTGTCCCCAGACCTTCTTGCTGCTGGCTCCCCCAGTGGGATGGGACAG
GGAGGCCACACGCACTGGTGCCTAAACAGGCCCTGCTGCCGCCCTCTGGAGGCTGCCTATGT
TGGGGGGGACCCCTGCCTCAGCTGACCCGGCTCTGCCCCACCAAGCCAAACTTGGTTCTGT
5 GAGAATAGTGGAGGAAGGTGAGATGGCCAGTTGAAGCCTGTGCCTCCAGCTAAATCCTAGCAG
GAGAGAGGCTCTGGGCAGCCCCATGGCTCTGCCCTTCAGGCCTACAGCCACATCCCCAAG
CCCACCAAGGTGTCAAGGATAGTCACAGTGTACAGTGTACAGACACTACCCCATATACACCTGGAAACA
TTGAGGATGGAAACTGGACTCACATTGACATAACCCACTGGGCACACGCACAAACACACACTA
TGGGGTGGGGTGGGTGTAGGGCTTACAAAGCCTTACACAGGGCAGGGGTTGGTGGGAGGGTTGG
10 CACCTGCACACTCCATCTCTGCTACCACCTGCCTTAATCTGAGCTGCAGCCTGGCTGGTCCTC
CCATTCTAAAGCTGAATGTCAAACAGTGCCTAAATGCTGGGCAGGGGTTGAAGAACCCCTGTGTC
CACCCCTAGCCACCAGTGTCTCCAAGTGCCCCCTCACCTCTCCAGGTGCTATTGTAACCATTTC
TCACTAGTGTCAAGGCCCTCAGTGGGACCATGCCACTGCCTGCACCTTCGGCAGAGGAAACCCCC
15 ACCAGACATCACCCCTTGCTTAGCAGGGTGACTIONTGTCTCTGGCTGGGCATCCTCCGCC
AATCTGGCCCTTACACACTCAGGCCTGTGCCACTCCCTATCTCTCCACACACACAC
TCCCTGCTTGCAAGGAGGCCAAACTGTCCCTCCCTGCTGAACACACACACACACACACAG
GTGGGACTGGGCACAGCTTTCACACCATTCTGGCATTTCCTGGCTGGGCATCCAGCCT
GGGGGCCAGTGGGAAGTGGGCAAGGGGATATAGTGATGGGCTCAGATGGACTGGGAGGAGGG
GGAGGGTGTGATTAAATTAAATGGCTCGTTAATTAAATGTCATGTTGCTGCTGCTTCTCAGTGT
20 GTGTGTGTGGTCCATGCCACTGCTGGTGCAGGGTGGGTGTCATGTGCACCCGGCTGGATGCC
AGCTGTGTCTCGGGGGCGTGTAACTGTAGTGTAGTCAGGTGCTCAATGGAGAATATAAAC
ATATACAGAAAAATATATATTAAAGTTAAAAAAACAGAAAAACAGACAAACATCCCCATCAGG
TAGCTGTCTAACCCCCCAGCTGGGTCTAATCTCTCATTACCCACCCGACCTGGCTGCCCTCACC
TTGGGCTGGGGACTGGGGGCCATTCTCTCTGCCCTTTTGTGTTCTATTGTACA
25 GACAAGTTGGAAAAACAAACAGCAGACAAAAAGTCAGAAACTTGTAAAATACAGTGTGATT
CCTTGTAAAATATTCTAAATGGTTATTACAGAAGATCAGTTATTAAATAATGTTCATATTTC
CTTC

(2) INFORMATION FOR SEQ ID NO: 2:

-4-

DQPQKCGPNSHCEMDCEVNNEDELLCVLIDDDGGFLVLSNQNHQWDQVGRFFSEVDANLMLALYNNSF
 YTRKESYDYQAACAPOPPGNLGAAPRGVFVPTVADFLNLAWWTAAAWSLFQQLLYGLIYHSWFQA
 DPAEAEGSPETRESSCVMQQTQYYFGSVNASYNAIIDCGNCSRLFHAQRLTNTNLLFVVAEKPLCS
 QCEAGRLLQKETHCPADGPEQCELVQRPRYRRGPHICFDYNATEDTSDCGRGASFPPSLGVLVSLQ
 5 LLLLLGLPPRPQPQVLVHASRRL

(2) INFORMATION FOR SEQ ID NO: 3:

- 10 (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH:
 - (B) TYPE:
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- 15 (ii) MOLECULE TYPE: cDNA
 - (ix) FEATURE:
 - (A) NAME/KEY: Coding Sequence
 - (B) LOCATION:
 - (D) OTHER INFORMATION: $\alpha 2\delta$ -C
- 20 (iii) MOLECULE TYPE: cDNA
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
 TACTATAGGGCGCCCGCAATTGGCACGAGGCGCGGAGCGGGAGCAGGCAGCCCCGCGCGCTC
 25 GCCACCAGCGCTCCCGCGCAGCTCCCCGGCGCTCTCGTCGCCGCCAGCGGGCGCGTCCGA
 GGGAGCCCAGCATGGCGGGGGCTCGCCGCCGCGTCCGGGGGGCTCGCGCTTCCTCG
 CTGCCGCCTCTCTACGCCGCGCTGGGGACGTGGTGCCTCGAGCAGCAGATACCGCTCTCCG
 TGGTGAAGCTCTGGGCCTCGGCTTTGGTGGGGAGATAAAATCCATTGCTAAGTACTCCGGTT
 CCCAGCTCTGCAAAGAAATACAAGAGATGAGAAAGACGTTGCCATAGAAGAAATTGATGCC
 30 TCCAACCTGTAAGAACGCTGGCAAAGAACATGGAAGAGATGTTCACAAAGAAGTCTGAGGCCGTCA
 GGCCTCTGGTGAGGCTGCAGAAGAACACCTGAAACATGAATTGATGCAGACTACAGTATG
 AATACTTCAATGCTGTGCTGATAAAATGAAAGGGACAAGACGGAATTGGAGCTGGGAAAGG
 35 AATTCACTTAGCCCCAAATGACCATTAAATAATTGCTGTGAAACATCAGTCAAGTGA
 CAGTACCAACGAACATGTACAACAAAGACCTGCAATTGTCATGGGTTATTGGTCTGAATCTC
 TAAACAAAGTTTGAGATAACTTGACCGTACCCGGGATTAAATGGAACCCAGATGAGAATGGAGT
 CATTGCCCTCGACTGCAGGAACCGAAAATGGTACATCCAGGCAACTCTCCGAAAGACGTGGTCA
 TTGACGTCACTGGGAGATGACTTCTTCACATAATTGCTTATAATGAGGAGCTTCACTATGTGG
 40 TGGATACACTGGGGATGACTTCTTCACATAATTGCTTATAATGAGGAGCTTCACTATGTGG
 AACCTGCTGAATGAACTTGGTCAAGCGACAGGACAACAAAGAGCACTTCAGGGAGCATC
 TGGACAAACTTTGCCAAAGGAATTGGAATGTTGGATATAGCTCTGAATGAGGCCCTCAACATT
 TGAGTGAATTCAACCCACACGGGACAAGGAAGTATCTGAGTCAGGCCATCATGCTCATAACTGATG
 45 GGCGGTGGACACCTATGATAACATCTTGCAAAATACAATTGGCCAGATCGAAAGGTTGCATCT
 TCACATACCTCATTGGACGAGAGGCTGCCATTGCAAGACAATCTAAAGTGGATGGCCTGTGCCAACA
 AAGGATTTTTACCCAGATCTCCACCTGGCTGATGTGCAAGGAGAATGTCATGGAATACCTTCACG
 TGCTTAGCCGCCAAAGTCATGACCGCAGGAGCATGATGTTGGACCGAAGCTACATTGACA
 GCACTCTGACTGATGATCAGGGCCCCGTCCTGATGACCACTGTAGCCATGCCATGTGTTAGTAAGC
 AGAACGAAACCAGATCGAAGGGCATTCTCTGGGAGTGGTGGCACAGATGTCCTGTGAAAGAAC
 TTCTGAAGACCATCCCCAAATACAAGTTAGGGATTACGGTTATGCCATTGCAATCACAAATAATG
 50 GRTATATCTGACCGCATCCGAACTCAGGCTGCTGTACGAAGAAGGAAAAAGCGAAGGAAACCTA
 ACTATAGTAGCCTGACCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTA
 TGGTGAATCGAAAGACGGGGAGTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGAAACGGG
 TTTTGGTGAATGACAATGACTACTATTATACAGACATCAAGGGTACTCCTTCAGTTAGGTGTGG
 CGCTTTCCAGAGGTCACTGGGAAATATTCTCCGAGGGAAATGTAACCATCGAAGAAGGCCTGCATG
 ACTTAGAACATCCCGATGTGTCCTGGCAGATGAATGGTCCTACTGCAACACTGACCTACACCCCTG
 55 AGCACCGCCATCTGTCAGTTAGAAGCGATTAAGCTCTACCTAAAAGGCAAAGAACCTTGCTCC
 AGTGTGATAAGAACATTGATCCAAGAAGTCCTTTGACGCGGGTGGAGTGCCTTGCATGAAAGCGT
 ATTGGACCAGCCTGGCCCTCAACAAATCTGAAAATTCTGACAAGGGCGTGGAGGTTGCCTCCTCG

-5-

GCACTCGCACGGGCCTCTCCAGAACATCAACCTGTTGTCGGGCTGAGCAGCTACCAATCAGGACT
 TCCGTAAAGCTGGCACAAGGAGAACATTAAACGAGACCATTCCCTCTGGTACCGAAGAG
 CCGCTGAGCAGATTCCAGGGAGCTCGTCACTCGATCCCATTAGCACTGGACCAGTCAATAAAA
 GCAATGTGGTGACAGCAAGTACATCCATCCAGCTCTGGATGAACGGAAATCTCCGTGGTGGCAG
 5 CTGTAGGCATTAGATGAAACTTGAATTTCAGCTGATGAGACTGTGAATTGTTACCTCATAGACA
 CTTCCCTGGATGGCAAATGCTCCATCAGCTGATGAGACTGTGAATTGTTACCTCATAGACA
 ATAATGGATTATTTGGTGTCAAGACTACACACAGACTGGAGACTTTTGTTGAGATCGAGG
 GAGCTGTGATGAACAAATTGCTAACATGGCTCTTAAAAGAATTACCTTTATGACTACCAAG
 CCATGTGAGGCCAACAGGAAGCAGCGATGGCGCCATGGCTCTGGATCCTTATAATGCCT
 10 TCCCTCTGCACTAAAGGATCATGACAGAACATTGCTTGTCTGGTGAATTAAACCTCTGCA
 GTTGGTGGCACTCCGATATGACAGCTAAAGCCCAGAAATTGAAACAGACCCGGCTGTGATA
 CTGAATATCCAGCATTGCTCTGAGCGCACCATCAAGGAGACTACAGGGAAATTGCTTGTGAG
 ACTGCTCCAAGTCCTTGTCATCCAGCAAATCCAAGCAGCAACCTGTCATGGTGGTGGGACA
 GCAGCTGCCCTGTGAATCTGTGGCCCCCATCACCATGGCACCCATTGAATCAGGTATAATGAAT
 15 CCCTTAAGTGTGAACGTCTAACAGGCCAGAAGATCAGAAGGCCAGAATCTTGTATGGCTTCC
 ATCCTGAGGAGAATGCAAGGGAGTGTGGGGTGCAGCTCCAAAGGCCAGACAGTCCCTTC
 TGCTCCCTGCTTTGATGCTCTCAAGGTGACACTGACTGAGATGTTCTTACTGACTGAG
 ATGTTCTCTGGCATGCTAAATCATGGATAAAACTGTGAACCAAATATGGTGAACATACGAGACA
 20 TGAATATAGTCCAACCATCAGCATCTCATGATTTAAACTGTGCGTGAATATAAAACTCTTAAAG
 ATATGTTGACAAAAAGTTATCTATCATCTTTACTTGCCAGTCATGCAATGTGAGTTGCCAC
 ATGATAATCACCTTCATCAGAAATGGGACCGCAAGTGGTAGGCAGTGTCCCTCTGCTTGAAC
 TATTGAAACCAATTAAAAGTGTACTTTAAATAAAAGTATATTAAACATAAAAAAAAAAAAAA
 AAAAAAAA

25

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

35 (ix) FEATURE:

- (A) NAME/KEY: Coding Sequence

(B) LOCATION:

- (D) OTHER INFORMATION: $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CCATGCCCTGCAACTCCCAACTTCTCGAACACCCAGCTCCAGCAGCCGCTGGATTCCCTCCAGC
 CAATGCCCTGCGCTGGCCTTGTGCAAGAACCTCGGCCCTCCTGTGGCTGCTGCTTAGGCA
 CCTCCCTGCCCCCTGCGTGGGACAGGCCAGATTCTCTGGAAACAGTGAAGCTATGGCTGACA
 45 CCTTGGGGGGACCTGTATAAACACTGTGACCAAATACTCAGGCTCTCTGCTGAGAAGAGT
 ACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGAGGTGGATGGCTTGGAGCTGGTGAAGGAAGTCT
 CAGAGGACATGGAGAACATGCTGCGGAGGGAAAGTCGAGGCGGTCCAGAAATCTGGTGAAGCTGCCG
 AGGAGGCCACCTGAACCAAGCAATTCAATGAATCCCTGGTGTGACTATTACAACCTGGCCTG
 50 TCAACGAGAGGGACGGAGAACAGGGCAACTTGTGGAGCTGGCGCCAGTTCTCTGGAGTCCAATG
 CTCACTTCAGCAACCTGGCGGTGAACACCTCCATCAGCAGCGTGCAGCTGCCACCAACGTGTACA
 ACAAAAGACCCAGATTTAAATGGAGTCTACATGTCTGAAGCCTTGAATGCTGTCTGGAGA
 ACTTCCAGAGAGACCCAACGTTGACCTGGCAATATTGGCAGTGCAACTGGGATTCTCAGGATCT
 ATCCAGGTATAAAATGGACACCTGTAGAGAACATGGAGTCATTACTTTGACTGCGAAACCGCGGCT
 GGTACATTCAAGCTGCTACTTCCTCCAAAGGACATAGTGAATTGGTAGGAGCTTCAAGGATCT
 55 AGGGGCTGAGGATGACTATTGCCAAGCACACCATCACCACATCTTGGACACCCTGGGAGAATG
 ACTTCGTTAATATCATAGCGTACAATGACTACGTCCATTACATCGAGCCTTGTAAAGGGATCC
 TCGTCCAGGCCAGGAGAACATCGAGAGGCAATTCAAAGTGTGGAGGGAGTTGATGGTCAAAG

-6-

GTGTGGGGTCGTGGACCAAGCCCTGAGAGAAGCCTCCAGATCCTGAAGCAGTTCCAAGAGGCCA
AGCAAGGAAGCCTCTGCAACCAGGCCATCATGCTCATCAGCGACGGCGCGTGGAGGACTACGAGC
CGGTGTTGAGAAGTATAACTGGCCAGACTGTAAGGTCCGAGTTTCACTTACCTATTGGGAGAG
AAGTGTCTTGCTGACCGCATGAAGTGGATTGCATGCAACAACAAAGGCTACTACACGCAGATCT
CAACGCTGGCGCACCCCAGGAGAACGTGATGGAATACCTGCACGTGCTCAGCCGCCCATGGTCA
TCAACCACGACCACGACATCATCTGGACAGAGGCCATGGACAGCAAGCTCCTCAGCTCGCAGG
CTCAGACGCTGACACTGCTCACCACGTGAGCTTCAAGAAGAACGAAACCGCGAT
CCCATGGCATTCTCTGGGTGTGGCTCAGATGTGGCCCTGAGAGAGCTGATGAAGCTGGCGC
CCCGTACAAGCTTGGAGTGCACGGATACGCCTTCTGAAACACCAACAATGGCTACATCCTCTCCC
ATCCCAGCCTCCGGCCCTGTACAGAGAGGGAGAAAACTAAAACCAAACCTAACTACAACAGTG
TGGATCTCTCGAAGTGGAGTGGGAAGACCAGGCTGAATCTCTGAGAACAGCCATGATCAATAGGG
AAACAGGTACTCTCGATGGATGTGAGGTTCCGATGGATAAAGGGAGCGAGTCTTTCTCTGA
CCAATGACTACTTCTTCAGGACATCAGCGACACCCCTTCAGTTGGGGTGGTGTGCTGCCCCGG
GCCACGGAGAATACATCCTCTGGGGAACACGCTGTGGAAGAAGGCTGCATGACTGCTTCACC
CAGACCTGGCCCTGGCGGGTGAUTGGATCTACTGCATCACAGATATTGACCCAGACCACCGGAAGC
TCAGCCAGCTAGAGGCCATGATCCGCTTCCCTCACAGGAAGGACCCAGACCTGGAGTGTGACGAGG
AGCTGGTCCGGGAGGTGCTGTTGACGGCGGTGGTACAGCCCCCATGGAAGCCTACTGGACAGCGC
TGGCCCTCAACATGTCGAGGGAGTCTGAAACACGTGGATGGACATGGCTTCTGGGACCCGGCTG
GCCTCTGAGAAGCAGCTTGTGCTGGCTCCGAGAAGGTCTCCGACAGGAAGTTCCTGACACCTG
AGGACGAGGCCAGCGTGTTCACCCCTGGACCGCTTCCCGCTGTGGTACCGCCAGGCCTCAGAGCATC
CTGCTGGCAGCTCGTCTTCAACCTCCGCTGGCAGAACGGGACAGAAAGTGCAGGGTGAACCCATGG
TGGTGAACGGCAAGCACAGCTGTCGAGGAGTCTGAAACACGTGGATGGACATGGCTTCTGGGACCCGG
GCGTCAAATGAAGCTGGAATTCTCCAGCGCAAATTCTGGCGGCAACCGCGAGTGCAGCACTG
TGGATGGGCCGTGACACAGAGCTGGAGGACAGTGAATCTGGACTGCTTCGTCATCGACACAAACG
GGTTCATCTGATCTCCAAGAGGTCCGAGAGAACGGGAAGATTCTGGGGAGGTGGATGGTGTGCTG
TCCTGACCCAGCTGCTCAGCATGGGGTGTTCAGCCAAGTGACTATGTATGACTATCAGGCCATGT
GCAAACCCCTCGAGTCACCAACAGTCAGGCCAGCCCCCTGGTCTGGAGTGGACTGCTGGGCTCT
CGGCGACCAGGTGGCTGCTGCAGGAGCTGGTGTGGTCTCTGCTGGAGTGGACTGCTGGGCTCT
GGTACGACAGAGGGGCCAGGGCCAAAAGTGTCTCCAGCATCTCCACAGTGTGACTGCTGGGCTACT
CGCTGCAGCCCTGCGACACGGAGTACCCCGTGTGCTGTGACCGCCAGGGCCATCCGGGAGGCCAACG
GGATCGTGGAGTGCAGGGCCCTGCCAGAAGGTATTGTTGGTGCAGCAGATTCCAAACAGTAACCTCC
TCCTCTGGTACAGACCCCACCTGTACTGCAAGCATCTCCACAGTGTGCTGCAGGAGGCCAG
AAGTCAAATATAATGCCTCTGTCAAATGTGACCGGATGCCCTGCTGGAGTGGACTGCCGCGCAG
ACTCCGCCACGCCCTCCATCCAGAGGAGAATGCCAGGGACTGCCGGGGCCCTCGGACACCTCAG
CCTGCCGCCCTACTCTGCTGCTGTGCTGGCTACTGCCCAACTCTGGGTGAC
ACCACCCAGCCTGACCTGTGTTGGCAAGGTGATCCTCCAGAGCCATCCAAAAGTCACTGCA
GACATGGGATGCACTGCAACTGCAAGTGGTCCGCCCCCAGGCCAACGCTCCTCTCAATCTGGGCTG
GTGGCCCTGGCTCCGGAGAATGCTGGATGGAACAGGAACCAATCACCTGGCACCCTTCAAGA
TGCTTCATGGTGCCCGTACCATCTGCCCTAGGTCTCAACATGAGCATACTTCTGACCTAACCTTC
CTGTCCTCTCGGGAGCCAGCGTGAAGCTCAGCTGGACCAAGACAAAATAATTAGTTAGTCTTCC
TGTACTCCAGAGTCCAGACCCAGCCAAGAAAGGGTCACTGTTCTGACCCCTTCTGTCGGAGTGG
TCTCTGGTAGAACCCAAGGACTTCTGGTACTGAGAACAGCAGCAGAACGAGGCAAAATCCAGAG
ATGAGGCTAAGGCAAGAATATGCCCAACTAAAGCATAGATTCCCAAAGTGGACTGAGGCTCATGGTGG
AGGCCACTCACCTCCCTAGCTGCTGCTGAAAAGGTTTGAAGTGTGTTGGGGGGGGTTGGTAA
GGGAATGGTCAAGACTGAGAAAGGAATGAAATCCATTAGGAAATATCGACAGGGCTACACGTGAT
GTCCCCAAACTGCTGCTATTGAGAACACTTCCAAAACCTCTTACAAAGGCCCTAAAGGAAAGTTG
CATCTATGAAAGCAATAGGCTGAGACATCCAATTGCTGACATGGAATTGATGTACATTCAAGGG
ACGGCAAAATAGCTGAAAATAGTGAAGGAGCAGTGGTGTGCTCTTCTGGCAATGATT
ACAAAAGAATCTACTTGACTCTGTCCTGGAGGAGCTCTATCTGGAAACTCACCCCCAGGCCACACA
CCAACCTGCTAACGAGGGTCCACTGGGAGGGAGCTCTATCTGGAAACTCACCCCCAGGCCACACA
CATCTCCCCCAGGGTCCCAAGGCCCGCAGCTCCTCCCCGACCAACCCCAAGACCTGGATCCC
AGGAGACAACAGTCTCACATGAGAGCAACATTAGGCAAGGCCATGGAGAACATGTGGAGAGGC
CGGCCCTAAATCTTCCATTAAACAAACCCAGTGTGGTATGGACAGCAGCATGCAAGGGCTTTGGG
GCGCTCCCCCGCTCTCCATCACCTCAGCTCCACACTCAAAGTCAAGTCAAGTCAAGACTGTT
AAGTTCCCTACCAAGCAAATAGCCCTAACATTGCTCTAGAGTAGGCCAAATGCCAACTCTGAAAAC
ACACTTACATTATCGGTTACAGAACATGTCACTCTTACCATCATGTCAGTGTGCAACAAACCTGTGAGGG
AGTATTAATGCCCTAACAGCAGAACACTGCAAGCTCGAAGAACAGCTTAAGTGGCAGAATAATG
CTAGAACAGCTAACGGTTACATGTACCAAATAACATGTTCAAGTCAAGTCAAGACTGTT
CCCTGAAAGTGGGTACTATCATTAGTCCCAGTGTATAGAAAATGCAAGCAGAGTTGAAAATTGCTC

-7-

CAAATTACCGGAAGAGTGTATGAAGATTGAATGTGATGTATTACGTAACATGCTTGAAACTGCCT
GGCATATACTAACGCTAAATAATACATGCTAATGCAAAAAAAAAAAAAAAA

5 (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY:

15 (B) LOCATION:

(D) OTHER INFORMATION: $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

20 MAGPGSPRRASRGASALLAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYSGSQL
QKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKSEAVRRLVEAAEEAHLKHEFDADIQYEYFN
AVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDPAIVNGVYWSESLNKV
FVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPDENGVIAFDCRNRKWYIQAATSPKDVVILVDVS
GSMKGLRLTIAKQTVSSILDTLGDDDFNIIAYNEELHYVEPCLNGTLVQADRTNKEHFRHLDKL
25 FAKGIGMLDIALNEAFNILSDFNHTGQGSICSQAIMLITDGAVDTYDTIFAKYNWPDRKVRIFTYL
IGREAAFADNLKWMACANKGFFTQISTLADVQENVMEMYLHVLSRPKVIDQEHDVWTEAYIDSTLT
DDQGPVLMTTVAMPVFSKQNERTRSKGILLGVVGTDVPVKELLKTPKYKLGIGHGYAFAITNNGYIL
THPELRLLYEGKKRKPNEYSSVSDLSEVEWEDRDDVLRNAMVRKTGKFSMEVKKTVDKGRVLVM
TNDDYYTDIKGTPFSLGVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCNTDLHPEHRH
30 LSQLEAIKLYLKGKEPLLQCDKELIQEVLFDAVVSAPIEAYWTSLALNKSENSDKGVEVAFLGTRT
GLSRINLFVGAEQLTNQDFLKAGDKENIFNADHFPLWYRRAAEQIPGSFVYSIPFSTGPVNKSNNV
TASTSIQLLDERKSPVVAAVGIQMKLEFFQRKFWTASRQCASLDGKCSISCDDETVCYLIIDNNGF
ILVSEDYTQTDGFGEIEGAVMNKLLTMGSFKRITLYDYQAMCRANKESSDGAHGLIDPYNAFLSA
35 VKWIMTELVLFLVLFNLCSWWHSDMTAKAQLKOTLEPCDTEYPAFVSETRIKETTGNIACEDCSK
SFVIQQIPSSNLFMVVVDSSCLCESVAPITMAPIEIRYNESLKCERLKAQKIRRRPESCHGFHPEE
NARECGGAPS LQAQTVLLLLPLLLMLFSR

40 (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY:

50 (B) LOCATION:

(D) OTHER INFORMATION: $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

-8-

MPATPNFLANPSSSRWIPLQPMPVAWFVQKTSALLWLLLGTSLSPA WGQAKI PLETVKLWADT
FGGDLYNTVKYSGSLLLQKKYKDVESSLKIEEV DGLELVRKFSEDMENMLRRKVEAVQNLVEAAE
EADLNHEFNE SLVFDY YNSVLINERDEKG NFVELGAEFLLESNAHFSNLPVNTSISSVQLPTNVYN
5 KDPDI LNGVYMSEALNAV FVENFQRDPTLTWQYFGSATGFFRIYPGIKWT PDENGVITFDCRN RGW
YIQAATSPKDIVILVDVGSMKGLRMTIAKHTITTILD LGENDFVNIIAYNDYVHYIEPCFKGIL
VQADRDNRHF KLLVEELMVKG VGVVDQALREA FQILKQFQEAKQGS LCNQAIMLISDGAVEDYEP
VFEKYNWPDC KVRVFTYLGREVS FADRMKWIACNNKG YYTQISTLA DTQENVM EYLHVLSRP MV
10 NHHDIIWTEAYMDSKLSSQAQSLTLLTVAMPVFSKKNETRSHGILLGVGVSDVALRELMK LAP
RYKLGVHGYAFLNTNNGYILSHPDLRPLYREGKKLKPKPNVNSVL SEVEWEDQAESLRTAMINRE
TGTLSMDVKVPM DKGRVLF LTNDYFFT DISDTPFSLGVVL SRGHGEYILLGNTSVE EGLHDLLHP
DLALAGDWIYC ITDIDPDHRKLSQLEAMI RFLTRKDPL ECDEELVREVLFDAVVTAPMEAYWTAL
ALNMSEESEHVV DMAFLGTRAGLRLSSLFVGSEK VSDRKFLT PEDEAS VTL DRFPLWYRQASEHP
AGSFVFNL RWAEGPESAGEPMVVTASTAVAVTVDKRTAIAAAAAGVQM KLEFLQRKFWAATRQCSTV
15 DGPCTQS CEDSDL DCFVI DNNGFIL SKRSRETGRFLGEVDGAVLTQ LLSMGVFSQV TMYDYQAMC
KPSSHHHSAAQPLVSPISAFLTATRWLLQELVLFLL EWSVWG SWYDRGA EAKSVFH SHKH KKQDP
LQPCDTEYPV FVYQPAIREANGIVECGPCQKV FVVQ QIPNSN LLLVTDPTCDCS IFPPV LQEATE
VKYNASVKCDRMR SQKLRRRPDSCHAFHPEENAQDCGGASDT SASP LLLPVCAWGLL PQLLR

20

(2) INFORMATION FOR SEQ ID NO: 7

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

30 (A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION:

(iii) MOLECULE TYPE: cDNA

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AGGATGGCCCTGGGGAAAAGAAGA

(2) INFORMATION FOR SEQ ID NO: 8

40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primer for $\alpha 2\delta$ -B

50

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

-9-

ATCATCAATGAGGACACAGA

(2) INFORMATION FOR SEQ ID NO: 9

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
10 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: 5' primers used for RT-PCR of $\alpha 2\delta$ -C
15 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

AGAACGAAACCAGATCGAAG

20 (2) INFORMATION FOR SEQ ID NO: 10

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: 3' primer used for RT-PCR of $\alpha 2\delta$ -C
30 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

35 CGATTCAACCATAGCATTCTC

(2) INFORMATION FOR SEQ ID NO: 11

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
45 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:

-10-

(D) OTHER INFORMATION: primer for $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

5 CTACCAAGCCATGTGTA

(2) INFORMATION FOR SEQ ID NO: 12

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primer to amplify mouse $\alpha 2\delta$ -C

20 (iii) MOLECULE TYPE: cDNA

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AGAACGAAACTAGGTCAAAG

(2) INFORMATION FOR SEQ ID NO: 13

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

35 (D) OTHER INFORMATION: 3' primer to amplify mouse $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CGATTACCATGGCATTTCGT

40

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

-11-

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

5 (D) OTHER INFORMATION: rat sequence for $\alpha 2\delta$ -c

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

10 GATTCTTCTGGGTGTGGTGGCACAGATGTCAGTAAAAGAGCTTCTGAAGACCATCCCCAAATA
CAAGTTAGGAATTATGGTTATGCCATCACGAATAATGGATACTTGTACACACCCCGGA
GCTCAGGCCCTGTATGAAGAAGGGAAAAGCGAAGGAAGCCTAATTACAGTAGTGTGGATCTCTC
GGAAGTCGAGGGAGATCGGGATGATGTGTTACGAAATGCCATGGTAAATCGAC

15 (2) INFORMATION FOR SEQ ID NO: 15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

25 (D) OTHER INFORMATION: (1690-1761) $\alpha 2\delta$ -D, human splice

variant

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

30 CCATGCCTGCAACTCCCAACTTCCCTCGCAAACCCAGCTCCAGCAGCCGCTGGATTCCCTCCAGC
CAATGCCGTGGCTGGCCTTGTGCAGAAGACCTCGGCCCTCCTGTGGCTGCTGCTTAGGCA
CCTCCCTGTCCCCTGCGTGGGACAGGCCAAGATTCTCTGGAAACAGTGAAGCTATGGCTGACA
CCTCGGCAGGGACCTGTATAACACTGTGACCAAATACTCAGGCTCTCTTGCTGCAGAAGAAGT
ACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGAGGGATGGCTTGGAGCTGGTGAAGGAAGTTCT
25 CAGAGGACATGGAGAACATGCTGCGAGGAAAGTCGAGGCGGTCCAGAATCTGGTGAAGCTGCCG
AGGAGGCCACCTGAACCACGAATTCAATGAATCCCTGGTGGTCACTATTACAACCTGGTCTGA
TCAACGAGAGGGACGAGAAGGGCAACTCGTGGAGCTGGCGCCAGTTCTCTGGAGTCCAATG
CTCACTTCAGCAACCTGCCGTGAACACCTCCATCAGCAGCGTGCAGCTGCCACCAACGTGTACA
ACAAGACCCAGATATTAAATGGAGTCTACATGTCGAAGCCTTGAATGCTGTCTCGTGGAGA
40 ACTTCCAGAGAGACCCAACGTTGACCTGGCAATATTGGAGTCACTGGATTCTCAGGATCT
ATCCAGGTATAAAATGGACACCTGTGAGAATGGAGTCATTACTTTGACTGCCAAACCGCGGCT
GGTACATTCAAGCTGCTACTTCTCCAAGGACATAGTGAATTGGTGGAGCTGAGCGGCAGTATGA
AGGGGCTGAGGATGACTATTGCAAGGCACACCATCACCACCATCTTGGACACCCCTGGGGAGAATG
ACTCGTTAATATCATAGCGTACAATGACTACGTCCATTACATCGAGCCTGTTAAAGGGATCC
45 TCGTCCAGGCCGAGACAATCGAGAGCATTCAAACCTGCTGGAGGGAGTTGATGGTCAAAG
GTGTGGGGCTGTGGACCAAGCCTGAGAGAAGCCTCCAGATCCTGAAGCAGTTCCAAGAGGCCA
AGCAAGGAAGCCTCTGCAACCAGGCCATCATGCTCATCAGCAGCGGCCGTGGAGGACTACGAGC
CGGTGTTGAGAAGTATAACTGGCCAGACTGTAAGGTCAGTTCACTTACCTCATTGGAGAG
AAGTGTCTTTGCTGACCGCATGAAGTGGATTGATGCAACAACAAGGCTACTACACGAGATCT
50 CAAAGCTGGCGACACCAGGAGAACGTGATGGAATACCTGCACGTGCTCAGCCGCCATGGTCA
TCAACCACGACCACGACATCATCTGGACAGAGGCCTACATGGACAGCAAGCTCAGCTCGCAGG

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH:
 - (B) TYPE:
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- 5 (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
 - (B) LOCATION:
- 10 (D) OTHER INFORMATION: human variant $\alpha 2\delta$ -D, EDGE screen
- (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

15 CCATGCCTGCAACTCCAACTTCCTCGCAAACCCCAGCTCCAGCAGCCGCTGGATTCCCTCCAGC
CAATGCCCGTGGCCTGGCCTTGTGCAGAAGACCTCGGCCCTCTGTGGCTGCTGCTTAGGCA
CCTCCCTGTCCCCCTGCGTGGGGACAGGCCAAGATTCTCTGGAAACAGTGAAGCTATGGCTGACA
CCTCGCGGGGACCTGTATAACACTGTGACCAAATACTCAGGCCTCTCTTGCTGCAGAAGAAGT
ACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGAGGTGGATGGCTGGAGCTGGTGGAGGAAGTTCT
CAGAGGACATGGAGAACATGCTGCGGAGGAAAGTCGAGGCCTCCAGAATCTGGTGGAAAGCTGCCG
20 AGGAGGCCGACCTGAACCACGAATTCAATGAATCCCTGGTGGTCACTATTACAACCTGGTCCCTGA
TCAACGAGAGGGACGAGAAGGGCAACTTCGTGGAGCTGGCGCCAGTTCTCTGGAGTCCAATG
CTCACTTCAGCAACCTGCGGTGAACACCTCCATCAGCAGCGTGCAGCTGCCACCAACGTGTACA
ACAAAGACCCAGATATTAAATGGAGTCTACATGTCGAAGCCTGAAATGCTGTCTCGTGGAGA
ACTTCCAGAGAGACCCAACGTTGACCTGGCAATATTGGCAGTGCAACTGGATTCTCAGGATCT
25 ATCCAGGTATAAAATGGACACCTGATGAGAATGGAGTCATTACTTTGACTGCCGAAACCGCGGCT
GGTACATTCAAGCTGCTACTTCTCCAAGGACATAGTGATTTGGTGGACGTGAGCAGCAGTATGA
AGGGGCTGAGGATGACTATTGCCAAGCACCCATCACCACCATCTGGACACCCCTGGGGAGAATG
ACTTCRTTAATATCATAGCGTACAATGACTACGTTCAATTACATCGAGCCTGTTAAAGGGATCC
TCGTCCAGGGGGACCGAGACAATCGAGAGCATTCAAACACTGCTGGAGGAGGTTGATGGTCAAAG
30 GTGTGGGGGTCGTGGACCAAGCCTGAGAGAAGCCTCCAGATCCTGAAGCAGTTCCAAGAGGCCA
AGCAAGGAAGCCTCTGCAACCAGGCCATCATGCTCATCAGCAGCGCCGTGGAGGACTACGAGC
CGGTGTTGAGAAGTATAACTGCCAGACTGTAAGGTCGAGTTCACTTACACTCATTGGAGAG
AAGTGTCTTTGCTGACCGCATGAAGTGGATTGATGCAACACAACAAAGGCTACTACACGAGATCT
CAACGCTGGGGACACCCAGGAGAACGTGATGGAATACCTGCACGTGCTCAGCCGCCCATGGTCA
35 TCAACCACGACCACGACATCATGGACAGAGGCCATACATGGACAGCAAGCTCCTCAGCTCGCAGG
CTCAGAGCCTGACACTGCTCACCACGTGTCAGGCCATGCAGCTTCAAGCAAGAACGAAACCGGAT
CCCATTGGCATTCTCTGGGTGTTGGCTCAGATGTGGCCCTGAGAGAGGCTGATGAAGCTGGCG
CCGGTACAAGCTGGAGTGCACGGGATACGCCCTTCTGAACACCAACAAATGGCTACATCCTCTCC
40 ATCCGACCTCCGGCCCTGTACAGAGAGGGAAAGAAAATAAACCCAAACCTAACTACAACAGTG
TGGATCTCTCGAAGTGGAGTGGGAAGACCCAGGCTGAATCTCTGAGAACAGCCATGATCAATAGGG
AAACAGGTACTCTCGATGGATGTGAAGGTTCCGATGGATAAAGGGAAAGCGAGTTCTTTCTGA
CCAATGACTACTTCTTCACGGACATCAGCGACACCCCTTCAGTTGGGGTGGTGTGCTCCCGGG
GCCACGGAGAAATACATCCTCTGGGAACACGTCTGGAAGAAGGCCCTGCATGACTGCTTCACC
CAGACCTGGCCCTGGCGGTGACTGGATCTACTGCATCACAGATATTGACCCAGACCACCGGAAGC
45 TCAGCCAGCTAGAGGCCATGATCCGCTTCCCTCACCAAGGAAGGCCAGACCTGGAGTGTGACGAGG
AGCTGGTCCGGGAGGTGCTTTGACCGGGTGGTACAGCCCCATGGAAGCCTACTGGACAGCGC
TGGCCCTCAACATGTCGAGGAGTCTGAACACGTGGACATGGCCTCTGGCAGCCGGCTG
GCCTCCTGAGAAGCAGCTTGTGTCGGCTCCGAGAAGGTCTCCGACAGGAAGTCTCTGACACCTG
AGGACGAGGCCAGCGTGTTCACCCCTGGACCGCTTCCCGTGTGGTACCGCCAGGCCCTCAGAGC
50 CTGCTGGCAGCTCGTCTTCAACCTCCGCTGGCAGAAGGACCAAGAAAGTGCAGGGTGAACCCATGG
TGGTGACGGCAAGCACAGCTGTGGCGGTGACCGTGGACAGGCCATTGCTGCAGCCGG
GCGTCCAAATGAAGCTGGAATTCTCCAGCGCAAATCTGGCGGCAACGCCAGTGCAGCAG
TGGATGGGGCGTGCACACAGAGCTGCAGGAGACAGTGAATCTGGACTGCTCGTCATGACAACACG
GGTCATTCTGATCTCAAGAGGTCCCGAGAGACGGGAAGATTCTGGGGAGGTGGATGGTGTG
55 TCCTGACCCAGCTGCTCAGCATGGGGTGGTCAAGCAAGTGAATGACTATGACTATCAGGCCATGT
GCAAACCCCTCGAGTCACCACACAGTGCAGCCCAGGCCCTGGTCAAGCCAAATTCTGCCTTGA

CGCGGACCAAGGTGGCTGTCAGGAGCTGGTCTTGAGTGGGGTAGACACGGGGCTGGTGGAG
 GCTGCATGCCAGGGTGGCTTAGGAGGGTGTCTTGATCAGGAGGCTGCAAGGTCTCCAGGACAACC
 CACTTGCTACCAAGACCCGGGAAGGGAGGGCACAAATCCCTGGCATGGACGCCACCTCTTCCCCTG
 CATGCTTGCCTGGGAGGGACCTCATTGCTCAACCAGAGGCCCTCAAGCAGGGAAAGAGGGTGTCT
 5 GGAGGAGAGGGATGGGCCGGGGCTGTCAAGGATACTCCAGCTCCTGGGAACCCAAGTCGGAG
 GGCTCAGAGGGTCTCGAGATTCACTGCTGTGACAGGTTCTGCTGGAGTGGAGTGTCTGGGG
 CTCCTGGTACGACAGAGGGGCCAGGGTGAAGTGCACGGAGCTGCAGGGCATGTGCTGAAGAGCAG
 TGCAAGTGGTCCACTAACGTGAGACCATCTCCATGGGGTGGGTGACAGTGGGGATAGGTGACC
 10 CTGAAGGCATCGTTGTTACATCTCACCCCTGCGTGGCCTCTCATCACATCCCTCACTCCTGGCT
 CTGTGTGACATCATCTGGGACACCAGCCACTCCATGTGCCATCATCACACCCCCATGACATCCT
 GCCCTCATGTGCCACCATGTTCTGTGCCGTGTCACCCCTGTGCTGGGTTATGTTCCGGCCAG
 CCAAAAGTGTCTTCCATCACTCCACAAACACAAGAACAGGAGGCAACGGGATGTGGAGTGCAGGGCC
 AGTACCCCGTGTGTCGAGCCGG : CCATCCGGGAGGGCAACGGGATGTGGAGTGCAGGGCC
 15 TGCCAGAAGGTATTGTGGTGCAGCAGATTCCAAACAGTAACCTCCCTCTGGTGAACAGACCCCC
 ACCTGTGACTGCAGCATCTCCCACCAAGTGTGCAAGGAGGCGACAGAACAGTCAAATATAATGCCTCT
 GTCAAATGTGACCGGATGCCGTCCCAGAACAGCTCCGGCGACAGACTCTGTCACGCCCTTCCAT
 CCAGAGGAGAATGCCAGGACTGCCGGYGGCGCCTCGGACACCTCAGCCTGCCGCCCTACTCTG
 CTGCCTGTGTGTCCTGGGGCTACTGCCCAACTCTGCGGTGACACCACCCAGCCTGACCTGTG
 20 TTTGGCAAGGTGATCTTCCAGAGCCATCCAAAAGTCAGCACTGACATGGGATGCAGCTAACT
 GCAGTTGGGTGCCCCCAGGCCAACGCTCTCAATCTGGCTGGTGGGGCTGGCTCCGGAGA
 ATGCTGGATGGAACAGGAACCCAATCACCTGGCACCACCTTCAAGATGCTCATGGTGGCCGGTAC
 CATCTGCCCTAGGTCTCAACATGAGCATACTTCTGACCTAACCTCCCTGTCTCTCGGGAAAGC
 CAGCGTGAAGCTCAGCTGGACCAAGACAAAATAATTAGTTAGTCTCTGTACTCCAGAGTCCAGAAC
 25 CAGCCAAGAAAGGGTCAGTTGTTCTGACCCCTTCTGCGGAGGGTCTCTGGTAGAACCCAAGGA
 CTTCTGGGTACTGAGAACAGCAGCAGCAGAACATGAGGCAAATGAGAGATGAGGCTAACGGCAAGAATA
 TGCCCAACTAAAGCATAGATTCCCCAAAGTGGACTCATGGTGGGAGGGCAACTCACCTCTAGC
 TGCTGCTCGAAAGGTTTGACTGTGTTGGGGTGGGGTAAGGAAATGGTCAAGACTGAGA
 AAGGAATGAAATCCATCAGGAATATCGACAGGGCTACACGTGATGTCCCCAAACTGCTGCTATT
 30 GAAGAACCTCCAAAACTCTTACAAAGCCCTAAAGGAAAGTTGCAATGAAAGCCAATAG
 GCTGAGACATCCAATTGCTGCATGGAAATTGATGTACATTGAGGGACGGCAAAATAGCTGTAAA
 ATAGTGAAAAGAGCAGTGGTTGTGCTCTTCTGGCAATGATTACAAAAGAACATCTTGACT
 CTGTCCTGGAGTGAATCTTACGGGAACTTGTGGAACATTCCAACCTGCTAACGGGTC
 CACTGGGAGGGAGCTCTATCTGGAACTCACCCCCAGCGCACACACATCTCCCCCAGGGTCCCAA
 35 GGGCCCGCAGCTCTCCCTCCCCGACCAAACCCCAAGACACTGGATCCCAGGGAGAACAGTCTCCACA
 TGAGAGCAACATTAAGGGCAAAGCCATGGAGAAATGTTGGAGAGGGCCGCTCAAATCTTCCATT
 TAACAAACCCAGTGTGTTGGACAGCATGCAAGGGCTTTGGGGCGCTTCCCCCGCTCTCC
 ATCACCCCTCAGCTCCACACTTCAAAGTCAAGTCAAGTCTCCTACAGCAAATA
 GCCCTAACTGCTCTAGAGTAGGCCAAATGCCAACTCTGTAAACACACTTACATTATCGGTTAC
 40 AGAATGTCACTCTTACCATCATGCTTGCAACAACCCGTGAGGGCAGTATTAATGCCCTTACA
 GCAGAAGACACTGCAGCTCGAAGACAGCTTAAGTGGCAGAATAATGCTAGAACAGCTAACGGTTAC
 ATGTACCAAATAACATGTTCTAGCTCATTCTCACAAACAGCCCCCTGAAAGTGGGTACTATC
 ATTAGTCCCATGTTAGAAACTGCAGCAGAGTTGAAAATTGCTCCAAATTACCGGAAGAGTGTGTA
 TGAAGATTGAATGTGATGTATTACGTAACATGCTGAAACTGCCATATACTAAACGCTAAA
 TAAATACATGCTAACTGCCAAAAA

45

(2) INFORMATION FOR SEQ ID NO: 17

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

50

55

-14-

(D) OTHER INFORMATION: human variant $\alpha 2\delta$ -D, EDGE screen

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

5 MPATPNFLANPSSSRWIPLQPMPVAWFVQKTSALLWLLLLGTSLSAWGQAKIPLTV
KLWADTFGGDLYNTVTKYSGLLLQKKYKDVESSLKIEVDGLELVRKFSEDMENMLRR
KVEAVQNLVEAAEEADLNHEFNECSVFDYYNSVLINERDEKGNFVELGAELLESNAHFS
NLPVNTSISSVQLPTNVYNKDPDILNGVYMSEALNAVVENFQRDPTLTWQYFGSATGFF
RIYPGIKWTPDENGVITFCRNRGHWYIQAATSPKDIVLVDSVSGSMKGLRMTIAKHTITIL
10 DTLGENDFVNIIAYNDYVHYIEPCFKGILVQADRDNRREHFKLLVEELMVKGVGVVDQALR
EAFQILKQFQEAKQGSLCNQAIMLISDGAVEDYEPVFEKYNWPDCKVRVFTYLIGREVSF
ADRMKWIACNNKGYYTQISTLAQTQENVMEMYLHVLSRPMVINHDHDIWTEAYMDSKLL
SSQAQSLTLLTTVAMPVFSKKNETRSHGILLGVVGSDVALRELMKLAAPRYKLGVHGYAFL
15 NTNNGYILSHPDLRPLYREGKKLKPKPNVNSVDSLSEVEWEDQAESKRLVLTNDYFTDI
SDTPFSLGVVLSRGHGEYILLGNTSVEEGLHDLLHPDLALAGDWIYCITDIDPDHRKLSQL
EAMIRFLTRKDPDLECDDEELVREVLFDAVVTAPMEAYWTALALNMSEESEHVVDMAFLG
TRAGLLRSSLFVGSEKVSDRKFLTPEDAEVFTLDRFPLWYRQASEHPAGSFVFNLRWAE
GPESAGEPMVVTASTAVAVTVDKRTAIAAAAGVQMKEFLQRKFWAATRQCSTVDGPC
20 TQSCEDSDLDCFVIDNNGFILISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYDYQA
MCKPSSHHSAAQPLVSPISAFLTATRWLLQELVLFLEWSVWGSWYDRGAEAKSVFHH
SHKHKKQDPLQPCDTEYPVFVYQPAIREANGIVECGPCQKVVFVQQIPNSNLLLVTDPTC
DCSIFPPVLQEATEVKYNASVKCDRMRSQLRRPDSCHAFHPEENAQDCGGASDTSASP
PLLLPVCAWGLLPQLLR

25

(2) INFORMATION FOR SEQ ID NO: 18

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primer for human $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GCGAGGACAGTGATCTGG

(2) INFORMATION FOR SEQ ID NO: 19

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

-15-

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primer for human $\alpha 2\delta$ -D

5 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GGGTCCCTCGTTCTTGTGTTT

10 (2) INFORMATION FOR SEQ ID NO: 20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

15 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

20 (B) LOCATION:

(D) OTHER INFORMATION: nested primer for human $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

25 TCAGCCTCCACACTTCAAAG

(2) INFORMATION FOR SEQ ID NO: 21

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

30 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TCCGCCTGGACGAGGATCC

(2) INFORMATION FOR SEQ ID NO: 22

45

-16-

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 5 (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
10 (D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D
- (iii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
GTGTCCAAGATGGTGGTGAT
- 15 (2) INFORMATION FOR SEQ ID NO: 23
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
20 (B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
25 (B) LOCATION:
(D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D (d20)
- (iii) MOLECULE TYPE: cDNA
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
ATCTACTGCATCACAGATATTG
- (2) INFORMATION FOR SEQ ID NO: 24
- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
40 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
45 (B) LOCATION:
(D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D ($\alpha 2\delta$ D2)
- (iii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

GGTGAGGAAGCGGATCATG

(2) INFORMATION FOR SEQ ID NO: 25

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
10 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: 5' primer mouse genomic of $\alpha 2\delta$ -B
15 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

TTCAACGAGAAGGCACAGCCT

20 (2) INFORMATION FOR SEQ ID NO: 26

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: 3' primer mouse genomic of $\alpha 2\delta$ -B
30 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

35 GTTGGCACAGGCCATCCACTG

(2) INFORMATION FOR SEQ ID NO: 27

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
45 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:

-18-

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
AGGCTGTGCCTCTCGTTGAA

(2) INFORMATION FOR SEQ ID NO: 28

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence
(B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
20 based on human

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GAGCCCCCAAGAAGATCG

25

(2) INFORMATION FOR SEQ ID NO: 29

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence
(B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
35 based on human

(iii) MOLECULE TYPE: cDNA

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
CGATCTTCTTGGGGGCTC

(2) INFORMATION FOR SEQ ID NO: 30

45

-19-

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

10 (D) OTHER INFORMATION: primer for sequencing mouse genomic,

based on human

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

15 CACGATGATGACCATGTC

(2) INFORMATION FOR SEQ ID NO: 31

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25 (ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,

based on mouse

30 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GGCAAGACCCCTACACTGTTG

35 (2) INFORMATION FOR SEQ ID NO: 32

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

45 (B) LOCATION:

-20-

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on mouse

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
CCTGGTAATAGCGAGTGAC

(2) INFORMATION FOR SEQ ID NO: 33

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence
(B) LOCATION:

(D) OTHER INFORMATION: 5' genomic sequence from 10kb

20 fragment for mouse $\alpha 2\delta$ -B

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

25 AAGCTTCTCTCATCACCAAGGAGGAAGACATCATGTACTACGATGCCAAGGGCTGACG
CCGAGCTGGTAAGTGTCCCCACCTTGCCTAGAGGATGGGGAGCAGCCAGAGCCAC
ACCTTGTCTCTGGGCCACAACAGTCTAGCTGTAAAGTGGGTGTTAGGGATCCATG
30 CTCACCTTCTGAACCTAACCAATTCTGTGTCGTGCTGGTCAGCCTCTCCTGTCCACA
GCTCCCTAGAGATCCTGACCCCTCCAGGGCGTGTCTCATCACCATTATAAGGCTAACG
TCCCCCTGCACCATGTGGAGCAAGCAGGGTGGTAGAGTGTGGATATCAGGGTGGTTC
CATCCCAGTATGAGGGGCTCTGGGCTCCATGGGAGTAGAGAGGGAGAAAGAAATGG
ACTCCAGGACCTCCTGGGTAGGTACATGGGAGTGAGACATGGTACATCTAACGCC
TGCCCAGGACAGTAGAGGGCTCCTTGTGATTGGGAACTTGCATCAAGCTAT
GTAGAAGAACCCATGG

35 (2) INFORMATION FOR SEQ ID NO: 34

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
40 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

45 (B) LOCATION:

(D) OTHER INFORMATION: 3' genomic sequence from 10kb

fragment for mouse $\alpha 2\delta$ -B

-21-

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

5 CAGGTGGCTGTGGCTGGGCCCTCTGAACACTCACAGTGGAGACAGGGCTGGCC
 ACAGNAGACCCCATCCTCTCCCTCAGGGCTGGGTTGGTGGTAACAGGAACCT
 CTCCCTGTTCAACCTGACACAGGATGGCCCTGGGAAAAGAAGGTGAGTTGCCAG
 TGGGTTATCTGGGGAGGAGTGGCATGCCCTGGAGCAGGTCTGGGGATGGAGGGAGGT
 TAGGGCATGCTACAGATTGGCAAAGCAGCTCCGTATCAGCAGCTTAGCCCTTAGG
 CCTGGGCCAGGGGTTCTACTATGGAGTTGACTCATTATAGCATACCTCCCATTCTT
 10 TGTGTCCAGAACCGAGTTAACCTGGGTGTCATGGCATCGATGTGGCTTGAATGACA
 TCAAAGGCTGACTCCAACTACACAGTAAGTGTCCACCTGCCCTTGCCCTGGTT
 GCTGTCCATAGTGACACAAGCCAGACTCAGCAGGGAGACATGGGACTGAAAGACC
 GTCACAGAAAGACTTCCAAAGGGTTGTTGAAGCTGTGGACAGCAAGC

15 (2) INFORMATION FOR SEQ ID NO: 35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

25 (B) LOCATION:

(D) OTHER INFORMATION: 1.8 kb mouse genomic sequence for

mouse $\alpha 2\delta$ -B

(iii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GCTTTCTGTGGCTGGGGCCTTGGAGTGCATGCTGAGTGGGTGAGCTCCCTGGGGC
 CGGCTGCAGGCTCCAGGCAAGCATGCTGGATGGGGCCAGCTCACAGCTCCCTGCC
 ACCCAGGCGGCCCTCTCCACAGGCCACAAACCATCAGCCCTGCTGCTCACCGAG
 GCTGGATGAGGGTAGGCTGAGATAATTCTTGATGATTAGAGGGAGAGCAA
 35 GAAAATCTCCCTGGAAAGAGCTGGTGTGGCCCACATGAGATCCTGGAAATCAAAGA
 AAGCCTGGGCAGGCAGAAAGCAGGGGAGGCCATGGAGATGGTTAGCAGGGGGCG
 ACCCTGAACCTCCCAACCCCAGCCTCTGCCCTGCCCCTCAGCTACCGTCATCCTCAAT
 GAGCTTAACCTGGACAGAGGCCCTGGAGAACGTCTTCATTGAGAACCGTAGGCAAGAC
 40 CCTACACTGTTGTGGCAAGTCTTGGCAGTGCCACGGGAGTCACTCGTATTACCCAG
 GTAGGCACCACTGTCCTCCCTGGCCCATTCCAGCACCGCTTGTCTCCATCTCAAGCCTA
 CCCATTCTGAGGTCCATGGGTACAATGAACCAAGGTCAATCCCCATCACTCCCGCTG
 CTCCAGTCAGACCCCTCTGCCGGGGCCCTTCACCCCTCTTCCACAGCCACAC
 CATGGCGAGCCCCAAGAAGATTGACCTGTACGATGTAGAACAGACGACCTGGTAG
 45 TGAGCAAGGGGGTGGAGGCAGAACACCCCTCAACTCCCCATCTCGTGGCCCGCTC
 CCCTCCCTCCCAATATCCAGACCTCCGAGCAGGGCGCAGCCAGCTCTATCCAATTTC
 ATTTCACACATCGCTGCCACTGGAAATGGATCCCATTGCCAGGCAAGCCGCCAGC
 TGCCCTGCCCTACGCCGCTGTCCTCAACTACCCAGCCCCCAGACCCACTCAGAACCT
 GAGAGCAGACCAAGGGAAAGGTGCTTCAGGGTAGCTAGAGCCTCCGTAGGTAGCC
 50 GGCCCCACCTACTCATTGATCCCTGGACACCCCGACCCCTGCTCTGCCCTCTCACA
 CTAACCCATGATCTCCCTCCCTCATTACACAGCCAGACTCTCTGGAGTCCTCT
 AGGACAGAGGACACAAGCCACTAAAGCCTCTGTCCCCGTGGATCACCTGCCCTTCC
 CCCTCACCTCTTGTAAATGAGGGAACCAAGATCACTCACGTACAAGAAAAAAA
 AAACTGTCTTTGTATTGAGCATGGTCTCCCCAGTGCCAGACCTATTCCAACCCCTG

TAGTGCCTGGTCAGTAGAACACAGGAATCAAGTGGGTGGAAGAAGGAAGACCCCGC
AGGTCCCAGGGGCCCTTAACGTGAGTCTTCACGGCAGGTATATAACAGGGGG
CCTCATCACCCAAAGGACATGGTCATCATTGTGGATGTGAGTGAGCCTTAGGCTG
5 GTGGGATGGGCTAGGACTGGACTCTGCCTCTGGGCACCTTATGAGGGAAGGGCGGG
AAAACCCTGAGAGGCCACATGCATGCGCCCTCCGTGCCTGGTTCCAGGAGTGGG
AGCGTGAGCGGCCTGACTCTGAAGCTGATGAAGACGTCCGTCTGTGAGATGCTAGAC
ACGCTCTCTGATGACTATGTGAACGTGGCCTCAGTGAGTGGCAAGGTGGCAGGC
AGGCTGGGTACCACTCACCCCCATCCAACCTGCTCCATGACAACCATCAGCCCTGTA
10 CAACAGCTGCACACTGTGTGCCAGCCTGAAGCCACTCACCAACCCCCACTGTCCCCA
CAG

(2) INFORMATION FOR SEQ ID NO: 36

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primers to amplify rat sequences for

α2δ-C, PCR 1

25 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GACAGGACCAACAAGGAGCAC

30 (2) INFORMATION FOR SEQ ID NO: 37

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

40 (B) LOCATION:

(D) OTHER INFORMATION: 3' primers to amplify rat sequences for

α2δ-C, PCR 1

(iii) MOLECULE TYPE: cDNA

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GCCAACACACCCAGAAGAAT

-23-

(2) INFORMATION FOR SEQ ID NO: 38

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primers to amplify rat sequences for

α2δ-C, PCR 5

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

AACGCACCATCAAGGAGACCA

(2) INFORMATION FOR SEQ ID NO: 39

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primers to amplify rat sequences for

α2δ-C, PCR 5

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

AGGGGCAGCAGCAGCAAG

(2) INFORMATION FOR SEQ ID NO: 40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: PCR1 product, rat α 2 δ -C

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

TTCAGGGAGCATTTGGACAAACTTTGCCAAAGGGATTGGAATGCTCGATATTGCCCTGAACGAG
GCCTCAATGTACTGAGCGATTCAACCACACGGACAAGGAAGCATTGAGCCAGGCCATTATG
CTCATAACCGATGGGGCARTGGACACCTACGAYACCATCTTGCAAAGTACAATTGGCCAGAGCGA
AAGGTTGCAATCTTCACTTACCTCATTGGACAGAGGGCTGCTTTGCAGACAATCTCAAGTGGATR
10 GCTTGTGCTAACAAAGGATTTTCACCCAGATCTCCACCTGGCTGATGTGAGGAAAATGTCATG
GAATACCTCCATGTACTCAGTCGACCCAAAGTCATCGACCAGGAACATGATGTGGTGTGGACCGAA
GCGTACATCGACAGCAGCTCCCTCAGGCTCAAAAGCTTGTGATGATCAGGGCCTCGTCTTGATG
ACACAGTGGCCATGCCGTGTTAGTAAGCAGAAACTAGGTCAAAGGGC

15

(2) INFORMATION FOR SEQ ID NO: 41

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

25 (A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: PCR5 product, rat α 2 δ -C

(iii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

CAGGGAACATTGCTTGTGAAGAYTGCTCCAAGTCCTTGTCATCCAGCAAATCCAAGTAGCAATC
TGGTCATGGGGTGGTGGACAGTAGCTGTCTGTGAGTCTGTGGCTCCTATCACCATGGCACCCA
TTGAAATCAGGTATAATGAATCCCTTAAGTGTGAACGGTTAAAGGCTCAGAAGATCAGACGACGTC
CGGAATCCTGCCACGGCTTCCATCCTGAGGAGAATGCGAGAGAGTGTGGGGTGCATCAAGTCTCC
35 AGGCCAGGT

(2) INFORMATION FOR SEQ ID NO: 42

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

45

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(D) OTHER INFORMATION: Human α 2 δ -D variant

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

5 MPATPNFLANPSSSRWIPLQMPMPVAWFVQKTSALLWLLLGTSLSPA WGQAKIPLTV
 KLWADTFGGDLYNTVTKYSGSLLLQKKYKDVESSLKIEVDGLELVRKFSED MENMLRR
 KVEAVQNLVEAAEEADLNHEFNESELVDYYNSVLINERDEKGNFVELGAEFLLESNAHFS
 NLPVNTSISSVQLPTNVYNKDPDILNGVYMSEALNAVFENFQRDPLTWQYFGSATGFF
 RIYPGIKWTPDENGVITFDCRNRGWIYQAATSPKDIVLVDSGSMKGLRMTIAKHTITI
 LDTLGENDFXNIIAYNDYVHYIEPCFKGILVQADRDNRHFKLLVEELMVKGVGVV DQAL
 REAFQILKQFQEAKQGSLCNQAIMLISDGAVEDYEPVFEKYNWPDCKVRVFTYLIGREVSF
 10 ADRMKWIACNNKGYYTQISTLADTQENVMEMYLHVLSPRMVINHDHDIIWTEAYMDSKLL
 SSQAQSLTLLTTVAMPVFSKKNETRSHGILLGVVGSVALRELMKLAPRYKLGVHGYAFL
 NTNNGYILSHPDLRPLYREGKKLKPKPNYSVDLSEVEWEDQAESLRTAMINRETGTL SM
 DVKVPMDKGKRVLFNLDYFFTSDTPTFSLGVVLSRGHGEYILLGNTSVEEGLHDLLHPD
 15 LALAGDWIYCITIDPDHRKLSQLEAMIRFLTRKDPDLECDEELVREVLFDAVVTAPMEA
 YWTALALNMSEESEHVVDMAFLGTRAGLRSSLFVGSEKVSDRKFLTPEDEASVFTLDRF
 PLWYRQASEHPAGSFVFNLRWAEGPESAGEPMVVTASTAVAVTVDKRTAIAAAAGVQM
 KLEFLQRKFWAATRQCSTVDGPCTQSCEDSLDCFVIDNNNGFILISKRSRETGRFLGEV DG
 AVLTQLLSMGVFSQVTMYDYQAMCKPSSHHSAAQPLVSPISAFLTATRWLLQELVLVS
 GGRHGAGGGCMRGWLRRVSLIRRLQGLQDNPLATKTPKEGTIPGHGRHLFPACLPLGG
 20 TSLLNQSPQAGKRVSWRRGDGPAGVRDTPAPWEPKSGGLRGLRDSVLCLTGSCWSGVSG
 APGTTEGPRVSARSCRAMC

(2) INFORMATION FOR SEQ ID NO: 43:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 30 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION:>1907 α 2 δ -C, potent. soluble form
 35 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

40 TACTATAGGGCGGCCGCGAATTCCGGCACGAGGGCGCGGAGCGGGAGCAGGCAGCCCCCGCGCGCTC
 GCCCACCGCCCGCTCCCGCGAGCTCCCCGGCGCTCTCGTCGCCGCCGCAGCGGGCGCTCGGA
 GGGAGCCCAGCATGGCCGGGGCTCGCCGCCGCGTCCCGGGGGGCCTCGCGCTTCTCG
 CTGCCCGCCTCTCTACGCCGCCTGGGGACGTGGTGCCTGGAGCAGCAGATAACCGCTCTCCG
 TGGTGAAGCTCTGGGCTCGGCTTTGGTGGGAGATAAAATCATTGCTGCTAAGTACTCCGGTT
 CCCAGCTCTGCAAAGAAAATACAAAGAGTATGAGAAAGACGTGCCATAGAAGAAAATTGATGGCC
 45 TCCAACTGGTAAAGAAAGCTGGCAAAGAACATGGAAGAGATGTTACAAGAAGTCTGAGGCCGTCA
 GGGCTCTGGGAGGCTGCAGAAGAAGCACACCTGAAACATGAATTGATGAGCAGACTTACAGTATG
 AATACTTCAATGCTGCTGATAAAATGAAAGGGACAAGACGGGAATTGGAGCTGGAAAGG
 AATTGATCTAGCCCCAAATGACCATTTAATAATTGCTGTAACATCAGTCTAAGTGACGTCC
 50 AAGTACCAACGAACATGTACAACAAAGACCCCTGCAATTGTCATGGGGTTATTGGTCTGAATCTC
 TAAACAAAGTTTGTAGATAACTTGACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTG
 CAAAGGGCTTTTAGGCAGTATCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATTGCT
 TCGACTGCAGGAACCGAAAATGGTACATCCAGGCAGCAACTTCCTCCGAAAGACGTGGTCATT TAG
 TTGACGTCAGTGGCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATT
 TGGATACACTGGGGATGATGACTTCTAACATAATTGCTTATAATGAGGAGCTTCACTATGTGG
 AACCTTGCTGAATGGAACCTTGGTGCAAGCCGACAGGACAACAAAGAGCACTTCAGGGAGCATC

TGGACAAACTTTCGCCAAAGGAATTGGAATGTTGGATATAGYCTGAATGAGGCCTCAACATTC
 TGAGTGATTCAACCACACGGGACAAGGAAGTATCTGCAGTCAGGCCATCATGCTCATAACTGATG
 GGGCGGTGGACACCTATGATACAACTTTGCAAATACAATTGCCAGATCGAAAGGTTCGCATCT
 5 TCACATACCTCATTGGACGAGAGGCTGCCTTGCAAGACAATCTAAAGTGGATGGCCTGTGCCAACA
 AAGGATTTTACCCAGATCTCACCTTGGCTGATGTGCAGGAGAATGTATGGAATACCTTCACG
 TGCTTAGCCGCCAAAGTCATCGACCAGGAGCATGATGTGGTGTGGACCGAAGCTTACATTGACA
 GCACTCTGACTGATGATCAGGGCCCGTCTGATGACCCTGTAGCCATGCCGTGTTAGTAAGC
 10 AGAACGAAACCAGATCGAAGGGCATTCTCTGGAGTGGTGGCACAGATGTCCCAGTGAAGAAC
 TTCTGAAGACCATCCCCAAATACAAGTTAGGGATTACGGTTATGCCCTTGCATCACAAATAATG
 GATATATCCTGACGCATCCGAACTCAGGCTGCTGTACGAAGAAGGAAAAAGCGAAGGAAACCTA
 ACTATAGTAGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTA
 TGGTGAATCGAAAGACGGGGAAAGTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGTACATT
 15 TTTCTCAAACATTTCGCTTAATTAAAACAAACCACTGTGAAAAATTAGCTTGAAGCTAT
 ATCTGGAATAAATATCTTCGCTGAAGG

15

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: $\alpha 2\delta$ -C, (2686-2745, 2892-3001)

(iii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

TACTATAGGGCGGCCCGAATTGGCACGAGGCGGCCGGAGCGGAGCAGGCAGCCCCGCGCGCTC
 GCCCACCGCCCGCTCCGCGAGCTCCCCGCGCGCTCTCGTCGCCGCCAGCGGGCGCGTCGGA
 35 GGGAGCCCAGCATGGCCGGGGCTCGCCGCGCCGCGTCCGGGGCCTCGCGCTTCTCG
 CTGCCGCGCTTCTCTACGCCGCGCTGGGGACGTGGTGCCTGGAGCAGCAGATAACCGCTCTCCG
 TGGTGAAGCTCTGGGCTCGGCTTTGGGGAGATAAAATCATTGCTAAGTACTCCGGTT
 CCCAGCTCTGCAAAGAAATACAAGAGTATGAGAAAGACGTGCCATAGAAGAAATTGATGCC
 TCCAACCTGGTAAAGAAGCTGGCAAAGAACATGGAAGAGATGTTCACAGAAGTCTGAGGCCGTCA
 40 GCGCTCTGGTGGAGGCTGCAGAAGAACGACACCTGAAACATGAAATTGATGAGACTACAGTATG
 AATACTTCAATGCTGTGCTGATAAAATGAAAGGGACAAAGACGGAAATTGGAGCTGGAAAGG
 AATTCACTTAGCCCCAAATGACCATTAAATAATTGCTGTGAACATCAGTCAAGTGAACGTC
 AAGTACCAACGAACATGTACAACAAAGACCTGCAATTGCAATGGGTTATTGGTCTGAATCTC
 45 TAAACAAAGTTTGTAGATAACTTGTACCGTGACCCATCTCATATGGCAGTACTTGGAAAGTG
 CAAAGGGCTTTTAGGCAGTATCCGGGATTAAATGGGACCCAGATGAGAATGGAGTCATTGCC
 TCGACTGCAGGAACCGAAAATGGTACATCCAGGCAGCAACTCTCCGAAAGACGTGGTCATTAG
 TTGACGTCACTGGCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATT
 TGGATACACTGGGGATGATGACTTCTTCACATAATTGCTTATAATGAGGAGCTTCACTATGTGG
 AACCTGCCCTGAATGGAACCTGGTGCAAGCCGACAGGACAAACAAAGAGCACTTCAGGGAGCATC
 50 TGGACAAACTTTGCCAAAGGAATTGGAATGTTGGATATAGCTCTGAATGAGGCCCTCAACATTC
 TGAGTGATTCAACCACACGGGACAAGGAAGTATCTGCAGTCAGGCCATCATGCTCATAACTGATG
 GGGCGGTGGACACCTATGATACAATCTTGCAAATACAATTGCCAGATCGAAAGGTTCGCATCT
 TCACATACCTCATTGGACGAGAGGCTGCCTTGCAAGACAATCTAAAGTGGATGGCCTGTGCCAAC
 AAGGATTTTACCCAGATCTCACCTTGGCTGATGTGCAGGAGAATGTATGGAATACCTTCACG
 TGCTTAGCCGCCAAAGTCATCGACCAGGAGCATGATGTGGTGTGGACCGAAGCTACATTGACA

GCACTCTGACTGATGATCAGGGCCCCGTCTGATGACCACTGTAGCCATGCCGTGTTAGTAAGC
 AGAACGAAACCAGATCGAAGGGCATTCTCTGGAGTGGTGGCACAGATGTCCCAGTGAAGAAC
 TTCTGAAGACCATCCCCAAATACAAGTTAGGGATTCA CGGTTATGCCTTGCAATCACAAATAATG
 GRTATATCCTGACGCATCCGGAACTCAGGCTGCTGACGAAGAAGGAAAAAGCGAAGGAAACCTA
 5 ACTATAGTAGCGTTGACCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTA
 TGGTGAATCGAAAGACGGGGAAAGTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGAAACGGG
 TTTGGTGTGACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTCAGTTAGGTGTGG
 CGCTTCCAGAGGTATGGGAAATTTCTCCGAGGGAATGTAACCATCGAAGAAGGCCCTGCATG
 10 ACTTAGAACATCCCAGTGTCTCAGTTAGAAGCGATTAAGCTACCTAAAAGGCAAAGAACCTCTGCTCC
 AGCACCGCCATCTGTCAGTTAGAAGCGATTAAGCTACCTAAAAGGCAAAGAACCTCTGCTCC
 AGTGTGATAAAGAATTGATCCAAGAACAGTCTTTGACGCGGTGGTGAGTGCCCCCATTGAAGCGT
 ATTGGACCAGCCTGGCCCTCAACAAATCTGAAAATTCTGACAAAGGGCGTGGAGGTTGCCCTCTCG
 GCACTCGCACGGGCCTCTCAGAATCAACCTGTTGCTGGGCTGAGCAGCTCACCAATCAGGACT
 TCCTGAAAGCTGGCGACAAGGAGAACATTAAACGACACCATTCCCTCTGGTACCGAAGAG
 15 CCGCTGAGCAGATTCCAGGGAGCTCGTCACTCGATCCATTCAAGCAGACTGGACAGTCATAAAA
 GCAATGTGGTGACAGCAAGTACATCCATCAGCTCCATGGATGACGAAATCTCCTGTGAGTGCAG
 CTGTAGGCATTCAAGATGAAACTTGAATTTCAAAGGAAGTTCTGGACTGCCAGCAGACAGTGTG
 CTTCCCTGGATGGCAAATGCTCCATCAGCTGTGATGAGACTGGAGACTTTTGGTGAGATCG
 AGGGAGCTGTGATGAAACAAATTGCTAACATGGCTCTTTAAAAGAATTACCTTATGACTACC
 20 AAGCCATGTGAGAGCAACAAAGGAAGCAGCGATGGCGCCATGGCCTCTGGATCCCAGAAATT
 GAAACAGACCCCTGGAGCCTTGTGATACTGAATATCCAGCATTCTGAGCGCACCATCAAGGA
 GACTACAGGAAATATTGCTGTGAAAGACTGCTCCAAGTCTTGTCACTCCAGCAAATCCAAGCAG
 CAACCTGTTCATGGTGGTGGACAGCAACTGCCTCTGTGAATCTGTGGCCCCCATCACCATGGC
 ACCATTGAAATCAGGTATAATGAATCCCTAACGCTCTGGATGAACTGCTAAAGGCCCAGAAGATCAGAAG
 25 GCGCCCAGAATCTGTCATGGCTCCATCTGAGGAGAATGCAAGGGAGTGTGGGGGTGCGCCGAG
 TCTCCAAGCCCAGACAGTCCCTCTGCTCCCTCTGCTTTGATGCTCTCAAGGTGACACTG
 ACTGAGATGTTCTTACTGACTGAGATGTTCTTGGCATGCTAAATCATGGATAAAACTGTGAAC
 CAAAATATGGTGCAACATACGAGACATGAATATAGTCAACCATCAGCATCTCATCATGATTTAA
 ACTGTGCGTGATATAAAACTCTTAAAGATATGTTGACAAAAGTTATCTATCATCTTACTTGC
 30 CAGTCATGCAAATGTGAGTTGCCACATGATAATCACCTCATCAGAAATGGGACCGCAAGTGGT
 AGGCAGTGTCCCTCTGCTTGAAACCTATTGAAACCAATTAAAAGTGTGACTTTAAATAAAG
 TATATTAAAATCATAAAAAAAAAAAAAAA

35 (2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: adapter primer

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

50 CCATCCTAACACGACTCACTATAGGGC

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

10 (D) OTHER INFORMATION: adapter primer

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

ACTCACTATAAGGCTCGAGCGGC

15

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

25 (A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: probe for Northern blot

(iii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

CTGTGAGTGAGCTGTAGGCATTAGATGAAACTTGAATTTCCAAAGGAAGTTCTGGACTGCCA
GCAGACAGTGTGCTTCCTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACTGGAGACTTT
TTGGTGAGATCGAGGGAGCTGTGATGAACAAATTGCTAACAAATGGCTCCTTAAAAGAATTACCC
TTTATGACTACCAAGCCATGTGAGGCCAACAGGAAAGCAGCGATGGGCCCATGGCCTCTGG
20 ATCCCAGAAATTGAAACAGACCCCTGGAGCCTTGTGATACTGAATATCCAGCATTGCTCTGAGCG
CACCATCAAGGAGACTACAGGGAAATTGCTTGTGAAAGACTGCTCCAAGTCTTGTGATCCAGCA
AATCCCAAGCAGCAACTGTTATGGTGGTGGACAGCAACTGCCTCTGTGAATCTGTGGCCCC
35 CATCACCATGGCACCCATTGAAATCAGGTATAATGAATCCCTTAAGTGTGAACGTCTAAAGGCCA
GAAGATCAGAAGGCAGCCAGAACATCTGTATGGCTTCCATCCTGAGGAGAATGCAAGGGAGTGTGG
40 GGGTGCGCCAGTCTCCAAGCCCAGACAGTCCTCCTCTGCTCCCTCTGCTTTGATGCTCTTC
AAGGTGACACTGACTGAGATGTTCTCTTACTGACTGAGATGTTCTCTGGCATGCTAAATCATGGA
TAAACTGTGAACCAAAATATGGTCAACATACGAGACATGAATATAGTCCAACCATCAGCATCTCA
TCATGATTTAAACTGTGCGTGAATAAACTCTAAAGATATGTTGACAAAAGTTATCTATCATC
50 TTTTACTTGGCCAGTCATGCAAATGTGAGTTGCCACATGATAATCACCTTCATCAGAAATGGG
45 ACCGCAAGTGGTAGGCAGTGTCCCTCTGCTTGAACCTATTGAAACCAATTAAAAGTGTACT
TTTAAATAAGTATATTAAAATCATAAAAAAAAAAAAAAA

(2) INFORMATION FOR SEQ ID NO: 48:

50

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
5 (A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: Edge 5' primer
(iii) MOLECULE TYPE: cDNA

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:
CTAGAGGCCATGATCCGCTTCCTCAC

(2) INFORMATION FOR SEQ ID NO: 49:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
20 (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: Edge 3' primer
(iii) MOLECULE TYPE: cDNA
25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:
GCCCACGAAACAAGCTGCTTC

Fine Mapping of Alpha2/delta to mouse chromosome 9


FIGURE 91
1/4

FIGURE #2


Human α 2S2 Tissue Distribution

Figure 3. [³H] Gabapentin binding activity by human $\alpha 2\delta 2$ in transiently transfected Cos 7 cells





FIGURE 84

1 2 3 4 5 6 7



Lane 1-Brain RNA

Lane 2-Kidney RNA

Lane 3-Testis RNA

Lane 4-Lung RNA

Lane 5-Heart RNA

Lane 6-Placenta RNA

Lane 7-Liver RNA

WO 00/20450

-1-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT:
 (A) NAME: Margaret Ann Johns
 (B) STREET:
 (C) CITY:
 (D) STATE:
 10 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 15 APPLICANT:
 (A) NAME: Brian Jay Moldover
 (B) STREET:
 (C) CITY:
 (D) STATE:
 20 (E) COUNTRY:
 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 25 APPLICANT:
 (A) NAME: James David Offord
 (B) STREET:
 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 30 (F) POSTAL CODE (ZIP):
 (G) TELEPHONE:
 (H) TELEFAX:
- 35 (ii) TITLE OF INVENTION: Alpha-2/Delta Gene
- 35 (iii) NUMBER OF SEQUENCES: 49
- 40 (iv) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- 45 (2) INFORMATION FOR SEQ ID NO: 1:
- 45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 50 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 55 (D) OTHER INFORMATION: α2δ-β
 (iii) MOLECULE TYPE: cDNA

-2-

-3-

CGCCTTGGGATGGGAAGTCUCAAAGCGGGACCCGCAAGGTGTTGGCACCCARATCACATCTCAC
 TCGAACTGTTCAAGTETCCCCAGACCCCTTCTTGCCCTGCTGGGCCTCCCCCAGTGGATGGGACAG
 GGAGGCCACACGGACTGGTGCCTAAACCGGCCCTCTGCCTGCCCTCCCTCCCTGCTGGTTCTGT
 5 TGGGGGGACCCCTGCCTCAGCTAACCCCCCTCTCTCCCCAACCTAACCCCCAACCTTGTTCTGT
 GAGATAGTGGAGGAAGGJGAGATGGCTAGTTGAAGCTGTGCTCCCAGCTTAATCTAGCAG
 GAGAGAGGCTCTGGGCCAGCCCCATGGGCTCCCTGGGCCCTAACAGCCACATCCCCAAG
 CCCAGGTGCAAGGATAGTCAGTGTACAGTGTACAGTACACCTAACCCUATATAACACTGGARACA
 TTGAGGATGGAAACTGGACTCACATTGACATAACCCCCACTGGGACACACACACACACTA
 TGGGGTGGGTGGGTGTAAGGGGCTAACAAAGCTTACACAGGGCAGGGGTGGTGGGGGTTGG
 10 CACCTGCACACTCCATCTCTGCTAACACACTGCCTCTAACAGCTGAGCTGCAAGCCTGGTCTC
 CCATTTCTAAGCTGCAATGTCRAACAGTCAGTGTGGCCCTACCCAGGAGGGGTCACACAAACCC
 CACCCCTAGGCCACCAGTGTCTCCAGTGCCTCCCCCTACCCCTCCAGGYGCTCATTCATAACCTTC
 TCACTAGTGTCAAGGCCCCAGTGGGAACACATUCCACTCCCTCACCTTCTGGCAGAGGAACCCCC
 15 ACCAGACATCAGCCCTTGCCCTAGCAAGGGGTGACTTTGTCTCTCTGGCTGGGCAATCCCTCCCC
 AACATGGCCCTAACACACTCAGGCCCTGTGCDCACTCCCTACTCTCTTCCACCCCTACACACAC
 TCCCTGCTTGCAGGAGGCCAAACTGTCCCTTCCCTGCTAACACACACACACACACACAG
 GTGGGGACTGGGACAGCTCTTCACACATTCAATGCTCATTTCTCCCCAAAGGCAATCCAGCCT
 GGGGGCAACTGGGAACTGAGGGCAACGGGATATAGTGTGGACTGGGACTGGGAGGGAGGG
 20 GCAGGGGTGATGCAATTAAATGCTTCGTAAATGTGATGTTGCTTGTGGCTTCTCAGTGT
 GTGTGTGTGGFCGATGCCACTGCTEGTGDCAGGGTGGGTGCTAACCCGGTTGGATGCC
 AGCTGTGJUCTTCGGGGCGTGCJCTAACCTACTGACTGAGCTGCTAACATGGAAATATAAAC
 ATATACAGAAAAATATATATTTTAACTTAAACACAGAAAAACAGACAAAACATCCCCATGAG
 JAGCTGTCACCCCCAGCTGGCTCTANTCTCTAACCCACCCGACCTGGCTCCCCCTCAC
 TTGGGCTGGGGGACTGGGGGCAATTCTCTCTGGCTTCTTGTGCTATTTGTACA
 GACAAGTTGGAAAAACACAGCGACAAAAAGTCAGAAACTTTCTAAATATCGTGTGTGATT
 25 CCTGTAAATATTTCAATGGTTATTACAGAAGATCAGTTATTAAATGTTCATATTTC
 CTTC

(2) INFORMATION FOR SEQ ID NO: 2:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 40 (D) OTHER INFORMATION: α 2 δ -B
 (iv) MOLECULE TYPE: protein
 (v) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
 45 MAVEARTCGASRPGPARTARPWPGCGPHPCPCTRKPTSCPPRLWLLLPJJ.PLLAAGGASAYSFPQ
 QHTMOMHARRLEQEVDGVMRI FGGVQQLREIYKDNRLNLFEVQENEPQKLVEKVAGDIESLLDRKVVQ
 ALKRLADAAENPQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSKASTLRLIFI KDPYNFK
 NKVNYSYAAVQIPTDIYKCSTVILNEINWTEALENVFWENRRQDPTLWQVTGSATGVTRYYPATP
 WRAPKKIDLYDVRRRPWYIQGASSPKIMVIIIVSGSVSGLTLLKLMKTSVCEMLDT18DDDYVNVA
 50 SFNEKXAPVSCPTHLVQANVRNNKKVFKERAVQGMVAKGTTGYKAGFELYAPDQIQLQNSNITRANCNKMI
 MFTDGGEDRVQDVFEKYNWNPNTIVRVEPTFSVGQHNYIVTPLQWMACANKGYYFEIPSIGAIRINT
 QEYLDVDLGRPMVLAGKEAKQVQRTMVYFDALGLGLVVTGTIPVFNLTDQDGPEEKKNQLILGVMGID
 VAINDIKRILTPNYTLGANGYVFAIDLNGVLLHFNLPQQTTFREPVTLDFLDAELEDENKEFIRR
 55 SMIDGNKGHKQIRTLVKSLDERYIDEVTRNYTWVPIRSTNYSLCLVLPY STFYLOQNLSDQILQV
 KYFELLPSSESEGTVFIAPREYCKDLNASDNTEFLKNFIEIMTKVTPDSKQCNNFLLNILID
 TGITOQOLVERVWRDQDLNTYSLLAFAATPGGT,TRVTFENKAEDWTENPEPFNASFYRRSLDNHGY
 VFKPSPHQDALLRPELENDTVGILVSTAVELSLGRRTLRPAVVGVKLULAEWAEKFRVLA8NRTHQ

-4-

DQPQKCGPNSHCEMDCEVNNEDELLCVLIDDGGELVI.SNQNHQIDQVGRFFSEVDANIMLALYNNSF
 YTRKESYDYORACAPQPPGNLEAAPRGVFVPTVADFTNLAWWTSAAWSLFQQLLYGLIYHSEWFQA
 DPAEAEGSPETRESSCVMQTYQYYFCKVNASYNATIDCGNC5RLPHAOQLTNTNLLFVARKPLCS
 QCEAGRLLQKETHCPADGPEQCELVQRPRYERGPH1CFDINATEDTGDCGRGASEPPS1GVLDV3LQ
 5 LLLLLG1.PPRPQPQVILVHAGRRL

(2) INFORMATION FOR SEQ ID NO: 3:

10 (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(i.x) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: α2δ-C

20 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TACTATAGGGCGGCCGCAGATTTCGGCACAGAGGGCGCGGGAGCGAACCCAGCCCGCGCGCTCG
 25 CCCACCCGCCCGCTCGCGCAGCTCCCCGCGGGCGCTCGCGCTCGCGCTCGCGCTCGCGCTCGCG
 GGGACCCCGAGCATGGCCCGGGCGGGCTCGCGCTCGCGCTCGCGCTCGCGCTCGCGCTCGCG
 CTGGCGCGCTCTCTAACGGCGGGCTGGGGGACGCTGGGTGCGCTCGGAGCAGCAGATACCGCTCTCG
 TGGTGAAGC1UTGGGCTCGGC1TTTCGCTGGGGAGATAAAATCCAAITGCTGCTAAGTAATCCGTT
 CCCAGCTCTGCAAAAGAAATAACAAGAGATATGAGAAAGACCTCCCATAGAAGAAATTCATGGC
 TCCAATCTGTAAGAAACCTGGCAAGAACATGGCAAGAGATGCTGCTAAGTGGCTGGGAAAG
 30 GGCGCTGTTGGAGGGCTGCAAGAAACCCACCTGAAACATGGCAAGAGATGCTGCTAAGTGGCTGGGAAAG
 ATTACTCAATGCTGCTGATAAAATGAAAGGGACAAAGACGGGAATTTTTGAGCTGGGAAAG
 ATTATCATCTTAGCCCCAAATGACCAATTAAATTTGCTCTGAAACATCAGTCTAAGTGACCTCC
 AAGTACCAACACACATGTAACACAAAGACCCCTGCAATTGTCATATEGGGTTAA1TCGCTUTGAAATCTC
 35 TAACAAAGTT1TTGAGATAAC1TCACCCGTGACCCATCTCTCATATCCCAGTAACTTGGAGTCATTGG
 CAAGGGCTTTTTAGGCAGTATCCGGGGATTAATGGGACACAGATGAGAATGGAGTCATTGG
 TCGACTTGACCAACCGAAATGGTACATCCAGGCAGCAACTTCTCGAAAGAGACGTGGTCATTGG
 TTGACGTCAGTGGCAGUATGAAAGACTCCGICCTGACTATCGCGAGACAG1U'CATCCATT
 TGGGATACATTGGGATGATEACTTCTCAACATATTGCTTATAATGAGGGAGCTTCACATATGG
 40 AACCTTGCTGAAATGGAC1TTGGTCAAGCCGACAGGACAAACAGCACTTCAGGGAGCCTC
 TGGGAAACTTTGECAAAGGAATTGGAATGTTGGATATGACTCTGAAATGAGGGCTTCACATGG
 TGAGT'GATTCACACACACGGAC1AGGAAGTATCTGCACTCAGCCCATCATGCTCATAACTGAG
 CGCCCGGTGGACACCTATGATAAAATCTTGUAAAATACANTTGGCAGPATCGAAAGGT'CGCAGTCT
 TCACATACATCTATGGAGGAGGGCTGGCTTTGCAGACATCTAAGTGGATGGGCTGTGCCAAC
 45 AAGGATTTTAACAGATCTCCACCTGGCTGATGTGCAAGGAGAATCTCATGGAAATACCTTCACG
 TGCTTAGCCGGCCCAACTCATCGACCAAGGAGCA1GATGTCCTGTGGACCGAAGCTTACATGG
 GCACTCTGACTGATGATCGAGGGCCCCGCTCTCATGACCACTCTACCCATGECTGTGTTAGTAAG
 AGAACGAAACCAGATCGAAGGGCATTCTCTGCGAGTGGTGGCAAGAGATGCTCCAGTGAACAAAC
 TTCTGAAAGACCATCTCCAAATACAAGTTAGGGATTACGGGTTATGCAUTTTCAATCACAAATTAATG
 GRTATACTCTGACGCACTCCGGAACTCTGGCTGTCAGGAGGAGATCTCATGGAAATACCTTCACG
 50 ACTATAGTAGCGTTGACCTCTGAGGTGGAGTGGCAAGGAGGAGATGACGTGTTGAGAAATGCTA
 TGCTGAATCGAAAGACGGGAAGTGTGCTTGGCAGATGAGCTGAAAGAAAGACAGTGGACAAAGGGAAACGCC
 TTTGGGTGATGACAATGACTACTATATACAGACATCAAGGGTACTCCCTTCACTTTAGGTGTGG
 CGCTTTCCAGAGGTGATGGGAATATTCTPCCGGGGAGATGTCAGGAGGAGATGCAACATCGAGGAGGGCTGCATG
 ACTTACAAACATCCCCATGTCAGTTAGAAGCGATTAAGCTACCTAAAGGCAAAGAACCTCTGCTCC
 55 AGCACCGCCCATCTGCTCACTGAGAAGCGATTAAGTCTACCTAAAGGCAAAGAACCTCTGCTCC
 AGTGTGATAAGAAATGATCCAAGAAGTCTTGTGACGGGGTGGTGAATGGCCCCCATGAAACCGT
 ATTGGGACCAAGCCTGGCCCTCAACAAATCTGAAATCTGACAAAGGGCTGGAGGTGCTCCTCCTCG

-5-

5 GCACCTGGCAGGGGCTCTCCAGAATCAACCTGTGTTGTCGGGCTGAGCAGCTCACCAATCAGGACT
 TCCGAAAGCTGGCGACAAGGAGAACATTAAACGCAAGCATTTCCTCTGGTACCGAAGAG
 UGGCTGAGCAGATTCCAGGGAGCTTCGTCTACCTGAACTCCCATTCAGCACTGGACAGCTCAATAAA
 GCAATGFGCTGACACUCAAGTACATCCATCCAGCTCTGGATGAAACGGAAATCTCCCTGTGGCGAG
 CTGTAGGCATTCAGTGAAGACTTGAATTTCTCAAAGGAGTTCTGGACTGCCACACAGACAGTG
 CTTCCTGGATGGCAAATGCTCCATCAGCTGTGATGAGACTGTGAATTGTTACCTCATAGACA
 ATATACTGATTTATTTGGTGTGAGACTACACACAGACUGGAGACTTTTGTTGAGATCGAGG
 GAGCTGTGATGAAACAAATTGCTAACAAATGGGCTCTTAAAGAATTACCTTTATGACTAACAG
 CCATGTGTAAGAGCCAAACGGAAAGCAUCGATGGCGCCATGGCCTCTGGATCUTTATAATGCT
 10 TCCTCTCTCAGTAAATGGATCATGACAGRACTTGTCTTGTCTGGTGAATTAAACCTCTGCA
 GTGGCTGGCACTCCGATATGACAGCTAAAGCCCAGAAAATGAACAGACCTGGAGCCTGGATA
 CTGAATNTCCAGCATTCTGCTCTGAGCCACATCAAGGAGACTACAGGGAAATTGCTTGTGAG
 ACTGCTCCAAGTCCCTTGTCTGAGCAAATCCCAACCACCAACCTGTTCATGGTGGTGGAGCA
 GCAGCTGUCTCTGAAATCTGTGCCCCCATCACCATGGCAGCCATTGAAATCAGGTATAATGPA
 15 CCCTTAAGTGTAAACGCTAAAGCCCCAGVAGATCAGAAGGGCCAGARTCTTCTCTGGCTTCC
 ATGCTGAGGAGAAATGCAACGGAAATGTGCBGGGTGCGGAGGCTTCAAGGCCAGACAGTCTC
 TGCTCCCTCTGCTTGTGCTCTCTCAAGGTGACACTGACTGACATGTTCTCTTACTGACTGAC
 ATGTTCTCTGGCATCTAAATCATGGATTAACCTCTGAACCAAAATATGGTGCACACAGAGACA
 20 TGAATATAGTCCAAACCATCAGCATCTCATCATGAAATTAAACTGTGCGTGATAATAAACTCTAAAG
 ATATGTTGACAAAAAGTTATCTATCATCTTTTACTTTGCGAGTCATCCAAATGTTGAGTTTGCAC
 ATGATTAATCAACCCCTCATCAGAAATGGGACGGCAACTGUTAGGCACTGTCTCTGCTTCAAAAC
 TATPGAAACCAATTAAACTGTGACTTTAAATAAAGTATAATPAAATCATAAAAAAAGAAAA
 AAAAAA

25

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA

35 (ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: a26-D

40 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

45 CCATGCGCTGCAACCTCCAACTTCTCGAAACCCAGCTCCAGCAGCDGCTGGATTCUUCCTCCAGC
 CAATGCCCGTGGCCTGGGCTTGTGAGAAGACCTGGCCCTCTGIGGGCTGCTCTTCTGAGGCA
 CTCUCCCTGTCCCCCTGCGTGGGACAGGCAAGATTCCTCTGGAAACAGTGAAGCTATGGGCTGAA
 CCTTGGGGGGACCTGTATAACACTGTGACCAAAATACTCAGGCTCTCTTGTGCTGAGAAGAAGT
 ACAGGGATGTGGAGTCCAGTGTGAGCATGCTGAGGGTGGATGGCTGGAGCTGGTGAAGGAAGTCT
 50 CAGAGGACATGGAGAACATGCTGGCAGGAAAGTCGAGGGGGTCCAGAAATCTGCTGAAAGCTGGCG
 AGGAGGCCCCGACCTGAAACUACGAAATTCAATGAAATCCCTGGTGTGACTATTAAACACTCBBGCTCTGA
 TCAACGGGGAGGAGAAGAAGGGCAACTTGTGGAGCTGGGGCCCCGGAGTTCCCTCTGGAGTCCAAATG
 CTCACCTTCAGCAACCTGCCGGTGAACACCTCCATCAGCAGCGTGCAGCTGCCAACCAACCTCTACA
 ACAAAGACCCAGATATTAAATGGAGTCATCATGTCTGAGGCTTGTAAATGCTGTCCTTCTGGAGA
 ACTTCCAGAGAGACCAACGTTGACCTGGCAATATTGGCAGTGCACACTGGGATTCTCAGGGATCT
 ATCCAGGTTATAAATGGACACCTGTGAGGAAATGGAGTCATTACTTGTGACTGCCGAACCCGGGCT
 GTCACATTCAAGCTGCTACTTCTCCAGGGACAAAGTGAATTGCTGGACGTGAGGGCAGTATG
 55 AGGGGCTGAGGAGTGCATATTGCCAAGGCACACCATGCCACCATCTGGACACCCCTGGGGAGAATG
 ACTTCGTTAATATCATAGCGTACAAATGACTACGTCCATTACATCGAGCCTTGTGTTAAAGGGATCC
 TCGTCCAGGGGGACGACAACTCAGACCCATTTCGAAACTGCTGGTGGAGGAGTGTGCTCAAAG

-6-

GTGTGGGGCTCGGACCAAGCCTGAGAGAAGCCCTTCCAGATCCYGAAGCACTTCAGAGGCCA
 AGCAAGGAGGCCTCTCCACCCAGGCCATCATGCTCATCAGCAACGGGGCCCTGGAGGCATACGCC
 CGGTGTTT'GAGAAGTATAACTGGCAAGACTCTAAGGTCGAGTTTCATTTACCTCATGGAGAC
 AAGTGTCTTTGCTEACCGCATCAGTGGNTTECATGCAAAACAAAAGGCTACTAACGGCGATCT
 5 TAAAGCTGGGGACACCCAGGAGAACGTGATGGAAATACCTGACCTGUTCAACCGMCCCCTGGTCA
 TCAACCACGACCACGGCATCATCTGGACAGACCCCTAACATGGACAGGCAAGCTCAGCTCGCGAT
 CTCAGAGGCTGACACTGTCACCCACTGTCAGGAGGCTTCTAGGCAAGAAGAACGAACGCCAT
 CCCATGGCATTCCTCTGGTGTGGCTGGCTAGATGGGACCTTCTGAACACACRACATGGCTACATCC
 CCCUGTACAAGCTGGACTCCACGGATACCCCTTCTGAACACACRACATGGCTACATCCCTCC
 10 ATCCCGACCTCCCGCCCCCTGTADPGAGAGGGGAAGAAAACAAAAACCTAACTACAAACAGTG
 TGATCTCTCGAAGTGGAGTGGGAAGACCGAGGCTCAATCTCTAGAACACAGCCATGATCAATAGGG
 AAACAGGTACTCTCTGGATGGATGTGAAGGTTCCGATCCATAAAACGAGGGAGTTTTTCTGGA
 CCAATGACTACTCTTCACGGGACATCAGCACACCCCTTCTAGTTGGGGTGGTGTCCCCGG
 GUCACGGAGNATACATCCTCTGGGGAACAGCTGTGGAAABAAGGCCCTGCACTGCTCCTCNCC
 15 CAGACTGGCCCTGGCCGGTGAATGGATCTACTGCAACAGATAATGACCCACACCCACCGGAAGC
 TCAGCCAGCTACAGGCCATGATCCGCTTCCTCACCAACUACACCCACACCTGGATGTGACCGAG
 AGCTGGTCCGGCAGGGTGTGGTTGAGGCTGGCTCACAGCCCCCATGGGACTACTGGACAGGCC
 TGGCCCTCAACATGTCCGAGGAGCTGTGACACAGTGGGACATGGCTCTGGCACAGGAAGTTCCTGACACCTG
 20 CCCTCTGAGAAGCAGCTTCTGGGCTCCGAGAAGGTCTCGACAGGCCATGGGACAGGCC
 AGGACGAGGGCACCGTGTTCACCCCTGGACCGGCTTCCTCTGCTCTGAGGCTGGGATGGGATGG
 CTGGTGGGAGCTTCGTCACCTCAGCTGGGAGGAGGACAGGAAAGTGGGGTGGGATGGGATGG
 TGTCACCGCAGCAAGCAGGCTGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
 GCGTCCAAATGAAGCCTGCAATTCTCCAGCGCAAAATCTGGGGGCAACGCGGAGTGCAGCACTG
 25 TGGATGGGCGGTGCAACAGAGCTGCGAGAACACTGATCTCCACTCTTCGTCATCBACAACACGG
 GTTICATTCTGATCTCCAGAGGTCGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
 TCTCTGACCCAGCTGCTCACCCATGGGGTGTTCAGCCAAGTGACTATGTAATGACTATCAGGGCJNTGT
 GCAAACCCCTCGAGTCACOCCACCAAGTGCAAGGCCAGCCCTGGTCAGCCCAATTCTGCGCTTCTTGA
 CGGCAGCCAGGGTGGCTGCAAGGAGCTGGTGGTCTCTCTGCACTGGGAGTGTGTGGGCTCT
 30 GGTACGACACGAGGGGCGAGGGCAAAAAGTGTCTCCATCACTCCCAACAAAGAACAGGAGG
 UGCTGGAGCCCTGGAGACACGGAGTACCCCGTGTGTACCGAGCCGGGUACATCCCCGAGGCCAAC
 GRATCGTGGAGTGGGGCCCTGGCAAGAGGTATTGIGGTGGCAGCAGATTTCACACGAAACCTCC
 TCCTCTGGTACACACCCCAACTGTGACTGCAGGATCTTCCACAGGAGGAGGAGGAGGAGG
 AAGTCAAATATAATGCTCTGCAAAATGTGACCCGATGCTCCCAGAAAGTCCGCGGCCGACAC
 ACYCTGCCACGCCCTCCATCCAGAGGAGAATGCECAGGACTBCCGGGGGCUCTGGACACCTGAG
 35 CCTCGCCGCCCTACCTCTGCTGCGCTGTGTGCTGGCTGGGCTACTGCGGCAACTCTGCGGTGAC
 ACCACCCAGCCGACTGTGGTITGGCAAGGTGATCTCCACCCATCCCCAAAAGTCAGCAC
 GACATGGGATGCAAGCTAACCTGCAAGTGGGCGCCCCAGGCCAACGGCTCTGCAATCTGGGCTG
 GTGGGCCCCCTGGCTCCGGAGAAATGTGGATGGAAACAGGAAACCTACCTGGCACCAATTTCACA
 40 TGGTTCATGGRGCCGGGJACCCATCTGCCCCTAGGTCTCAACATGAGCATACTTGTGACCTAACTTC
 CTGTCCTCDTCTTCGGGAAGCCAGCGTGAGGTCACTGGGACCAAGAACAAAATTTAGTTCTTC
 TGTAATCCAGACTCCAGGCCAGCAAGAACGGCTCAAGTGGTGTGACCCCTTCTGCGGAGGG
 TCTCTGGTACGAAACCCAGGACTCTGGGTACTGAGAACCCAGCAGAATGAGGCCAATGCAAG
 ATGAGGCTPAGGUPAGGAAATATGCCCAACTAAAGCATAAGATTCCCCAAAGTGAGGCTCATGGGG
 45 AGGCCACTCACCTTCTAGCTGCTGCTGAAAGGTTTTCACJGTGTTGGGCTGGGCTACACGTGAT
 GGAAFFGGTCAAGACTGAGAGAGGAATGAAATCCATCAGGAATATGCAAGGGCTACACGTGAT
 GTCCCCAAACTGCTGCTATTGAGAAGACTTCCCACAAACTCTTACAAAGGCCCTAAGGGAAAGTTC
 CATCTATGAAAGCCAAATAGGCTGAGACATCCATGGCTGCAATGGAAATTTGATGTACATTGAGGG
 ACCCCAAAATAGCTGAAATAGTGGAAAAGAGGAGCTGGTTGTGCTCTTCTGCCCCAAATGATT
 50 ACAGAAGAACTACTTGACTCTGTCTCCATGGAGTGAAGATCCCTTAGLGGTGGTCAACTTGTGGGACATT
 CCACACTTGCTPAGCAGGGTCCACTGGGAGGCCAGCTCTATCTGGAAACTCACCCCCAGGCCACACA
 CATCTCCCCCAGGGTCCAGGCCAGGCCAGCTCTGGGAAACTCACCCCCAGGCCATGGGATCCC
 AGGAGACAACAGTCTCCACATGAGAGCAACATTAGGGCAAPGCCATGGAGAAATGTGGCAGAGGCC
 CGGCCTCAAAATCTTCCATTTAACAAACCCAGTGATGGGTATGGACAGCATCCAGGGCTTTGGG
 GCGCTTCCCCCGCTCTCCATCACCCCTGAGCTCCACACTTCAAAATTCAGGTCAGGCAAAATGCC
 55 AGTTTCTACCAAGCAAAATAGCCCTAACTTGCCCTGCTCTAGAGTAGGCAAAATGCCAACTCTGTA
 AGACTTACATTATCGTTACAGAATGTCACCTCTTACCATCATGCTCTGCAACAAACCTGAGGG
 ACTATTAAATGCCCTTACAGCAGAAGACACTGCAAGCTCGAAGACAGCTTGTGGCAGAATAATG
 CTAGAACAGCTAAGGTTTACATGTAACCAAAATAACATGTTCAACCTCATCCATCCACACAGCC
 CCCTGAAAGTGGGACTATCATTAOTCCCATGTTAGAAAATGCAAGCAGAGTTGAAATTGCTC

-7-

CAATT'ACCGGAAGAGTGTATGAAAGATTCAATGTGATGTATTACCGTAACATGCJTGAAACTCCCT
GGCATTA'ACTAAGCTAAATAAATAACATGCTAAGTGCAAAAAAAAAAAAAAAA

S (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

{B} TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(117) 1988-0000

САДЫ ВОЛГАРЬЯ

(B) LOCATION:

(B) OTHER INFORMATION: a2d-c

(iii) MOLECULE TYPE: protein

(z) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

NAGPGSPRRASRGASALLAVALLYAALGOVVRSEQQIPLSVVKLMAASAEGBEIKSIAAKYSGSOLL
QKKYKEYEKVAIEEIDGLQJVKKLAQNMELMFHKKSEAVRLVEAARFJMLKHEFDADLQYEYEN
AVLINEERUKDGNFLEJGKEFILAPNJDHFNNLPVNISIISDVQVPTNNYNKDEAIVNGVYWS9LNKV
FVDNFKDROPSJTWQYFGSAKGPFQYPTKWEFDENGVIAEDCRNRKWy1QAATSPKDWWVJJDVS
CSMKGLRJTLAKQTVSSILNTLGDDDFFMIIAYNEELHYVEPCLNCTLVQADRTNKEHFRKLDKL
FAKGIGMLDEALNEAFNLLSDENHTGQGS1CSQAIMLITDGAVDTYTIFAKYNNPORKVRIFTYL
IGREAAFAADNLKWMACANKGFFTQ1STLADVQENVMEMYLHVLSPRNVIDQEHODVVWTLEYIDSLTL
DDQGPVLMITTVAMPVESKQNETRSKCILLGVVSTDVPVKEELLKTIFKYKLGIHCYAFATNNGYIL
THFELRJYEEGKKIURKPNYSSVDPJSEVEMEDRDDVULKNAMEVRKTGKFMSMEVKKTVDKGKRVLV
TNQYYTIDIKGTPFSLGVALSRGHGKYFPRGNVTIEEGIJIDLEMPDVSLADEWSYCNDLHPEHRH
LSQLEAJKLYLKGEPLLQCDKELIQEVLFDAVVSAPIEAYNTSLAUNKSENSDKGVVTAFIGTRT
GLSKINLFVGAEQOLTNQDFLRKACDKENIFNADHFPLWYRAAEQIPGSFVY51PPSTGPVNKSNNV
TASTSIQLLDERKSPPVVAAGVQONKLEFFORKFWIASMKQCASLNGKCSJSCDDETVCNCYLIDNNGY
ILVSEDXTQTGDFFCETIEGAVMVKLISNGSPKRITLYDYQAMCRANKES3DGAHGLL0PYNAFLSA
VKWIMTELVLFLVCFNLLCSWWHSUMTAKAOKLKOTLEPCDTEYPAFVSERTIKETTGNIACEDCEK
SFVIQOPIPSSNLEMVVVUDSSCLCERGVAPITMAPIEIRYNESLKCERLKAQNJRRRPESCHGFHPEE
NARECGGGAPSLOBOTVLLLLPLIJNIFSR

40 (2) INFORMATION FOR SEQ ID NO: 6:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(c) STRANGEDNESS: single

{D} TOPOLOGY: linear

(11) MINUTE

— 1 —

(B) LOCATION:

(B) OTHER INFORMATION:

iii) MOLECULE TYPE: protein

-8-

MPATPNFLANPSSSSRWIPLQPMFVANAFVQKTSALLWLLLGTSLAPAWGQAKIPLETVKLWADT
 PGGDLYNTVTKYSGSLLLQKKYKINVESSLKIEEVDGLELVRKFSEDMENMJRRKVEAVQNLVEPAE
 EANLNKEFNESELVFDYNSVLINERDFKGNFVELGAELLESNAHFSKLPVNTSISSVQLPJVNVN
 KDPDI LMGVYMSEALNAVFTEN FQDPTLTWQYFGSATGFFTRIYFGIKWTFIDENGVITFDCRNRSW
 5 YIQRATSPKDIVI), VDVS GSMKELRMIIAKHTTITLDTLGENFPVNIIAYNDVIVIYIEPCPKGIL
 VQADRDNRHFKLLVEELMVKGCVVVDQALREAFQJL KOFQFAKQGSTCNGAIMLI SDGAVEDYEP
 VFEKYNWPDCCKVRVFTYLIGREVSFADRMKWIACNNKGYYTQTSTIAPIQENVMEMYL6VL3KPMVI
 NHHDII IMTEAYMDSKLLSQAQSI TLLTFTVAMFTVEKNETRSHGILLGGVVGSDVALRELMKILAP
 RYKLGVHGYAFLNNTNNGYI LSKPDLRFLYREGKKLKPKPNYNSVDLSEVERWDQAESLRTAMJNRE
 10 TGTLSMDVXVPMPKGKRVLFITNDYPFTDISDTPFSLGVVL8RGHGEYI LIGNTSVEEGLHD1LHP
 DLALAGDMIYCITO1DYDHRKLSQLRAMIRFTRKDPDLECDEELREVLFDAVVVFAPMEAYWTAL
 ALNMSEEEHVDMALFCSTRAGJ I.RSGLFVGSEKVEDRKFLTPEDERAVFTLDK8PLWVWQASEHP
 AGSFVENLJMAECPEASAGEPMVVTASTAVAVTVDKRTAIAAAAGVQMKLEFLQRKFWAATRCSTV
 DGPCTQSCESDLDCEVIDNNGF1L SKRSRETGRPLCEVDCAVLTOllSMGVTSQVTMYDYQAMC
 15 KPS5HHHSAAQPLVSP18AFLTATRWI.LQFIVI.FLLEWSVWGSWYDRGAEAKSVEHHSHKHKKQDP
 IQPCITEYFVEVYQPAIREANGIVECGPCQKVFFFQQIPNSNLLLLVTDFTCDCS1PPFV1Q8ATE
 VKYNASVCKDRNRSQKLRRRPDSCHAHFPEENAQDCGGASDT8ASFPLLLL PVCANCLLPOLLR

20

(2) INFORMATION FOR SEQ ID NO: 7

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION:

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7;

AGGATGCCCTGGGGAAAGAAAGA

(2) INFORMATION FOR SEQ ID NO: 8

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primer for α 2 δ -B

50

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8;

-9-

ATCATCAATGAGGAACACACA

(2) INFORMATION FOR SEQ ID NO: 9

- 5 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:
- (D) OTHER INFORMATION: 5' primers used for RT-PCR of α 2 δ -C
- 15 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

AGAACGAAACCAAGATCGAAG

20 (2) INFORMATION FOR SEQ ID NO: 10

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:
- (D) OTHER INFORMATION: 3' primer used for RT-PCR of α 2 δ -C
- 30 (iii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

35 CGATTCAUCCATAGCATTTC

(2) INFORMATION FOR SEQ ID NO: 11

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 45 (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
- (E) LOCATION:

-10-

(D) OTHER INFORMATION: primer for α 2 δ -C

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

5 CTACCAAGCCATCTGTA

(2) INFORMATION FOR SEQ ID NO: 12

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(iii) MOLECULE TYPE: cDNA

15 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primer to amplify mouse α 2 δ -C

20 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

ACAAACCAAACCTAGGTCAAAG

(2) INFORMATION FOR SEQ ID NO: 13

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30 (iii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

35 (D) OTHER INFORMATION: 3' primer to amplify mouse α 2 δ -C

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CGATTTACCATGGCATTTCGT

40

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

45

-11-

(iii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: rat sequence for $\alpha 2\delta$ -c

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

5 GATTCTTCTGGGTGGTGGCACAGATGTCCCAGTAAAGAGCTTGAGGACCACTCCAAATA
 10 CAACTTAGGNNATTCATGGTTATGCCCTTGCCATCACCATAATCGATACATCTTGACACACCCGGA
 15 CCTCAGGGCCCTGTATGARGAAGGGAAACCCAAACCAACCCCTAATTACACTACTGTGGATCTCTC
 20 GGAAGTGCAGTGGGAACATCGGGATGATGTGTTACGAAATGCCATGGTAAATCGAC

(2) INFORMATION FOR SEQ ID NO: 15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: (1690-1761) $\alpha 2\delta$ -D, human splice

variant

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

30 CCATGCCCTGCRACTCCCCAACCTTCCTGCACAAACCCAGCTCCAGCAGCGCTGGATTOCCCTCCAGC
 CAACTGCCCTGGCCTGGGCTTGTGCAAGAAGACCTCGGCCCTCTGTGGCTGCAGCT
 35 CCTGCCCTGGGACCTGTATAACACTGTGACCAAATACTCAAGCTCTCTCTGTGCAAGAAGAAGT
 ACAAGGATGTGGAGTCAGTCTCAAGATCCAGGAGCTCCATUCCTTCCAGCTGGTGAGGAAGTTCT
 40 CGAGGAGATGGAGAACATGCTGGGGAGGAAGTCAGGGCGGTCCAGAATCTGGTGGAGCTGCCG
 AGGAGGCCGACCTGAACCAACGAAATCCCTGGTGTTCGACTATTACAACCTGGTCTGA
 45 TCAUGAGAGGCCAGAGAAGGGCAACTTCGTGGAGCTGGGCGCGAGTTCCTGGAGTCCAATC
 CTCACCTTCAGCAACCTGGGCTGAACACCTCCATCAGCACCCGTGCAAGCTCCCCACCAACGTGTA
 ACAAAAGACCCAGATATTITABATGCAAGTCTACATGTCAGCTGGCAGCTTCGAATGCTGTCTCGTGGAGA
 ACTTCCAGAGAGACCCAACGTTGAACTGGCAATATTTGGCAGTGCAGCTGGATTCTTCAGGACT
 50 ATCCAGGTTATAAAATGGACACCTGTGAGAAATGGAGTCATTACTTTGACTGGCGAAACCGGGGUC
 CGTACATTCAAGCTGCTACATCAGCCAGGACATAGTGATTTGGCTGGACGCTGAGCCGGACTATGA
 AGGGGCTGAGGATGACTATTGGGAGACACCCATCACCAACCATCTTCACACCCCTGGGGGAGAATG
 ACTTCGTTAATATCATGAGCTACATGACTACGTCACATTACATGAGGCTTGTTTAAAGGGGATCC
 TCGTCCAGGGGGACGGAGACATCGAGAGCATTCAAACTGCTGGTGGAGGAGTTGATEGGTCAAG
 55 GIGTGGGGGTCTGGACCAAGCCTGAGAGAAGGCTTCCAGATCTGAAAGCAGTTCAGAAGGGCUCA
 ACCAAGGAAGGCTCTGCAACCGGCCATCATGCTCATCAGCGAGGCGCCCTGGAGGACTACCGAGC
 CGGTGTTGAGAAGTAACTGGCCAGACTGTAGGGTTCGAGTTTCACTTACCTCATGGAGAG
 AAGTGTCTTTGCTGACCCGCAATGGAAGTGGATTGACATGCAACACACAAAGGCTACTACACGCAAGATCT
 60 CAACGCTGGGGACACCCAGGAGAACGTGATGGAATAACCTGCACGTGCTAGCCGCCCCAAGGTCA
 TCAACCACGACCAAGCAATCTGGCACAGAGCCCTACATGGACAGCAACCTCCCTCAGCTCCAGC

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(iii) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

10 (D) OTHER INFORMATION: human variant α 2 δ -D, EDGE screen

(iv) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

15 CCATGCCCTGCAAATCCCCAACTTCC'TCGUAAAACCCCCAGCTCCAGCACCCCCCTCCATTCCCCCTCGAGC
 CAATGCCCTGGGCTGGGCCTTTCTGCAGAGAGACCTCGGCCCTCCTGTGGGTGCTGCTTCTAGGCA
 CCTCCCTGTCCCCCTGCCTGGUGACAGGCGCAGATCTCTCTGGAAACAGTGAAGGTATGGCTGACA
 CCTTCGGGGGGGACCTGTATAACACTGTGACCAAATACTCAGGCTCTCTCTTGCTGCAGAGAAGT
 ACJAGGATGTGGAGTCCAGTCTGAAGAGTCAGCAGGAGGTGHATGCTTGTGAGCTGTGACCCAACTTCT
 CAGAGGACATGGAGAACATGCTCCGGAGGNNAGTCGAGGGCGGTCCAGAACTCTGGTGGAAAGCTGCGC
 20 AGGAGGGCGAACCTGAACCACGAAATTCAATGATTCATGGTGTGCTGACTTATACAACTCTGGCTCTGA
 TCAACGGAGAGGGGACGAGAAGGGGAACTTCGTGGAGCTGGGCGCCGAGTTCTCTCTGGAGTCCAAATG
 CTCACTTCAAGCAACCTGCGGGTGAACACCTCCATCAGCAGCTGCAAGCTGCCACCAACGTGTACA
 ACAAAAGACCCAGATATTTAAATGGAGTCTACATGTCTGAAGCTTGAATGCTGTCTCTGGAGA
 ACTTCCAGAGAGACCCAAACGTTGACCTGGCAATATTCTGGCAGTGCACACTGGATTCTCRGGATCT
 25 ATCCAGGTATAAAATGGACACCTGTGAGAAATGGAGTCATTACTTTGACTGCCAAACCCCCGGCT
 CGTACATTCAACCTGCTACTCTCCCAAGGACATACTCATTTGGTGGACGTCAGCCCAACTATCA
 AGGGGCTGAGGGATGACTATTGCUAAGGACACCCATCAGCAGCTTGGACACCCCTGGGGAGGAAATG
 ACTTCRTTAATATCAAGCCTACAATGACTAAGTCCATTACATCGAGCCTGTTTAAAGGGATCC
 TCGTCCAGGGGGACGGACAAATCGAGAGCATTCAAAACTGGCTGGGAGGAGTTGGATGGTCAAAG
 30 GTCCTGGGCTCGTGGACCAAGCCCTGAGAGAAACCCCTTCCAGATTTGAAAGCAGTTCCAAGAGGGCA
 ACCAAGCAACCCCTCTGCAACCAAGGCCATCATCCTCATCAGCAGGGCGCCGTGGAGGAACTCGGAC
 CGGTGTTGAGAAAGTATAACGGCCAGACTGTAGGTCGAGPTTCACTACCTCATGGGAGAG
 AAGTGTCTTTGCTGACUCCATGAGTGGGTTGCTGCAACACAAAGGGCTACTACACGCAAGATCT
 35 CAACGCTGGGGACACCCAGGAGAACGTGATGGAAATACCTCCACCTCCTCACCCUCCCCAGTGTCA
 TCAACCAACGACCACGACATCATCTGGACAGAGGCTTACATGGCAGGCTCTCACGTCGGAG
 CTCAGACCCCTGACACTGTCTACOACTGTGCCCATGCCAGTCTTCAGCAGAGAACGAAACGGCAT
 CCCATGGCAATTCTCTGGGTGTGGTGGGCTCAGATGTGGCCCTGAGAGAGCTGATGAAACCTGGG
 40 CCGGGTACAAAGCTTGGAGTGCAGGGATAACGCCCTCTCTGAACACCAACAAAGGGCAACATCCCTCTCC
 ATCCCCACCTCCGGCCCTGTAAACAGAGGGGAAGAAACTAAACCCAAACCTAACTACAAACAGTC
 TGGATCTCTCGAACGGTGGAGTCAGAACAGCTGGCTGAATCTCTGAGAACAGCCATGATGAAATAGG
 AAACAGGTACTCTCTGATCGATGTGAAAGGTTCCGATGGATAAAGGGAAAGCGAGTTCTTTCTG
 45 CCAATGACTACTCTTCACGGACATCAGGACACCCCTTTCAGTGTGTGGGGTGGTGTGCTCCGG
 GCCACGGGAGATACTCTTCTGGGGAAACACGTCTGTGGAGACAAACCCCTGCATCACTGCTTCACC
 CAGACCTGGCCCTGGCAGGTTGACTCGATCTACTGCAATCACAGATATTGACCCAGACCAACGGAGC
 TCAAGCCAGCTAGAGGGCCATGATCGCTTCCCTACCCAGGAAGGGACACCTGGAGTGTGACBAGG
 AGCTGGTCCGGGGAGGTCTGTGTTGACGDGGFTGGTGAACAGCCCCCATGGRAAGGCTTACTGGACAGGGC
 TGCCCTCTCACATGTCTCGAGGAGTCTGAAACACCGTGGGACATGCCCTCTGGGACACCCGGGGCTG
 GCCTCTGAGAAGCAGCTGTGTTGCTGGGCTCCAGAGAGGTCTCCGACAGGAAGTTCTGACACCTC
 AGGACGAGGGCCAGCGTGTTCACCCCTGGGACCGCTTCCCTGCTGTGGTACCGCCAGGGCTTCAAG
 50 CTGCTGGGAGCTTCGTCCTCAACCTCCGCTGGGAGAGGACAGGAGAAAGTGGGGGTGAAACCCATG
 TGGTGAAGGCAAGCACAGCTGTGGCGGTGACCGTGGGACAAGAGAGGACAGGCTTACTGCTGAGCCGG
 GCGTCCAAATGAAGCTGAAATTCTCCAGCGCAAAATCTCTGGGGGGAAACGGGGCAGTGCAGCACTG
 TGGATGGGCGGTGCAACACAGAGCTGGAGGACAGTGTCTGAGACTGCTGCTTCATCAACAAAC
 GTTCAATTCTGATCTCAGAACAGGTCCCCGAGAGACGGGAAGAATTCTGGGGGGAGGTGGATGGTGTG
 55 TCTGACCCAGCTGCTCAAGCATGGGGTGTTCAGCCAAAGTGTACTATGATGACTATCAAGGGCAATG
 GCAAAACCTCGAGTCACCCACCAAGTGCAGCCCTGGCTAGCCCCAATTTCTGCCCTCTG

CGGGCACCACGGTGGCTGCTGCAGGAGCTGGTGCCTTGAGTGGGGGTAGACACCGGGCTGGTGGAG
 GCTGCAATGCCAGGGTGGCTTAGGAGGGTGCCTTGATCAGGAGCTGCAGGGTCTCCAGGACAACC
 CACTTGCTACCAAGACCCCCGGGGAAACAGGCCACAAATCCCTGGGCAATGGACGCCACCTCTGCCCTG
 CTGGCTTGCCTCTGGGAGGGACCTCATTCATTGCTCAGCCAGAAGCCCTCAACCCACGGPAGACGGTGTCT
 5 GGGAGAGAGGGGATGGCCAGGGGCTGTCAAGGATACTCCAGCTCCCTGGAAACCCAGTCGGGAG
 GGCCTAGAGGCTCTCCGAGATTCACTGCCTGGTCTGAAGGTTCTGCTGGAGTGGAGTGTCTGGGU
 CTCTGGTACGACAGGGGGCGAGGGTGAAGTGCACGGAGCTGCAGGGCCTATGTGCTGAAGAGCAC
 TGGTATTTCTCCACTAACGGAGAGACCATTCCTGTGGCCTGGPACAGTGGGATAGCTGACC
 10 CTGAAGCATCBTTGTTCACATCTCACCCCTGGTGGCCCTCTCTCATCACATCCCTCACTCTGGCT
 CTGTGTGTGACATCATCTGGGACACCGCCTACCTGTCATCATCACACACCCATGACATCT
 CCCCTCATGTGCCACCATGTTCTCTGTCCTGGCTGTCCACCCCTGTCGCTGGGCTATGTCGACAGGG
 CCAAAACTGTCCTTCCATCACCTCCACAAACACAAAGAACAGGACACGGCTGCAGGCCCTGGACACGG
 AGTACCCCGTGTTCGTGTACCGAGGG
 15 TGCCAGAAGGTATTTGGGTGCAAGATTCACAGTAACCTCTCTCTCTGGTGAAGACCCC
 ACCTGTCGACTCCACGCTTCCACCAAGTGTCAAGGAGGGGCAACGGGATGTCGAGTGGAGTGCCT
 ATCAAAATGTCACGGATGCGCTCCUAGGAAAGCTCCGGCCGGCCACCCAGACTCCGGCCTTCCT
 CCAGAGGGAAATGCCAGGACTCCGGYGGCCCTCGGGACACCTCAGCCCTCCGGGGGGGGGGGGGG
 CTGCGCTGTGTGTCGCTGGGCTACTGCCCAACTCTCTGCGGTGACACCCAGGCTGACCTGTG
 20 TTTGGCAAGGTGATCTTCCAGAGCCATCCUAAAAGTCAGCACTGACATGGGATGAGCTAAC
 CCAGTTGGCTGCCCTCCAGGCCAACGGCTCTCTCAATCTGGGCTGGGGGGGGGGGGGGGGGGGG
 ATGCTGGATGGAAACAGGAAACCCATCACCTGGCACCAACTTCAGATGCTCATGGTGCCTGGTAC
 CATCTGCCCTAGGTCTACATGAGCACTCTGACCTAACCTCTGTCCTCTCTGGGAAAG
 CAGCGTGAAGCTAGCTGGGCCAACGAAATTAATTAGTTAGTCTTCTGTAATCTCAGAGTCCAGAAC
 25 CAAGCCAAGAAAGCGTCAAGTGTTCGACCCCTTCCTCTGAGGAGGGCTCTGGTAGAGAACCCAGGA
 CTTCTGGGTACTGAGAAGCAGCAGCAGAACATGAGGMAAATCCAGAGATGAGGCTAAGGCAAGAA
 TGCCCCAACATAAGCATAGATTCCCAAAGTGGAGGCTCATGGTGGGAGGGCACTCACCTCTAGC
 TGCTGCTCGAAAAGGTTTTGACTGTGTTGGGGTTGGGTAAAGGGAAATGGTCAGAGACTGAGA
 AAGGAATGAAATCCATTCAAGGAAATAAGCAGGGCTAACCGTGAATGCTCCCAAPATGCTCT
 30 GAAGAACTTCCAAAATCTCTTACAAAGCCCTAAACGAAAGTTTGCACTCATTCAGGGGACCCUAAA
 GCTGAGACATCCATTGCTGUATGAAATTGATGTAATTCAGGGGACCCUAAAATAGCTGTAAA
 ATAGTGAAGAAAGAGCACTGGTTGTGCTCTTCTGGCAATGATTTACAAAGAAATCTACTTGACT
 CTGTCCTGGAGTCAGAATCTTCTAGGGTGGGACTTCGGGAAACTCACCCCGAGGCCACACATCT
 CACTGGCAGGGAGCTCTATCTGGCAACTCACCCAGGAGACTGGATCCTGGGAGACAGTCTCCACA
 35 GGGCCCGCAGCTTCTCTCCAGGAAACCTAACCCCAAGAACGACTGGATCTGGGAGACAGTCTCC
 TAAGAGCAACATTAAGGCCAAGGCCATGGAGAAATGTGGGAGAGBCCGGCCTCAAAATCTTCCATT
 TAACAAACCCAGTGTGGGATAGCAGCACTTCAAAATTCAAGTCAAGCTCTCAACTTCTACAGCAAA
 40 ATCACCCCTCAGCCTCCACACTTCAAAATTCAAGTCAAGCTCTCAACTTCTACAGCAAA
 GCCTTAATCTGCTCTAGACTAGGGCCARATGCCAACTCTGTAAAACACACTTACATTATCGGTAC
 AGAATGTCACCTTACATCATGCTCTTGCACCAACCCCTGTGAGGGCAGTATTAAATGCCCCCTAAC
 GCAGAAGAGACACTCCAGCTGGAAAGACAGCTTAAGTGGCAGAAATATGCTJAGAACAGCTAACGTT
 45 ATGTACCAAATAACATGTTCACTCATTCTCATCTCACAAACAGCCCCCTGAAAGTGGTACTATC
 ATTACTCCCATGTTAGAAACTGCCAGCAGGTTGAAAATTGCTCCAAATTACCGGAAGAGTGT
 TGAAGAGTTGAATGTTGATGTTACGTAACRTGCTTGTGAAACTGCCTGGCATATACTAAACBCTAAR
 TAATAACATGCTAACTGCCAAGAAAAAA

45

(2) INFORMATION FOR SEQ ID NO: 17

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

50

55

-14-

(D) OTHER INFORMATION: human variant α 2 δ -B, EDGE screen

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

5 MPATPNFLANPSSSSRWIPLQPMPVAWAFVQKTSALLWLILLGTSLSPAWGQAKIPLTV
 KLWADTRGGDLYNITVKYSGSLLLQKVKDVESSLKIBEVGDLELVRKFSDMENMLRR
 KVBAVQNLLVEAAEEADLNIIIFPNEISVFDYYNSVLJNERDEKONFVELGABFLIRSNAHFS
 10 NLPVNNTSJSSVQLPIMVYNKDPDIILNGVYMSRAINAIVFVBENFQRDPITLWQYFPGSATGPP
 RIVPGIKWTPDENGVITDCRNRGWIQQAATSPKDIVLVDVSGSMKGLRMTIAKHTTITIL
 DTLGBNDFVNIIAYNDYVHYIEPCFKGLVQADRDNRHFKLLVBELEMVKGVGVVDQALR
 15 EAFQILKQIPOEAKQGSLCNQAIMLISDGAVEDYEPVREKYNWPDCKVRVFTYLICREVSF
 ADRMKWIAACNNKGYYTQISTLADTQENVMEMYLHVLSRPMVINHDHDIIWTEAYMDSKLL
 SSQAQSL'LLLTIVAMPVPSKKNETR&HIGLLGVVGSDVALRELMK1APRYKLOVIIGYAFL
 20 NTNNGYILSHPDLRPLYREGKKLKPKNYNSVDSLSEVEWEDQAEISKRLVLFITNDYFFTDI
 SDTPFSLOVVLSRGHGBYILLGNTSVGEGLHDLLHPDLALAGDWIYCITDIDPDHRKLSQI
 EAMIRFLTRKDPLCDDELYREVLFDAAVTAPMEAYWTALALNM8LEESHHVVDMARLG
 TRAGLLRSSLFVGSEKVSDRKFLTPEDEAESPJLDRFPLWYRQASEHPAGSFVFNLWRWE
 GPESAGEPMVVTASTAVAVITVDKRTAIAAAACVQMKLEFLQRKIPWAATRCSTVDGPC
 'TQSCEDEDLDCPVIDNNNGPILLSKRSRETGRFLGEBVDGAVLTQLLSMCVESQVTMYDYOA
 MCKPSSHHTHSAAQPLVSPISAFITATRWLIQBI.VI.FLLEWSVWGSWYDRGABAKSVPHH
 SHKHKKQDPLQPCDTEYPVFWYQPAITRANGIVBCGPQQKVFVWQQITNSNLLLLVTDPTC
 DCSEFPPVQLBATEVKYNASVKCDRMRSQKLRRRPDSCHAFLPEBNAQDQGGASDTSASP
 PLLIJPVCAGLLPOLLR

25

(2) INFORMATION FOR SEQ ID NO: 18

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primer for human α 2 δ -B

(iii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GCGAGGGACAGTGATCTGG

45

(2) INFORMATION FOR SEQ ID NO: 19

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

-15-

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primer for human α 2 δ -D

5 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GGGTCCCTCGTTCTTGTGTTT

10 (2) INFORMATION FOR SEQ ID NO: 20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

15 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(iii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

20 (B) LOCATION:

(D) OTHER INFORMATION: nested primer for human α 2 δ -D

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

25 TCAAGCCTCCACACTTCAAAG

(2) INFORMATION FOR SEQ ID NO: 21

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

30 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(iii) MOLECULE TYPE: cDNA

35 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: primer for human α 2 δ -D

40 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TCCGCCTGGACGAGGGATCC

45 (2) INFORMATION FOR SEQ ID NO: 22

-16-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

(D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GTGTCCGAGATGGTGGTGT

15

(2) INFORMATION FOR SEQ ID NO: 23

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

(D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D (d20)

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

ATCTACTGCATCACAGATAATTG

(2) INFORMATION FOR SEQ ID NO: 24

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

(D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D ($\alpha 2\delta$ D2)

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

GGTGAGGAAGCGGATCATG

(2) INFORMATION FOR SEQ ID NO: 25

- 5 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH:
 - (B) TYPE:
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
 - (B) LOCATION:
- (D) OTHER INFORMATION: 5' primer mouse genomic of $\alpha 2\delta$ -B
- 15 (iii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

TTCAACGAGAAAGGCACAGCCT

20 (2) INFORMATION FOR SEQ ID NO: 26

- 25 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH:
 - (B) TYPE:
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (iii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
 - (B) LOCATION:
- (D) OTHER INFORMATION: 3' primer mouse genomic of $\alpha 2\delta$ B
- 30 (iii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

35 GTTGGCACAGGCCATCCACTG

(2) INFORMATION FOR SEQ ID NO: 27

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH:
 - (B) TYPE:
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- 45 (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
 - (B) LOCATION:

-18-

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
AGGCTGTGCCTCTCGTTGAA

(2) INFORMATION FOR SEQ ID NO: 28

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

20 (D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
GATCCCCCAAGAACATCG

25 (2) INFORMATION FOR SEQ ID NO: 29

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

30 (D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human

(iii) MOLECULE TYPE: cDNA

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
CGATCTTCTTGGGGCTC

45 (2) INFORMATION FOR SEQ ID NO: 30

-19-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,

based on human

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

CCCCATGATGACCAGTC

(2) INFORMATION FOR SEQ ID NO: 31

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,

based on mouse

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GGCAAGACCCCTACACTCTTG

(2) INFORMATION FOR SEQ ID NO: 32

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:

45

-20-

(D) OTHER INFORMATION: primer for sequencing mouse genomic, based on mouse

(i.ii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

CCTGGTAATAGCGACTGAC

(2) INFORMATION FOR SEQ ID NO: 33

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' genomic sequence from 10kb

20 fragment for mouse $\alpha 2\delta$ -B

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

25 AAGCTTCTCTCATCACCAAGGAGAACATCATGTACTACGGATGCCAAGGCTGACG
CCGAGCTGGTAAGINGTCCCCACCTTGCGGTAGAGGATGGGGAGCAGCCAGAGCCAC
ACCTTGTCTCTGGGCCACAAACAGTCAGCTGTAAAGTGGGTGTAGGGATCCATG
CTCACCTTCTGAACTCACCAACATTCTGTGTCGTGCTGGTCAGGCTCTCCCTGTOACA
GCTCCCTAGAGATCTGACCCCTCCAGGGGGTGTCTTCATCAACATTATAAGGCTAAC
TCCCGTGCACCATGTTGAGGGCTCTGGGGCTCCATGGGAGTAGAGAGAGAAAGAAATGG
30 CATCCCAGTATGAGGGGCTCTGGGGCTCCATGGGAGTAGAGAGAGAAAGAAATGG
ACTCCAGGACCTCTGGGGTAGGTACATGGGAGTGAGACATGGTACATCTAACCC
TGGCCAGGACAGTAGAGGGCTCTTCCTTCCTGTGATTGGGAACITIYCCATCAAGCTAT
GTAGAAGAACCCATGG

35 (2) INFORMATION FOR SEQ ID NO: 34

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' genomic sequence from 10kb

45 fragment for mouse $\alpha 2\delta$ -B

(iii) MOLECULAR TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

5 CAGGTGGCTGTGGCTGGGOCOCTCTCTGAACACCTCACAGTGGAGACAGGGCTGCC
 ACAGNAGACCCCATCTCTCTCTCAGGGCTGGGGTGGTGGTAACAGGAACCT
 CTOCTGTTCAACCTGACACAGGAATGGGCCGGGGAAAGAAGGTGAGTCTGCCAG
 TGGGTTATCTGGGGAGGGATGGCATGCGAGGCTGGGATGGAGCTGGGATGGAGGGT
 TAGGGCATGCTACAGATTGGCAAAGCAGCTCTGGTATCAGAGCTAACCCCTTGG
 CCTGGGCCAGGGGGTCTACTATGGAGTGGACATATAGCATACCTTCCATTGCTT
 10 TGTGTOCAGAACCAAGTAACTCTGGGATGGCATGGCACTGGATGTGGCTGGAAATGACA
 TCAGAACCAAGGCTGACTCCCACACAGTAAGTGGCACCTGCCCTGGCCCTGGGTT
 GCTGTOCATAGTGACACAAGCCAGACTCACCAAGGGAGACATGGGACGGAAAGACC
 GTCAAGAAAAGACTTCCAAAGGGTTCTGAAGCTGGACAGCAAGC

15 (ii) INFORMATION FOR SEQ ID NO: 35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

25 (B) LOCATION:

(D) OTHER INFORMATION: 1.8 kb mouse genomic sequence for

mouse α 2 δ -B

(iii) MOLECULAR TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GCTTCTCTGTGGCTGGGOCCTCTGGAGTGCCTGAGCTGGCTGGCTCCCTGGGGGC
 CGGCTGCAGGCTTCAAGCAAGCATGCTGGATGGGGGCCAGCTCACAGCTCCCTGCC
 ACCCAGGOGGGCCCTCTCCACAGGCCACAAACACATCAGCCCTGCTTGCTCACCGAG
 GCCTGGATGAGGGTCTGGCTGAGATACTCTTGATGATTTAGAAGGAGGGAGAGCAA
 35 GAAAATCTCCCTGGAAACAGCTGGTGGGGCCACATGAGATGGCTGGAAATCAAAGA
 AAGCCTGGGCAGGCAGAAACAGGGAGGCCATGGAGATGGCTTAGCAGGGGGCG
 ACCTGAACCTCCCAACCCAGCCCTCTGCCCTGCGCTCAGCTACCGTCATCCCAAT
 GAGCTTAACCTGGACAGAGGGCCCTGGAGAACGTCCTCATGAGAACCGTAGGCAAGAC
 CCTACACTGTTG1GCCAAGTCCTTGGCAGTGCACGGGAGTCACTOGTATTACCCAG
 40 GTAGGCACACAGTCCTGGCOCATCCAGCAACCGCTCTGCTCCATCTGCAAGCCTA
 CCCATTCTGAGGTCATGGGTACAATGAACCAAGGTCAATCCCCATCACTCCCGCTG
 CTCCAGTCAGACCCCTCTGCCGGGCGGGCCCTTCACCCCTCTTTCACAGCCACAC
 CATGGCGAGCCCCAAAGAAGATTGACCTGTACGATGTCAGAAGAAGGAODLTGGTGA
 TGACCAAGGGGGGGAGGGAGACACCCCTCAACTTCCATCTGCTGGCCCGCTC
 45 CCCTCCCTCCAATATCCAGACCTCCGAGCAGGGGCGCAGCCAGCTCTATCCAATTTTC
 ATTCAACACATGCTTCACTGGAAAATGGATGGATGGATGGCTTCCAGGGCAAGCCGGCG
 TCCCTCTGGCCCCACACGGTGTGGTCCACTAACCAAGCCCCCCCCAACACCCACTCAGAACT
 GAGAGCAGACCAGGGAGGGTGGCTCCAGGGTAGCTAGAGCCTODGTCAAGGTCAAGGC
 50 GGCCCCACCTACTCTTGTATGGACACGGGGAGACACCCCTCAACTTCCATCTGCTGGCC
 CTACTCCATGATTTCTCTCTCTCTGCTTACACAGCCAGACTCTGTGGAGTCTCT
 AGGACAGAGGGACACAAGCCACTAAAGCCCTCTGTCDGGATCACCTGGCCCTTCC
 CCCTCACCTCTGTCTACTTAAAGGGAAACAGATCACTCACGTCACGTCACAAGAAAAAAA
 AACTGTCTTTGTATTGAGCATGGTCTCCCACTGCCCCAGACCTATTCCAACCCCTG

5 TAGTGCCTGGTCAGTAGAAACACAGGAATCAAGTGGGIGGAAGAAOGGAAGACCCCCC
AGGTGDDGGAGGTGCCCTOCTTAACTGAGTCTCTCACTGGCAAGTATATACAGGGGG
CCTCATCAOCCAAGGACATGGTCATCATTGTGGATGTGAGTGAGCCTTGTAGGCTG
GTGGGATGGCTAGGACTGGACTCTGCTTGTGGCACCTTATGAGGCAAGGGGGGG
AAAACCCCTGAGAGGOCACATGATGATGCCGCCCCCTTGGCTGGTTGGATGAGGAGTGGG
AGCGTGAGGOGGCCCTGACTCTGAAGCTGATGAAGAOGTGGCTGTGAGATGCTAGAC
ACGGCTCTCTGATGATGACTATGTGAACGTGGCCCTGAGTGAGTGGCAAGGTGCGAGGC
ACGGCTGGGTACCACTCAACCCCATCAACCTGCTGGATGACAACCATCAGGCGCTGTA
CACAGCTGCACACTGTGTGGCCAGCCGTGAAGCCACTCACCCACXXXXXXACTGTCCCCA
10 CAG

(2) INFORMATION FOR SEQ ID NO: 36

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primers to amplify rat sequences for

α2S-C, PCR 1

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GACRGGGADCAACAAAGGAGCAC

30 (2) INFORMATION FOR SEQ ID NO: 37

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primers to amplify rat sequences for

α2S-C, PCR 1

(iii) MOLECULE TYPE: cDNA

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GCCAACACACCCAGAAGAAT

-23-

(2) INFORMATION FOR SEQ ID NO: 38

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primers to amplify rat sequences for

α2δ-C, PCR 5

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

AACGCACCATCAAGGAGACCA

(2) INFORMATION FOR SEQ ID NO: 39

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primers to amplify rat sequences for

α2δ-C, PCR 5

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

AGGGGCAGCAGCAGCAAG

(2) INFORMATION FOR SEQ ID NO: 40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: PCR1 product, rat α 2 δ -C

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

TTCAGGGGAGCCATTGGACAAACTTTTGCCTAAACCGATTCCGATGCTGGATATTGGGGCTGACGAC
GCCCTCAATGTACTGAGCGATTTCAACCAACCCGGACAAAGGAAGCATTTCAGCCAGGCCATTATG
CTCATTAACCGATGGGGCARTGGACACCTACGCRYACCATCTTGCAAAAGTACAAATTGGCCAGAGCGA
AAGGTTGCAATCTTCACTTACCTCATGGGAGGAGGGCTGCTTTGAGACACRTCTCAAGTGGATR
GCTTGTGCTAACAAAGGATTTTCAACCCAGATCTCCACCTTGGCTGATGTCAGGAAAATGTCATG
GAATACCCCATGACTGAGTCAGTCACCCANAGTCATGACCCACACATGATGCTGGTGTGGACCCUA
CCCTACATGACAGCAGCTCTCCCTAGGCTCAAAGGTTGCTGATGNTCAAGGGCTCGTCTTGTGNTG
ACCAACAGTGGCCATGCCGTGTGTTAGTAAGCAGAACCAAACTRGGTCARAGGBC

15

(2) INFORMATION FOR SEQ ID NO: 41

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

25 (A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: PCR5 product, rat α 2 δ -C

(iii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

CAGGGAACATTGCTTGTGAGAYTGCTCCAGTCCTTTGTATCCAGCAAAATCCCAAGTAGCAATC
TGGTCATGGYGGTGGTGGACAGTAGCTGCTCTGTGACTCTGCTGGCTCCJATCACCATGGCACCCA
TTGAAATCAGGTATAATGAATCCCTTAAGTGTGAAAGGTTAAAGGCTCAEAAGATCAGACACCACCTC
CGGAATCTGMCACGGCTCCATCCTGAGGAGAAATGCGAGAGAGTGTGGGGTGCATCAAGTCTCC
AGGCCAGGT

40 (2) INFORMATION FOR SEQ ID NO: 42

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

45 (ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(D) OTHER INFORMATION: Human α 2 δ -D variant

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

5 MPATPNFIANPSSSSRWIPLQPMPPVAVAFVQKTSALLWLLLLG1SLSPA WGQQAKIPLTV
 KIWADTFGGDLYNTVKYSGLLLQKKYKDVESSLKIEVDGLELVRKPSEDMENMLRR
 KVEAVQNLVBAABEADLNHEFNESELVFDYYNSVLINEDEKGNIKVELGAEFLLESNAHFS
 NLPVNTSISSVQLPTNVYRKDPDILNOVYMSAELNAVVENFQRDPTLTWQYPGSATGFF
 RIYPGIKWTPDENGVITFDRCNRGWCYIQLAATSPKDIVLVDVSCSMKGLRMTIAKIIITTI
 LDTLGRBNDFXNIIAYNDYVHYIEPCFKGILVQADRDNREHFKLLVEELMVKGVCVVDQAJ.
 10 REARQILKQFQBAKQGSCLCNQAIMLJSIDGAVEDYEPYFEKYNWPDCKVRVPTYLIGRBVSP
 ADRMKWIAACNNKGYYTQI8TLADTQENVMBYLHVLSPRMVINHDIDIWTEAYMDSKII.
 SSQAQSLTLLTTVAMPVFSKKNBTTRSHGILLGVVGSVALRRIMKIAPRYKLGVHGYAFL
 NTNNGYILSHPDLRPLYRBGKLKPKPNYNNSVDLSEVEWEDQARSIRTAMTNRETGTLSM
 DVKVPMDKCKRVLPLTDYFYJDIISDTPESLGVVLSRGHGRYILLGNTSVBRGI.HDLLHPD
 15 LALAGDWIYCITDIDPDHRKLSQLRAMIRFLTRKDPLBCTDBELVRVVI.PDAVVTAPMBA
 YWTALALNMSEESETIVVDMAFLGTRAGLLRSSLPVGSEKVSDRKPI.TPDBASVFTLDRE
 PLWYRQASEEPAGSFVFNI.RWABGPBSAGEPMVWVASTAVAVTVDKRTAIAAAAGVQM
 KLEPLQRKFWAATRQCSTVDGPCTQSCESDLDCTVIDNNGFIIJSKRSRRTGRFLGEVODG
 20 AVLQQLLSMGVFSQVTMYDYQAMCKPSSHHSAAQPLVSPISARLTATRWLLQBLVVS
 GGRHGAGGCCMRGWLRRLVSLIRRLQQLQDNPLATKTPGKEGTIPGHGRHLPPACPLGG
 TELLNQSPQAGKRVSWRRGDGPGAVRDTAPWEPKSGGLRGLRDSVLCLTGSCWSGVSG
 APGTTIEGPRVSARSCRAMC

(2) INFORMATION FOR SEQ ID NO: 43:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 30 (ii) MOLECULE TYPE: cDNA

(iix) FEATURE:
 (A) NAME/KEY: Coding sequence
 (B) LOCATION:
 (D) OTHER INFORMATION:>1907 α28 C, potent, soluble form

35 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

40 TACTATAAGGGCGCGCCCGCGNATTCCGGCACCGAGGCAGCGAGCTAGCCCCCGCGCGCTC
 GCCCACCGCCCCCCCCTCCGCGCAGCTCCUCCGCGCGC'CTCGTCGCCCCCGCAAGCGCGCGGTUGGA
 GGGAGGCCAGGCTGGCCGGGGCGTCCCCCCCCCCCCCGTCCCGGGGGCGCTCGCCCGCTTCCTCG
 CTGGCGCGCTCTCTACCCCCCGCGCTGGGGAGCTGGGGAGATAAAATCATTGCTGCTAAGTACTCCGGTT
 TGTTGAAGCTCTGGGCCTCGGCTTTGGGGAGATAAAATCATTGCTGCTAAGTACTCCGGTT
 CCCAGCTTCGAAAAGAAAATACAAAAGAGTATGAGAAAAGACGCTTGCTTAAGGAAATTGATGCC
 45 TCCAACTGGCTAAAGAAAGCTGGCAAAAGAACATGGAAAGAGATGTTCACAAAGAAGTCTGAGGCCGTCA
 GGGGTCTGGTGGAGGTGCAGAAGAAGAACACCTGAAACATCAATTGATCCAGACTTACAGTATG
 AATACTTCATGCCTGTGCTGATAAAATGAAAGGGACAAAGACGGGAATTTTGGAGCTGGGAAGGG
 50 AATTCACTCTTAGCCCCCAGTACCATTTAAATTCGCTGAAACATCTGCTAAGTGGCGTCC
 AACTACCAACCGAACATGTACAACAAAGACCCUTGCAATTGCTAATGGGTTATGGGCTGAAATCTC
 TAACAGTTTTGTAGATAACTTTRACCGTGACCCATCTCTCATATCGCACTTACAGTATGGAAAGTG
 CAAAGGGCTTTTACCGAGTATCCGGGGATTAAATGGGAACCGAGATGAGAATGGAGTCATTGCT
 TCAGCTGGAGAACCGAATGGTACATCGAGGCAACTTCTCCGAAAGACGTGGTCATTTCAG
 TTGACGCTAGTCCCAGCATGAAGGGACTCUGTCTGACTATCGCGAAGCAACAGTCTCATCCATT
 TGGATACACTTGGGGATGATGACTCTTCACACATAATTCTTATAATGAGGACCTCACATATGTGG
 AACCTTGCTGAATGGAACCTTGGTGCAAGCCGACAGGAAACAAAGAGCAGTCAGGGAGCAGTC

TGGGACAAAATTTCTGCCAAAGGAATTGGAAATGGTGGATAACYCTGAAATGAGGCCCTCAGAACATTG
TGAGTGATTTCAACCACACCGACAAGGAAGTATCTGCACATCACCCCATCATGCTCATAGTGATG
GGGCGGTGGAAACCTATGATACAAATTTGCAAAATACAAATGGCCAGATCGAAAGGTTCGATCT
TCACATACCTCATGGAGGAGGGCTGGCGTTGCAGAACATCTAAGTGGATGGCCCTGTGCCAACCA
AAGGATTTTACCCAGATCTCCACUUTGGCTGATGTCACCUAGAAATGTCATUCAATACCTTCACG
TGCTTAGCCCCCCTAAAGTCATCGACAGBAGCATGATGTGGTGTGGACCCGAGCTTACATTGACA
GCACTCTGACTGATGATGAGGGCCCGTCTGATGACCATGTCAGCCATGCTGTGTTAGTAAGC
AGAAUGAAACCAAGATCGAAGGGCATTCCTCTGGAGTGGTGGCACAGATGTCAGTGGAAAGAC
TTCTGAAGACCCATCCCCAAATACAAGTTAGGGATTCAACGGTTATGCCCTTCCAAATCACAAATAATG
GATATATCTGACGGCATCCGGAACTCNGGCTGCTGATCGAAAGAAGGAAAGGCGAAGGGAAACCTA
ACTATACTAGCGTTGAACTCTCTGAGGGTGGAGTGGGARGACCCGAGATGACGTGTTGAGAAATGCTA
TGGTGAATCGAAAGACGGGAGTTTCCATGGAGGTGAAAGAAGACAGTGGCAAAAGGGGGTACATT
TTTCTCAAACATTTTGCTGCTTAATTAAAAACAAACCTCTCAAAATTAAGCTTTGAAAGCTAT
ATCTGGAAATAAAATCTTCTGCCGTGAAGG

(2) INFORMATION FOR SEO ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
 - (B) TYPE:
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- ## FEATURE:

(A) NAME/KEY: G

- Digitized by srujanika@gmail.com

6.1.1. MOLECULE TYPES: SPAN

44-11 SEQUENCE DESCRIPTION: SEQ ID NO: 44.

TACTATAGGGCCGCCGCGAATTGGCAAGGGCGGCAGGGAGCGGAGCAGGGAGCGGAGCGCT
GCCUACCGCCCCCTCGCGCAGCTCCCCGCGGGCGCTCTCGTCGCCCGCAGCGGGCGCGCTCGGA
GGGAGCCCAGCATGGCCGGGGCGGGCTCGCGCGCGCGUGTUCGGGGCGCTCGCGCTCTCG
CTGGCGGGCGCTCTCGACCCCCCGCTGGGGAGCTGGTGTGCCCTGGAGACAGCGAGTACCGCTCTCG
TGGTGAAGCTCTGGGCTCGGCTTTGGTGGGGAGATAAAATCCATTGCTGCTAAGTACTCCGGTT
CCCAGCTCTGCAADAGAAATACAAAGAGTATGAGRAAGACGCTTGCCATAGAGAAAATTGATGGCC
TCCAACCTGGTAAGAGGCTGGCAAAGAACATGGAGAGAGTCTTCAAAAGAAGTCGGAGGCCGTCG
GGCGTCTGGTGGAGGCTGCCAGAGAACAGCACCTGAAACATGAAATTGATGCAAGACTAACGTATCG
AAATACCTCAATGCTGTGCTGATAAAATGAAACGGACAAAGACGGGAATTTCGGAGCTGCCAAAGG
AAATTCACTCTAGCCCCAAATGACCATTTCATATTTCGGCTGTGAAACATCAGTCAGTCAGTCAGTC
AAGTACCAACGAAACATGACACAAAGACCCCTGCCATTGTCATGGGTTTATTGGTCTGAAATCTC
TAAACAAGCTTTTGTRGATAAAGTCTTGGACCGTGACCCATCTCTCATATGGCAGTACTTGGAAAGTG
CAAAGGGCTTTTAGGCAGTATCGGGGATTAAARTGGGAACCAAGATGAGARTGGAGTCATTGCCCT
TCGACTGCAAGAACCGAAAAATGGTACATCCAGGCGCAACTTCTCCGAAAGACGTTGGTCATTTCAG
TTCAGCTCAAGTGGCAGCATGAAAGGACTCGCTGTGACTATCGCPAGCRAACAGTCATCCATT
TGGATACACTTGGGATGATGCTUTGCAACATAATTGCTTATAGAGGGAGCTTCAGTATGTGCG
AACCTTGCCTGAAAGGAACTTGGTGCAGACGGGACAGGACAAACAAAGAGCACTCAGGGAGCAGTC
TGGACAAACTTTGCCAAAGGAATTGGAAATGTTGGATATAGCTCTGAAATGAGGCGCTTCAGCATTC
TGAGTGAATTCAACACACGGGACAGGAAGTATCTGCAGTCAGGCCATCATGCTCATTAAGTGTG
GGCGCGTGGACACCTATGATACAACTTGGCAAAAGACAGTATGGCGAGATUGAAGGAGCTCGCATC
TCACATACCTCATGGAGAGAGGCTGGCTTGGCAAGACAACTTAAAGTGGATGGCCTGTCGCCAAACA
AAGGATTTTACCCAGATCTCCACCTTGGCTGATGTGCAACAGAAATGTCATGGAATACCTCACC
TGCTTAGCCGGUCRAGTCAAGACACGGAGCATGATGTGGTGTGGACCGAGCTTACATGAC

GCACTCTGACTGATGATCAGGGCCCCGTCCTGATGACCACTGTAGCCATGCCCTGTGTTTAGTAA
 AGAACGAAACCAAGATCGAAGGGCATTCCTGGGAGTGGTTGGCACAGATGTCCTGGAAAGAAC
 TTCTGAAAGACCATCCCCAATTAACACTTAGCCATTCACGUTTATGCCCTTGCAATCACAAATAATG
 5 GATATATCCTGACCCATCCGGAACTCAGGGATGCTGTACGAAAGAAGAAAAGCCGAAACCAACCTA
 ACTATAGTAGCCTTGACCTCTGAGGTGGAGTGGGAAGACCCGAGATGACGTGTTGAGAAATGCTA
 TGGTGAATCGAAAGACGGGGAAATTTCCTGGAGGTGAAGAAGACAGTGGACARAGGGAAACGGG
 TTTCTGATGACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTCAGTTAGGTGTGG
 CGCTTTCAGAGGTCAAGGGAAATTATTCTCCACCCGAACTGTAACCAATGAAAGGGCCCTGCATC
 10 ACTTAGAACATCCCAGTGTGTCAGTTAGAAGCGATTAAGCTCTACCTAAAGGCAANGAACCTCTGCTCC
 AGCACUGCCATCTGTCAGTTAGAAGCGATTAAGCTCTACCTAAAGGCAANGAACCTCTGCTCC
 AGTGTGATAAGAATTGATCCAAGAAGTCUUTTGAGCCGGTGGTGAAGTGCDCCCCATTGAAAGCGT
 ATTCGACCGNGCTBGCCTCTCAAAATCTGAAATTCTGAAATTCTGAAAGGCTGGCCCTGCAGGACT
 GCACTCGCAGGGGCTCTCCACAACTCAACCTGTTGTCGGGGCTGAGCAGCAGAACCTGAGGAACT
 15 TCCCTGAAAGCTGGGCAAGGGAGAACATTTTAACGCAAGGCAATTCTCTCTGAACTGGAGAG
 CUCCTGAGCAGATTCCAGGGAGCTTCGCTACTCGATCCCATTAGCACTGGACCCAGTCATAAAA
 GCAATGTCGGTGAAGGCAACTACATCCATCCATTCTCCATGCAAGGGAAATTCTCTGACTGCAAG
 CTGTAAGGCATTCAAGAAGAAACTTCAATTTCCTGAGACTCTGCTGATGAGTGGAGACTGGGAGACT
 20 CTTCCCTGGATGGCAAATGCTCCATCAGCTGTGATGAGTGGAGACTGGGAGACTTTTGAGATGCG
 AGGGAGCTGTGATGAAACAAATTGCTAACAAATTGGCTCTTTAAAGAATTACCCCTTTATGACTAAC
 AGGCAATGTCGGTGAAGGCAACAAAGGAAACCGGATGGGGCCATGGGCTCTGGATCCAGAAAATT
 GAAACAGACCCCTGGACCCCTGTGATGACTGAAATTCCTGAGACTCTGCTCCATCCAGGATTCTCTG
 GACTACAGGGAAATTTCCTTGTGAGACTCTGCTCCATGAGCTGGGAGACTGGGAGACTGGGAGACT
 25 CAACCTGTTCATGGTGGTGGACAGCAACTGCTCTGCTGAACTCTGCTCTGCTGAACTCTG
 ACCCATTGAANTCAGGTATAATGAAATCCCCATGAGCTGAGCCTAAAGGGAGACTGGGAGACTGG
 GCGCCCAGAAATCTTGTGATGGCTCCATCTGAGGACAATGCAAGGGAGTGIGGGGGTGCCCCGAC
 TCTCCAAAGCCCAGACAGPCTCTCTGCTCCCTCTGCTTTGATGCTCTCTCAAGGTGACACTG
 ACTGAGATGTTCTCTACTGACTGAGATGTTCTCTGCTGATGCTAAATCATGGATAAACTGTGAAAC
 30 CAAAATATGTCACAACTACGAGACATGAAATATACTGCAACCATCAGCATCTCATGATTTAA
 ACTGTGCGTGTATAAACTCTTAAAGATATGTCACAAAAGTATCTATCATCTTTTACTTTC
 CAGTCATGCAAAATGTGAGTTGCAACATGTAATCACCCCTCATCACAAATGGGACCCAAAGTGGT
 AGGCAGTGTCCTCTGCTGAAACCTATTGAAACCAATTAAACTGTGATGTTTAAAG
 TATATTAATCATAAANAAAAAA

35 (2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(i.) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: adapter primer

(i,i.) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

50 CCATCCTAATACGACTCACTATAGGGC

(2) INFORMATION FOR SEQ ID NO: 46:

-28-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: adapter primer

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

ACTCACTATAGGGCTCGAGCGGC

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: probe for Northern blot

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

CTGTGAGTGAGCTGTAGCCATTGAGATGAACTTCATTTTCCAAAGGAACCTCTGGACTGCCA
GAGAGAGGTGTGCTTCCCTGGATGCCAAATGCTCCATCACCTCTGATGATGAGACTGGAGACTTTT
TTGGTGAGATCGAGGGAGCTGTGATGAAACAAATTGCTAACAGGAGGGCTCTTTAAGAATTACCC
TTTATGACTACCAAGMCATETGTAGAGCCAACARGGAAAGCAGCGATGGGCCCATGGCCTCTGG
ATCCCAGAAATTGAAACAGACCCGGAGCTTGTGATACTGAAATATCCAGCAGTCGTCCTCTGAGCG
CACCATCAAGGGAGACJACAGGAAATATTGCTTGTGAAGACTCCCTCIAACTCCCTTGTCACTCCAGCA
AATCCCAAGCAGCAACCTCTTCATGGTGGTGGACAGCAACTCCCTCTGTGAATCTGTGGCCCC
CATCACCATGGCACCCATTGAAATCAGGTATAATGAATCCCTTAAAGTGTGAACGTCTAAAGGCCCA
GAAGATCAGAAGGCAGCCAGAATCTTGTATGGUTCCATCTGAGGAGAAATGCAAGGGAGTGTGG
GGGTGCAGCAGACTCTCAGGAGACAGACAGTCCTCTGCTCCCTCTGCTTGTGATGCTCTTC
AAGGTGACACTGACTGAGATGTTCTCTACTGACTGAGATGTTCTCTGGCATGCTAAATCATGGA
TAAACTGTGAACTTAAATATGGTGCACATACAGAGACATGAATATACTCCAAACCATCAGCATCTCA
TCATGATTTAAACTGTGCGTGAATATAACTCTTAAAGATATGTTGAACAAAGTTATCTATCATC
TTTTTACTTTGCCAGTCATGCAAAATGTGAGGTTGCAACATGATAATCACCCCTCATCAGAAATGGG
ACCGCAAGTGGTAGGCAAGTGTCCCTCTGCTTCAAACTATTGAAACCAATTAAAATCTGTACT
TTTAAATAAAGTATAATTAAATCATAAAAA

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single

- 29 -

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(i.x) FEATURE:
(A) NAME/KEY: Coding Sequence
5 (B) LOCATION:
(D) OTHER INFORMATION: Edge 5' primer
(iii) MOLECULE TYPE: cDNA

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:
CTAGAGGCCATGATCCGCTTCCTCAC

(2) INFORMATION FOR SEQ ID NO: 49:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
20 (ii) MOLECULE TYPE: cDNA
(i.x) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: Edge 3' primer
(iii) MOLECULE TYPE: cDNA
25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:
GUCCACCGAACAGCTGGCTC

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, C07K 14/705, 14/47, 16/18, 16/28, C12Q 1/68, A61K 38/17, G01N 33/68, A61K 48/00		A3	(11) International Publication Number: WO 00/20450
			(43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/23519			(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 7 October 1999 (07.10.99)			Published <i>With international search report.</i>
(30) Priority Data: 60/103,322 7 October 1998 (07.10.98) US 60/106,473 30 October 1998 (30.10.98) US 60/114,088 29 December 1998 (29.12.98) US			(88) Date of publication of the international search report: 23 November 2000 (23.11.00)
(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): JOHNS, Margaret, Ann [US/US]; 2800 Deake Avenue, Ann Arbor, MI 48108 (US). MOLDOVER, Brian [US/US]; 4893 S. Ridgeside Circle, Ann Arbor, MI 48105 (US). OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US).			
(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			

(54) Title: CALCIUM CHANNEL ALPHA-2/DELTA GENE**(57) Abstract**

The present invention relates to three novel genes and polypeptides derived therefrom encoding " α 2 δ -C" and/or " α 2 δ -D" proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/23519

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12N15/12 C07K14/705 C07K14/47 C07K16/18 C07K16/28
 C12Q1/68 A61K38/17 G01N33/68 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, STRAND, MEDLINE, BIOSIS, SCISEARCH, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA190607, 21 January 1997 (1997-01-21) HILLIER, L. ET AL.: "zq44e03.r1 Stratagene hNT neuron, Homosapiens cDNA clone IMAGE: 632572 5' similar to TR:G179762 G179762 Calcium Channel Alpha-2B subunit; mRNA Sequence" XP002136760 see the whole document: 97,6% identity in 413bp overlap with SEQ ID No. 3; 96,8% identity in 340bp overlap with SEQ ID No. 43; 97,6% identity in 413bp overlap with SEQ ID No. 44</p> <p>---</p> <p style="text-align: center;">-/-</p>	1,2,22, 23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 July 2000

Date of mailing of the international search report

24.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Alt, G

INTERNATIONAL SEARCH REPORT

Final Application No
PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! AC Z44942, 6 November 1994 (1994-11-06) AUFFRAY, C. ET AL.: "Homo sapiens partial cDNA sequence; clone c-2dd03" XP002136761 see the whole document: 99,7% identity in 340 bp overlap with SEQ ID No. 3; 100% identity in 17bp overlap with SEQ ID No. 11 ---	1,2,22, 23
X	DATABASE EMBL 'Online! AC R20288, 23 April 1995 (1995-04-23) HILLIER, L. ET AL.: "yg20f03.rl Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:32708 5', mRNA sequence" XP002136762 see the whole document: 97,6% identity in 340 bp overlap with SEQ ID No. 3 ---	1,2
X	DATABASE EMBL 'Online! AC AA459684, 13 June 1997 (1997-06-13) HILLIER, L. ET AL.: "zx49d08.s1 Soares testis NHT Homo sapiens cDNA clone 759567 3' EST" XP002136763 see whole document: 100% identity in 304bp overlap with SEQ ID No. 3 ---	1,2
X	WO 95 04822 A (SALK INST BIOTECH IND) 16 February 1995 (1995-02-16) see SEQ ID No. 31: 34,4% identity in 540 aa overlap with SEQ ID No. 5; 29,1% identity in 1122aa overlap with SEQ ID No. 6; ---	8
X	DATABASE EMBL 'Online! ACAC005343, 4 August 1998 (1998-08-04) MUZNY, D. ET AL.: "Homo sapiens chromosome 12p13.3 BAC RPCI 11-21K20 (Roswell Park Cancer Institute Human BAC Library) complete sequence" XP002143146 see the whole document: 98,5% identity in 1847 bp overlap with SEQ ID No. 4, 15, 16; ---	1,2,22, 23
X	DATABASE EMBL 'Online! AC AA719773, 7 January 1998 (1998-01-07) HILLIER, L. ET AL.: "zh38g01.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 414384 3'" XP002143147 see the whole document: 98,4% identity in 436 bp overlap with SEQ ID NO. 4 ---	1,2,22, 23
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA001473, 20 July 1996 (1996-07-20) HILLIER, L. ET AL.: "ze45d04.r1 Soares retina N2b4Hr Homo sapiens cDNA clone 361927 5'" XP002143148 see the whole document: 97,8% identity in 489bp overlap with SEQ ID NO. 4, 15, 16</p> <p>---</p>	1,2,22, 23
X	<p>WO 98 11131 A (CHEN AI RU SUN ;FRANCO RODRIGO (US); AMERICAN HOME PROD (US); SHUE) 19 March 1998 (1998-03-19) see SEQ ID NO.4: 29,0% identity in 1129aa overlap with SEQ ID No. 6</p> <p>---</p>	8
X	<p>DATABASE EMBL 'Online! AC Z75742, 9 July 1996 (1996-07-09) WILKINSON; J.: "Human DNA sequence from cosmid LUCA10 on chromosome 3p21.3 contains ESTs" XP002143149 see the whole document: 82,8% identity in 87bp overlap with SEQ ID No. 33</p> <p>---</p>	23
A	<p>DATABASE EMBL 'Online! AC AB011130, 10 April 1998 (1998-04-10) OHARA, O. ET AL.: "Homo sapiens mRNA for KIAA0558 protein, partial cds." XP002143150 see the whole document; 100% identity in 1145aa overlap with SEQ ID No. 2</p> <p>---</p>	22-26,34
Y	<p>GEE N S ET AL: "THE NOVEL ANTICONVULSANT DRUG, GABAPENTIN (NEURONTIN), BINDS TO THEALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5768-5776, XP002022221 ISSN: 0021-9258 cited in the application see the whole document</p> <p>---</p> <p style="text-align: center;">-/-</p>	34

INTERNATIONAL SEARCH REPORT

Final Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BROWN J P ET AL: "CLONING AND DELETION MUTAGENESIS OF THE ALPHA 2 DELTA CALCIUM CHANNEL SUBUNIT FROM PORCINE CEREBRAL CORTEX" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 39, 1998, pages 25458-25465, XP000887190 ISSN: 0021-9258 see the paragraph bridging pages 25461-25462 ---	34
P,X	KLUGBAUER, N. ET AL.: "Molecular diversity of the calcium channel alpha 2 delta subunit" NEUROSCIENCE, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 684-691, XP000886459 see Figure 1; 89,4% identity in 1902bp overlap with SEQ ID 3; 94,0% identity in 251bp overlap with SEQ ID No. 14; 94,8% identity in 561 bp overlap with SEQ ID NO. 40; 96,0% identity in 273bp overlap with SEQ ID No. 41; 88,0% identity in 1494bp of SEQ ID NO. 43; 88,1% identity in 1494bp overlap with SEQ ID NO. 44; 57,1% identity in 2962bp overlap with SEQ ID No. 4; 65,6% identity in 1454bp overlap with SEQ ID NO. 15; 65,6% identity in 1454bp overlap with SEQ ID No. 16; ---	1,2,4, 6-10,22, 23
E	WO 00 12711 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); CORLEY NEIL C (US); REDDY R) 9 March 2000 (2000-03-09) see SEQ ID No. 28: 98,1% identity in SEQ ID No. 28: 1276bp overlap with SEQ ID 3; 89,5% identity in 516bp overlap with SEQ ID No. 40; 98,0% identity in 1276bp overlap with SEQ ID No. 43; 98,1% identity in 1276bp overlap with SEQ ID No. 44; 67,0% identity in 1268bp overlap SEQ ID NO. 4 and SEQ ID No. 28; 67,0% identity in 1268bp overlap with SEQ ID No. 15; 67,0% identity in 1268bp overlap with SEQ ID No. 16; ---	1,2,8, 22,23

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WILLIAMS, M.E. ET AL.: "Structure and functional expression of alpha 1, alpha2, and beta subunits of a novel human neuronal calcium channel subtype" NEURON, vol. 8, January 1992 (1992-01), pages 71-84, XP000886416 see Figure 3; last paragraph, second column, page 84 -----	1
A	WALKER, D. AND DE WAARD, M.: "Subunit interaction sites in voltage-dependent Ca ²⁺ channels: role in channel function" TRENDS IN NEUROSCIENCES, vol. 21, no. 4, 1998, XP000887176 cited in the application see the whole document -----	1

INTERNATIONAL SEARCH REPORT

B x I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 19, 20, 31-33
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta C protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 3; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 5; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta C"; claims 22-26 as far as they relate to SEQ ID Nos. 11, 14, 40, 41, 43, 44, 47-49; claims 34 as far as it is related to accession nos. from AU022914.1 to AI051759.1 and SEQ ID Nos. 3, 5, 9-14, 36-41, 43, 44, 47

2. Claims: 1-26 (all partially), 27-30, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta D protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 4; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 6; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta D"; claims 22-26 as far as they relate to SEQ ID Nos. 15, 16, 21-24; claim 34 as far as it is related to accession nos. from T70594.1 to AA001473.1 and SEQ ID Nos. 4, 6, 15, 16, 18-24, 42, 45, 46, 48, 49.

3. Claims: 22-26, 34

subject-matter related to calcium channel alpha 2 delta B protein: claims 22-26 as far as they relate to SEQ ID Nos. 31-35; claim 34 as far as it relates to accession no. AF040709.1 and accession nos. from T80372.1 to Z84492.1 as well as SEQ ID Nos. 1, 2, 7, 8, 25-35.

4. Claim : 34 (partially)

method of using polynucleotides sequences to identify the binding potential of polynucleotide sequences to gabapentin: claim 34 as far as it is related to accession nos. not mentioned before

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 33 directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 19, 20, 31, 32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 19, 20, 31-33

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/23519

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9504822 A	16-02-1995	US	5874236 A	23-02-1999
		AU	3390499 A	19-08-1999
		AU	707793 B	22-07-1999
		AU	7632294 A	28-02-1995
		EP	0716695 A	19-06-1996
		GB	2284814 A, B	21-06-1995
		JP	9509041 T	16-09-1997
WO 9811131 A	19-03-1998	US	6040436 A	21-03-2000
		AU	4343097 A	02-04-1998
WO 0012711 A	09-03-2000	AU	6137699 A	21-03-2000

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 April 2000 (13.04.2000)

PCT

(10) International Publication Number
WO 00/20450 A3

(51) International Patent Classification?: **C12N 15/12, C07K 14/05, 14/47, 16/18, 16/28, C12Q 1/68, A61K 38/17, G01N 33/68, A61K 48/00**

(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 et al. (US).

(21) International Application Number: **PCT/US99/23519**

(81) Designated States (national): AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA.

(22) International Filing Date: **7 October 1999 (07.10.1999)**

(25) Filing Language: **English**

(84) Designated States (regional): ARJPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: **English**

Published:
— With international search report.

(30) Priority Data:
60/103,322 7 October 1998 (07.10.1998) US
60/106,473 30 October 1998 (30.10.1998) US
60/114,088 29 December 1998 (29.12.1998) US

(88) Date of publication of the international search report:
23 November 2000

(71) Applicant (for all designated States except US):
WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(48) Date of publication of this corrected version:
5 April 2001

(72) Inventors: and
(75) Inventors/Applicants (for US only): **JOHNS, Margaret, Ann [US/US]; 2800 Deake Avenue, Ann Arbor, MI 48108 (US). MOLDOVER, Brian [US/US]; 4893 S. Ridgeside Circle, Ann Arbor, MI 48105 (US). OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US).**

(15) Information about Correction:
see PCT Gazette No. 14/2001 of 5 April 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A3
WO 00/20450 A3

(54) Title: **CALCIUM CHANNEL ALPHA-2/DELTA GENE**

(57) Abstract: The present invention relates to three novel genes and polypeptides derived therefrom encoding " $\alpha 2\delta$ -C" and/or " $\alpha 2\delta$ -D" proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.

-1-

ALPHA-2/DELTA GENE

FIELD OF THE INVENTION

The present invention relates to novel genes and polypeptides derived and identified therefrom encoding polypeptides related to the alpha-2-delta (" $\alpha 2\delta$ ") protein that is a subunit of the voltage-sensitive calcium channel. In particular, three human novel genes and polypeptides derived and identified therefrom encoding three human polypeptides related to the $\alpha 2\delta$ protein are disclosed. The invention also describes vectors and host cells comprising the novel genes. The invention also describes methods for using the novel genes, polypeptides, and antibodies specifically targeting the polypeptides in the detection of genetic alterations of the gene, subcellular localization of the polypeptide, gene therapy applications, diagnostics for syndromes associated with altered $\alpha 2\delta$ expression, such as neurological diseases and disorders, diabetes, cancer, and other diseases associated with $\alpha 2\delta$ expression, and binding assays in connection with chemical databases, specifically, development of proprietary screening strategies for molecules which modify $\alpha 2\delta$ protein activity.

BACKGROUND OF THE INVENTION

The voltage activated calcium channels ("VSCCs") of vertebrates have been shown to be involved in a variety of different physiological processes including muscle contraction, insulin release from the pancreas, and neurotransmitter release in the nervous system (Greenberg D. Annals of Neurology, 1997;42:275-82; Catterall W.A., Trends in Neurosciences, 1993;16:500-506; Catterall W., Epstein P.N., Diabetologia, 35(Suppl 2:S23-33) 1992; Birnbaumer L., et al., Neuron, 1994;13; Rorsman P., et al., Diabete Metab., 1994;20:138-145).

VSCCs are most highly expressed in excitable tissues including brain, skeletal muscle, and heart. They are multiprotein complexes composed of a

-2-

central $\alpha 1$ pore-forming subunit variably associated with beta, gamma, and/or an $\alpha 2\delta$ subunit. Nine different functional classes of VSCCs have been described, based on biophysical and pharmacological studies. These functional classes are mainly determined by the $\alpha 1$ subunit composition. The beta, gamma, and $\alpha 2\delta$ subunits modulate channel function, affecting the kinetics of activation and inactivation, voltage-dependence, peak amplitude, and ligand binding. Walker N., De Waard M., Trends in Neurosciences, 1998;21(4):148-154.

A number of compounds useful in treating various diseases in animals, including humans, are thought to exert their beneficial effects by modulating functions of voltage-dependent calcium channels. Many of these compounds bind to calcium channels and alter cellular calcium flux in response to a depolarizing signal. However, a lack of understanding of the structure of channel subunits and the genes that code for them has hampered scientists both in discerning the pharmacology of compounds that interact with calcium channels and in the ability to rationally design compounds that will interact with calcium channels to have desired therapeutic effects. The lack of understanding is due in part to the fact that it has not been possible to obtain the large amounts of highly purified channel subunits that are required to understand, at the molecular level, the nature of the subunits and their interactions with one another, with the cell membranes across which the channels allow calcium ions to pass, with calcium and other ions, and with low molecular weight compounds that affect channel function.

Further, the lack of information on genes that code for calcium channel subunits has prevented the understanding of the molecular properties of the mature calcium channel subunits and their precursor proteins (i.e., the mature subunits with signal peptides appended to the amino-terminus) and the regulation of expression of calcium channel subunits. An understanding of these properties, and of how expression of calcium channel subunits genes is regulated, may provide the basis for designing therapeutic agents which have beneficial effects through affecting calcium channel function or concentration. Furthermore, the availability of sequences of genes coding for calcium channel subunits would make possible the diagnosis of defects, which might underlie a number of diseases, in genes coding for such subunits.

-3-

5 Expression experiments in *Xenopus* oocytes have demonstrated that in order to produce fully functional calcium channels, the $\alpha 1$ and $\alpha 2\delta$ subunits must both be expressed. Absence of the $\alpha 2\delta$ subunit results in a nonfunctional channel, even though the $\alpha 1$ subunit, through which ions flow, is fully expressed. Indeed, not only the ion flux through these channels, but the pharmacological properties of the $\alpha 1$ are different in the absence of the $\alpha 2\delta$ subunit. The $\alpha 2\delta$ subunit, therefore, is a critical component of VSCCs and one that must be studied if one is to better characterize VSCC function.

10 A detailed understanding of VSCC operation is beginning to reveal some mechanisms for interceding in the progression of diseases associated with abnormal VSCC functions. US Patent No. 5,618,720, which issued April 8, 1997, references $\alpha 1$ and $\alpha 2\delta$ subunits and the polynucleotide sequences that encode the subunits. The publication, however, does not disclose any additional $\alpha 2\delta$ subunits and in light of the importance of the $\alpha 2\delta$ subunit, it can be understood that the 15 identification and characterization of new $\alpha 2\delta$ subunits and the genes encoding these subunits would advance molecular genetic and pharmacological studies to understand the relations between the structure and the function of VSCCs.

20 Also, a further understanding of the biochemical mechanisms behind these subunits and their effect on mammals may lead to new opportunities for treating and diagnosing diseases related to abnormal (high or low) VSCC operation. Stated another way, a better understanding of the molecular mechanisms of VSCC operation will allow improved design of therapeutic drugs that treat diseases related to abnormal VSCC expression, and specifically abnormal $\alpha 2\delta$ expression.

25 The cDNAs, oligonucleotides, peptides, antibodies for the $\alpha 2\delta$ proteins, which are the subject of this invention, provide a plurality of tools for studying VSCC operations in various cells and tissues and for diagnosing and selecting inhibitors or drugs with the potential to intervene in various disorders or diseases in which altered $\alpha 2\delta$ expression is implicated. Such disease states affected include epilepsy and other seizure-related syndromes, migraine, ataxia and other 30 vestibular defects (for review, Terwindt, GM et. Al., Eur J Hum Genet 1998 Jul-Aug; 6(4):297-307), chronic pain (Backonja M, JAMA 1998 Dec 2;280(21):1831-6), mood, sleep interference (Rowbotham M, JAMA 1998 Dec

-4-

2;280(21):1837-42), anxiety (Singh et al., Psychopharmacology 1996 Sep. 127(1): 1-9), ALS (Mazzini L et. Al., J Neurol Sci 1998 Oct, 160 Suppl 1:S57-63), multiple sclerosis (Metz L, Semin Neurol 1998;18(3):389-95), mania (Erfurth A, et al., J Psychiatr Res 1998 Sep-Oct;32(5):261-4), tremor (Evidente VG, et al., Mov Disord 1998 Sep;13(5):829-31), parkinsonism (Olson WL, et al., Am J Med 1997 Jan;102(1):60-6) substance abuse/addiction syndromes (Watson, WP et al., Neuropharmacology 1997 Oct;36(10):1369-75), depression, and cancer, since at least one $\alpha 2\delta$ gene is located in a region of the genome which is thought to harbor an important tumor suppressor gene (Kok K., et al., Adv Cancer Res 1997;71:27-92).

The $\alpha 2\delta$ gene is also thought to play a part in proliferative diseases other than cancer, such as inflammation. Treatment with compounds which bind to $\alpha 2\delta$ lead to changes in the signal transduction mechanism of certain proteins. This includes altered levels of MEK (eg, MEK1 and MEK2) which activates the MAP kinase. Inhibitors of MEK appear to mimic the analgesic activities associated with the binding of gabapentin to $\alpha 2\delta$. Activation of MAP kinase by mitogens appears to be essential for proliferation, and constitutive activation of this kinase is sufficient to induce cellular transformation.

20

SUMMARY OF THE INVENTION

While the $\alpha 1$ subunit is known to be coded for by 9 genes, the beta subunit by 4 genes, and the gamma subunit by 2 genes, previously only two human $\alpha 2\delta$ genes were known: " $\alpha 2\delta$ -A (cDNA Accession No. M76559.1 and protein Accession No. P54289.1) and $\alpha 2\delta$ -B (cDNA SEQ ID NO 1 and protein SEQ ID NO 2). The $\alpha 2\delta$ -A gene codes for at least five different splice variants which show tissue-specific expression (Angelotti T., Hoffman F., FEBS, 1996;397:331-337). Translation of the $\alpha 2\delta$ -A gene produces a polypeptide which is post-translationally cleaved into the $\alpha 2$ and the δ subunits. $\alpha 2$ and δ are then joined by disulfide bonds (De Jongh K., JBC, 1990;265(25):14738-14741; Jay S., JBC, 1991;266(5):3287-3293). $\alpha 2$ is thought to be completely extracellular and is heavily glycosylated, while δ probably forms a single transmembrane domain with five intracellular amino acids at its c-terminus (Brickley K., FEBS,

-5-

1995;364:129-133). This transmembrane domain anchors the protein to the membrane. A2δ-B is related to α2δ-A and is available in the public database, GENBANK.

The inventors, however, have discovered the existence of two new human
5 α2δ genes, hereinafter referred to as “α2δ-C”, and “α2δ-D” genes (gene names CACNA2C and CACNA2D). The present invention, therefore, relates to the isolation of polynucleotide sequences which identify and encode novel α2δ-related proteins (preferably α2δ-C and α2δ-D proteins) that are expressed in various cells and tissues, both the polynucleotide sequences for the full length
10 genes and any splice variants and their encoded proteins. The polynucleotide sequences are identified in SEQ ID NOS 3-4 and the amino acid sequences of the α2δ proteins encoded by the three novel genes are set forth in SEQ ID NOS 5-6.

The invention also concerns a purified or isolated nucleic acid comprising
15 at least 20 consecutive nucleotides of the nucleotide sequences SEQ ID NOS 3-4, or a nucleotide sequence complementary thereto.

A2δ-C protein of SEQ ID NO 5 is 28% identical and 48% similar at the protein level to α2δ-A protein. A2δ-C protein is 28% identical and 47% similar to α2δ-B. A2δ-C gene of SEQ ID NO 3 contains a mapped marker (known as an STS) within its nucleotide sequence which has been mapped to human
20 chromosome 3p21.1. This region of the human genome is thought to harbor an important tumor suppressor gene, thus α2δ-C gene is a candidate tumor suppressor gene (Kersemaekers AM, et al., Br J Cancer 1998;77(2); 192-200).

A2δ-D protein of SEQ ID NO 6 is 28% identical and 47% similar at the protein level to α2δ-A protein. A2δ-D protein is 28% identical and 46% similar to α2δ-B protein. A2δ-D gene of SEQ ID 4 maps to a previously published
25 cosmid contig on human chromosome 12p13.3.

The unique full length polynucleotides of the present invention were initially discovered by mining the genbank database for sequences with homology to α2δ, by utilizing known nucleotide sequences and various methods known in the art, including tools provided by Compugen Systems Ltd. See Sequence Analysis Primer by Michael Gribskov, John Devereux, Oxford University Press, 30 1994. After identification of expressed sequenced tags (ESTs) and full-length

-6-

sequences related to $\alpha 2\delta$ -A, cloning methods were used to obtain, in hand, full-length sequences for $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, see Examples 1, 2 and 3. In short, an arrayed human, kidney cDNA library obtained from Origene, was screened by PCR, using oligonucleotide primers derived from the database sequences. Clones identified from the library screen were sequenced by standard methods for verification. A summary of the sequencing information is provided in Example 3.

Analysis of the cloned sequences for $\alpha 2\delta$ -B, $\alpha 2\delta$ -C, and $\alpha 2\delta$ -D led to the identification of a conserved domain and of a number of splice variants. The conserved domain is known as a vonWillebrand factor A3 domain (Huizinga, EG, et. al., Structure 1997, Sept 15;5(9):1147-56). This domain has been described in a large number of proteins and is thought to mediate cell adhesion. Interesting splice-variants of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D were also identified. These variants result in a c-terminal truncation of the respective protein sequences. Truncation of the c-terminus may lead to the production of a soluble, secreted $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein with new functions beyond that previously described for $\alpha 2\delta$.

The $\alpha 2\delta$ proteins are of interest because they play an important role in many disease states. In one example, $\alpha 2\delta$ -A has been shown to be a high-affinity binding target of the anti-convulsant drug gabapentin (NEURONTIN) (Gee N., JBC 1996;271:5768-5776). This property of the $\alpha 2\delta$ -A protein has the potential to have profound physiological effects. Thus, by regulating the levels or activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, or by modulating their function, desirable physiological effects may be obtained. Such effects may be used to treat a variety of diseases involving abnormal expression of $\alpha 2\delta$ or the abnormal expression of VSCCs (i.e., disease states include, but are not limited to epilepsy, chronic pain, anxiety, diabetes, ALS, mania, cancer, tremor, parkinsonism, migraine, ataxia, mood, sleep interference, depression, multiple sclerosis, inflammation).

The rationale for the therapeutic use of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins to design or discover treatment for these diseases is based upon the fact that gabapentin has been successfully used for treating epilepsy, chronic pain, and ALS, and has implications for use in the treatment of mania, tremor, parkinsonism, migraine, ataxia, mood, inflammation, sleep interference, and/or multiple sclerosis). Gabapentin is known to bind to $\alpha 2\delta$ -A with high affinity and

-7-

this binding is thought to represent the mechanism of action of gabapentin. Therefore, gabapentin and/or other compounds which bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may have similar, or related, therapeutic effects to the effects seen with gabapentin. Also, compounds which are known to have therapeutic effects on calcium channels are regulated in their affinity by the presence of $\alpha 2\delta$. Thus, pharmacological or genetic approaches to alleviating this deficiency will have a major impact on the diseases described above.

One aspect of the invention is to provide purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The purified proteins may be obtained from either recombinant cells or naturally occurring cells. The purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention may be mammalian in origin. Primate, including human-derived $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, are examples of the various proteins specifically provided for. The invention also provides allelic variants and biologically active derivatives of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

Another aspect of the invention is to provide polynucleotides encoding the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention and to provide polynucleotides complementary to polynucleotide coding strand. The polynucleotides of the invention may be used to provide for the recombinant expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may also be used for genetic therapy purposes so as to 1) treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 2) test for presence of a disease, or susceptibility to a disease, due to alterations or deletions in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 3) analyze or alter the subcellular localization of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide, 4) clone or isolate discrete classes of RNA similar to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, 5) express discrete classes of RNA in order to alter the levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes.

The invention also relates to oligonucleotide molecules useful as probes or primers, wherein said oligonucleotide molecules hybridize specifically with any nucleotide sequence comprising or related to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, particularly the sequences of SEQ ID NOS 3-4. These oligonucleotides are useful

-8-

either as primers for use in various processes such as DNA amplification and microsequencing or as probes for DNA recognition in hybridization analyses.

A nucleic acid probe or primer according to the invention comprises at least 8 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3-4, preferably from 8 to 200 consecutive nucleotides, more particularly from 10, 15, 20 or 30 to 100 consecutive nucleotides, more preferably from 10 to 90 nucleotides, and most preferably from 20 to 80 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3 or 4. Preferred probes or primers of the invention comprise the oligonucleotides selected from the group consisting of the oligonucleotides set forth in the examples below.

The invention also concerns a method for the amplification of a region of the α 2 δ -C and/or α 2 δ -D genes. The method comprises the step of: contacting a test sample suspected of containing the desired α 2 δ -C and/or α 2 δ -D sequence or portion thereof with amplification reaction reagents, comprising a pair of amplification primers such as those described above, the primers being located on either side of the α 2 δ -C and/or α 2 δ -D nucleotide region to be amplified. The method may further comprise the step of detecting the amplification product. For example, the amplification product may be detected using a detection probe that can hybridize with an internal region of the amplified sequences. Alternatively, the amplification product may be detected with any of the primers used for the amplification reaction themselves, optionally in a labeled form.

The invention also concerns diagnostic kits for detecting the presence of at least one copy of a α 2 δ -C and/or α 2 δ -D DNA in a test sample, said kits containing a primer, a pair of primers or a probe according to the invention.

In a first embodiment, the kit comprises primers such as those described above, preferably forward and reverse primers which are used to amplify the α 2 δ -C and/or α 2 δ -D gene or a fragment thereof.

In a second embodiment, the kit comprises a hybridization DNA probe, that is or eventually becomes immobilized on a solid support, which is capable of hybridizing with the α 2 δ -C and/or α 2 δ -D gene or a fragment thereof. The

-9-

techniques for immobilizing a nucleotide primer or probe on a solid support are well-known to the skilled person.

The kits of the present invention can also comprise optional elements including appropriate amplification reagents such as DNA polymerases when the kit comprises primers, reagents useful in hybridization reactions and reagents useful to reveal the presence of a hybridization reaction between a labeled hybridization probe and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene.

Another aspect of the invention is to provide antibodies capable of binding to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention. The antibodies may be polyclonal or monoclonal. The invention also provides methods of using the subject antibodies to detect and measure expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins either *in vitro* or *in vivo*, or for detecting proteins that interact with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or molecules that regulate any of the activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

Another aspect of the invention is to provide assays for the detection of proteins that interact with $\alpha 2\delta$ -C or $\alpha 2\delta$ -D using genetic approaches. A preferred embodiment involves the use of yeast two-hybrid approaches for this screening. (Bartel and Fields, *The Yeast Two-Hybrid System*, Oxford University Press, 1997)

Another aspect of the invention is to provide assays for the detection or screening of therapeutic compounds that interfere with, or mimic in any way, the interaction between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins and ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

In a first embodiment, such a method for the screening of a candidate substance comprises the following steps :

- a) providing a polypeptide comprising the amino acid sequence of SEQ ID NO 5 and/or 6, or a peptide fragment or a variant thereof;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance; and
- d) detecting the complexes formed between said polypeptide and said candidate substance.

-10-

In one embodiment of the screening method defined above, the complexes formed between the polypeptide and the candidate substance are further incubated in the presence of a polyclonal or a monoclonal antibody that specifically binds to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention or to the peptide fragment or variant thereof.

5

The candidate substance or molecule to be assayed for interacting with the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide may be of diverse nature, including, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides.

10

In another embodiment of the present screening method, increasing concentrations of a substance competing for binding to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein with the considered candidate substance is added, simultaneously or prior to the addition of the candidate substance or molecule, when performing step c) of said method. By this technique, the detection and optionally the quantification of the complexes formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof and the candidate substance or molecule to be screened allows the one skilled in the art to determine the affinity value of said substance or molecule for said $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof.

15

20

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein having the amino acid sequence of SEQ ID NO 5 and/or 6 or a peptide fragment or a variant thereof, and optionally means useful to detect the complex formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or its peptide fragment or variant and the candidate substance. In a preferred embodiment the detection means consist in monoclonal or polyclonal antibodies directed against the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a peptide fragment or a variant thereof.

25

30

The assays of the invention therefore comprise the step of measuring the effect of a compound of interest on binding between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and the ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. Binding may be measured in a variety of ways, including the use of labeled $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or labeled ligands. These ligands may include, but are not limited to,

-11-

neutral alpha-amino acids, which have been shown to bind to $\alpha 2\delta$ -A, or therapeutic compounds such as gabapentin or related analogues.

Another aspect of the invention is to provide assays for the discovery of proteins that interact directly or indirectly with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The assays of the invention comprise a method for detecting such interactions in cells, or in biochemical assays. These interactions may be detected in a variety of ways, including the use of the cDNA encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins themselves, or fragments or modifications thereof. The assays may also comprise a method for detecting the interaction between $\alpha 2\delta$ subunits and other subunits of the calcium channel, such as $\alpha 1$ subunits. These assays may involve measuring the interaction between the proteins directly, or assaying the activity of a fully assembled calcium channel.

Before the present sequences, polypeptides, methods for making and using the invention are described, it is to be understood that the invention is not to be limited only to the particular sequences, polypeptides and methods described. The sequences, polypeptides and methodologies may vary, and the terminology used herein is for the purpose of describing particular embodiments. The foregoing is not intended and should not be construed as limiting the invention in any way since the scope of protection will ultimately depend upon the claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto.

BRIEF DESCRIPTION OF THE INVENTION

Figure 1: Fine-mapping of $\alpha 2\delta$ -B to mouse chromosome 9

Figure 2: Human $\alpha 2\delta$ -B tissue distribution

Figure 3: [3 H] gabapentin binding activity by human $\alpha 2\delta$ -B in transiently transfected COS7

Figure 4: Human $\alpha 2\delta$ -C tissue distribution

-12-

DETAILED DESCRIPTION OF THE INVENTION

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutshcer, ed., (1990) Academic Press, Inc.); *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), and *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, N.J.) *Sequence Analysis Primer* (Gibskov, et al., 1994, Oxford University Press).

In one aspect, the present invention provides novel isolated and purified polynucleotides, hereinafter referred to as alpha-2-delta-C and alpha-2-delta-D ("α2δ-C", "α2δ-D") genes, encoding α2δ-C and α2δ-D proteins, wherein the polynucleotide sequences are substantially similar to those shown in SEQ ID NOS 3-4 and the polypeptide sequences are substantially similar to those shown in SEQ ID NOS 5-6. The terms "α2δ-C" and "α2δ-D" are used broadly herein. Unless noted otherwise, the terms "α2δ-C" and "α2δ-D" include any natural mammalian-derived form of α2δ-C and α2δ-D and the like. It is preferred that the terms α2δ-C and α2δ-D include all mammals, including but not limited to primates and humans.

The polynucleotides provided for may encode complete α2δ-C and/or α2δ-D proteins or portions thereof. The polynucleotides of the invention may be produced by a variety of methods including *in vitro* chemical synthesis using well known solid phase synthesis technique, by cloning or combinations thereof. The polynucleotide of the invention may be derived from cDNA or genomic libraries. Persons of ordinary skill in the art are familiar with the degeneracy of the genetic code and may readily design polynucleotides that encode α2δ-C and/or α2δ-D proteins that have either partial or polynucleotide sequence homology to naturally

-13-

occurring polynucleotide sequences encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may be single stranded or double stranded.

Polynucleotide complementary to polynucleotides encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are also provided.

5 Polynucleotides encoding an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein can be obtained from cDNA libraries prepared from tissue believed to possess $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or mRNA and to express it at a detectable level. For example, a cDNA library can be constructed by obtaining polyadenylated mRNA from a cell line known to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, and using the mRNA as a template to synthesize double stranded cDNA.

10 Libraries, either cDNA or genomic, are screened with probes designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include monoclonal and polyclonal antibodies that recognize and specifically bind to an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein. For cDNA 15 libraries, suitable probes include carefully selected oligonucleotide probes (usually of about 20-80 bases in length) that encode known or suspected portions of an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the same or different species, and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene, and/or homologous genomic DNAs or fragments thereof.

20 Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in Chapters 10-12 of Sambrook et al., Molecular Cloning: A Laboratory Manual, New York, Cold Spring Harbor Laboratory Press, 1989).

25 A preferred method of practicing this invention is to use carefully selected oligonucleotide sequences to screen cDNA libraries from various tissues. The oligonucleotide sequences selected as probes should be sufficient in length and sufficiently unambiguous that false positives are minimized. The actual nucleotide sequence(s) is/are usually designed based on regions of an $\alpha 2\delta$ protein that have the least codon redundancy. The oligonucleotides may be degenerate at 30 one or more positions. The use of degenerate oligonucleotides is of particular importance where a library is screened from a species in which preferential codon usage is not known.

-14-

The oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use ATP (e.g., T32P) and polynucleotide kinase to radiolabel the 5' end of the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

cDNAs encoding $\alpha 2\delta$ proteins can also be identified and isolated by other known techniques of recombinant DNA technology, such as by direct expression cloning or by using the polymerase chain reaction (PCR) as described in U.S. Patent No. 4,683,195, in section 14 of Sambrook, et al . , Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, New York, 1989, or in Chapter 15 of Current Protocols in Molecular Biology, Ausubel et al. eds., Green Publishing Associates and Wiley-Interscience 1991. This method requires the use of oligonucleotide probes that will hybridize to DNA encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

As defined herein, "substantially similar" includes identical sequences, as well as deletions, substitutions or additions to a DNA, RNA or protein sequence that maintain any biologically active portion thereof of the protein product and possess any of the conserved motifs. This includes, but is not limited to, any splice variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D which are found to exist. Preferably, the DNA sequences according to the invention consist essentially of the DNA sequence of SEQ ID NOS 3-4. These novel purified and isolated DNA sequences can be used to direct expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and for mutational analysis of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein function.

Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein, and techniques well known in the art.

In a preferred embodiment, the present invention comprises a nucleotide sequence that hybridizes to the nucleotide sequence shown in SEQ ID NOS 3-4 under high stringency hybridization conditions. As used herein, the term "high stringency hybridization conditions" refers to hybridization on a filter support at 65°C in a low salt hybridization buffer to the probe of interest at 2×10^8 cpm/ μ g for between about 8 hours to 24 hours, followed by washing in 1% SDS, 20 mM

-15-

phosphate buffer and 1 mM EDTA at 65°C, for between about 30 minutes to 4 hours. In a preferred embodiment, the low salt hybridization buffer comprises between, 0.5-10% SDS, and 0.05M and 0.5 M sodium phosphate. In a most preferred embodiment, the low salt hybridization buffer comprises, 7% SDS, and 0.125M sodium phosphate.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about Tm-5°C (5°C below the melting temperature (Tm) of the probe) to about 20°C to 25°C below Tm. As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The polynucleotides of the invention have a variety of uses, some of which have been indicated or will be addressed in greater detail, *infra*. The particular uses for a given polynucleotide depend, in part, on the specific polynucleotide embodiment of interest. The polynucleotides of the invention may be used as hybridization probes to recover α 2 δ -C and/or α 2 δ -D proteins from genetic libraries. The polynucleotides of the invention may also be used as primers for the amplification of α 2 δ -C and/or α 2 δ -D protein encoding polynucleotides or a portion thereof through the polymerase chain reaction (PCR) and other similar amplification procedures. The polynucleotides of the invention may also be used as probes and amplification primers to detect mutations in α 2 δ -C and/or α 2 δ -D protein encoding genes that have been correlated with diseases, particularly diseases related to an altered function for α 2 δ -A protein. Including, but not limited to, those diseases stated above.

-16-

The invention also provides a variety of polynucleotide expression vectors, comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or a sequence substantially similar to it subcloned into an extra-chromosomal vector. This aspect of the invention allows for *in vitro* expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene, thus permitting an analysis of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene regulation and $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein structure and function. As used herein, the term "extra-chromosomal vector" includes, but is not limited to, plasmids, bacteriophages, cosmids, retroviruses and artificial chromosomes. In a preferred embodiment, the extra-chromosomal vector comprises an expression vector that allows for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein production when the recombinant DNA molecule is inserted into a host cell. Such vectors are well known in the art and include, but are not limited to, those with the T3 or T7 polymerase promoters, the SV40 promoter, the CMV promoter, or any promoter that either can direct gene expression, or that one wishes to test for the ability to direct gene expression.

In a preferred embodiment, the subject expression vectors comprise a polynucleotide sequence encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in functional combination with one or more promoter sequences so as to provide for the expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (or an anti-sense copy of the sequence suitable for inhibition of expression of an endogenous gene). The vectors may comprise additional polynucleotide sequences for gene expression, regulation, or the convenient manipulation of the vector, such additional sequences include terminators, reporters, enhancers, selective markers, packaging sites, and the like. Detailed description of polynucleotide expression vectors and their use can be found in, among other places Gene Expression Technology: Methods in Enzymology Volume 185 Goeddel ed, Academic Press Inc., San Diego, CA (1991), Protein Expression in Animal Cells Roth ea., Academic Press, San Diego, CA (1994).

The polynucleotide expression vectors of the invention have a variety of uses. Such uses include the genetic engineering of host cells to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. In a further aspect, the present invention provides recombinant host cells that are stably transfected with a recombinant DNA molecule comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D subcloned into an extra-chromosomal

-17-

vector. The host cells of the present invention may be of any type, including, but not limited to, bacterial, yeast, mammalian cells, and *Xenopus* oocytes.

Transfection of host cells with recombinant DNA molecules is well known in the art (Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, 1989) and, as used herein, includes, but is not limited to calcium phosphate transfection, dextran sulfate transfection, electroporation, lipofection and viral infection. This aspect of the invention allows for *in vitro* and *in vivo* expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D and its gene product, thus enabling high-level expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. In a further aspect of the invention the RNA molecules containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D can be injected into *Xenopus* oocytes along with other calcium channel subunit clones and calcium flux across the oocyte membrane can be measured using standard electrophysiological techniques.

In another aspect of the invention transgenic animals can be constructed by injection of the nucleotide sequence for $\alpha 2\delta$ -C or $\alpha 2\delta$ -D cloned in suitable expression vectors into germ cells.

Other uses of the polynucleotide expression vectors, discussed in greater detail, *infra*, include, their use for genetic therapy for diseases and conditions in which it may be desirable to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins at levels greater than naturally occurring expression levels. Alternatively, it may be desirable to use the subject vectors for anti-sense expression to reduce the naturally occurring levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

$\alpha 2\delta$ -C and $\alpha 2\delta$ -D share amino acid homology to $\alpha 2\delta$ -A, thus it is very likely that they share some structural and functional characteristics with $\alpha 2\delta$ -A. $\alpha 2\delta$ -A is known to interact with other subunits of voltage-sensitive calcium channels, such as $\alpha 1$ and beta. When calcium channels are expressed in oocytes, a functional channel is only produced when an $\alpha 2\delta$ subunit is present. Therefore, $\alpha 2\delta$ is required for calcium channel function. In addition, $\alpha 2\delta$ -A has been shown to bind to gabapentin, a drug used to treat epilepsy, chronic pain, ALS, and potentially other neurological diseases. The mechanism of action of gabapentin is thought to be through its interaction with $\alpha 2\delta$. Given the homology between the $\alpha 2\delta$ proteins, it is likely that $\alpha 2\delta$ -C and $\alpha 2\delta$ -D also share these functions.

-18-

The polynucleotide sequences of SEQ ID NOS 3-4 were mapped to human chromosomes using the nucleotide sequences for the cDNA from library sources (See Examples 2-3) to generate probes. The sequences were mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include *in situ* hybridization to chromosomal spreads, and PCR-based mapping by amplifying DNA from standard radiation hybrid cell lines. (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, NYC. A₂δ-C of SEQ ID NO 3 maps to human chromosome 3p21.1. A₂δ-D of SEQ ID NO 4 maps to a previously published cosmid contig on human chromosome 12p13.3.

In another aspect, the present invention provides a substantially purified recombinant protein comprising a polypeptide substantially similar to the α₂δ-C and/or α₂δ-D polypeptides shown in SEQ ID NOS 5-6. Furthermore, this aspect of the invention enables the use of α₂δ protein in several *in vitro* assays described below. As used herein, the term "substantially similar" includes deletions, substitutions and additions to the sequences of SEQ ID NOS 5-6 introduced by any *in vitro* means, or any genetic alterations naturally seen *in vivo*. As used herein, the term "substantially purified" means that the protein should be free from detectable contaminating protein, but the α₂δ-C and/or α₂δ-D protein may be co-purified with an interacting protein, or as an oligomer. In a most preferred embodiment, the protein sequence according to the invention comprises an amino acid sequence of SEQ ID NOS 5-6. Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein and techniques well known in the art. This aspect of the invention provides a novel purified protein that can be used for *in vitro* assays, and as a component of a pharmaceutical composition.

A₂δ-C and/or α₂δ-D proteins may be used to discover molecules that interfere with its activities. For example, molecules that prevent the binding of α₂δ-C and/or α₂δ-D to ligands such as neutral alpha-amino acids (for example (L)-leucine), or to other molecules such as other subunits of the voltage-sensitive calcium channels.. Additionally, α₂δ-C and/or α₂δ-D proteins may be used to

-19-

find other proteins with which it directly interacts, and potentially representing additional important regulators of VSCC transport.

The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the present invention have a putative biological activity of modulating the cellular flux of calcium, potentially including both intracellular and extracellular calcium stores. The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention may be isolated from a variety of mammalian animal species. Preferred mammalian species for isolation are primates and humans. The invention also contemplates allelic variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. A 2δ -C and/or $\alpha 2\delta$ -D proteins may be prepared from a variety of mammalian tissues. Preferably, $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are obtained from recombinant host cells genetically engineered to express significant quantities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. A 2δ -C and/or $\alpha 2\delta$ -D proteins may be isolated from non-recombinant or recombinant cells in a variety of ways well known to a person of ordinary skill in the art.

The terms “ $\alpha 2\delta$ -C protein” and “ $\alpha 2\delta$ -D protein” as used herein refers not only to proteins having the amino acid residue sequence of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, but also refers to functional derivatives and variants of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. A “functional derivative” of a native polypeptide is a compound having a qualitative biological activity in common with the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Thus, a functional derivative of a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein is a compound that has a qualitative biological activity in common with a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, e.g., binding to other calcium channel subunits and modulating the flux of calcium in cells, or binding to neutral alpha-amino acids and other cognate ligands. “Functional derivatives” include, but are not limited to, fragments of native polypeptides from any animal species (including human), and derivatives of native (human and non-human) polypeptides and their fragments, provided that they have a biological activity in common with a respective native polypeptide. “Fragments” comprise regions within the sequence of a mature native polypeptide. The term “derivative” is used to define amino acid sequence and glycosylation variants, and covalent modifications of a native polypeptide, whereas the term “variant” refers to amino acid sequence and glycosylation

-20-

variants within this definition. Preferably, the functional derivatives are polypeptides which have at least about 70% amino acid sequence similarity, more preferably about 80% amino acid sequence similarity, even more preferably at least 90% amino acid sequence similarity, most preferably at least about 99% amino acid sequence similarity with the sequence of a corresponding native polypeptide. Most preferably, the functional derivatives of a native α 2 δ -C and/or α 2 δ -D protein retain or mimic the region or regions within the native polypeptide sequence that directly participate in ligand binding. The phrase "functional derivative" specifically includes peptides and small organic molecules having a qualitative biological activity in common with a native α 2 δ -C and/or α 2 δ -D protein.

"Identity" or "homology" with respect to a native polypeptide and its functional derivative is defined herein as the percentage of amino acid residues in the candidate sequence that are similar to residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Neither N- or C-terminal extensions nor insertions, nor alternatively-spliced variants, shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known in the art.

Amino acid sequence variants of native α 2 δ -C and/or α 2 δ -D proteins and α 2 δ -C and/or α 2 δ -D protein fragments are prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant α 2 δ -C and/or α 2 δ -D protein encoding DNA, or by *in vitro* synthesis of the desired polypeptide. There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. With the exception of naturally-occurring alleles, which do not require the manipulation of the DNA sequence encoding the α 2 δ -C and/or α 2 δ -D protein, the amino acid sequence variants of α 2 δ -C and/or α 2 δ -D protein are preferably constructed by mutating the DNA, either to arrive at an allele or an amino acid sequence variant that does not occur in nature.

-21-

Alternatively or in addition, amino acid alterations can be made at sites that differ in α 2 δ -C and/or α 2 δ -D proteins from various species, or in highly conserved regions, depending on the goal to be achieved.

Sites at such locations will typically be modified in series, e.g. by

5 (1) substituting first with conservative choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue or residues, or (3) inserting residues of the same or different class adjacent to the located site, or combinations of options 1-3.

10 One helpful technique is called "alanine scanning" Cunningham and Wells, Science 244, 1081-1085 (1989). Here, a residue or group of target residues is identified and substituted by alanine or polyalanine. Those domains demonstrating functional sensitivity to the alanine substitutions are then refined by introducing further or other substituents at or for the sites of alanine substitution.

15 After identifying the desired mutation(s), the gene encoding an α 2 δ -C and/or α 2 δ -D protein variant can, for example, be obtained by chemical synthesis.

More preferably, DNA encoding an α 2 δ -C and/or α 2 δ -D protein amino acid sequence variant is prepared by site-directed mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the α 2 δ -C and/or α 2 δ -D protein. Site-directed (site-specific) mutagenesis allows the production of 20 α 2 δ -C and/or α 2 δ -D protein variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 20 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered. In general, the techniques of site-specific mutagenesis are well known in the art, as exemplified by publications such as, 25 Edelman et al., DNA 2:183 (1983). As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. This and other phage vectors 30 are commercially available and their use is well known to those skilled in the art.

-22-

A versatile and efficient procedure for the construction of oligodeoxyribonucleotide directed site-specific mutations in DNA fragments using M13-derived vectors was published by Zoller, M.J. and Smith, M., Nucleic Acids Res. 10, 6487-6500 [1982]). Also, plasmid vectors that contain a single-stranded phage origin of replication, Veira et al., Meth. Enzymol. 153:3 (1987)] may be employed to obtain single-stranded DNA. Alternatively, nucleotide substitutions are introduced by synthesizing the appropriate DNA fragment in vitro, and amplifying it by PCR procedures known in the art.

In general, site-specific mutagenesis may be performed by obtaining either a double-stranded or a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant protein. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea et al., Proc. Natl. Acad. Sci. USA 75, 5765 (1978). This primer is then annealed with the single-stranded protein sequence-containing vector, and subjected to DNA-polymerizing enzymes such as, E. coli polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate host cells such as HB101 cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement. Thereafter, the mutated region may be removed and placed in an appropriate expression vector for protein production.

The PCR technique may also be used in creating amino acid sequence variants of an α 2 δ -C and/or α 2 δ -D protein. When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the

-23-

opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 500-5000 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primes can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

Further details of the foregoing and similar mutagenesis techniques are found in general textbooks, such as, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd edition, Cold Spring Harbor Press, Cold Spring Harbor (1989), and Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley and Sons (1995).

Naturally-occurring amino acids are divided into groups based on common side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophobic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gin, his, lys, erg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, pine.

Conservative substitutions involve exchanging a member within one group for another member within the same group, whereas non-conservative substitutions will entail exchanging a member of one of these classes for another. Variants obtained by non-conservative substitutions are expected to result in significant changes in the biological properties/function of the obtained variant, and may result in α 2 δ -C and/or α 2 δ -D protein variants which block α 2 δ -C and/or α 2 δ -D protein biological activities, i.e., modulation of calcium flux, or binding to neutral, alpha-amino acids. Amino acid positions that are conserved among

-24-

various species are generally substituted in a relatively conservative manner if the goal is to retain biological function.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous.

5 Deletions may be introduced into regions not directly involved in ligand binding.

Amino acid insertions include amino- and/or carboxyl terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e. insertions within the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein amino acid sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5 residues, more preferably 1 to 3 residues. Examples of terminal insertions include the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins with an N-terminal methionyl residue, a naturally-occurring N-terminal signal sequence, an artifact of direct expression in bacterial recombinant cell culture, and fusion of a

15 heterologous N-terminal signal sequence to the N-terminus of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to facilitate the secretion of the mature $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein from recombinant host cells. Such signal sequences will generally be obtained from, and thus homologous to, the intended host cell species. Suitable sequences include STII or Ipp for E. coli, alpha factor for yeast, and viral signals such as herpes gD for mammalian cells. Other insertional variants of the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein molecules include the fusion of the N- or C-terminus of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to immunogenic polypeptides, e.g. bacterial polypeptides such as betalactamase or an enzyme encoded by the E. coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin regions (preferably immunoglobulin constant regions), albumin, or ferritin, as described in PCT published application WO 25 89/02922.

Since it is often difficult to predict in advance the characteristics of a variant $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, it will be appreciated that screening will be needed to select the optimum variant. For this purpose biochemical screening assays, such as those described herein below, will be readily available.

30 In a further aspect, the present invention provides antibodies and methods

-25-

for detecting antibodies that selectively bind polypeptides with an amino acid sequence substantially similar to the amino acid sequence of SEQ ID NOS 5-6. As discussed in greater detail, *infra*, the antibody of the present invention can be a polyclonal or a monoclonal antibody, prepared by using all or part of the sequence of SEQ ID NOS 5-6, or modified portions thereof, to elicit an immune response in a host animal according to standard techniques (Harlow and Lane (1988), eds. Antibody: A Laboratory Manual, Cold Spring Harbor Press). In a preferred embodiment, the entire polypeptide sequence of SEQ ID NOS 5-6 is used to elicit the production of polyclonal antibodies in a host animal.

The method of detecting $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D antibodies comprises contacting cells with an antibody that recognizes $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and incubating the cells in a manner that allows for detection of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein-antibody complex. Standard conditions for antibody detection of antigen can be used to accomplish this aspect of the invention (Harlow and Lane, 1988). This aspect of the invention permits the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein both *in vitro* and *in vivo*.

The subject invention provides methods for the treatment of a variety of diseases characterized by undesirably abnormal cellular levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D. Diseases may be treated through either *in vivo* or *in vitro* genetic therapy. Protocols for genetic therapy through the use of viral vectors can be found, among other places, in Viral Vector Gene Therapy and Neuroscience Applications, Kaplit and Lowry, Academic Press, San Diego (1995). Gene therapy applications typically involve identifying target host cells or tissues in need of the therapy, designing vector constructs capable of expressing a desired gene product in the identified cells, and delivering the constructs to the cells in a manner that results in efficient transduction of the target cells. The cells or tissues targeted by gene therapy are typically those that are affected by the disease that the vector construct is designed to treat. For example, in the case of cancer, the targeted tissues are malignant tumors.


The genetic therapy methods of the present invention comprise the step of introducing a vector for the expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (or inhibitory anti-sense RNA) into a patient cell. The patient cell may be either in

-26-

the patient, i.e., *in vivo* genetic therapy, or external to the patient and subsequently reintroduced into the patient, i.e., *in vitro* genetic therapy. Diseases that may be treated by the subject genetic therapy methods include, but are not limited to epilepsy, chronic pain, ALS, mania, cancer, anxiety, diabetes, tremor, parkinsonism, migraine, ataxia, mood, sleep interference, multiple sclerosis and inflammation).

In a preferred aspect of the invention, a method is provided for protecting mammalian cells from abnormal levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in cells, comprising introducing into mammalian cells an expression vector comprising a DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4, that is operatively linked to a DNA sequence that promotes the expression of the DNA sequence and incubating the cells under conditions wherein the DNA sequence of SEQ ID NOS 3 or 4 will be expressed at high levels in the mammalian cells. Suitable expression vectors are as described above. In a preferred embodiment, the coding region of the human $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene

PUBLICATION



Nombre de pages.....88

BD/AB.....1

.....

25 BD/AB.....

DE.....3

CL.....49

DR.....56

SR.....

SR.....

Controlé par..... Scanné par PL

Nbre de copies..... Article 20.....

ive $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D

ition, a method is provided
and/or $\alpha 2\delta$ -D in VSCCs,
ells an expression vector
stantially similar to the DNA
eratively linked to a DNA
> DNA sequence. The cells
> DNA sequence of SEQ ID
malian cells.

uence consists essentially of
ment, the expression vector
 $\alpha 2\delta$ -D cDNA is operatively
us (CMV) promoter to allow
D antisense cDNA in a host

-27-

cell. In a preferred embodiment, the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D adenoviral expression vector is introduced into cells by injection into a mammal.

Another aspect of the invention is to provide assays useful for determining if a compound of interest can bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. This binding

5 may interfere with, or mimic, the binding of ligands to the VSCCs, or this binding may affect the function of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in modulating calcium flux. The assay comprises the steps of measuring the binding of a compound of interest to an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Either the $\alpha 2\delta$ -C and/or the $\alpha 2\delta$ -D protein or the

10 compound of interest to be assayed may be labeled with a detectable label, e.g., a radioactive or fluorescent label, so as to provide for the detection of complex formation between the compound of interest and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

In another embodiment of the subject assays, the assays involve measuring the interference, i.e., competitive binding, of a compound of interest with the binding interaction between an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and a ligand already known to bind to $\alpha 2\delta$ -A protein. For example, the effect of increasing quantities of a

15 compound of interest on the formation of complexes between radioactivity labeled ligand and an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein may be measured by quantifying the formation of labeled ligand- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein complex formation. In

20 another embodiment of the subject assays, the assays involve measuring the alteration, i.e., non-competitive inhibition, of a compound of interest with the activity of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (compounds which bind to a different region of $\alpha 2\delta$ and inhibit $\alpha 2\delta$ activity, but don't prevent binding of ligands such as gabapentin).

25 Polyclonal antibodies to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins generally are raised in animals by multiple subcutaneous (se) or intraperitoneal (ip) injections of an $\alpha 2\delta$ protein and an adjuvant. It may be useful to conjugate the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g. keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues),

-28-

N-hydroxysuccinimide (through lysine resides), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}_1\sim\text{N}=\text{C}=\text{NR}$, where R and R_1 are different alkyl groups.

5 Animals are immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 fig of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein antibody titer.

10 Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, but also may be conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

15 Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. For example, the anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein monoclonal antibodies of the invention may be made 20 using the hybridoma method first described by Kohler & Milstein, Nature 256:495 (1975), or may be made by recombinant DNA methods [Cabilly, et al, U.S. Pat. No. 4,816,567].

25 Antibodies can also be generated using phage display. In this approach libraries of peptides of random sequence are generated in antibody genes cloned into phage. These phage libraries are screened for antibodies by screening against the immobilized protein. (Hoogenboom-HR, Trends-Biotechnol. 1997 Feb; 15(2): 62-70)

30 In the hybridoma method, a mouse or other appropriate host animal, such a hamster is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*.

-29-

Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Coding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (academic Press, 1986)].

The anti- α 2 δ -C and/or α 2 δ -D protein specific antibodies of the invention have a number of uses. The antibodies may be used to purify α 2 δ -C and/or α 2 δ -D proteins from either recombinant or non-recombinant cells. The subject antibodies may be used to detect and/or quantify the presence of α 2 δ -C and/or α 2 δ -D proteins in tissue samples, e.g., from blood, skin, and the like.

Quantitation of α 2 δ -C and/or α 2 δ -D proteins may be used diagnostically for those diseases and physiological or genetic conditions that have been correlated with particular levels of α 2 δ -C and/or α 2 δ -D protein expression levels.

In a further aspect, the present invention provides a diagnostic assay for detecting cells containing α 2 δ -C and/or α 2 δ -D deletions, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4.

This aspect of the invention enables the detection of α 2 δ -C and/or α 2 δ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool. The PCR primers can be chosen in any manner that allows the amplification of an α 2 δ -C and/or α 2 δ -D gene fragment large enough to be detected by gel electrophoresis. Detection can be by any method, including, but not limited to ethidium bromide staining of agarose or polyacrylamide gels, autoradiographic detection of radio-labeled α 2 δ -C and/or α 2 δ -D gene fragments, Southern blot hybridization, and DNA sequence analysis. In a preferred embodiment, detection is accomplished by polyacrylamide gel electrophoresis, followed by DNA sequence analysis to verify the identity of the deletions. PCR conditions are routinely determined based on the length and base-content of the primers selected according to techniques well known in the art (Sambrook et al., 1989).

An additional aspect of the present invention provides a diagnostic assay for detecting cells containing α 2 δ -C and/or α 2 δ -D deletions, comprising isolating total cell RNA and subjecting the RNA to reverse transcription-PCR amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4. This

-30-

aspect of the invention enables the detection of α 2 δ -C and/or α 2 δ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool.

Reverse transcription is routinely accomplished via standards techniques (Ausubel et al., in Current Protocols in Molecular Biology, ed. John Wiley and Sons, Inc., 1994) and PCR is accomplished as described above.

The present invention may be better understood with reference to the accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

10

Examples

Example 1

The sequence for human α 2 δ -A, c-DNA Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). Four full-length RNA sequences were identified (c-DNA Accession Nos. AF040709.1, AF042792.1, AF042793.1, and AB011130.1) which were highly homologous to α 2 δ -A. The DNA sequence of α 2 δ -B is provided by SEQ ID NO 1 and the amino acid sequence of α 2 δ -B is provided by SEQ ID NO 2. Using standard alignment tools, these four sequences were found to represent 4 different variants of the same gene. This gene was named α 2 δ -B. Further searches of the sequence databases, and analysis of proprietary clustered sequences generated using Compugen software, led to the identification of additional sequences related to α 2 δ -B. This includes human ESTs (Accession Nos. T80372.1, AA360556.1, AI563965.1, N53512.1, a mouse EST (Accession No. AA000341.1), and a sequence from C.elegans (Accession No. CAA90091.1). Since the initial identification of α 2 δ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (human: AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1,

-31-

AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1,
AA435601.1, AI094263.1; **mouse:** AA008996.1; **rat:** AI105056.1,
AI502878.1).

A2δ-B is 53 % identical and 69% similar at the amino acid level to α2δ-A.

5 The α2δ-B mRNA is 5482 bp long, and codes for a protein of 1145 amino acids.
The three splice-variants of α2δ-B which were identified differ only in the 5'
untranslated region, and do not alter the amino acid sequence. A2δ-B aligns to
genomic sequence from a previously published cosmid contig on human
chromosome 3p21.3. This DNA contig covers more than 600kb of sequence. The
10 Accession Nos. for these genomic sequences are Z84493.1, Z84494.1, Z75743.1,
Z75742.1, and Z84492.1. Analysis of the DNA sequences flanking α2δ-B led to
the identification of genes flanking α2δ-B on human chromosome 3p21.3 which
had been mapped in both human and mouse. These flanking genes include CIS,
HyaL1, GNAI-2, and GNAT-1. In mouse, all of the flanking genes were localized
15 to mouse chromosome 9, 60cM. Analysis of mapping data stored in the Mouse
Genome Database, by Jackson Laboratory, led to the identification of three mouse
neurological phenotypes that had been genetically mapped to the same mouse
chromosome 9, 60cM region. These phenotypes include epilepsy1, ducky and
tippy. Epilepsy1 and ducky both have spike-wave activity consistent with
epilepsy. This tentatively maps α2δ-B to the chromosome 9, 60cM region in
20 mouse, and identifies α2δ-B as a candidate gene for the mouse mutants ducky,
tippy, and El1 (for overview of mapping data see Figure 1).

25 Northern and RT-PCR analysis of RNA expression levels of human α2δ-B
were performed to analyze the expression pattern of α2δ-B. For Northern
analysis, multiple tissue Northern blots and brain blots were obtained from
Clontech. Non-isotopic DNA probes for α2δ-B were generated by PCR using
SEQ ID NOS 7-8 and SEQ ID NO 1 as a template. Hybridization and washing
conditions were in accordance with the manufacturer's instructions (Boehringer
Mannheim). A2δ-B was found to have highest expression in lung, and was also
30 detected in brain, heart, skeletal muscle, and at lower levels in all tissues tested
(Figure 2). For the Northern blot surveying different areas of human brain, α2δ-B
had the highest level of expression in the cerebral cortex, but was detected in all

-32-

areas of the human brain (Figure 2). RT-PCR expression analysis of human $\alpha 2\delta$ -B was also performed. RT-PCR analysis, using a cDNA tissue panel obtained from Clontech and SEQ ID NOS 7-8 for PCR-based gene amplification (cycles: 1X at 94 C 1', 35X at 94 C 0.5', 55 C 1', 72 C 2'; 1X at 72 C 10'), produced an expression pattern for $\alpha 2\delta$ -B consistent with results from Northern analysis.

Overall, the expression pattern of $\alpha 2\delta$ -B is consistent with a proposed role of $\alpha 2\delta$ -B in epilepsy.

In order to determine if $\alpha 2\delta$ -B has functional properties comparable to $\alpha 2\delta$ -A, the ability of $\alpha 2\delta$ -B to bind to amino acids and gabapentin was measured. For this analysis, COS-7 cells were transiently transfected with the full-length porcine $\alpha 2\delta$ -A, and human $\alpha 2\delta$ -B genes each in the vector pcDNA3 (Invitrogen)(pcDNA3.1 for $\alpha 2\delta$ -B) by the lipofectamine mediated transfection method. The cells were transfected and membranes harvested by the generic methods outlined below. The K_D for binding of [3 H] gabapentin to $\alpha 2\delta$ -B, as compared to $\alpha 2\delta$ -A, can be found in Table 1. Additional binding studies were performed using techniques similar to those outlined below. Alterations to the protocol are listed below under the subheading "Alternative Method for Measuring [3 H] Gabapentin binding". The data for these binding studies are in figure 3. Overall, the binding and Western data demonstrated that the porcine $\alpha 2\delta$ -A and human $\alpha 2\delta$ -B full-length gene-products expressed transiently in the COS-7 system bind [3 H]gabapentin with high affinity.

Table 1: Saturation binding data for $\alpha 2\delta$ -B

Porcine $\alpha_2\delta$ -A (n=2)	Human $\alpha_2\delta$ -B (n=2)
K_D , 23.1 nM	K_D , 32.6 nM
K_D , 21.2 nM	K_D , 87.2 nM
<i>Mean = 22.2 nM</i>	<i>Mean = 59.9 nM</i>

-33-

Transient Transfection method (150mm plate)

1: Seed 3.9×10^6 COS-7 cells/150mm plate in 42ml DMEM + 10% FBS +
5u/ml Penicillin / 5 μ g/ml Streptomycin on 150mm plate. Grow O/N.

5 2: Setup

Tube A – 30ug DNA in 300ul TE + 1.8ml Optimem (5u/ml Penicillin /
5 μ g/ml Streptomycin)

Tube B – 150ul Lipofectamine + 1.95ml Optimem (5u/ml Penicillin /
10 5 μ g/ml Streptomycin)

15 3: At time=0 mix tubes A and B and leave at RT for 45 minutes.

4: Wash cells with 30ml Optimem (5u/ml Penicillin / 5 μ g/ml
Streptomycin) twice then add 16.8ml Optimem (5u/ml Penicillin / 5 μ g/ml
Streptomycin) to the plates. At t=45 minutes add A/B mix to plates.

15 5: At t=6 hours add 21ml of Optimem (5u/ml Penicillin / 5 μ g/ml
Streptomycin).

6: At t=24 hours replace medium with 42ml Optimem (5u/ml Penicillin /
5 μ g/ml Streptomycin)

7: At t=48 hours rinse the cells twice with 20ml of PBS then harvest.

20

Membrane preparation (perform at 4°C)

1 Harvest cells into a 2ml eppendorf in 1.5ml 1mM EDTA/1mM
EGTA/0.1mM PMSF (added immediately prior to use from a 1000x
stock)/20% Glycerol/10mM HEPES pH7.4 @ 4°C using a cell scraper.

25 2 Mix cells end-over-end for 30 minutes at 4°C then centrifuge at
20,000 x g for 5 minutes.

3 3 Resuspend pellet in 1.5ml 1mM EDTA/1mM EGTA/20%
Glycerol/10mM HEPES pH7.4 @ 4°C then immediately re-centrifuge at
20,000 x g for 5 minutes.

-34-

4 Resuspend pellet to ~1mg/ml (protein concentration as determined by the Bradford protein assay) in 1mM EDTA/1mM EGTA/20% Glycerol/10mM HEPES pH7.4 @ 4°C

5 For total [³H] binding, cells were sonicated for 30-40 seconds, centrifuged for 10' at 750-1000Xg, and the supernatant was centrifuged for 30' at 50,000Xg. The resulting pellet was resuspended in 5mM

[³H]Gabapentin saturation binding assay methodology and data analysis

10 Assays were carried out at 21°C in a final volume of 250µl in 96-well deep-well plates. Duplicate wells were set up for both 'total' and 'non-specific' binding. Specific binding was defined as that remaining after subtraction of the 'non-specific binding' values from the 'total' binding values. Assay components were added in the following order (all reagents were diluted in 15 10mM HEPES (pH 7.4 at 21°C)):

Total binding 200µl 10mM HEPES pH 7.4

Non-specific binding 175µl 10mM HEPES pH 7.4 and 25µl 100µM
(S+)-3-isobutyl GABA

25µl Appropriate COS membrane sample

20 25µl [³H]gabapentin

The reaction was incubated at 21°C for 45 minutes then filtered through GF/B filters soaked in 50 mM Tris-Cl pH 7.4 @4°C (wash buffer), filters were washed three times with wash buffer.

25

The filters were then counted in a scintillation counter.

Saturation experiments were performed with 12 duplicate data points ('Total' and 'Non-Specific' binding determined in duplicate for each 30 concentration of [³H]gabapentin tested) and a [³H]gabapentin concentration range from ~1 to 400nM. Data was analyzed using KEL-RADLIG for Windows.

-35-

Alternative Method for Measuring [³H] Gabapentin binding

The method described above was followed with the following exceptions:

5 **1) COS7 transfection:** 20ug of $\alpha 2\delta$ -A or $\alpha 2\delta$ -B plasmid DNA were incubated with 30ul of lipofectamine. The mixture was overlaid onto the cells in 1.5ml of serum-free medium and incubated for 5 hours. Then FBS was added to the dishes to bring the final concentration to 10%. The medium was changed the next morning. Forty-eight hours after transfection the cells were harvested for membrane preparation.

10 **2) Membrane preparation:** Cells were washed twice with cold PBS and then scraped off the tissue culture plates in cold 5mM of Tris/5mM EDTA (pH7.4) containing PMSF (0.1mM), leupeptin (0.02mM), and pepstatin (0.02mM). The cells were incubated on ice for 30 minutes and then sonicated for 30-40 seconds. The homogenate was centrifuged for 10 minutes at 750-1000xg, and then the supernatent was centrifuged for 30 minutes at 50,000xg. The resulting pellet was resuspended in the same buffer as described above.

15 **3) Binding Assays:** The radioligand binding assay was done using 0.05 mg of membrane protein incubated in the presence of 20 nM of [³H] gabapentin. The membranes were incubated in 10 mM Hepes (pH 7.4) for 40-50 minutes at room temperature, and then filtered onto pre-wetted GF/C membranes and quickly washed five times with 3ml of ice cold 50mM tris buffer pH7.4. The filters were dried and counted in a liquid scintillation counter. To determine background binding, 10 uM of isobutyl GABA was used and the resulting counts subtracted from the total counts of each sample.

Detection of $\alpha 2\delta$ -A and $\alpha 2\delta$ -B expression with anti- α_2 polyclonal antibodies

30 Using affinity purified anti- α_2 polyclonal antibodies (antigen derived from porcine $\alpha 2\delta$ -A; See Brown and Gee (1998) *JBC* 273 25458-25465 for pAb

-36-

generation details) the expression of the porcine $\alpha_2\delta$ -A and human $\alpha_2\delta$ -B proteins (over and above control levels - COS cells transfected with the parent pcDNA3 vector) was confirmed. N.B. Cross reaction of the pAb's with $\alpha_2\delta$ -B was not unexpected given the ~50% amino acid sequence identity. Furthermore, and with reference to Example 2, expression of $\alpha_2\delta$ -C was not detected using this antibody (sequence identity with $\alpha_2\delta$ -A ~30%).

Example 2

The sequence for human $\alpha_2\delta$ -A, Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession Nos. AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1) corresponding to a new gene, with similarity to $\alpha_2\delta$ -A, named $\alpha_2\delta$ -C. Additional searches of the sequence databases led to the identification of other sequences related to $\alpha_2\delta$ -C. This includes a mouse EST (Accession No. AU022914.1, AI843362.1), and an STS (Accession No. G36524.1) which maps to human chromosome 3p21.1. Since the initial identification of $\alpha_2\delta$ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (human ESTs: AA459804.1, AI696320.1, AI051759.1, AI696214.1; human genomic sequence: AC010180.1; mouse EST: AA445859.1, mouse RNA: AJ010949.1).

In order to clone a full-length $\alpha_2\delta$ -C, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 9-10) based on sequence derived from EST clone accession number AA190607.1 which were designed to amplify a 273 bp fragment. A positive clone was identified in a kidney library. After sequencing, this clone was identified as a novel 3' splice variant (SEQ ID NO 43). The protein sequence, which can be derived from SEQ ID NO 43, of this novel splice variant is a truncated, potentially secreted soluble form of $\alpha_2\delta$ -C. PCR was performed, using primers (SEQ ID NOS 9 and 11) and a human adult

-37-

brain library from LTI as a template, and the resulting fragment of 248 bp was cloned in pBS and sequence verified. A SacI-NcoI fragment from the kidney clone, a NcoI-KpnI fragment from the PCR center clone, and a KpnI-NotI fragment from a clone obtained from the IMAGE consortium (corresponding to Accession No. R43629.1) were ligated together, using methods standard to the art, to create a full-length clone. Each individual clone, and the full-length clone (SEQ ID NO 3), were sequence verified. A number of other EST clones from the IMAGE consortium were also obtained and sequenced. One of these clones (corresponding to Accession No. AI051759.1) contained a two novel splice-variants which result in a truncated, potentially soluble $\alpha_2\delta$ -C (SEQ ID NO 44).

Full-length $\alpha_2\delta$ -C is 28 % identical and 48% similar at the amino acid level to $\alpha_2\delta$ -A. The $\alpha_2\delta$ -C mRNA sequence (SEQ ID NO 3) is 3770 bp long, and codes for a protein of 1085 amino acids (SEQ ID NO 5). In addition, three splice variants of $\alpha_2\delta$ -C were identified . Two of the variants contain deletions of internal exons. The third variant contains a novel 3' end. Two of these splice-variants produce a truncated protein which is devoid of the membrane anchoring delta subunit. These variants may represent a secreted alpha2 protein which could have additional functions beyond regulation of voltage-sensitive calcium channels.

In order to identify sequences for $\alpha_2\delta$ -C from other species, human and mouse specific primers (SEQ ID NOS 9-10 and 12-13, respectively) were used to amplify $\alpha_2\delta$ -C RT-PCR products. RNA from human brain was purchased from Invitrogen, Carlsbad, CA (catalog #D6030-15). RNA from rat and mouse brain was isolated using standard in-house protocols. First-strand cDNA synthesis was completed using Superscript Choice System (LTI, Bethesda, MD, catalog #18090-019). Ethanol precipitated cDNA was added to PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ High Fidelity (LTI, Bethesda, MD). Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. Products

-38-

were purified using Millipore Ultrafree-MC PCR purification filter units (catalog # UFC3LTKOO) prior to DNA sequence analyses. Using this approach, three sets of primers (SEQ ID NO 36, 37; SEQ ID NO 12, 13, SEQ ID NO 38, 39) where used for PCR amplification of rat $\alpha_2\delta$ -C. Three partial rat sequences for $\alpha_2\delta$ -C were identified (SEQ ID NOS 40, SEQ ID NO 14, SEQ ID NO 41).

RT-PCR analysis of RNA expression levels were performed to analyze the expression pattern of $\alpha_2\delta$ -C. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes.

PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. The primers used for this amplification from the human template correspond to SEQ ID NOS 9-10, and from the mouse template correspond to SEQ ID NOS 12-13. By RT-PCR, $\alpha_2\delta$ -C was found to be expressed in a wide variety of tissues (Table 2). The highest levels of $\alpha_2\delta$ -C were detected in human brain, and also in human testis and kidney. In addition to RT-PCR, the cDNA sequence for this gene has been detected in a human, adult brain library and also libraries from: infant brain, hNT neural cell line, testis, total fetus, alveolar rhabdomyosarcoma, adenocarcinoma, and a pooled germ cell library.

Northern blot analysis was performed using $\alpha_2\delta$ -C as a probe. Human total RNA was obtained from Invitrogen (Carlsbad, CA) (brain, total RNA(Cat #D6030-01), kidney total RNA (Cat #D6070-01), testis total RNA(Cat #D6121-01), liver total RNA(Cat # D6080-015)) or Ambion Inc(Austin, TX)(placenta total RNA Cat#7950, heart total RNA Cat #7966), lung total RNA(Cat #7968)) RNA was electrophoresed in formaldehyde agarose gels then transferred to charged nylon membranes(Ambion Inc. (Austin TX) Cat #10104. The EST clone (SEQ ID NO 47) was digested with BamHI and used as template in an RNA synthesis

-39-

reaction that yielded 32P labeled probe. The nylon membranes containing the RNA were prehybridized for 2 hours in ExpressHyb hybridization solution (Clontech Inc. (Palo Alto, CA)(Cat # 8015-1). After the prehybridization 4X106 cpm of RNA probe labeled with 32P were added to the solution and the hybridization was performed in the same solution for 2 hours. After hybridization the nylon filter was washed for 1 hour with 4 changes of 2X SSC, 0.5% SDS at room temperature. The nylon filter was transferred to a solution of 0.2X SSC, 0.5% SDS at 68°C and washed with 4 changes of solution. The nylon filters were then exposed to phosphorimager screens Molecular Dynamics(Sunnyvale, CA)and read on a Storm phosphorimager.Molecular Dynamics(Sunnyvale, CA). Results from Northern analysis (Figure 4) indicate that $\alpha_2\delta$ -C has highest levels of expression in human brain, kidney, and testis.

Since $\alpha_2\delta$ -C has sequence homology to $\alpha_2\delta$ -A, and $\alpha_2\delta$ -A functions as a subunit of VSCCs, experiments were undertaken to determine if $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A and produce functional VSCCs. Xenopus oocytes were isolated using standard techniques and injected with cRNA for α_{1B} , β_{1C} and $\alpha_2\delta$ -C subunits of voltage-gated Ca^{2+} channels. Four days to 1 week following injection of cRNA, Ca^{2+} channel currents were measured using two-electrode voltage clamp with 5 mM Ba^{2+} as the charge carrier. Test pulses to +10 mV from a holding membrane potential of -80 mV were applied to evoke Ca^{2+} channel currents. Peak inward currents evoked during the test pulse were measured. The amplitude of inward currents is proportional to the expression level of voltage-gated Ca^{2+} channels.

Expression of α_{1B} , β_{1C} without $\alpha_2\delta$ subunits produced currents with an average amplitude of 105 ± 13 nA ($n=20$). Co-injection of $\alpha_2\delta_c$ with α_{1B} and β_{1C} subunits produced a significant increase in current amplitude to 213 ± 12 nA ($n=20$, $p < 0.01$ compared to no $\alpha_2\delta$ subunits). These data suggest that $\alpha_2\delta_c$ has an effect on Ca^{2+} channels similar to $\alpha_2\delta_A$, enhancing the level of channel expression. However, $\alpha_2\delta_c$ did not produce as large of an effect on channel expression as $\alpha_2\delta_A$, producing a 2-fold increase in current compared to a 20-fold increase observed with the co-injection of $\alpha_2\delta_A$. Overall, these initial functional

-40-

studies indicate that $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A in voltage-sensitive calcium channels after co-injection into *Xenopus* oocytes with the $\alpha 1$ and beta subunits.

Table 2: RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA C

	<i>Tissue</i>	<i>Human a2d-C</i>	<i>Mouse a2d-C</i>
5	Brain	+++	+
	Heart	++++	-
	Kidney	++	++
10	Liver	-	-
	Colon	+	not assayed
	Lung	+	++
	Small Intestine	++	+
15	Muscle	++++	++
	Stomach	++	-
	Testis	+++	++
	Placenta	++	not assayed
	Salivary Gland	++	not assayed
20	Thyroid Gland	++	not assayed
	Adrenal Gland	++	-
	Pancreas	++	not assayed
	Ovary	++	-
25	Uterus	++	-
	Prostate	++	++
	Skin	++	-
	PBL	-	not assayed
	Bone Marrow	-	not assayed
	Fetal Brain	++	not assayed
30	Fetal Liver	++	not assayed

Example 3

The sequence for human $\alpha_2\delta$ -A, Accession No. M76559.1, was used to perform BLASTP searches against the Genbank non-redundant protein database

-41-

and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession No. T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1) corresponding to a new gene, with similarity to $\alpha 2\delta$ -A, named $\alpha 2\delta$ -D. Additional searches of the sequence databases led to the identification of other sequences related to $\alpha 2\delta$ -D. This includes genomic sequence derived from human chromosome 12p13.3 (Accession No. AC005342.1, AC005343.1). Since the initial identification of $\alpha 2\delta$ -D, additional related sequences have been deposited into the Genbank database. These sequences correspond to Accession Nos. (human ESTs: T96900.1, AI457823.1, AI377638.1, and AI433691.1).

To isolate a full-length $\alpha 2\delta$ -D clone, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 18-19) based on sequence derived from EST clone Accession No. AA001473.1 which were designed to amplify a 372 bp fragment. A positive clone was identified in a placental library, and was confirmed using a nested internal primer (SEQ ID NO 20). This clone was fully sequenced. The sequence extended 350 bp 5' of the sequence obtained from the EST sequences, but did not include the 5' end.

To obtain the 5' end, two approaches were undertaken. One approach utilized 5' RACE (Rapid Amplification of cDNA Ends). For 5' RACE, placenta poly A+ RNA from Clontech was used to construct a RACE-ready cDNA library using a Marathon cDNA Amplification kit purchased from Clontech. The 5'-end sequence of $\alpha 2\delta$ -D was obtained by 5' RACE PCR using first set of primers: Marathon cDNA adapter primer 1 (SEQ ID NO 45) and gene specific primer I (SEQ ID NO 21). The PCR product was re-amplified using a set of nested primers: adapter primer 2 (SEQ ID NO 46) and gene specific primer II (SEQ ID NO 22). A resulting 1 kb PCR product was cloned into a TA vector (Invitrogen) and sequenced. Sequence analysis revealed that it contains the 5' sequence of $\alpha 2\delta$ -D.

A second method undertaken to identify the 5' end of $\alpha 2\delta$ -D was a PCR-based library screen performed by Edge, using the 5' most sequence known for $\alpha 2\delta$ -D. Nine clones were PCR amplified by the methods indicated above, for

-42-

verification using primers with SEQ ID NOS 48 and 49. These nine positive clones were then sequenced for verification by standard methods. All nine clones were identical to each other, and all were short of the 5' end by approximately 500 bp. However, these clones contained novel splice-variants of $\alpha 2\delta$ -D, with 5 insertions of novel nucleotide sequences (SEQ ID NO 16).

The full-length sequence of $\alpha 2\delta$ -D is 28 % identical and 47% similar at the amino acid level to $\alpha 2\delta$ -A. The $\alpha 2\delta$ -D mRNA is 5,073 bp long (SEQ ID NO 4), and codes for a protein of 1120 amino acids (SEQ ID NO 6) . In addition, two splice variants of $\alpha 2\delta$ -D were identified. One of the variants contains a 72 bp 10 deletion of an internal exon (SEQ ID NO 15). The amino acid sequence of this variant can be found in SEQ ID NO 17. The second variant contains two novel insertions, one of 338 bp and one of 305 bp (SEQ ID NO 16). These insertions appear to result in a truncated protein (SEQ ID NO 42), comparable to the truncated protein sequence identified for $\alpha 2\delta$ -C in Example 2.

RT-PCR analysis of RNA expression levels of human $\alpha 2\delta$ -D were performed in order to analyze the tissue distribution of $\alpha 2\delta$ -D. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X 20 PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100 25 volts for 45 minutes. Gels were visualized under UV and photographed. In the case of the $\alpha 2\delta$ -D human panels two separate sets of primers were used to distinguish splice variants and wild type species (SEQ ID NOS 18 & 20, SEQ ID NOS 23 & 19, respectively).

Analysis of the results from RT-PCR of $\alpha 2\delta$ -D (see Table 3) indicate that 30 $\alpha 2\delta$ -D is expressed in a wide variety of tissues, with highest levels in placenta, adrenal gland and pancreas, but also detected in all tissues other than colon. Of note, $\alpha 2\delta$ -D was detected in human brain, consistent with a potential role in

-43-

neurological disease. In addition, based on the tissue distribution of EST sequences, the cDNA sequence for $\alpha_2\delta$ -D has been detected in human libraries from: adult brain, retina, fetal liver/spleen, fetal heart, pineal gland, and testis.

5 Table 3. RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA D

	Tissue	Human $\alpha 2\delta$ -D **	Human $\alpha 2\delta$ -D
	Brain	+++	+++
	Heart	+++	-
10	Kidney	+++"*	-
	Liver	++	-
	Colon	-	-
	Lung	++	-
	Small Intestine	+*	-
15	Muscle	++	-
	Stomach	++	-
	Testis	+++	-
	Placenta	++++*	-
	Salivary Gland	++	++++
20	Thyroid Gland	+++	++++
	Adrenal Gland	++++	+++
	Pancreas	++++*	++
	Ovary	+*	++
	Uterus	+*	++
25	Prostrate	++*	+
	Skin	+	-

-44-

PBL	+++	-
Bone Marrow	+++	-
Fetal Brain	+++	-
Fetal Liver	++	-

5 *2 products: wt and splice variant
** Primers d2+dhD-2 detects splice region

10 **Example 4. Knockout of $\alpha 2\delta$ -B**

In order to create a mouse knockout of $\alpha 2\delta$ -B, Genome Systems (Catalog: BAC 4922 Mouse ES 129Svj PCR based Library Screen) performed a PCR-based screen of a mouse BAC library using primers SEQ ID NOS 25-26, which were predicted to amplify an 650 bp cDNA or genomic fragment. One positive BAC clone (Genome Systems DNA control number: BAC-22401) from this screen was received. The same primers were used to generate a human DNA probe. This probe was used on a Southern blot to identify a ~10kb HindIII mouse genomic fragment from the BAC, which was subcloned into the HindII site of plasmid vector pRS416 (Stratagene). Two separate subclones were sequenced by standard techniques, using the T3 and T7 primers and SEQ ID NOS (25-32). Two 500 bp regions of sequence from the 5' and 3' ends of the 10kb genomic fragment (SEQ ID NOS 33 and 34, respectively), plus a 1.8kb sequence contig (SEQ ID NO 35) were identified. This genomic sequence can be used to identify the intron/exon structure of a portion of mouse $\alpha 2\delta$ -B gene, and may contain regulatory elements important for $\alpha 2\delta$ -B gene expression.

25 **Example 5. Identification of amino acids encoded by $\alpha 2\delta$ gene**

The amino acid sequences of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, indicated in SEQ ID NOS 5 and 6, were determined by translating the nucleotide sequences described in SEQ ID NOS 3 and 4, and aligning the amino acid sequences of $\alpha 2\delta$ -A, $\alpha 2\delta$ -B, $\alpha 2\delta$ -C, and $\alpha 2\delta$ -D. The correct open reading frame for each amino acid sequence was determined based on homology of the amino acid sequences to other $\alpha 2\delta$ -A

-45-

homologs. At the amino acid level, $\alpha 2\delta$ -C is 28% identical and 48% similar to $\alpha 2\delta$ -A and is 28% identical and 47% similar to $\alpha 2\delta$ -B, and $\alpha 2\delta$ -D is 28% identical and 47% similar to $\alpha 2\delta$ -A and is 28% identical and 46% similar to $\alpha 2\delta$ -B. Although $\alpha 2\delta$ -C and $\alpha 2\delta$ -D are related to $\alpha 2\delta$ -A, they are distinctly new and different genes.

5

Example 6. Proposed method of detecting the $\alpha 2\delta$ -C and $\alpha 2\delta$ -D proteins by using an $\alpha 2\delta$ -C and $\alpha 2\delta$ -D antibody

10 Antibodies could be developed which specifically detect epitopes unique to $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, or which detect all $\alpha 2\delta$ proteins. These antibodies could be developed by either synthesizing a peptide which is identical to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or by bacterially-expressing a fusion protein containing either $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and then injecting these peptides into a research animal in order to stimulate an immunogenic response. Antibodies generated in such a manner could be used to detect levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in cells. This could be done by immunocytochemistry, where whole cells are fixed and then the antibody is used on the whole cells to detect expression of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and to detect the subcellular localization of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D. Or, cells may be lysed and protein extracts generated and analyzed for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D expression.

15

20

Example 7. Isolation of RNA for cDNA Library

25

30

In order to isolate $\alpha 2\delta$ -C or $\alpha 2\delta$ -D from cells, RNA could be isolated by lysing cells from any tissue of interest using standard methods known in the field. After isolation, RNA is reverse-transcribed into cDNA using the enzyme reverse transcriptase and a poly(T) primer or a mix of random primers. A mix of cDNA is produced, representing a large number of the genes which are expressed in the beginning cell population at a particular point in time. Once the cDNA pool has been created, it can be restricted and then ligated into a cloning vector using methods standard in the field. This results in a cDNA library.

-46-

Example 8. cDNA Cloning Procedure

A₂ δ -C or α 2_δ-D could be cloned from a cDNA library, created as above, by using primers specific for A₂_δ-C or α 2_δ-D nucleotide sequences in a polymerase chain reaction, with the cDNA used as a template. Alternatively, 5 A₂_δ-C or α 2_δ-D sequences could be used as a probe in order to screen the cDNA library by hybridization. Using either technique, single clones are ultimately isolated from the library and sequenced using standard techniques. By sequencing multiple clones from a library, one could look for the existence of alternatively-spliced variants of A₂_δ-C or α 2_δ-D, or for the existence of single nucleotide polymorphisms, or for mutations/alterations in A₂_δ-C or α 2_δ-D.

Example 9. Screening cDNA Library with Antibody

A cDNA library could also be screened by using an antibody to A₂_δ-C or α 2_δ-D. The cDNA library is cloned into a vector which allows induction of protein expression of the cloned inserts. The complete cDNA library is induced to express a protein representing the cloned insert, then single clones which contain an insert that codes for A₂_δ-C or α 2_δ-D are identified if they hybridize to an antibody generated against A₂_δ-C or α 2_δ-D. Positive clones are isolated, and then sequenced using standard methods.

It is to be understood that the invention is not to be limited to the exact details of operation, or to the exact compounds, compositions, methods, procedures or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art, and the invention is therefore 25 to be limited only by the full scope of the appended claims.

-47-

We claim

1. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4.
2. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS 3 or 4 under high stringency hybridization conditions.
3. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS 3 or 4.
4. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS 5 or 6.
5. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS 3 or 4.
6. A recombinant DNA molecule comprising the isolated and purified DNA sequence of Claim 3 or 4 subcloned into an extra-chromosomal vector.
- 15 7. A recombinant host cell comprising a host cell transfected with the recombinant DNA molecule of Claim 6.
8. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 5 or 6.
- 20 9. A substantially purified recombinant polypeptide of Claim 8, wherein the polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 5 or 6.
10. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID NOS 5 or 6.

-48-

11. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 8.
12. A method of detecting α 2 δ -C or α 2 δ -D protein in cells, comprising contacting cells with the antibody of Claim 11 and incubating the cells in a manner that allows for detection of the α 2 δ -C or α 2 δ -D protein-antibody complex.
5
13. A diagnostic assay for detecting cells containing α 2 δ -C or α 2 δ -D mutations, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 or by analyzing the genomic DNA directly by a hybridization method and determining whether the resulting PCR product contains a mutation.
10
14. A diagnostic assay for detecting cells containing α 2 δ -C or α 2 δ -D mutations, comprising isolating total cell RNA, subjecting the RNA to reverse transcription-PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 and determining whether the resulting PCR product contains a mutation.
15
15. A method for the amplification of a region of the DNA sequence of Claim 1, 2, or 3, the method comprising the step of: contacting a test sample suspected of containing the desired sequence of Claim 1, 2, or 3 or portion thereof with amplification reaction reagents.
20
16. A diagnostic kit for detecting the presence of at least one copy of the DNA sequence of Claim 1, 2, or 3 in a test sample, said kits containing a primer, a pair of primers or a probe, and optionally amplification reagents .

-49-

17. An assay for the detection or screening of therapeutic compounds that interfere with or mimic the interaction between the polypeptide of Claim 8, 9, or 10 and ligands that bind to the polypeptide of Claim 8, 9, or 10.

18. The assay of Claim 17, herein the assay comprises the steps of:

- 5 a) providing a polypeptide of Claim 8, 9, or 10;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance;
and
- d) detecting the complexes formed between said polypeptide and said candidate substance.

10 19. A method for protecting mammalian cells from abnormal calcium flux, comprising introducing into mammalian cells an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the isolated and purified DNA sequence in mammalian cells.

15 20. A method for treating or preventing epilepsy, comprising introducing into a mammal an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the antisense strand of the isolated and purified DNA sequence in mammalian cells.

20 21. A method for purifying α 2 δ -C or α 2 δ -D protein from cells, comprising:

- a) transfecting a host cell with a vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3 operatively linked to a promoter capable of directing gene expression in a host cell;

-50-

b) inducing expression of the isolated and purified DNA sequence in the cells;

c) lysing the cells;

d) isolating $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the cells ; and

e) purifying $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the isolate.

5 22. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

23. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49 under high stringency hybridization conditions.

10 24. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

15 25. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

20 26. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

27. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 17 or 42.

28. A substantially purified recombinant polypeptide of Claim 26, wherein the

-51-

polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 17 or 42.

29. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID NOS 17 or 42.

5 30. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 26.

10 31. A method of using polynucleotide sequences to treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of:

M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1,

15 AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1,

20 Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1,

25 AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.

30 32. The method of claim 31 wherein the disease is selected from the group consisting essentially of: seizure-related syndromes, migraine, ataxia, vestibular defects, chronic pain, mood, sleep interference, anxiety, ALS, multiple sclerosis,

-52-

mania, tremor, parkinsonism, substance abuse/addiction syndromes, mood, depression, and cancer.

33. A method of using polynucleotide sequences to test for presence of a disease, or susceptibility to a disease, due to alterations or deletions in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.


34. A method of using polynucleotide sequences to identify the binding potential of the polynucleotide sequences to gabapentin, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1,

-53-

AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1,
AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1,
AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1,
AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1,
5 AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1,
T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1,
AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1,
H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and
10 AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID
NOS 1-16, 18-41, or 43-49.

1/4


FIG. 1 FINE MAPPING OF ALPHA2DELTA TO MOUSE CHROMOSOME 9



SUBSTITUTE SHEET (RULE 26)


2/4

FIG. 2 HUMAN α 2 β 2 TISSUE DISTRIBUTION




3/4

FIG. 3 $[^3\text{H}]$ GABAPENTIN BINDING ACTIVITY BY HUMAN $\alpha 2\alpha 1$ IN TRANSIT LY TRANSFECTED Cos 7 CELLS



4/4

FIG. 4



SEQUENCE LISTING

<110> Johns, Margaret Ann
Moldover, Brian Jay
Offord, James David

<120> Alpha-2/Delta Gene

<130> Combined Applications 5947L1,L2,L3

<140> PCT/US99/23519

<141> 1999-10-07

<150> 60/103,322

<151> 1998-10-07

<150> 60/106,473

<151> 1998-10-30

<150> 60/114,088

<151> 1998-12-29

<160> 49

<170> PatentIn Ver. 2.1

<210> 1

<211> 5482

<212> DNA

<213> Homo sapiens

<400> 1

cgggcagcgc agcccgaga ggcgctgcgg cccgtgcagc cccggaggcc cctcgccggag 60
aaggcggcgg cgaggagag gccgagttac cggccgcgc ccgcgcggcc ccaacccgc 120
cgccgcgcgc gcccggcca ctgccccccc tccccgcggc gcccgcattt gaatggaaac 180
atggcggtgc cggctcgac ctggcgcc ttcggcccg gcccgcgcg gactgcgcgc 240
ccctggcccg gctgcggccc ccaccctggc cccggcaccc ggccgcggac gtccggggccc 300
ccgcgcgcgc tgtggctgtc gtcgcgcattt ctaccgcgtc tcgcgcgcgc cggcgccctt 360
gcctacagct tcccccaagca gcacacgtc cagcactggg cccggcgatc ggagcaggag 420
gtcgacggcg tgatgcggat ttttgaggc gtcccgacgc tccgtgagat ttacaaggac 480
aaccggaaacc tggtcgaggt acaggagaat gggctcaga agttgggta gaaggtggca 540
ggggacattt agggcattt ggacaggaat gtgcaggccc tggatggact ggctgtatgt 600
gcagagaact tccagaaagc acaccgcgtt caggacaaca tcaaggagga agacatcgat 660
tactatgcgc ccaaggctga cgctgagctg gacgaccctg agagtgagga tggatggaaagg 720
gggtctaagg ccagcaccctt aaggctggac ttcatcgagg acccaaactt caagaacaag 780
gtcaactatt catacgccgc tgtacagatc cctacggaca tctacaaagg ctccactgtc 840
atcctcaatg agctcaactg gacagaggcc ctggagaatg tggatggaaatc aaaccgcaga 900
caagacccca cactgctgtc gcaggatctt ggcagcgcgc caggagtac tcgctactac 960

ccggccaccc cgtggcgagc ccccaagaag atcgacctgt acgatgtccg aaggagaccc 1020
tggtatatcc agggggcctc gtcacccaaa gacatggta tcacatgttgc ttttgatggc 1080
agtgtgagcg gcctgaccct gaagctgatg aagacatctg tctgcagat gctggacacg 1140
ctgtctgtatg atgactatgt gaatgtggcc tcgttcaacg agaaggcaca gcctgtgtca 1200
tgcttcacac acctggtgca ggccaatgtg cgcaacaaga aggtgttcaa ggaagctgtg 1260
cagggcatgg tggcaaggg caccacaggc tacaaggccg gctttgatg tgcctttgac 1320
cagctgcaga actccaacat cactcggcc aactgcaaca agatgatcat gatgttcacg 1380
gatggtggtg aggaccgcgt gcaggacgtc tttgagaagt acaattggcc aaaccggacg 1440
gtgcgcgtgt ttactttctc cgtgggcag cataactatg acgtcacacc gctgcagtgg 1500
atggcctgtg ccaacaaagg ctactatTTT gagatccctt ccatcgagc catccgcac 1560
aacacacagg aatatctaga tgtgttggc aggcccattt tgctggcagg caaggaggcc 1620
aagcaggttC agtggaccaa cgtgtatgatgatgactgg gactgggtt ggtggtaaca 1680
gggaccctcc ctgtttcaa cctgacacag gatggccctg gggaaaaagaa gaaccagctg 1740
atcctggcg ttagtggcat tgacgtggct ctgaatgaca tcaagaggct gaccccaac 1800
tacacgcttC gagccaacgg ctatgtttt gccattgacc tgaacggcta cgtgttgctg 1860
caccacaaatc tcaagcccc gaccaccaac ttccgggagc ctgtgactct ggacttcctg 1920
gatgcggagc tagaggatga gaacaaggaa gagatccgtc ggagcatgat ttagtggcaac 1980
aaggggccaca agcagatcag aacgttggc aagtccctgg atgagaggta catagatgag 2040
gtgacacgga actacacctg ggtgcctata aggagcacta actacagcct ggggctgtg 2100
ctccccaccc acagcacctt ctacccctt gccaatctca gtgaccagat cctgcaggtc 2160
aagtattttt agttcctgtct ccccagcagc tttgagttctg aaggacacgt tttcattgtct 2220
cccagagagt actgcaagga cctgaatgcc tcagacaaca acaccgagtt cctgaaaaaac 2280
tttatttggagc tcatggagaa agtgaatcca gactccaagc agtcaacaa ctcccttcctg 2340
cacaacctga tcttggacac gggcatcactg cagcagctgg tagagcgtgt gtggaggggac 2400
caggatctca acacgtacag cctactggcc gtgttcgtct ccacagacgg tggcatcacc 2460
cgagtcttcc ccaacaaggc agctgaggac tggacagaga accctgagcc cttcaatgcc 2520
agttcttacc gcccgcaccc ggataaccac gtttatgtct tcaagcccc acaccaggat 2580
gcccgtttaa ggccgcttggc gctggagaat gacactgtgg gcattctcgat cagcacagct 2640
gtggagctca gccttaggcag ggcacactg aggccagcag tggggccgt caagctggac 2700
ctagaggctt gggcttggagaa gttcaagggtt cttagccacca accgttccca ccaagaccag 2760
cctcagaatgt gcccggccaa cagccactgt gagatggact gcgaggtaa caatgaggac 2820
ttactctgtt tcctcatttga ttagtggagga ttccctggc tttcaatgccca gaaccatcag 2880
tgggaccagg tggcagggtt cttagtgcag gtggatgccca acctgatgtct ggcactctac 2940
aataacttcc tctacaccccg caaggagtcc tatgactatc aggccgcctg tggcccttcag 3000
ccccctggca acctgggttc tgcacccccc ggtgttcttgc tggccaccgt tgcagatttcc 3060
cttaacctgg cctggggac ctctgtgtcc gcctggccc tggccatgc gcttcttctac 3120
ggcctcatct accacagctg gttccaaagca gaccccccgg aggccgaggg gagcccccgg 3180
acgcgcgaga gcagctgcgt catgaaacag acccagactt acttcggctc gttaaacgcc 3240
tcctacaacg ccatcatcga ctgcggaaac tgcgtccaggc tggccacgc gcagagactg 3300
accaacacca atttctctt tttgggtggc gagaaggccg tttgcagccca tttgcgaggct 3360
ggccggctgc tgcagaagga gacgcactgc ccagcggacg gcccggagca tttgtgagct 3420
gtgcagagac cgccgataccg gagaggccc cacatctgt tttgcactacaa cgccgacagaa 3480
gatacctcag actgtggccg cggggccctt tttccggccgt cgttggccgt cttggcttcc 3540
ctgcaactgc tgcgtccctt gggccctggc ccccccggcc acgcctcaatgt cttcggtccac 3600
gcctctcgcc gcctctgagc accctggccc accccaccc tttcccccacc tttcccccggcc 3660
tcttcgcctt tcccaaccctc ctggcccaacatcc cttcccccgcct tagagcctcg tccctccctc 3720
actgaaggac ctgagctggc caggccctga gtttgcgttgg tttgcgttgg gatggggagg 3780
ccaaagccgg gacgcggcag tttggca cccaaatcac atctcacacc cgaactgttc 3840

aagtgtcccc agacccttct tgcctgctgg gctcccccgtggatggg acagggaggc 3900
 cacacgcact ggtgcaaaaa ccaggcctct gctgccccc ttccctggagg ctgcctatgt 3960
 tgggggggac cctgcctcag ctgaccggc ctctctgccc caccgaagcc caaacttggt 4020
 ttctgtgaga atagtggagg aaggtgagat gcccagttg aagcctgtgc ctcccagctt 4080
 aaatccttagc aggagagagg ctctgggca gccccatgg gtcctgccc ctttcaggcc 4140
 tacagccaca tccccaagcc caccaggtgt caggatagtc acagtatac cagttcagac 4200
 actaccccat atacacctgg aacattgagg atggaaaactg gactcacatt cgacataccc 4260
 cactggcac acgcacaaac acacacacta tgggtgggg tgggtgttagg ggcttacaaa 4320
 gccttacaca gggcgagggg ttgggtggag gttggcacc tgacactcc atctcctgct 4380
 caccacatgc ctctaattctg agctgcagcc tggctggtcc tcccatatttctt aaagctgaat 4440
 gtcaaacagt gccaaatgct ggggcagggg gtgaagaacc ctctgtccca cccctagcca 4500
 ccagtgtctt ccaagtgcctt cctcaacttccaggtgtctt attgttaacca ttctcaacta 4560
 gtgtcaggcc cccagtggttccacatgcctt ctgcctgcac ctggcggcag aggaaccccc 4620
 accagacatc accctttgccc tttagcagggg tgactttgtc tctcctggctt gggccatcct 4680
 tccgccaatc tggcccttac acactcaggc ctgtgcccac tccctatctc ttcccacccc 4740
 ctacacacac actccctgct tgcaggaggc caaactgtcc ctccctgtt gaacacacac 4800
 acacacacac acacacaggt gggactggg cacagcttttccatc attctggtca 4860
 tttcccccaa aggcatccca gcctggggc cagtggttccatc ctgagggcaa gggatata 4920
 ttagtgggctt cagatggact gggaggagggg ggagggtgttgcattaaatta atggcttcgt 4980
 taattaatgtt catgttgctt gtcgcttctt cagtggtgtt gtgtggtcca tgcccactgc 5040
 tgggtccagg gtgggtgtcc atgtgcaccc ggcctggatg ccagctgtgtt cttcggggg 5100
 cgtgcgtgttactgttagtgtt agtcagggtgc tcaatggaga atataaacat atacagaaaa 5160
 atatatattt taagtttaaa aaacagaaaa acagacaaaa caatccccat caggttagctg 5220
 tctaaccccc agctgggtctt aatccttcttattaccacc cgcacctggctt gcccctcacc 5280
 ttgggctggg gqactggggg gccatttctt tttctctgccc ttttttgtt tgttcttattt 5340
 tgtacagaca agttggaaaa acaacagcga caaaaaagtc aagaaaactt gtaaaatatc 5400
 gtgtgtgtga ttccctgttaa aatatttca aatggtttat tacagaagat cagttattaa 5460
 ataatgttca tattttact tc 5482

<210> 2
<211> 1145
<212> PRT
<213> Homo sapiens

<400> 2
Met Ala Val Pro Ala Arg Thr Cys Gly Ala Ser Arg Pro Gly Pro Ala
1 5 10 15

Arg Thr Ala Arg Pro Trp Pro Gly Cys Gly Pro His Pro Gly Pro Gly
20 25 30

Thr Arg Arg Pro Thr Ser Gly Pro Pro Arg Pro Leu Trp Leu Leu Leu
35 40 45

Pro Leu Leu Pro Leu Leu Ala Ala Pro Gly Ala Ser Ala Tyr Ser Phe
50 55 60

Pro Gln Gln His Thr Met Gln His Trp Ala Arg Arg Leu Glu Gln Glu
65 70 75 80

Val Asp Gly Val Met Arg Ile Phe Gly Gly Val Gln Gln Leu Arg Glu
85 90 95

Ile Tyr Lys Asp Asn Arg Asn Leu Phe Glu Val Gln Glu Asn Glu Pro
100 105 110

Gln Lys Leu Val Glu Lys Val Ala Gly Asp Ile Glu Ser Leu Leu Asp
115 120 125

Arg Lys Val Gln Ala Leu Lys Arg Leu Ala Asp Ala Ala Glu Asn Phe
130 135 140

Gln Lys Ala His Arg Trp Gln Asp Asn Ile Lys Glu Glu Asp Ile Val
145 150 155 160

Tyr Tyr Asp Ala Lys Ala Asp Ala Glu Leu Asp Asp Pro Glu Ser Glu
165 170 175

Asp Val Glu Arg Gly Ser Lys Ala Ser Thr Leu Arg Leu Asp Phe Ile
180 185 190

Glu Asp Pro Asn Phe Lys Asn Lys Val Asn Tyr Ser Tyr Ala Ala Val
195 200 205

Gln Ile Pro Thr Asp Ile Tyr Lys Gly Ser Thr Val Ile Leu Asn Glu
210 215 220

Leu Asn Trp Thr Glu Ala Leu Glu Asn Val Phe Met Glu Asn Arg Arg
225 230 235 240

Gln Asp Pro Thr Leu Leu Trp Gln Val Phe Gly Ser Ala Thr Gly Val
245 250 255

Thr Arg Tyr Tyr Pro Ala Thr Pro Trp Arg Ala Pro Lys Lys Ile Asp
260 265 270

Leu Tyr Asp Val Arg Arg Arg Pro Trp Tyr Ile Gln Gly Ala Ser Ser
275 280 285

Pro Lys Asp Met Val Ile Ile Val Asp Val Ser Gly Ser Val Ser Gly
290 295 300

Leu Thr Leu Lys Leu Met Lys Thr Ser Val Cys Glu Met Leu Asp Thr
305 310 315 320

(
Leu Ser Asp Asp Asp Tyr Val Asn Val Ala Ser Phe Asn Glu Lys Ala
325 330 335

Gln Pro Val Ser Cys Phe Thr His Leu Val Gln Ala Asn Val Arg Asn
340 345 350

Lys Lys Val Phe Lys Glu Ala Val Gln Gly Met Val Ala Lys Gly Thr
355 360 365

Thr Gly Tyr Lys Ala Gly Phe Glu Tyr Ala Phe Asp Gln Leu Gln Asn
370 375 380

Ser Asn Ile Thr Arg Ala Asn Cys Asn Lys Met Ile Met Met Phe Thr
385 390 395 400

Asp Gly Gly Glu Asp Arg Val Gln Asp Val Phe Glu Lys Tyr Asn Trp
405 410 415

Pro Asn Arg Thr Val Arg Val Phe Thr Phe Ser Val Gly Gln His Asn
420 425 430

Tyr Asp Val Thr Pro Leu Gln Trp Met Ala Cys Ala Asn Lys Gly Tyr
435 440 445

Tyr Phe Glu Ile Pro Ser Ile Gly Ala Ile Arg Ile Asn Thr Gln Glu
450 455 460

Tyr Leu Asp Val Leu Gly Arg Pro Met Val Leu Ala Gly Lys Glu Ala
465 470 475 480

Lys Gln Val Gln Trp Thr Asn Val Tyr Glu Asp Ala Leu Gly Leu Gly
485 490 495

Leu Val Val Thr Gly Thr Leu Pro Val Phe Asn Leu Thr Gln Asp Gly
500 505 510

Pro Gly Glu Lys Lys Asn Gln Leu Ile Leu Gly Val Met Gly Ile Asp
515 520 525

Val Ala Leu Asn Asp Ile Lys Arg Leu Thr Pro Asn Tyr Thr Leu Gly
530 535 540

Ala Asn Gly Tyr Val Phe Ala Ile Asp Leu Asn Gly Tyr Val Leu Leu
545 550 555 560

His Pro Asn Leu Lys Pro Gln Thr Thr Asn Phe Arg Glu Pro Val Thr
565 570 575

Leu Asp Phe Leu Asp Ala Glu Leu Glu Asp Glu Asn Lys Glu Glu Ile
580 585 590

Arg Arg Ser Met Ile Asp Gly Asn Lys Gly His Lys Gln Ile Arg Thr
595 600 605

Leu Val Lys Ser Leu Asp Glu Arg Tyr Ile Asp Glu Val Thr Arg Asn
610 615 620

Tyr Thr Trp Val Pro Ile Arg Ser Thr Asn Tyr Ser Leu Gly Leu Val
625 630 635 640

Leu Pro Pro Tyr Ser Thr Phe Tyr Leu Gln Ala Asn Leu Ser Asp Gln
645 650 655

Ile Leu Gln Val Lys Tyr Phe Glu Phe Leu Leu Pro Ser Ser Phe Glu
660 665 670

Ser Glu Gly His Val Phe Ile Ala Pro Arg Glu Tyr Cys Lys Asp Leu
675 680 685

Asn Ala Ser Asp Asn Asn Thr Glu Phe Leu Lys Asn Phe Ile Glu Leu
690 695 700

Met Glu Lys Val Thr Pro Asp Ser Lys Gln Cys Asn Asn Phe Leu Leu
705 710 715 720

His Asn Leu Ile Leu Asp Thr Gly Ile Thr Gln Gln Leu Val Glu Arg
725 730 735

Val Trp Arg Asp Gln Asp Leu Asn Thr Tyr Ser Leu Leu Ala Val Phe
740 745 750

Ala Ala Thr Asp Gly Gly Ile Thr Arg Val Phe Pro Asn Lys Ala Ala
755 760 765

Glu Asp Trp Thr Glu Asn Pro Glu Pro Phe Asn Ala Ser Phe Tyr Arg
770 775 780

Arg Ser Leu Asp Asn His Gly Tyr Val Phe Lys Pro Pro His Gln Asp
785 790 795 800

Ala Leu Leu Arg Pro Leu Glu Leu Glu Asn Asp Thr Val Gly Ile Leu
805 810 815

Val Ser Thr Ala Val Glu Leu Ser Leu Gly Arg Arg Thr Leu Arg Pro
820 825 830

Ala Val Val Gly Val Lys Leu Asp Leu Glu Ala Trp Ala Glu Lys Phe
835 840 845

Lys Val Leu Ala Ser Asn Arg Thr His Gln Asp Gln Pro Gln Lys Cys
850 855 860

Gly Pro Asn Ser His Cys Glu Met Asp Cys Glu Val Asn Asn Glu Asp
865 870 875 880

Leu Leu Cys Val Leu Ile Asp Asp Gly Gly Phe Leu Val Leu Ser Asn
885 890 895

Gln Asn His Gln Trp Asp Gln Val Gly Arg Phe Phe Ser Glu Val Asp
900 905 910

Ala Asn Leu Met Leu Ala Leu Tyr Asn Asn Ser Phe Tyr Thr Arg Lys
915 920 925

Glu Ser Tyr Asp Tyr Gln Ala Ala Cys Ala Pro Gln Pro Pro Gly Asn
930 935 940

Leu Gly Ala Ala Pro Arg Gly Val Phe Val Pro Thr Val Ala Asp Phe
945 950 955 960

Leu Asn Leu Ala Trp Trp Thr Ser Ala Ala Ala Trp Ser Leu Phe Gln
965 970 975

Gln Leu Leu Tyr Gly Leu Ile Tyr His Ser Trp Phe Gln Ala Asp Pro
980 985 990

Ala Glu Ala Glu Gly Ser Pro Glu Thr Arg Glu Ser Ser Cys Val Met
995 1000 1005

Lys Gln Thr Gln Tyr Tyr Phe Gly Ser Val Asn Ala Ser Tyr Asn Ala
1010 1015 1020

Ile Ile Asp Cys Gly Asn Cys Ser Arg Leu Phe His Ala Gln Arg Leu
1025 1030 1035 1040

Thr Asn Thr Asn Leu Leu Phe Val Val Ala Glu Lys Pro Leu Cys Ser
1045 1050 1055

Gln Cys Glu Ala Gly Arg Leu Leu Gln Lys Glu Thr His Cys Pro Ala
1060 1065 1070

Asp Gly Pro Glu Gln Cys Glu Leu Val Gln Arg Pro Arg Tyr Arg Arg
1075 1080 1085

Gly Pro His Ile Cys Phe Asp Tyr Asn Ala Thr Glu Asp Thr Ser Asp
 1090 1095 1100

Cys Gly Arg Gly Ala Ser Phe Pro Pro Ser Leu Gly Val Leu Val Ser
 1105 1110 1115 1120

Leu Gln Leu Leu Leu Leu Gly Leu Pro Pro Arg Pro Gln Pro Gln
 1125 1130 1135

Val Leu Val His Ala Ser Arg Arg Leu
 1140 1145

<210> 3
<211> 3770
<212> DNA
<213> Homo sapiens

<400> 3

tactataggg cggccgcgaa ttcggcacga ggcggcgccg agcggagcag gcagccccgc 60
 gcgctcgccc accgccccgtc ccgcgcagct ccccgccggcc gctctcgctc cccgcgcagc 120
 gggcgcgtcg gagggagcccg agcatggccg ggccgggctc gccgcgcgcgc gcgtcccccgg 180
 gggcctcggc gcttctcgct gccgcgccttc tctacgcgcgc gctgggggac gtggtgcgct 240
 cggagcagca gataccgcgtc tccgtggta agctctggc ctcggctttt ggtggggaga 300
 taaaatccat tgctgctaag tactccgggtt cccagcttct gcaaaagaaaa tacaaagagt 360
 atgagaaaaga cggtgccata gaagaaaattt atggcctcca actggtaaag aagctggcaa 420
 agaacatgga agagatgttt cacaagaagt ctgaggccgt caggcgtctg gtggaggctg 480
 cagaagaagc acacacctgaaa catgaatttg atgcagactt acagtatgaa tacttcaatg 540
 ctgtgctgat aaatgaaaagg gacaagacg gaaattttt ggagctggaa aaggaattca 600
 tcttagcccc aaatgaccat tttataatt tgcctgtgaa catcagtcta agtgacgtcc 660
 aagtaccaac gaacatgtac aacaagacc ctgcaattgtt caatggggtt tattggctg 720
 aatctctaaa caaagttttt gtagataact ttgaccgtga cccatctctc atatggcagt 780
 actttggaaag tgcaaaggc tttttaggc agtatccggg gattaaatgg gaaccagatg 840
 agaatggagt cattgccttc gactgcagga accgaaaatg gtacatccag gcagcaactt 900
 ctccgaaaga cgtggtcatt ttatgtgacg tcagtggcag catgaaagga ctccgtctga 960
 ctatcgcaaa gcaaacagtc tcatccattt tggatacact tggggatgat gacttctca 1020
 acataatgc ttataatgag gagcttact atgtggaaacc ttgcctgaat ggaactttgg 1080
 tgcaagccga caggacaaac aaagagcaact tcagggagca tctggacaaa ctttcgcca 1140
 aaggaatgg aatgttggat atagctctga atgaggccctt caacattctg agtgatttca 1200
 accacacggg acaaggaagt atctgcagtc aggccatcat gctcataact gatggggcgg 1260
 tggacaccta tgatacaatc tttgcaaaat acaattggcc agatcgaaag gttcgcatct 1320
 tcacataacct cattggacga gaggctgcgt ttgcagacaa tctaaagtgg atggcctgtg 1380
 ccaacaaagg atttttacc cagatctcca cttggctga tgtgcaggag aatgtcatgg 1440
 aatacctca cgtgcttagc cggcccaaag tcatcgacca ggagcatgat gtggtgtgga 1500
 ccgaagctta cattgacagc actctgactg atgatcaggg ccccgctctg atgaccactg 1560
 tagccatgcc tttgttttagt aagcagaacg aaaccagatc gaagggcatt ttctggag 1620
 tggttggcac agatgtccca gtgaaagaac ttctgaagac catccccaaa tacaagttag 1680
 ggattcacgg ttatgccttt gcaatcacaa ataatggrrta tattcctgacg catccggAAC 1740

tcaggctgct gtacgaagaa ggaaaaaaagc gaaggaaacc taactatagt agcgttgacc 1800
 tctctgaggt ggagtggaa gaccgagatg acgtgttag aatgttatg gtgaatcgaa 1860
 agacgggaa gtttccatg gaggtgaaga agacagtggaa caaaggaaa cgggtttgg 1920
 tgatgacaaa tgactactat tatacagaca tcaagggtac tccttcagt ttaggtgtgg 1980
 cgcttcag aggtcatggg aaatattct tccgagggaa tgtaaccatc gaagaaggcc 2040
 tgcgtactt agaacatccc gatgtgtct tggcagatga atggcctac tgcaacactg 2100
 acctacaccc tgagcaccgc catctgtctc agttagaagc gattaagctc tacctaaaag 2160
 gcaaagaacc tctgctccag tgtgataaag aattgatcca agaagtcctt tttgacgcgg 2220
 tggtgagtgc cccattgaa gcgtattgga ccagcctggc cctcaacaaa tctgaaaatt 2280
 ctgacaaggg cgtggagggt gccttcctcg gcactcgcac gggcctctcc agaatcaacc 2340
 tggggcgg ggctgagcag ctcaccaatc aggacttcct gaaagctggc gacaaggaga 2400
 acatTTTaa cgcagaccat ttccctctt ggtaccgaag agccgctgag cagattccag 2460
 ggagcttcgt ctactcgatc ccattcagca ctggaccagt caataaaagc aatgtggtga 2520
 cagcaagtac atccatccag ctccctggatg aacggaaatc tcctgtgtg gcagctgtag 2580
 gcattcagat gaaacttgaa ttttccaaa ggaagttctg gactgccagc agacagtgtg 2640
 ctccctgga tggcaaatgc tccatcagct gtgatgatga gactgtgaat tggtaacctca 2700
 tagacaataa tggatttatt ttgggtgtctg aagactacac acagactgga gactttttg 2760
 gtgagatcga gggagctgtg atgaacaaat tgctaacaat gggctccctt aaaagaatta 2820
 cccttatga ctaccaagcc atgttagag ccaacaagga aagcagcgat ggcgcctcatg 2880
 gcctcctgga tccttataat gccttcctct ctgcagtaaa atggatcatg acagaacttg 2940
 tcttggcctt ggtggattt aacctctgca gttggggca ctccgatatg acagctaaag 3000
 cccagaaatt gaaacagacc ctggagccctt gtgatactga atatccagca ttctgtctcg 3060
 agcgcaccat caaggagact acagggaaata ttgcttgtga agactgctcc aagtcccttg 3120
 tcatccagca aatcccaagc agcaacctgt tcatgggtt ggtggacagc agtcgcctct 3180
 gtgaatctgt ggccccccatc accatggcac ccattggaaat caggtataat gaatccctta 3240
 agtgtgaacg tctaaaggcc cagaagatca gaaggcgccc agaatcttg catggcttcc 3300
 atcctgagga gaatgcaagg gagtgtgggg gtgcgcggag tctccaagcc cagacagtcc 3360
 tccttctgtct ccctctgtt ttgatgtct tctcaagggtg acactgactg agatgttctc 3420
 ttactgactg agatgttctc ttggcatgct aaatcatgga taaaactgtga accaaaatat 3480
 ggtgcaacat acgagacatg aatatagtcc aaccatcagc atctcatcat gatTTAAAC 3540
 tggcggtat ataaactctt aaagatatgt tgacaaaaag ttatctatca tctttttact 3600
 ttgccagtc tgcaaatgtg agtttgcac atgataatca cccttcatca gaaatgggac 3660
 cgcaagtgtt aggcagtgtc ccctctgtt gaaacctatt gaaaccaatt taaaactgtg 3720
 tacttttaa ataaagtata taaaatcat aaaaaaaaaa aaaaaaaaaa 3770

<210> 4
 <211> 5073
 <212> DNA
 <213> Homo sapiens

<400> 4
 ccatgcctgc aactcccaac ttccctcgaa accccagctc cagcagccgc tggattcccc 60
 tccagccaaat gcccgtggcc tgggcctttg tgcagaagac ctcggccctc ctgtggctgc 120
 tgcttctagg cacccctcg tcccctgcgt ggggacagggc caagattcct ctggaaacag 180
 tgaagctatg ggctgacacc ttccgggggg acctgtataa cactgtgacc aaatactcag 240
 gctctctctt gctcagaag aagtacaagg atgtggagtc cagtctgaag atcgaggagg 300
 tggatggctt ggagctgggtg aggaagttct cagaggacat ggagaacatg ctgcggagga 360

aagtcgaggc ggtccagaat ctggtggaaag ctgccgagga ggccgacctg aaccacgaat 420
 tcaatgaatc cctgggttgc gactattaca actcggtct gatcaacgag agggacgaga 480
 agggcaactt cgtggagctg ggcgccgagt tcctcctgga gtccaatgct cacttcagca 540
 acctgccgtt gaacacacctc atcagcagcg tgcagctgcc caccacatgt tacaacaaag 600
 acccagatata tttaaatgga gtctacatgt ctgaagcctt gaatgctgtc ttcgtggaga 660
 acttccagag agacccaacg ttgacctggc aatattttgg cagtgcaact ggattcttca 720
 ggatctatcc aggtataaaa tggacacctg atgagaatgg agtcattact tttgactgcc 780
 gaaaccgcgg ctggtacatt caagctgcta cttctcccaa ggacatagtg attttggtgg 840
 acgtgagcgg cagtagtgaag gggctgagga tgactattgc caagcacacc atcaccacca 900
 tcttggacac cctggggggag aatgacttcg ttaatatcat agcgtacaat gactacgtcc 960
 attacatcga gccttgtttt aaagggatcc tcgtccaggc ggaccgagac aatcgagagc 1020
 atttcaaact gctggtgag gagttgatgg tcaaagggtt gggggctgt gaccaaggccc 1080
 tgagagaagc cttccagatc ctgaagcagt tccaagagggc caagcaagga agcctctgca 1140
 accaggccat catgctcatc agcgacggcg ccgtggagga ctacgagccg gtgtttgaga 1200
 agtataactg gccagactgt aaggtccgag ttttcaactt cctcatttggg agagaagtgt 1260
 ctttgctga cccatgaaag tggattgcat gcaacaacaa aggctactac acgcagatct 1320
 caacgctggc ggacacccag gagaacgtga tggaaatacct gcacgtgctc agccgccccca 1380
 tggtcatcaa ccacgaccac gacatcatct ggacagagggc ctacatggac agcaagctcc 1440
 tcagctcgca ggctcagagc ctgacactgc tcaccactgt ggccatgcca gtcttcagca 1500
 agaagaacga aacgcgatcc catggcattc tcctgggtgt ggtggctca gatgtggccc 1560
 tgagagagct gatgaagctg gcgcgggtt acaagcttgg agtgcacggc tacgccttgc 1620
 tgaacaccaa caatggctac atcctctccc atcccgaccc cggggccctg tacagagagg 1680
 ggaagaaaact aaaacccaaa cctaactaca acagtgtgg tctctccgaa gtggagtggtt 1740
 aagaccagggc tgaatctctg agaacagcca tgatcaatag gggaaacaggt actctctcga 1800
 tggatgtgaa ggttccgatg gataaaggga agcgagttct tttcctgacc aatgactact 1860
 tcttcacgga catcagcgac acccctttca gtttgggggt ggtgtgtcc cggggccacg 1920
 gagaatacat ccttctgggg aacacgtctg tggaaagaagg cctgcatgac ttgcttcacc 1980
 cagacctggc cctggccgggt gactggatct actgcacatc agatattgac ccagaccacc 2040
 ggaagctcag ccagctagag gccatgatcc gcttcctcac caggaaggac ccagacctgg 2100
 agtgtgacga ggagctggc cgggaggtgc tggttgcac ggtggtgaca gccccatgg 2160
 aagcctactg gacagcgctg gcccctaaca tgtccgagga gtctgaacac gtggtgacca 2220
 tggccttctt gggaccccg gctggcctcc tgagaaggcag cttgttgcgtg ggtcccgaga 2280
 aggtctccga caggaagttc ctgacacctg aggacgaggc cagcgtgttc accctggacc 2340
 gcttcccgct gtggtaccgc caggcctcag agcatcctgc tggcagctc gtctcaacc 2400
 tccgctggc agaaggacca gaaagtgcgg gtgaacccat ggtggtgacg gcaaggacac 2460
 ctgtggcggt gaccgtggac aagaggacag ccattgctgc agccgcggc gtccaaatga 2520
 agctgaaatt cctccagcgc aaattctggg cggcaacgcg gcagtgacgc actgtggatg 2580
 ggccgtgcac acagagctgc gaggacagtg atctggactg cttcgatc gacaacaacg 2640
 ggttcattct gatctccaag aggtcccgag agacgggaag atttctgggg gaggtggatg 2700
 gtgctgtcct gacccagctg ctcagcatgg ggggtttcag ccaagtgact atgtatgact 2760
 atcaggccat gtgcaaaaccc tcgagtcacc accacagtgc agcccagccc ctggtcagcc 2820
 caatttctgc cttcttgacg gcgaccaggt ggctgctgca ggagctgggtg ctgttcctgc 2880
 tggagtggag tgtctggggc tcctggatcg acagaggggg cgagccaaa agtgtcttcc 2940
 atcactccca caaacacaag aagcaggacc cgctgcagcc ctgcacacg gagtaccccg 3000
 tggcgtgtt ccagccggcc atccgggagg ccaacgggat cgtggatgtc gggccctgcc 3060
 agaaggatt tgggtgcag cagattccca acagtaacct ctcctcctg gtgacagacc 3120
 ccacctgtga ctgcagcata tcctccaccag tgctgcagga ggccgacagaa gtcaaata 3180
 atgcctctgt caaatgtgac cggatgegct cccagaagct ccggccggcga ccagactcc 3240

gccacgcctt ccatccagag gagaatgccc aggactgcgg cggcgcctcg gacacccctag 3300
 cctcgccgcc cctactcctg ctgcctgtgt gtgcctgggg gctactgccc caactccctgc 3360
 ggtgacacca cccagcctga cctgtttt ggcaaggta tccttccaga gccatccaa 3420
 aaagtcatcga ctgacatggg atgcagctaa ctgcagttgg gtcgcggggca ggccaacgct 3480
 cctctcaatc ctgggcttgtt ggccctggc tccggagaat gctggatgga acagggaaacc 3540
 aatcacctgg caccacttc aagatgcttc atggtccccg gtaccatctg ccctaggtct 3600
 caacatgagc atacttctga cctaacccttc ctgtctcctc ttggaaagc cagcgtgagc 3660
 tcagcttgaa ccaagacaaa ataatttagt tcttcctgtta ctccagagtc cagacccagc 3720
 caagaaaggg tcagttttt ctgaccctt ctgtcgaggt ggtctcttgtt agaaccctaa 3780
 gacttctggg tactgagaag cagcagcaga atgaggccaa atgcagagat gaggctaagg 3840
 caagaatatg ccccaactaa agcatagatt ccccaaagtg aggctcatgg tgggaggcca 3900
 ctcaccttcc tagctgtgc tcgaaaaggt tttgactgtg ttgggtggg gttgggttaa 3960
 gggaatggtc aagactgaga aaggaatgaa atccattcag gaaatatcga cagggctaca 4020
 cgtgatgtcc cccaaactgct gctattgaag aacttcccaa aacttctta caaagcccta 4080
 aaggaaagtt tgcatactatg aaaagccaat aggctgagac atccaattgc tgcataggaaa 4140
 ttgatgtaca ttcaaggggac ggcaaaaata gctgtaaaat agtaaaaaag agcagtggtt 4200
 gtgctctttt ctggccatg atttacaaaa gaatctactt gactctgtcc ctggagtgaa 4260
 atccttaggg ttgaaacttg tggaaacatt ccaacttgct aagcagggtc cactgggagg 4320
 gaagctctat ctggaaactc acccccacgc cacacacatc tcccccaagg tcccaaggcc 4380
 ccgcagcttc ctccccccgac caaaccctaa gacctggatc ccaggagaca acagtctcca 4440
 catgagagca acattaaggg caaagccatg gagaatgtg ggagaggccg gcctcaaattc 4500
 tttccattta acaaaccctaa gtgatggta tggacagcat gcagggttt tggggcgctt 4560
 ccccccgcctc ctccatcacc ctcagcctcc acacttcaaa gttcaagttc aaagctgttc 4620
 aagtttccta ccagcaaata gcccataactt gcctcttagag taggccaaat gccaactctg 4680
 taaaacacac ttacattatc gttacagaa tgtactt accatcatgt cttgcaaccaa 4740
 ccctgtgagg gcagtattaa tgccccctta cagcagaaga cactgcagct cgaagacagc 4800
 ttaagtggca gaataatgct agaacagctt aggtttacat gtaccaata acatgttca 4860
 gctcatttcca tcctcacaac agccccctga aagtgggtac tatcatttagt cccatgttat 4920
 agaaactgca gcagagttga aaattgcctc caaattaccg gaagagtgtt tgaagatgaa 4980
 atgtatgttta ttcaacgttac atgcttgaaa ctgcctggca tatactaaac gctaaataaa 5040
 tacatgctaa ctgaaaaaaaaaaa aaa 5073

<210> 5
 <211> 1085
 <212> PRT
 <213> Homo sapiens

<400> 5
 Met Ala Gly Pro Gly Ser Pro Arg Arg Ala Ser Arg Gly Ala Ser Ala
 1 5 10 15

Leu Leu Ala Ala Leu Leu Tyr Ala Ala Leu Gly Asp Val Val Arg
 20 25 30

Ser Glu Gln Gln Ile Pro Leu Ser Val Val Lys Leu Trp Ala Ser Ala
 35 40 45

Phe Gly Gly Glu Ile Lys Ser Ile Ala Ala Lys Tyr Ser Gly Ser Gln
50 55 60

Leu Leu Gln Lys Lys Tyr Lys Glu Tyr Glu Lys Asp Val Ala Ile Glu
65 70 75 80

Glu Ile Asp Gly Leu Gln Leu Val Lys Lys Leu Ala Lys Asn Met Glu
85 90 95

Glu Met Phe His Lys Lys Ser Glu Ala Val Arg Arg Leu Val Glu Ala
100 105 110

Ala Glu Glu Ala His Leu Lys His Glu Phe Asp Ala Asp Leu Gln Tyr
115 120 125

Glu Tyr Phe Asn Ala Val Leu Ile Asn Glu Arg Asp Lys Asp Gly Asn
130 135 140

Phe Leu Glu Leu Gly Lys Glu Phe Ile Leu Ala Pro Asn Asp His Phe
145 150 155 160

Asn Asn Leu Pro Val Asn Ile Ser Leu Ser Asp Val Gln Val Pro Thr
165 170 175

Asn Met Tyr Asn Lys Asp Pro Ala Ile Val Asn Gly Val Tyr Trp Ser
180 185 190

Glu Ser Leu Asn Lys Val Phe Val Asp Asn Phe Asp Arg Asp Pro Ser
195 200 205

Leu Ile Trp Gln Tyr Phe Gly Ser Ala Lys Gly Phe Phe Arg Gln Tyr
210 215 220

Pro Gly Ile Lys Trp Glu Pro Asp Glu Asn Gly Val Ile Ala Phe Asp
225 230 235 240

Cys Arg Asn Arg Lys Trp Tyr Ile Gln Ala Ala Thr Ser Pro Lys Asp
245 250 255

Val Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu Arg Leu
260 265 270

Thr Ile Ala Lys Gln Thr Val Ser Ser Ile Leu Asp Thr Leu Gly Asp
275 280 285

Asp Asp Phe Phe Asn Ile Ile Ala Tyr Asn Glu Glu Leu His Tyr Val
290 295 300

Glu Pro Cys Leu Asn Gly Thr Leu Val Gln Ala Asp Arg Thr Asn Lys
305 310 315 320

Glu His Phe Arg Glu His Leu Asp Lys Leu Phe Ala Lys Gly Ile Gly
325 330 335

Met Leu Asp Ile Ala Leu Asn Glu Ala Phe Asn Ile Leu Ser Asp Phe
340 345 350

Asn His Thr Gly Gln Gly Ser Ile Cys Ser Gln Ala Ile Met Leu Ile
355 360 365

Thr Asp Gly Ala Val Asp Thr Tyr Asp Thr Ile Phe Ala Lys Tyr Asn
370 375 380

Trp Pro Asp Arg Lys Val Arg Ile Phe Thr Tyr Leu Ile Gly Arg Glu
385 390 395 400

Ala Ala Phe Ala Asp Asn Leu Lys Trp Met Ala Cys Ala Asn Lys Gly
405 410 415

Phe Phe Thr Gln Ile Ser Thr Leu Ala Asp Val Gln Glu Asn Val Met
420 425 430

Glu Tyr Leu His Val Leu Ser Arg Pro Lys Val Ile Asp Gln Glu His
435 440 445

Asp Val Val Trp Thr Glu Ala Tyr Ile Asp Ser Thr Leu Thr Asp Asp
450 455 460

Gln Gly Pro Val Leu Met Thr Thr Val Ala Met Pro Val Phe Ser Lys
465 470 475 480

Gln Asn Glu Thr Arg Ser Lys Gly Ile Leu Leu Gly Val Val Gly Thr
485 490 495

Asp Val Pro Val Lys Glu Leu Leu Lys Thr Ile Pro Lys Tyr Lys Leu
500 505 510

Gly Ile His Gly Tyr Ala Phe Ala Ile Thr Asn Asn Gly Tyr Ile Leu
515 520 525

Thr His Pro Glu Leu Arg Leu Leu Tyr Glu Glu Gly Lys Lys Arg Arg
530 535 540

Lys Pro Asn Tyr Ser Ser Val Asp Leu Ser Glu Val Glu Trp Glu Asp
545 550 555 560

Arg Asp Asp Val Leu Arg Asn Ala Met Val Asn Arg Lys Thr Gly Lys
565 570 575

Phe Ser Met Glu Val Lys Lys Thr Val Asp Lys Gly Lys Arg Val Leu
580 585 590

Val Met Thr Asn Asp Tyr Tyr Thr Asp Ile Lys Gly Thr Pro Phe
595 600 605

Ser Leu Gly Val Ala Leu Ser Arg Gly His Gly Lys Tyr Phe Phe Arg
610 615 620

Gly Asn Val Thr Ile Glu Glu Gly Leu His Asp Leu Glu His Pro Asp
625 630 635 640

Val Ser Leu Ala Asp Glu Trp Ser Tyr Cys Asn Thr Asp Leu His Pro
645 650 655

Glu His Arg His Leu Ser Gln Leu Glu Ala Ile Lys Leu Tyr Leu Lys
660 665 670

Gly Lys Glu Pro Leu Leu Gln Cys Asp Lys Glu Leu Ile Gln Glu Val
675 680 685

Leu Phe Asp Ala Val Val Ser Ala Pro Ile Glu Ala Tyr Trp Thr Ser
690 695 700

Leu Ala Leu Asn Lys Ser Glu Asn Ser Asp Lys Gly Val Glu Val Ala
705 710 715 720

Phe Leu Gly Thr Arg Thr Gly Leu Ser Arg Ile Asn Leu Phe Val Gly
725 730 735

Ala Glu Gln Leu Thr Asn Gln Asp Phe Leu Lys Ala Gly Asp Lys Glu
740 745 750

Asn Ile Phe Asn Ala Asp His Phe Pro Leu Trp Tyr Arg Arg Ala Ala
755 760 765

Glu Gln Ile Pro Gly Ser Phe Val Tyr Ser Ile Pro Phe Ser Thr Gly
770 775 780

Pro Val Asn Lys Ser Asn Val Val Thr Ala Ser Thr Ser Ile Gln Leu
785 790 795 800

Leu Asp Glu Arg Lys Ser Pro Val Val Ala Ala Val Gly Ile Gln Met
805 810 815

Lys Leu Glu Phe Phe Gln Arg Lys Phe Trp Thr Ala Ser Arg Gln Cys
 820 825 830

 Ala Ser Leu Asp Gly Lys Cys Ser Ile Ser Cys Asp Asp Glu Thr Val
 835 840 845

 Asn Cys Tyr Leu Ile Asp Asn Asn Gly Phe Ile Leu Val Ser Glu Asp
 850 855 860

 Tyr Thr Gln Thr Gly Asp Phe Phe Gly Glu Ile Glu Gly Ala Val Met
 865 870 875 880

 Asn Lys Leu Leu Thr Met Gly Ser Phe Lys Arg Ile Thr Leu Tyr Asp
 885 890 895

 Tyr Gln Ala Met Cys Arg Ala Asn Lys Glu Ser Ser Asp Gly Ala His
 900 905 910

 Gly Leu Leu Asp Pro Tyr Asn Ala Phe Leu Ser Ala Val Lys Trp Ile
 915 920 925

 Met Thr Glu Leu Val Leu Phe Leu Val Glu Phe Asn Leu Cys Ser Trp
 930 935 940

 Trp His Ser Asp Met Thr Ala Lys Ala Gln Lys Leu Lys Gln Thr Leu
 945 950 955 960

 Glu Pro Cys Asp Thr Glu Tyr Pro Ala Phe Val Ser Glu Arg Thr Ile
 965 970 975

 Lys Glu Thr Thr Gly Asn Ile Ala Cys Glu Asp Cys Ser Lys Ser Phe
 980 985 990

 Val Ile Gln Gln Ile Pro Ser Ser Asn Leu Phe Met Val Val Val Asp
 995 1000 1005

 Ser Ser Cys Leu Cys Glu Ser Val Ala Pro Ile Thr Met Ala Pro Ile
 1010 1015 1020

 Glu Ile Arg Tyr Asn Glu Ser Leu Lys Cys Glu Arg Leu Lys Ala Gln
 1025 1030 1035 1040

 Lys Ile Arg Arg Arg Pro Glu Ser Cys His Gly Phe His Pro Glu Glu
 1045 1050 1055

 Asn Ala Arg Glu Cys Gly Gly Ala Pro Ser Leu Gln Ala Gln Thr Val
 1060 1065 1070

Leu Leu Leu Leu Pro Leu Leu Met Leu Phe Ser Arg
1075 1080 1085

<210> 6
<211> 1120
<212> PRT
<213> Homo sapiens

<400> 6
Met Pro Ala Thr Pro Asn Phe Leu Ala Asn Pro Ser Ser Ser Arg
1 5 10 15

Trp Ile Pro Leu Gln Pro Met Pro Val Ala Trp Ala Phe Val Gln Lys
20 25 30

Thr Ser Ala Leu Leu Trp Leu Leu Leu Gly Thr Ser Leu Ser Pro
35 40 45

Ala Trp Gly Gln Ala Lys Ile Pro Leu Glu Thr Val Lys Leu Trp Ala
50 55 60

Asp Thr Phe Gly Gly Asp Leu Tyr Asn Thr Val Thr Lys Tyr Ser Gly
65 70 75 80

Ser Leu Leu Leu Gln Lys Lys Tyr Lys Asp Val Glu Ser Ser Leu Lys
85 90 95

Ile Glu Glu Val Asp Gly Leu Glu Leu Val Arg Lys Phe Ser Glu Asp
100 105 110

Met Glu Asn Met Leu Arg Arg Lys Val Glu Ala Val Gln Asn Leu Val
115 120 125

Glu Ala Ala Glu Glu Ala Asp Leu Asn His Glu Phe Asn Glu Ser Leu
130 135 140

Val Phe Asp Tyr Tyr Asn Ser Val Leu Ile Asn Glu Arg Asp Glu Lys
145 150 155 160

Gly Asn Phe Val Glu Leu Gly Ala Glu Phe Leu Leu Glu Ser Asn Ala
165 170 175

His Phe Ser Asn Leu Pro Val Asn Thr Ser Ile Ser Ser Val Gln Leu
180 185 190

Pro Thr Asn Val Tyr Asn Lys Asp Pro Asp Ile Leu Asn Gly Val Tyr
195 200 205

Met Ser Glu Ala Leu Asn Ala Val Phe Val Glu Asn Phe Gln Arg Asp
210 215 220

Pro Thr Leu Thr Trp Gln Tyr Phe Gly Ser Ala Thr Gly Phe Phe Arg
225 230 235 240

Ile Tyr Pro Gly Ile Lys Trp Thr Pro Asp Glu Asn Gly Val Ile Thr
245 250 255

Phe Asp Cys Arg Asn Arg Gly Trp Tyr Ile Gln Ala Ala Thr Ser Pro
260 265 270

Lys Asp Ile Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu
275 280 285

Arg Met Thr Ile Ala Lys His Thr Ile Thr Thr Ile Leu Asp Thr Leu
290 295 300

Gly Glu Asn Asp Phe Val Asn Ile Ile Ala Tyr Asn Asp Tyr Val His
305 310 315 320

Tyr Ile Glu Pro Cys Phe Lys Gly Ile Leu Val Gln Ala Asp Arg Asp
325 330 335

Asn Arg Glu His Phe Lys Leu Leu Val Glu Glu Leu Met Val Lys Gly
340 345 350

Val Gly Val Val Asp Gln Ala Leu Arg Glu Ala Phe Gln Ile Leu Lys
355 360 365

Gln Phe Gln Glu Ala Lys Gln Gly Ser Leu Cys Asn Gln Ala Ile Met
370 375 380

Leu Ile Ser Asp Gly Ala Val Glu Asp Tyr Glu Pro Val Phe Glu Lys
385 390 395 400

Tyr Asn Trp Pro Asp Cys Lys Val Arg Val Phe Thr Tyr Leu Ile Gly
405 410 415

Arg Glu Val Ser Phe Ala Asp Arg Met Lys Trp Ile Ala Cys Asn Asn
420 425 430

Lys Gly Tyr Tyr Thr Gln Ile Ser Thr Leu Ala Asp Thr Gln Glu Asn
435 440 445

Val Met Glu Tyr Leu His Val Leu Ser Arg Pro Met Val Ile Asn His
450 455 460

Asp His Asp Ile Ile Trp Thr Glu Ala Tyr Met Asp Ser Lys Leu Leu
465 470 475 480

Ser Ser Gln Ala Gln Ser Leu Thr Leu Leu Thr Thr Val Ala Met Pro
485 490 495

Val Phe Ser Lys Lys Asn Glu Thr Arg Ser His Gly Ile Leu Leu Gly
500 505 510

Val Val Gly Ser Asp Val Ala Leu Arg Glu Leu Met Lys Leu Ala Pro
515 520 525

Arg Tyr Lys Leu Gly Val His Gly Tyr Ala Phe Leu Asn Thr Asn Asn
530 535 540

Gly Tyr Ile Leu Ser His Pro Asp Leu Arg Pro Leu Tyr Arg Glu Gly
545 550 555 560

Lys Lys Leu Lys Pro Lys Pro Asn Tyr Asn Ser Val Asp Leu Ser Glu
565 570 575

Val Glu Trp Glu Asp Gln Ala Glu Ser Leu Arg Thr Ala Met Ile Asn
580 585 590

Arg Glu Thr Gly Thr Leu Ser Met Asp Val Lys Val Pro Met Asp Lys
595 600 605

Gly Lys Arg Val Leu Phe Leu Thr Asn Asp Tyr Phe Phe Thr Asp Ile
610 615 620

Ser Asp Thr Pro Phe Ser Leu Gly Val Val Leu Ser Arg Gly His Gly
625 630 635 640

Glu Tyr Ile Leu Leu Gly Asn Thr Ser Val Glu Glu Gly Leu His Asp
645 650 655

Leu Leu His Pro Asp Leu Ala Leu Ala Gly Asp Trp Ile Tyr Cys Ile
660 665 670

Thr Asp Ile Asp Pro Asp His Arg Lys Leu Ser Gln Leu Glu Ala Met
675 680 685

Ile Arg Phe Leu Thr Arg Lys Asp Pro Asp Leu Glu Cys Asp Glu Glu
690 695 700

Leu Val Arg Glu Val Leu Phe Asp Ala Val Val Thr Ala Pro Met Glu
705 710 715 720

Ala Tyr Trp Thr Ala Leu Ala Leu Asn Met Ser Glu Glu Ser Glu His
725 730 735

Val Val Asp Met Ala Phe Leu Gly Thr Arg Ala Gly Leu Leu Arg Ser
740 745 750

Ser Leu Phe Val Gly Ser Glu Lys Val Ser Asp Arg Lys Phe Leu Thr
755 760 765

Pro Glu Asp Glu Ala Ser Val Phe Thr Leu Asp Arg Phe Pro Leu Trp
770 775 780

Tyr Arg Gln Ala Ser Glu His Pro Ala Gly Ser Phe Val Phe Asn Leu
785 790 795 800

Arg Trp Ala Glu Gly Pro Glu Ser Ala Gly Glu Pro Met Val Val Thr
805 810 815

Ala Ser Thr Ala Val Ala Val Thr Val Asp Lys Arg Thr Ala Ile Ala
820 825 830

Ala Ala Ala Gly Val Gln Met Lys Leu Glu Phe Leu Gln Arg Lys Phe
835 840 845

Trp Ala Ala Thr Arg Gln Cys Ser Thr Val Asp Gly Pro Cys Thr Gln
850 855 860

Ser Cys Glu Asp Ser Asp Leu Asp Cys Phe Val Ile Asp Asn Asn Gly
865 870 875 880

Phe Ile Leu Ile Ser Lys Arg Ser Arg Glu Thr Gly Arg Phe Leu Gly
885 890 895

Glu Val Asp Gly Ala Val Leu Thr Gln Leu Leu Ser Met Gly Val Phe
900 905 910

Ser Gln Val Thr Met Tyr Asp Tyr Gln Ala Met Cys Lys Pro Ser Ser
915 920 925

His His His Ser Ala Ala Gln Pro Leu Val Ser Pro Ile Ser Ala Phe
930 935 940

Leu Thr Ala Thr Arg Trp Leu Leu Gln Glu Leu Val Leu Phe Leu Leu
945 950 955 960

Glu Trp Ser Val Trp Gly Ser Trp Tyr Asp Arg Gly Ala Glu Ala Lys
965 970 975

Ser Val Phe His His Ser His Lys His Lys Lys Gln Asp Pro Leu Gln
980 985 990

Pro Cys Asp Thr Glu Tyr Pro Val Phe Val Tyr Gln Pro Ala Ile Arg
995 1000 1005

Glu Ala Asn Gly Ile Val Glu Cys Gly Pro Cys Gln Lys Val Phe Val
1010 1015 1020

Val Gln Gln Ile Pro Asn Ser Asn Leu Leu Leu Leu Val Thr Asp Pro
1025 1030 1035 1040

Thr Cys Asp Cys Ser Ile Phe Pro Pro Val Leu Gln Glu Ala Thr Glu
1045 1050 1055

Val Lys Tyr Asn Ala Ser Val Lys Cys Asp Arg Met Arg Ser Gln Lys
1060 1065 1070

Leu Arg Arg Arg Pro Asp Ser Cys His Ala Phe His Pro Glu Glu Asn
1075 1080 1085

Ala Gln Asp Cys Gly Gly Ala Ser Asp Thr Ser Ala Ser Pro Pro Leu
1090 1095 1100

Leu Leu Leu Pro Val Cys Ala Trp Gly Leu Leu Pro Gln Leu Leu Arg
1105 1110 1115 1120

<210> 7
<211> 24
<212> DNA
<213> Homo sapiens

<400> 7
aggatggccc tggggaaaag aaga 24

<210> 8
<211> 20
<212> DNA
<213> Homo sapiens

<400> 8
atcatcaatg aggacacaga 20

<210> 9
<211> 20
<212> DNA
<213> Homo sapiens

<400> 9
agaacgaaac cagatcgaag

20

<210> 10
<211> 21
<212> DNA
<213> Homo sapiens

<400> 10
cgattcacca tagcatttct c

21

<210> 11
<211> 17
<212> DNA
<213> Homo sapiens

<400> 11
ctaccaagcc atgtgta

17

<210> 12
<211> 20
<212> DNA
<213> Mus musculus

<400> 12
agaacgaaac taggtcaaag

20

<210> 13
<211> 21
<212> DNA
<213> Mus musculus

<400> 13
cgattcacca tggcatttcg t

21

<210> 14

21

<211> 254
<212> DNA
<213> Rattus rattus

<400> 14
gattcttctg ggtgtggttg gcacagatgt cccagtaaaa gagcttctga agaccatccc 60
caaatacaag ttaggaattc atggtatgc ctttgccatc acgaataatg gatacatctt 120
gacacacccg gagctcaggc ccctgtatga agaagggaaa aagcgaagga agcctaatta 180
cagtagtgtg gatctctcg aagtgcagtg ggaagatcgg gatgatgtgt tacgaaatgc 240
catggtaaat cgac 254

<210> 15
<211> 5001
<212> DNA
<213> Homo sapiens

<400> 15
ccatgcctgc aactcccaac ttccctcgcaa accccagctc cagcagccgc tggattcccc 60
tccagccaat gcccgtggcc tgggcctttg tgcagaagac ctcggccctc ctgtggctgc 120
tgcttcttagg cacctccctg tcccctgcgt ggggacagggc caagattcct ctggaaacag 180
tgaagctatg ggctgacacc ttcggcgggg acctgtataa cactgtgacc aaatactcag 240
gctctctctt gctgcagaag aagtacaagg atgtggagtc cagtcgtaa atcgaggagg 300
tggatggctt ggagctggtg aggaagttct cagaggacat ggagaacatg ctgcggagga 360
aagtgcagggc ggtccagaat ctggtggaaag ctgccgagga ggccgacctg aaccacgaat 420
tcaatgaatc cctgggtgttc gactattaca actcggtctt gatcaacgag agggacgaga 480
agggcaacctt cggtggagctg ggcgcccagt tcctcctgga gtccaatgct cacttcagca 540
acctgcccgtt gaacacacctcc atcagcagcg tgcagctgcc caccaacgtg tacaacaaag 600
acccagatata tttaaatggc gtctacatgt ctgaagcctt gaatgctgtc ttcgtggaga 660
acttccagag agacccaacg ttgacctggc aatattttgg cagtcact ggattcttca 720
ggatctatcc aggtataaaa tggacacctg atgagaatgg agtcattact tttgactgcc 780
gaaaccgcgg ctggtagattt caagctgcta cttctcccaa ggacatagtg attttgggtgg 840
acgtgagcgg cagtatgaag gggctgagga tgactattgc caagcacacc atcaccacca 900
tcttggacac cctggggggag aatgacttcg ttaatatcat agcgtacaat gactacgtcc 960
attacatcga gccttggttt aaaggatcc tgcgtccaggg ggaccgagac aatcgagagc 1020
atttcaaaact gctgggtggag gagttgatgg tcaaagggtt ggggttcgtg gaccaagccc 1080
tgagagaagc cttccagatc ctgaagcagt tccaagaggc caagcaagga agcctctgca 1140
accaggccat catgctcatc agcgacggcg ccgtggagga ctacgagccg gtgtttgaga 1200
agtataactg gccagactgt aaggtccgag ttttcaactt cctcattggg agagaagtgt 1260
cttttgcgtga ccgcatttcaag tggatttgcattt gcaacaacaa aggctactac acgcagatct 1320
caacgctggc ggacacccag gagaacgtga tggaaatacct gcacgtgctc agccgcggcc 1380
tggtagatcaa ccacgaccac gacatcatct ggacagaggc ctacatggac agcaagctcc 1440
tcagctcgca ggctcagagc ctgacactgc tcaccactgt ggccatgcca gtcttcagca 1500
agaagaacga aacgcgatcc catggcattt tcctgggtgt ggtggctca gatgtggccc 1560
tgagagagct gatgaagctg ggcggccgg acaagcttgg agtgcacggc tacgccttcc 1620
tgaacacccaa caatggctac atcctctccc atcccgacct ccggccctg tacagagagg 1680
ggaagaaaact aaaacccaaa cctaactaca acagtgtgga tctctccgaa gtggagtggtgg 1740
aagaccaggc tgaatctaag cgagttctt tcctgacccaa tgactacttc ttcacggaca 1800

tcagcgacac cccttcagt ttgggggtgg tgctgtcccg gggccacgga gaatacatcc 1860
 ttctgggaa cacgtctgtg gaagaaggcc tgcacatgactt gcttcaccca gacctggccc 1920
 tggccggta ctggatctac tgcacatcacag atattgaccc agaccacgg aagctcagcc 1980
 agcttagaggc catgatccgc ttcctcacca ggaaggaccc agacctggag tgtgacgagg 2040
 agctggtccg ggaggtgctg tttgacgcgg tggtgacagc ccccatggaa gcctactgga 2100
 cagcgctggc cctcaacatg tccgaggagt ctgaacacgt ggtggacatg gccttcctgg 2160
 gcacccgggc tggcctcctg agaagcagct tggtcggtgg ctccgagaag gtctccgaca 2220
 ggaagttcct gacacctgag gacgaggcca gcgtgttac cctggaccgc ttcccgtgt 2280
 ggtaccggca ggcctcagag catcctgctg gcagcttctg cttaaacctc cgctggcag 2340
 aaggaccaga aagtgcgggt gaaccatgg tggtgacggc aagcacagct gtggcggta 2400
 ccgtggacaa gaggacagcc attgctgcag ccgcggcgt ccaaataaag ctggattcc 2460
 tccagcgc aaattctggcg gcaacgcggc agtgcagcac tggatggg ccgtgcacac 2520
 agagctgcga ggacagtgtat ctggactgct tcgtcatcga caacaacggg ttcatctga 2580
 tctccaagag gtcccggag acgggaagat ttctggggg ggtggatggt gctgtcctga 2640
 cccagctgct cagcatgggg gtgttacgac aagtactat gtatgactat caggccatgt 2700
 gcaaaccctc gagtaccac cacagtgcag cccagccct ggtcagccca atttctgcct 2760
 tcttgacggc gaccaggtgg ctgctgcagg agctgggtgt gttcctgctg gagtggagtg 2820
 tctggggctc ctggtaacgac agagggccg aggccaaaag tgcgttccat cactccaca 2880
 aacacaagaa gcaggacccg ctgcagccct gcgcacacgga gtacccctg ttcgtgtacc 2940
 agccggccat ccggggaggcc aacgggatcg tggagtgcgg gccctgccc aaggtatgg 3000
 tggtgacca gattccaaac agtaacctcc tcctccttgt gacagacccc acctgtgact 3060
 gcagcatctt cccaccaggc ctgcaggagg gcacagaatg caaatataat gcctctgtca 3120
 aatgtgaccg gatgcgtcc cagaagctcc gccggcgacc agactcctgc cacgccttcc 3180
 atccagagga gaatgcccag gactgcggcg gcgcctcgga cacctcagcc tcgcccggcc 3240
 tactcctgtc gcctgtgtgt gcctggggc tactgccccca actcctgcgg tgacaccacc 3300
 cagcctgacc tgggtttgg caaggtgatc cttccagagc catccaaaa agtcagact 3360
 gacatgggat gcagctaact gcagttgggt cggcccccagg ccaacgctcc tctcaatcct 3420
 gggctgggtgg cccctggctc cggagaatgc tggatggAAC agggaaacca tcacctggca 3480
 ccactttcaa gatgcttcat ggtgcgggt accatctgcc cttagtctca acatgagcat 3540
 acttctgacc taacccctt gtcctctt cgggaagcga gcgtgagctc agcttgacc 3600
 aagacaaaaat aatttagttc ttctgtact ccagacttca gaccagccca agaaagggtc 3660
 agttgttct gaccctttct gtcggagtgg tctctggtag aacccaagga cttctggta 3720
 ctgagaagca gcagcagaat gaggccaaat gcagagatga ggctttagca agaatatgcc 3780
 ccaactaaag catagattcc ccaaagttag gctcatggg ggaggccact caccttccta 3840
 gctgtgctc gaaaagggtt tgactgtgtt ggggtgggg ttgggttaagg gaatggtaaa 3900
 gactgagaaa ggaatgaaat ccattcagga aatatcgaca gggctacacg tgatgtcccc 3960
 aaactgctgc tattgaagaa cttccaaaaa cttctttaca aagccctaaa ggaaagggtt 4020
 catctatgaa aagccaaatag gctgagacat ccaattgctg catggaaatt gatgtacatt 4080
 caggggacgg caaaaatagc tgaaaaatag tgaaaaagag cagtggtgt gctctttct 4140
 ggccaatgtat ttacaaaaga atctacttga ctctgtccct ggagtggaaat ctttaggggtt 4200
 ggaacttggtgg ggaacattcc aacttgctaa gcagggtcca ctggggaggga agctctatct 4260
 gggaaactcac ccccagcgca cacacatctc ccccaagggtc ccaaggcccc gcagcttcct 4320
 ccccccacca aaccccaaga cctggatccc aggagacaac agtctccaca tgagagcaac 4380
 attaaggcga aagccatggaa gaaatgtggg agaggccggc ctcaaataat tccatttaac 4440
 aaaccccaagt gatgggtatg gacagcatgc agggcttttgg gggcgcttcc ccccgcttcc 4500
 ccatcaccct cagcctccac acttcaaagt tcaagttcaa agctgttcaa gtttccttacc 4560
 agcaaatacg cctaacttgc ctcttagatg ggccaaatgc caactctgtaa aacacactt 4620
 acattatcggtt acatcttac catcatgtct tgcaacaacc ctgtgaggc 4680

agtattaatg cccccttaca gcagaagaca ctgcagctcg aagacagctt aagtggcaga 4740
 ataatgttag aacagctaag gtttacatgt accaaataac atgttcagc tcattccatc 4800
 ctcacaacag cccccctgaaa gtgggtacta tcattagtcc catgttataag aaactgcagc 4860
 agagttgaaa attgcctcca aattaccgga agagtgtatg aagattgaat gtgatgtatt 4920
 cacgtAACAT gctgaaaact gcctggcata tactaaacgc taaaataata catgctaact 4980
 gaaaaaaaaaaaaaaa aaaaaaaaaa a 5001

<210> 16
 <211> 5712
 <212> DNA
 <213> Homo sapiens

<400> 16
 ccatgcctgc aactcccaac ttccctcgcaa accccagctc cagcagccgc tggattcccc 60
 tccagccaat gcccgtggcc tggccctttg tgcagaagac ctcggccctc ctgtggctgc 120
 tgcttctagg cacctccctg tcccctgcgt ggggacaggc caagattcct ctggaaacag 180
 tgaagctatg ggctgacacc ttccgggggg acctgtataa cactgtgacc aaatactcag 240
 gctctcttt gctcagaag aagtacaagg atgtggagtc cagtcgtaaatcagc 300
 tggatggctt ggagctgggtt aggaagttct cagaggacat ggagaacatg ctgcggagga 360
 aagtcgagggc ggtccagaat ctgggtggaaat ctgcccggagga ggccgacactg aaccacgaat 420
 tcaatgaatc cctgggtttc gactattaca actcggctt gatcaacagag agggacgaga 480
 agggcaactt cgtggagctg ggcgccgagt tcctccttgcgtt cacttcagca 540
 acctgcccgtt gaacaccccttccatcagcagcg tgcagctgcc caccacgtt tacaacaaag 600
 acccagatattttaatggaa gtctacatgt ctgaagccctt gaatgtgtc ttctgtggaga 660
 acttccagag agacccaaacg ttgacctggc aatattttgg cagtcactt ggattcttca 720
 ggatctatcc aggtataaaa tggacacactg atgagaatgg agtcattact ttgtactgcc 780
 gaaaccgcgg ctggcacattt caagctgtt cttctcccaa ggacatagtg attttgggg 840
 acgtgagccgg cagtatgaag gggctgagga tgactattgc caagcacacc atcaccacca 900
 tcttggacac cctggggggag aatgacttcr ttaatatcat agcgtacaat gactacgtcc 960
 attacatcga gccttggttt aaagggatcc tcgtccaggc ggaccgagac aatcgagagc 1020
 atttcaact gctgggtggag gagttgatgg tcaaagggtt gggggctgtt gaccaagccc 1080
 tgagagaagc ctccagatc ctgaagcagt tccaagagggc caagcaagga agcctctgca 1140
 accaggccat catgctcatc agcgacggcg ccgtggagga ctacgagccg gtgtttgaga 1200
 agtataactg gccagactgt aaggtcccgag ttttactt cctcattggg agagaagtgt 1260
 cttttgttca ccgcatttcaag tggattgttcat gcaacaacaa aggctactac acgcagatct 1320
 caacgctggc ggacacccag gagaacgttca tggaaatacct gcacgttgc agccgccccca 1380
 tggtcatcaa ccacgaccac gacatcatct ggacagagggc ctacatggac agcaagctcc 1440
 tcagctcgca ggctcagagc ctgacactgc tcaccactgt ggccatgcca gtcttcagca 1500
 agaagaacga aacgcgttccatc catggcattt ccctgggtgtt ggtggctca gatgtggccc 1560
 tgagagagct gatgaagctg ggcggccggta acaagcttgg agtgcacggta tacgccttcc 1620
 tgaacaccaa caatggctac atcctctccc atcccgacctt ccggccctt tacagagagg 1680
 ggaagaaact aaaacccaaa ccttaactaca acagtgttca tctctccgaa gtggagtgaaa 1740
 aagaccagggc tgaatctctg agaacacggca tgatcaatag ggaacacaggta actctctcga 1800
 tggatgtgaa ggttccgtt gataaaggga agcgagttct tttcttgcacc aatgactact 1860
 tcttcacggc catcagcgac acccccttca gtttgggggtt ggtgttgc cggggccacg 1920
 gagaatacat ccttctgggg aacacgttctg tggaaagg cctgcatttgc ttgcttcacc 1980
 cagacctggc cctggccggta gactggatctt actgcatttgc agatatttgc ccagaccacc 2040

ggaagctcag ccagcttagag gccatgatcc gtttcctcac caggaaggac ccagacctgg 2100
 agtgtgacga ggagctggc cgggaggtgc tggggacgc ggtggtgaca gcccccatgg 2160
 aaggctactg gacagcgctg gcccctaaca tgtccgagga gtctgaacac gtgggtgaca 2220
 tggccttccct gggcacccgg gctggctcc tgagaagcag cttgttcgtg ggctccgaga 2280
 aggtctccga caggaagttc ctgacacac cggacgaggc cagctgttc accctggacc 2340
 gtttcccgct gtggtaaccgc caggcctcag agcatctgc tggcagctc gtctcaacc 2400
 tccgctggc agaaggacca gaaagtgcgg gtgaacccat ggtggtgacg gcaaggcacag 2460
 ctgtggcggt gaccgtggac aagaggacag ccattgtgc agccgcgggc gtccaaatga 2520
 agctggatt cttccagcgc aaattctggg cggcaacgcg gcagtgcgc actgtggatg 2580
 gggcgtgcac acagagctgc gaggacagtg atctggactg cttcgtcata gacaacaacg 2640
 ggttcatctt gatctccaag aggtcccggag agacgggaag atttctgggg gaggtggatg 2700
 gtgtgtccct gaccctggct ctcagcatgg ggggtgttca ccaagtact atgtatgact 2760
 atcaggccat gtgcaaacc tcgagtcacc accacagtgc agcccgccc ctggtcagcc 2820
 caatttctgc cttcttgacg gcgaccagggt ggctgctgca ggagctggtg cttgtgagtg 2880
 ggggttagaca cggggctggt ggaggctgca tgcgagggtg gcttaggagg gtgtccttga 2940
 tcaggaggct gcaaggctc caggacaacc cacttgcac caagaccccg gggaaaggagg 3000
 gcacaatccc tgggcatgga cgccacctt tccctgcatg cttggccctg ggagggacct 3060
 cattgctcaa ccagagccct caagcaggga agagggtgtc ctggaggaga gggatgggc 3120
 cgggggtgtc caggataact ccagctcctt gggaaacccaa gtcgggagggg ctcagaggc 3180
 tccgagattc agtcctgtgt ctgacagggt cctgctggag tggagtgtct ggggctcctg 3240
 gtacgacaga ggggcccggg gtgagtgac gtagctgcag ggccatgtgc tgaagagcag 3300
 tggcattttg gtccactaac gtgagaccat tccctgtggg gtgggtgaca gtggggatag 3360
 gtgaccctga agcatcggtt ttcacatctc accctgcgtg gcctctctc atcacatccc 3420
 tcactcctgg ctctgtgtgt gacatcatct tgggacacccg ccactccatg tgccatcatc 3480
 accaccccat gacatcctgc cctcatgtgc caccatgtt tccctgtccg tgcacccct 3540
 gtgctgggt tatgttccgg ccagccaaaa gtgttcca tcactcccac aaacacaaga 3600
 agcaggaccc gctgcagccc tgcgacacgg agtacccctg gttcgtgtac cagccggcca 3660
 tccgggaggc caacgggatc gtggagtgcg gcccctgcca gaaggattt gtggtgacg 3720
 agattccaa cagtaacctc ctcctctgg tgacagaccc cacctgtac tgcagcatct 3780
 tcccaccagt gctgcaggag gcgcacagaag tcaaataataa tgcctctgtc aaatgtgacc 3840
 ggatgcgtc ccagaagctc cggcggcgcac cagactcctg ccacgcctc catccagagg 3900
 agaatgccc ggaactgcggg ggcgcctcgg acacctcagc ctcggccccc ctactcctgc 3960
 tgcctgtgtg tgcctgggg ctactcccc aactcctgcg gtgacaccac ccagcctgac 4020
 ctgtgtttt gcaagggtat cttccagag ccattccaaa aagttagcac tgacatggga 4080
 tgcagctaac tgcagttggg tgcctccag gccaacgcctc ctctcaatcc tgggctgggt 4140
 gcccctggct cggagaatg ctggatggaa cagaaacca atcacctggc accacttca 4200
 agatgctca tggtgcggg taccatctgc cctaggcttc aacatgagca tacttctgac 4260
 ctaaccttcc tgcctccctc tcgggaagcc agcgtgagct cagcttggac caagacaaaa 4320
 taatttagtt ttccctgtac tccagactcc agacccagcc aagaaagggt cagttgttcc 4380
 tgacccttcc tgcctgggt gtcctgtac gaacccaaagg acttctgggt actgagaagc 4440
 agcagcagaa tgaggccaaa tgcagagatg aggctaaggc aagaatatgc cccaaactaaa 4500
 gcatagattc cccaaagtga ggctcatggt gggaggccac tcacccctt agctgctgct 4560
 cggaaaagggt ttgactgtgt tgggggggg gttgggttaag ggaatggtca agactgagaa 4620
 aggaatgaaa tccattcagg aaatatcgac agggctacac gtgatgtccc caaactgctg 4680
 ctattgaaga acttccaaa acttcttac aaagccctaa aggaaagttt gcatctatga 4740
 aaagccaata ggctgagaca tccaaattgtc gcatggaaat tgcgttacat tcaggggacg 4800
 gcaaaaaatag ctgtaaaata gtgaaaaaga gcagtggttgc tgccttttc tggccaaatga 4860
 ttacaaaag aatctacttg actctgtccc tggagtgaaa tccttagggt tggaaacttgc 4920

gggaacattc caacttgcta agcagggtcc actgggaggg aagctctatc tgggaactca 4980
 cccccagcgc acacacatct cccccagggt cccaaggccc cgcaagttcc tcccccgacc 5040
 aaaccccaag acctggatcc caggagacaa cagtctccac atgagagcaa cattaaggc 5100
 aaagccatgg agaaatgtgg gagaggccgg cctcaaatac ttccatttaa caaacccag 5160
 tgatgggtat ggacagcatg cagggcttt gggcgcttc ccccgctcc tccatcaccc 5220
 tcagcctcca cacttcaaag ttcaagttca aagctgttca agtttcctac cagcaaata 5280
 ccctaacttgccttagagt aggc当地atg ccaactctgt aaaacacact tacattatcg 5340
 gttacagaat gtcactctta ccatcatgtc ttgcaacaac cctgtgaggg cagtattaa 5400
 gcccccttac agcagaagac actgcagtc gaagacagct taatggcag aataatgcta 5460
 gaacagctaa ggtttacatg taccaaataa catgtttcag ctcattccat cctcacaaca 5520
 gccccctgaa agtgggtact atcattagtc ccatgttata gaaactgcag cagagttgaa 5580
 aattgcctcc aaattaccgg aagagtgtat gaagattgaa tgtgatgtat tcacgtaaca 5640
 tgcttgaaac tgcttggcat atactaaacg ctaaataaat acatgctaac tgcaaaaaaaa 5700
 aaaaaaaaaa aa 5712

<210> 17
 <211> 1096
 <212> PRT
 <213> Homo sapiens

<400> 17

Met	Pro	Ala	Thr	Pro	Asn	Phe	Leu	Ala	Asn	Pro	Ser	Ser	Ser	Ser	Arg
1															15

Trp	Ile	Pro	Leu	Gln	Pro	Met	Pro	Val	Ala	Trp	Ala	Phe	Val	Gln	Lys
															30
20															
25															

Thr	Ser	Ala	Leu	Leu	Trp	Leu	Leu	Leu	Gly	Thr	Ser	Leu	Ser	Pro
35														
40														
45														

Ala	Trp	Gly	Gln	Ala	Lys	Ile	Pro	Leu	Glu	Thr	Val	Lys	Leu	Trp	Ala
50															
55															
60															

Asp	Thr	Phe	Gly	Gly	Asp	Leu	Tyr	Asn	Thr	Val	Thr	Lys	Tyr	Ser	Gly
65															
70															
75															
80															

Ser	Leu	Leu	Leu	Gln	Lys	Lys	Tyr	Lys	Asp	Val	Glu	Ser	Ser	Leu	Lys
85															
90															
95															

Ile	Glu	Glu	Val	Asp	Gly	Leu	Glu	Leu	Val	Arg	Lys	Phe	Ser	Glu	Asp
100															
105															
110															

Met	Glu	Asn	Met	Leu	Arg	Arg	Lys	Val	Glu	Ala	Val	Gln	Asn	Leu	Val
115															
120															
125															

Glu	Ala	Ala	Glu	Glu	Ala	Asp	Leu	Asn	His	Glu	Phe	Asn	Glu	Ser	Leu
130															
135															
140															

Val Phe Asp Tyr Tyr Asn Ser Val Leu Ile Asn Glu Arg Asp Glu Lys
145 150 155 160

Gly Asn Phe Val Glu Leu Gly Ala Glu Phe Leu Leu Glu Ser Asn Ala
165 170 175

His Phe Ser Asn Leu Pro Val Asn Thr Ser Ile Ser Ser Val Gln Leu
180 185 190

Pro Thr Asn Val Tyr Asn Lys Asp Pro Asp Ile Leu Asn Gly Val Tyr
195 200 205

Met Ser Glu Ala Leu Asn Ala Val Phe Val Glu Asn Phe Gln Arg Asp
210 215 220

Pro Thr Leu Thr Trp Gln Tyr Phe Gly Ser Ala Thr Gly Phe Phe Arg
225 230 235 240

Ile Tyr Pro Gly Ile Lys Trp Thr Pro Asp Glu Asn Gly Val Ile Thr
245 250 255

Phe Asp Cys Arg Asn Arg Gly Trp Tyr Ile Gln Ala Ala Thr Ser Pro
260 265 270

Lys Asp Ile Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu
275 280 285

Arg Met Thr Ile Ala Lys His Thr Ile Thr Thr Ile Leu Asp Thr Leu
290 295 300

Gly Glu Asn Asp Phe Val Asn Ile Ile Ala Tyr Asn Asp Tyr Val His
305 310 315 320

Tyr Ile Glu Pro Cys Phe Lys Gly Ile Leu Val Gln Ala Asp Arg Asp
325 330 335

Asn Arg Glu His Phe Lys Leu Leu Val Glu Glu Leu Met Val Lys Gly
340 345 350

Val Gly Val Val Asp Gln Ala Leu Arg Glu Ala Phe Gln Ile Leu Lys
355 360 365

Gln Phe Gln Glu Ala Lys Gln Gly Ser Leu Cys Asn Gln Ala Ile Met
370 375 380

Leu Ile Ser Asp Gly Ala Val Glu Asp Tyr Glu Pro Val Phe Glu Lys
385 390 395 400

Tyr Asn Trp Pro Asp Cys Lys Val Arg Val Phe Thr Tyr Leu Ile Gly
405 410 415

Arg Glu Val Ser Phe Ala Asp Arg Met Lys Trp Ile Ala Cys Asn Asn
420 425 430

Lys Gly Tyr Tyr Thr Gln Ile Ser Thr Leu Ala Asp Thr Gln Glu Asn
435 440 445

Val Met Glu Tyr Leu His Val Leu Ser Arg Pro Met Val Ile Asn His
450 455 460

Asp His Asp Ile Ile Trp Thr Glu Ala Tyr Met Asp Ser Lys Leu Leu
465 470 475 480

Ser Ser Gln Ala Gln Ser Leu Thr Leu Leu Thr Thr Val Ala Met Pro
485 490 495

Val Phe Ser Lys Lys Asn Glu Thr Arg Ser His Gly Ile Leu Leu Gly
500 505 510

Val Val Gly Ser Asp Val Ala Leu Arg Glu Leu Met Lys Leu Ala Pro
515 520 525

Arg Tyr Lys Leu Gly Val His Gly Tyr Ala Phe Leu Asn Thr Asn Asn
530 535 540

Gly Tyr Ile Leu Ser His Pro Asp Leu Arg Pro Leu Tyr Arg Glu Gly
545 550 555 560

Lys Lys Leu Lys Pro Lys Pro Asn Tyr Asn Ser Val Asp Leu Ser Glu
565 570 575

Val Glu Trp Glu Asp Gln Ala Glu Ser Lys Arg Val Leu Phe Leu Thr
580 585 590

Asn Asp Tyr Phe Phe Thr Asp Ile Ser Asp Thr Pro Phe Ser Leu Gly
595 600 605

Val Val Leu Ser Arg Gly His Gly Glu Tyr Ile Leu Leu Gly Asn Thr
610 615 620

Ser Val Glu Glu Gly Leu His Asp Leu Leu His Pro Asp Leu Ala Leu
625 630 635 640

Ala Gly Asp Trp Ile Tyr Cys Ile Thr Asp Ile Asp Pro Asp His Arg
645 650 655

Lys Leu Ser Gln Leu Glu Ala Met Ile Arg Phe Leu Thr Arg Lys Asp
660 665 670

Pro Asp Leu Glu Cys Asp Glu Glu Leu Val Arg Glu Val Leu Phe Asp
675 680 685

Ala Val Val Thr Ala Pro Met Glu Ala Tyr Trp Thr Ala Leu Ala Leu
690 695 700

Asn Met Ser Glu Glu Ser Glu His Val Val Asp Met Ala Phe Leu Gly
705 710 715 720

Thr Arg Ala Gly Leu Leu Arg Ser Ser Leu Phe Val Gly Ser Glu Lys
725 730 735

Val Ser Asp Arg Lys Phe Leu Thr Pro Glu Asp Glu Ala Ser Val Phe
740 745 750

Thr Leu Asp Arg Phe Pro Leu Trp Tyr Arg Gln Ala Ser Glu His Pro
755 760 765

Ala Gly Ser Phe Val Phe Asn Leu Arg Trp Ala Glu Gly Pro Glu Ser
770 775 780

Ala Gly Glu Pro Met Val Val Thr Ala Ser Thr Ala Val Ala Val Thr
785 790 795 800

Val Asp Lys Arg Thr Ala Ile Ala Ala Ala Gly Val Gln Met Lys
805 810 815

Leu Glu Phe Leu Gln Arg Lys Phe Trp Ala Ala Thr Arg Gln Cys Ser
820 825 830

Thr Val Asp Gly Pro Cys Thr Gln Ser Cys Glu Asp Ser Asp Leu Asp
835 840 845

Cys Phe Val Ile Asp Asn Asn Gly Phe Ile Leu Ile Ser Lys Arg Ser
850 855 860

Arg Glu Thr Gly Arg Phe Leu Gly Glu Val Asp Gly Ala Val Leu Thr
865 870 875 880

Gln Leu Leu Ser Met Gly Val Phe Ser Gln Val Thr Met Tyr Asp Tyr
885 890 895

Gln Ala Met Cys Lys Pro Ser Ser His His His Ser Ala Ala Gln Pro
900 905 910

Leu Val Ser Pro Ile Ser Ala Phe Leu Thr Ala Thr Arg Trp Leu Leu
915 920 925

Gln Glu Leu Val Leu Phe Leu Leu Glu Trp Ser Val Trp Gly Ser Trp
930 935 940

Tyr Asp Arg Gly Ala Glu Ala Lys Ser Val Phe His His Ser His Lys
 945 950 955 960

His Lys Lys Gln Asp Pro Leu Gln Pro Cys Asp Thr Glu Tyr Pro Val
965 970 975

Phe Val Tyr Gln Pro Ala Ile Arg Glu Ala Asn Gly Ile Val Glu Cys
 980 985 990

Gly Pro Cys Gln Lys Val Phe Val Val Gln Gln Ile Pro Asn Ser Asn
 995 1000 1005

Leu Leu Leu Leu Val Thr Asp Pro Thr Cys Asp Cys Ser Ile Phe Pro
1010 1015 1020

Pro Val Leu Gln Glu Ala Thr Glu Val Lys Tyr Asn Ala Ser Val Lys
1025 1030 1035 1040

Cys Asp Arg Met Arg Ser Gln Lys Leu Arg Arg Arg Pro Asp Ser Cys
1045 1050 1055

His Ala Phe His Pro Glu Glu Asn Ala Gln Asp Cys Gly Gly Ala Ser
 1060 1065 1070

Asp Thr Ser Ala Ser Pro Pro Leu Leu Leu Leu Pro Val Cys Ala Trp
1075 1080 1085

Gly Leu Leu Pro Gln Leu Leu Arg
1090 1095

```
<210> 18  
<211> 18  
<212> DNA  
<213> Homo sapiens
```

<400> 18
gcgaggacag tgatctgg 18

<210> 19

<211> 20
<212> DNA
<213> Homo sapiens

<400> 19
gggtcctcgta ctttgtt 20

<210> 20
<211> 20
<212> DNA
<213> Homo sapiens

<400> 20
tcagcctcca cacttcaaag 20

<210> 21
<211> 19
<212> DNA
<213> Homo sapiens

<400> 21
tccgcctgga cgaggatcc 19

<210> 22
<211> 20
<212> DNA
<213> Homo sapiens

<400> 22
gtgtccaaga tggtggtat 20

<210> 23
<211> 22
<212> DNA
<213> Homo sapiens

<400> 23
atctactgca tcacagatat tg 22

<210> 24
<211> 19
<212> DNA
<213> Homo sapiens

<400> 24
ggtgaggaag cg~~gat~~catg 19

<210> 25
<211> 21
<212> DNA
<213> *Mus musculus*

<400> 25
ttcaacgaga aggacagagcc t 21

<210> 26
<211> 21
<212> DNA
<213> *Mus musculus*

<400> 26
gttggcacag gccatccact g 21

<210> 27
<211> 21
<212> DNA
<213> *Mus musculus*

<400> 27
aggctgtgcc ttctcggtga a 21

<210> 28
<211> 18
<212> DNA
<213> *Mus musculus*

<400> 28
gagcccccaa gaagatcg 18

<210> 29
<211> 18
<212> DNA
<213> *Mus musculus*

<400> 29
cgatcttctt gggggctc 18

<210> 30
<211> 18
<212> DNA
<213> Mus musculus

<400> 30
cacgatgatg accatgtc

18

<210> 31
<211> 20
<212> DNA
<213> Mus musculus

<400> 31
ggcaagaccc tacactgttg

20

<210> 32
<211> 19
<212> DNA
<213> Mus musculus

<400> 32
cctggtaata gcgagtgac

19

<210> 33
<211> 536
<212> DNA
<213> Mus musculus

<400> 33
aagcttctct ctcatcacca ggaggaagac atcatgtact acgatgccaa ggctgacgcc 60
gagctggtaa gtgtccccac ct当地cgta gaggatgggg agcagccaga gccacacctt 120
gttcttctgg gccacaacag tctcagctgt aaagtgggtg ttagggatcc atgctcacct 180
ttctgaactc aaccattctg tgcgtgtc ttgcagcctc tc当地gtcca cagctcccta 240
gagatccttgc accctccagg gc当地gtcttc atcaccattt taggctaagc tccccc当地ca 300
ccatgtggag caagcagggt ggttagagtgt tggatatcag ggtggttcca tccc当地gtatg 360
aggggctctc tggctccat gggagtagag aggagaaaaga aatggactcc aggacctcct 420
ggggtaggta catgggagtg agacatggtg acatctaagc cctgcccagg acagtagagg 480
ctcctttctc tgtgatttgg ggaactttgc atcaagctat gtagaagaac ccatgg 536

<210> 34
<211> 572

<212> DNA

<213> Mus musculus

<400> 34

caggtggcct gtggctgggc cccttctctg aacactcaca gtggagacag ggctggccac 60
 agnagacccc atccttctct ccttcaggg gctgggttg gtggtaacag gaacttctcc 120
 ctgtttcaa cctgacacacag gatggccctg gggaaaagaa ggtgagttgc ccagtgggtt 180
 atctggggag gagttggcat gcctggagca ggtctgggga tggaggaggg ttagggcatg 240
 ctacagattt ggcaaagcag ctctccgtat cagcagctt gccccttaggc ctggccagg 300
 gggttctact atggagttga ctcattatacg cataccttcc cattcctttg tgtccagaac 360
 cagttaatcc tgggtgtcat gggcatcgat gtggccttga atgacatcaa aaggctgact 420
 cccaactaca cagtaagtgt ccacctgccc ctctgccctg gtttgctgtc catagtgaca 480
 caagccagac tcagcagggg agacatgggg actgaaagac cgtcacagaa agacttccca 540
 aagggtttgt tctgaagctg tggacagcaa gc 572

<210> 35

<211> 1853

<212> DNA

<213> Mus musculus

<400> 35

gctttcttgt ggctgcgggc cttggagtgc atgctgagtg ggtgagctcc ctggggggccg 60
 gctgcaggct ccaggcaagc atgctggatg gggggcccagc tcacagctcc ctgcccaccca 120
 ggcggccctt ctccacagggc cacaaaccac atcagccctg cttgtctacc gaggccttgg 180
 tgagggtag gctgagatat ttctttgatg atttagagga gggagagcaa gaaaatctcc 240
 ctggaagagc tgggtgtggcc ccacatgaga tcctggaaaa tcaaagaaag cctggcagg 300
 cagaaagcag gggaggccat ggagatgggt ttagcagggg ggcaccctga acctccaaac 360
 cccagccttc tgccctgccc ctcagctacc gtcatcctca atgagctta ctggacagag 420
 gccctggaga acgtcttcat tgagaaccgt aggcaagacc ctacactgtt gtggcaagtc 480
 tttggcagtg ccacgggaggt cactcgctat taccaggtt ggcaccactg tctcccttgg 540
 ccatccagca cccgtttgc tccatctcca agcctaccca ttctgaggtc catgggtac 600
 aatgaaccag gtcaatcccc atcactcccc cctgctccag tcagaccctt ctgcccggcc 660
 gggcccccctt acccccttcc tccacagcca caccatggcg agcccccaag aagattgacc 720
 tgtacgatgt cagaagacga ccctggtag tgagcaaggg gggtagggc gagacacccc 780
 ctcaactccc catctctcgat gcccgcctcc ctccctccca atatccagac ctccgagcag 840
 ggcgcagcca gcttatcca attttcattt cacacatcgat tgccacttgg aaatggatcc 900
 catgcccag gcaagccgcc cagctgcctc tgccccacg cgtgtcgatcc actacccagc 960
 ccccccacac ccactcagaa ctgagagcag accaggaaag gtgcttccag gggtagctag 1020
 agcctccgtc aggtcagccg gccccaccta ctcatttgat ccctggacac cccgaccctc 1080
 tgctctgcct ctctcacact actccatgat ctccctccca tcctccatta cacagccaga 1140
 ctctctggag tctctcttagg acagaggaca caagccacta aagccttctg tccccgttgg 1200
 tcacctgccc cttccccctc acctcttgg tacttaatga gggaaaccaga tcactcacgt 1260
 cacaagaaaa aaaaaactgt cttttgtat tgagcatgtt ctcccccagt cccagaccta 1320
 ttccaacccc ttagtgcgt ggtcagttaga aacacaggaa tcaagtggtt ggaagaagga 1380
 agaccccgca ggtcccgag gtgccgtct taactgagtc ttctcactgg caggtatata 1440
 cagggggcct catcacccaa ggacatggtc atcattgtgg atgtgtgagt gagccttggta 1500
 ggctggtagg atggactct gcttccctgg caccttatga gggaaaggcgc 1560

ggaaaaccct gagagccac atgcatgcgc ccccttccgt gcctggttc caggagtggg 1620
agcgtagcg gcctgactt gaagctgatg aagacgtccg tctgtgagat gctagacacg 1680
ctctctgtatg atgactatgt gaacgtggcc tcagtgatgt gcaaggtggc aggcaggctg 1740
ggtaccactc acccccattcc aacctgctcc catgacaacc atcagccctg tacaacagct 1800
gcacactgtg tggccagcct gaagccactc accacccccc actgtccccca cag 1853

<210> 36
<211> 21
<212> DNA
<213> Rattus rattus

<400> 36
gacaggacca acaaggagca c

21

<210> 37
<211> 21
<212> DNA
<213> Rattus rattus

<400> 37
gccaaaccaca cccagaagaa t

21

<210> 38
<211> 21
<212> DNA
<213> Rattus rattus

<400> 38
aacgcaccat caaggagacc a

21

<210> 39
<211> 18
<212> DNA
<213> Rattus rattus

<400> 39
aggggcagca gcagcaag

18

<210> 40
<211> 516
<212> DNA
<213> Rattus rattus

<400> 40
ttcagggac attggacaa acttttgcc aaaggattg gaatgctcg tattgcgtg 60
aacgaggcct tcaatgtact gagcgattt aaccacaccg gacaaggaag cattgcagc 120
caggccatta tgctcataac cgatggggca rtggcacacct acgayaccat ctttgcaaag 180
tacaattggc cagagcgaaa ggttcgaatc ttcaattacc tcattggacg agaggctgct 240
tttgcagaca atctaagtg gatrgcttgt gctaacaaag gattttcac ccagatctcc 300
accttggctg atgtgcagga aaatgtcatg gaatacctcc atgtacttag tcgacccaaa 360
gtcatcgacc aggaacatga tgtggtgtgg accgaagcgt acatcgacag cactctccct 420
caggctcaaa agcttgctga tgatcagggc ctcgtttga tgaccacagt ggccatgcct 480
gtgttagta agcagaacga aactaggtca aaggc 516

<210> 41
<211> 274
<212> DNA
<213> Rattus rattus

<400> 41
cagggAACAT tgcttgtgaa gaytgctcca agtcctttgt catccagcaa atcccaagta 60
gcaatctgtt catgggggtg gtggacagta gctgtctctg tgagtctgtg gctccttatca 120
ccatggcacc cattgaaatc aggtataatg aatcccttaa gtgtgaacgg taaaaggctc 180
agaagatcag acgacgtccg gaatcctgcc acggcttcca tcctgaggag aatgcgagag 240
agtgtggggg tgcataagt ctccaggccc aggt 274

<210> 42
<211> 1096
<212> PRT
<213> Homo sapiens

<400> 42			
Met Pro Ala Thr Pro Asn Phe Leu Ala Asn Pro Ser Ser Ser Arg			
1	5	10	15
Trp Ile Pro Leu Gln Pro Met Pro Val Ala Trp Ala Phe Val Gln Lys			
20	25	30	
Thr Ser Ala Leu Leu Trp Leu Leu Leu Gly Thr Ser Leu Ser Pro			
35	40	45	
Ala Trp Gly Gln Ala Lys Ile Pro Leu Glu Thr Val Lys Leu Trp Ala			
50	55	60	
Asp Thr Phe Gly Gly Asp Leu Tyr Asn Thr Val Thr Lys Tyr Ser Gly			
65	70	75	80
Ser Leu Leu Leu Gln Lys Lys Tyr Lys Asp Val Glu Ser Ser Leu Lys			
85	90	95	

Ile Glu Glu Val Asp Gly Leu Glu Leu Val Arg Lys Phe Ser Glu Asp
100 105 110

Met Glu Asn Met Leu Arg Arg Lys Val Glu Ala Val Gln Asn Leu Val
115 120 125

Glu Ala Ala Glu Glu Ala Asp Leu Asn His Glu Phe Asn Glu Ser Leu
130 135 140

Val Phe Asp Tyr Tyr Asn Ser Val Leu Ile Asn Glu Arg Asp Glu Lys
145 150 155 160

Gly Asn Phe Val Glu Leu Gly Ala Glu Phe Leu Leu Glu Ser Asn Ala
165 170 175

His Phe Ser Asn Leu Pro Val Asn Thr Ser Ile Ser Ser Val Gln Leu
180 185 190

Pro Thr Asn Val Tyr Asn Lys Asp Pro Asp Ile Leu Asn Gly Val Tyr
195 200 205

Met Ser Glu Ala Leu Asn Ala Val Phe Val Glu Asn Phe Gln Arg Asp
210 215 220

Pro Thr Leu Thr Trp Gln Tyr Phe Gly Ser Ala Thr Gly Phe Phe Arg
225 230 235 240

Ile Tyr Pro Gly Ile Lys Trp Thr Pro Asp Glu Asn Gly Val Ile Thr
245 250 255

Phe Asp Cys Arg Asn Arg Gly Trp Tyr Ile Gln Ala Ala Thr Ser Pro
260 265 270

Lys Asp Ile Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu
275 280 285

Arg Met Thr Ile Ala Lys His Thr Ile Thr Thr Ile Leu Asp Thr Leu
290 295 300

Gly Glu Asn Asp Phe Xaa Asn Ile Ile Ala Tyr Asn Asp Tyr Val His
305 310 315 320

Tyr Ile Glu Pro Cys Phe Lys Gly Ile Leu Val Gln Ala Asp Arg Asp
325 330 335

Asn Arg Glu His Phe Lys Leu Leu Val Glu Glu Leu Met Val Lys Gly
340 345 350

Val Gly Val Val Asp Gln Ala Leu Arg Glu Ala Phe Gln Ile Leu Lys
355 360 365

Gln Phe Gln Glu Ala Lys Gln Gly Ser Leu Cys Asn Gln Ala Ile Met
370 375 380

Leu Ile Ser Asp Gly Ala Val Glu Asp Tyr Glu Pro Val Phe Glu Lys
385 390 395 400

Tyr Asn Trp Pro Asp Cys Lys Val Arg Val Phe Thr Tyr Leu Ile Gly
405 410 415

Arg Glu Val Ser Phe Ala Asp Arg Met Lys Trp Ile Ala Cys Asn Asn
420 425 430

Lys Gly Tyr Tyr Thr Gln Ile Ser Thr Leu Ala Asp Thr Gln Glu Asn
435 440 445

Val Met Glu Tyr Leu His Val Leu Ser Arg Pro Met Val Ile Asn His
450 455 460

Asp His Asp Ile Ile Trp Thr Glu Ala Tyr Met Asp Ser Lys Leu Leu
465 470 475 480

Ser Ser Gln Ala Gln Ser Leu Thr Leu Leu Thr Thr Val Ala Met Pro
485 490 495

Val Phe Ser Lys Lys Asn Glu Thr Arg Ser His Gly Ile Leu Leu Gly
500 505 510

Val Val Gly Ser Asp Val Ala Leu Arg Glu Leu Met Lys Leu Ala Pro
515 520 525

Arg Tyr Lys Leu Gly Val His Gly Tyr Ala Phe Leu Asn Thr Asn Asn
530 535 540

Gly Tyr Ile Leu Ser His Pro Asp Leu Arg Pro Leu Tyr Arg Glu Gly
545 550 555 560

Lys Lys Leu Lys Pro Lys Pro Asn Tyr Asn Ser Val Asp Leu Ser Glu
565 570 575

Val Glu Trp Glu Asp Gln Ala Glu Ser Leu Arg Thr Ala Met Ile Asn
580 585 590

Arg Glu Thr Gly Thr Leu Ser Met Asp Val Lys Val Pro Met Asp Lys
595 600 605

Gly Lys Arg Val Leu Phe Leu Thr Asn Asp Tyr Phe Phe Thr Asp Ile
610 615 620

Ser Asp Thr Pro Phe Ser Leu Gly Val Val Leu Ser Arg Gly His Gly
625 630 635 640

Glu Tyr Ile Leu Leu Gly Asn Thr Ser Val Glu Glu Gly Leu His Asp
645 650 655

Leu Leu His Pro Asp Leu Ala Leu Ala Gly Asp Trp Ile Tyr Cys Ile
660 665 670

Thr Asp Ile Asp Pro Asp His Arg Lys Leu Ser Gln Leu Glu Ala Met
675 680 685

Ile Arg Phe Leu Thr Arg Lys Asp Pro Asp Leu Glu Cys Asp Glu Glu
690 695 700

Leu Val Arg Glu Val Leu Phe Asp Ala Val Val Thr Ala Pro Met Glu
705 710 715 720

Ala Tyr Trp Thr Ala Leu Ala Leu Asn Met Ser Glu Glu Ser Glu His
725 730 735

Val Val Asp Met Ala Phe Leu Gly Thr Arg Ala Gly Leu Leu Arg Ser
740 745 750

Ser Leu Phe Val Gly Ser Glu Lys Val Ser Asp Arg Lys Phe Leu Thr
755 760 765

Pro Glu Asp Glu Ala Ser Val Phe Thr Leu Asp Arg Phe Pro Leu Trp
770 775 780

Tyr Arg Gln Ala Ser Glu His Pro Ala Gly Ser Phe Val Phe Asn Leu
785 790 795 800

Arg Trp Ala Glu Gly Pro Glu Ser Ala Gly Glu Pro Met Val Val Thr
805 810 815

Ala Ser Thr Ala Val Ala Val Thr Val Asp Lys Arg Thr Ala Ile Ala
820 825 830

Ala Ala Ala Gly Val Gln Met Lys Leu Glu Phe Leu Gln Arg Lys Phe
835 840 845

Trp Ala Ala Thr Arg Gln Cys Ser Thr Val Asp Gly Pro Cys Thr Gln
850 855 860

Ser Cys Glu Asp Ser Asp Leu Asp Cys Phe Val Ile Asp Asn Asn Gly
865 870 875 880

Phe Ile Leu Ile Ser Lys Arg Ser Arg Glu Thr Gly Arg Phe Leu Gly
885 890 895

Glu Val Asp Gly Ala Val Leu Thr Gln Leu Leu Ser Met Gly Val Phe
900 905 910

Ser Gln Val Thr Met Tyr Asp Tyr Gln Ala Met Cys Lys Pro Ser Ser
915 920 925

His His His Ser Ala Ala Gln Pro Leu Val Ser Pro Ile Ser Ala Phe
930 935 940

Leu Thr Ala Thr Arg Trp Leu Leu Gln Glu Leu Val Leu Val Ser Gly
945 950 955 960

Gly Arg His Gly Ala Gly Gly Cys Met Arg Gly Trp Leu Arg Arg
965 970 975

Val Ser Leu Ile Arg Arg Leu Gln Gly Leu Gln Asp Asn Pro Leu Ala
980 985 990

Thr Lys Thr Pro Gly Lys Glu Gly Thr Ile Pro Gly His Gly Arg His
995 1000 1005

Leu Phe Pro Ala Cys Leu Pro Leu Gly Gly Thr Ser Leu Leu Asn Gln
1010 1015 1020

Ser Pro Gln Ala Gly Lys Arg Val Ser Trp Arg Arg Gly Asp Gly Pro
1025 1030 1035 1040

Gly Ala Val Arg Asp Thr Pro Ala Pro Trp Glu Pro Lys Ser Gly Gly
1045 1050 1055

Leu Arg Gly Leu Arg Asp Ser Val Leu Cys Leu Thr Gly Ser Cys Trp
1060 1065 1070

Ser Gly Val Ser Gly Ala Pro Gly Thr Thr Glu Gly Pro Arg Val Ser
1075 1080 1085

Ala Arg Ser Cys Arg Ala Met Cys
1090 1095

<210> 43

<211> 2008
 <212> DNA
 <213> Homo sapiens

 <400> 43
 tactataggg cggccgcgaa ttccggcacga ggccggcgccc agcggagcag gcagccccgc 60
 ggcgtcgccc accggcccgct ccgcgcagct ccccgccggcc gctctcgctg ccgcgcagc 120
 gggcgcgtcg gagggagccc agcatggccg ggccgggctc gccgcgcgc gcgtccccgg 180
 gggcctcggc gcttctcgct gccgcgttc tctacgcccgc gctggggac gtggtgcgt 240
 cggagcagca gataccgctc tccgtggta agctctggc ctcggctttt ggtggggaga 300
 taaaatccat tgctgctaag tactccggtt cccagcttct gaaaaagaaaa tacaaagagt 360
 atgagaaaaga cgttgccata gaagaaaattt atggcctcca actggtaaag aagctggcaa 420
 agaacatgga agagatgttt cacaagaagt ctgaggccgt caggcgtctg gtggaggctg 480
 cagaagaagc acacctgaaa catgaattt atgcagactt acagtatgaa tacttcaatg 540
 ctgtgctgtat aaatgaaaagg gacaaagacg ggaattttt ggagctggaa aaggaattca 600
 tcttagcccc aaatgaccat tttaataatt tgccgtgaa catcgtcta agtgcgtcc 660
 aagtaccaac gaacatgtac aacaaagacc ctgcaattttt caatggggtt tattggtctg 720
 aatctctaaa caaagttttt gtagataact ttgaccgtga cccatctctc atatggcagt 780
 actttggaaag tgcacaaaggcc tttttaggc agtatccggg gattaaatgg gaaccagatg 840
 agaatggagt cattgccttc gactgcagga accgaaaatg gtacatccag gcagcaactt 900
 ctccgaaaaga cgtggtcatt ttagttgacg tcagtgccag catgaaagga ctccgtctga 960
 ctatcgcaaa gcaacacgtc tcatccattt tggatacact tggggatgtat gacttcttca 1020
 acataatttc ttataatgag gagcttcact atgtggaaacc ttgcctgaat ggaactttgg 1080
 tgcaagccga caggacaaac aaagagcact tcagggagca tctggacaaa ctttcgcaca 1140
 aaggaattgg aatgttggat atagytcgtat atgaggcctt caacattctg agtgatttca 1200
 accacacggg acaaggaagt atctgcagtc aggccatcat gctcataact gatggggccg 1260
 tggcacacca ttagataactc tttgcaaaat acaattggcc agatcgaaag gttcgatct 1320
 tcacataacct cattggacga gaggctgcgt ttgcagacaa tctaaagtgg atggcctgtg 1380
 ccaacaaagg atttttacc cagatctcca ccttggctga tgtgcaggag aatgtcatgg 1440
 aataccttca cgtgccttagc cggcccaaag tcatcgacca ggagcatgat gtggtgtgaa 1500
 ccgaagcttca cattgacagc actctgactg atgatcaggg ccccgctctg atgaccactg 1560
 tagccatgcc tgggttttagt aagcagaacg aaaccagatc gaagggcatt cttctggag 1620
 tgggtggcac agatgtccca gtgaaagaac ttctgaagac catccccaaa tacaagttag 1680
 ggattcacgg ttatgccttt gcaatcacaa ataatggata tattcgtacg catccggAAC 1740
 tcaggctgtct gtacgaagaa ggaaaaaaagc gaaggaaacc taactatagt agcggtgacc 1800
 tctctgaggt ggagtggaa gaccgagatg acgtgtttagt aaatgtatg gtgaatcgaa 1860
 agacggggaa gtttccatg gaggtgaaga agacagtggaa caaagggtt cattttctc 1920
 aaacattttt gctgcttaat tttaaaacaaa ccactgtgaa aaatttagctt tgaaagctat 1980
 atctgaaata aatatcttcc gctgaagg 2008

<210> 44
 <211> 3598
 <212> DNA
 <213> Homo sapiens

<400> 44
 tactataggg cggccgcgaa ttccggcacga ggccggcgccc agcggagcag gcagccccgc 60

gcgctcgccc accgccccgtt ccgcgcagct ccccgccggcc gctctcgctg ccggccgc 120
 gggcgcgctg gagggagccc agcatggccg ggccgggctc gccgcgcgc gcgtccggg 180
 gggcctcgct gcttctcgctt gccgcgttc tctacgcccgc gctggggac gtggtgctg 240
 cggagcagca gataccgctc tccgtggta agctctggc ctcggctttt ggtggggaga 300
 taaaatccat tgctgctaag tactccggttt cccagcttct gaaaaagaaa tacaaagagt 360
 atgagaaaaga cgttgccata gaagaaattt atggcctcca actggtaaag aagctggcaa 420
 agaacatgga agagatgtt cacaagaatg ctgaggccgt caggcgtctg gtggaggctg 480
 cagaagaagc acacctgaaa catgaattt atgcagactt acagtatgaa tacttcaatg 540
 ctgtgctgat aaatgaaagg gacaaagacg ggaattttt ggagctggaa aaggaattca 600
 tcttagcccc aaatgaccat ttataattt tgccctgtgaa catcagtcta agtgacgtcc 660
 aagtaccaac gaacatgtac aacaaagacc ctgcaattt gatggggttt tattggctg 720
 aatctctaaa caaaatggggttt gtagataact ttgaccgtgat cccatctctc atatggcagt 780
 acttttggaaag tgcaaaggcc ttttttaggc agtacccggg gattaaatgg gaaccagatg 840
 agaatggagt cattgccttc gactgcagga accgaaaatg gtacatccag gcagcaactt 900
 ctccgaaaaga cgtggtcatt ttatggacg tcagtgccag catggaaagga ctccgtctg 960
 ctatcgcaa gcaaacagtc tcatccattt tggatacact tggggatgat gacttcttca 1020
 acataatttc ttataatgag gagtttcaact atgtggaaacc ttgcctgaaat ggaactttgg 1080
 tgcaagccga caggacaaac aaagagact tcagggagca tctggacaaa ctttcgcca 1140
 aaggaattgg aatgttggat atagctctgat atgaggccctt caacattctg agtgatttca 1200
 accacacggg acaaggaatg atctgcagtc aggccatcat gctcataact gatggggccg 1260
 tggacaccta tgatacaatc tttgcaaaat acaattggcc agatcgaaag gttcgcatct 1320
 tcacataacctt catggacga gaggctgcgt ttgcagacaa tctaaatgtgg atggcctgtg 1380
 ccaacaaagg atttttacc cagatcttca ccttggctgat tgcaggag aatgtcatgg 1440
 aataccttca cgtgttttagc cggcccaaag tcatcgacca ggagcatgat gtgggtgtgaa 1500
 ccgaagcttca cattgcacagc actctgactg atgatcgagg cccgcctctg atgaccactg 1560
 tagccatgcc tgggttttagt aagcagaac aaaccagatc gaagggcatt tttctggag 1620
 tgggtggcac agatgtccca gtgaaagaac ttctgaaagac catccccaaatacaagtttag 1680
 ggattcacgg ttatgcctt gcaatcacaa ataatggrrtatacctgacg catccggAAC 1740
 tcaggctgct gtacgaagaa gggaaaaaagc gaaggaaacc taactataatg agcggttgcacc 1800
 tctctgaggt ggagtggaa gaccgagatg acgtgtttagt aaatgttatg gtgaatcgaa 1860
 agacggggaa gtttccatg gaggtgaaga agacagtggaa caaaggaaaa cgggttttgg 1920
 tgatgacaaa tgactactat tatacagaca tcaagggtac tcctttcagt ttaggtgtgg 1980
 cgctttccag aggtcatggg aaatatttct tccgagggaa tgtaaccatc gaagaaggcc 2040
 tgcacatgactt agaacatccc gatgtgtcct tggcagatgat atggctctac tgcaacactg 2100
 acctacacccc tgagcaccgc catctgtctc agttagaagc gattaagctc tacctaaaag 2160
 gcaaagaacc tctgctccag tggataaaat aattgatcca agaagtccctt tttgacgcgg 2220
 tggtgagtgcc cccattgaa gcgtattgga ccagcctggc cctcaacaaa tctgaaaattt 2280
 ctgacaaggg cgtggaggtt gccttcctcg gcactcgcac gggcctctcc agaatcaacc 2340
 tgggtgtccgg ggctgagcag ctcaccaatc aggacttcctt gaaagctggc gacaaggaga 2400
 acatttttaa cgcagaccat ttccctctctt ggtaccgaag agccgctgag cagattccag 2460
 ggagcttcgtt ctactcgatc ccattcagca ctggaccagt caataaaagc aatgtggta 2520
 cagcaagtac atccatccag tcctgttgcgtt aacggaaatc tcctgttgcgtt gcagctgttag 2580
 gcattcagat gaaacttgaa tttttccaaa ggaagttctg gactgccagc agacagtgtg 2640
 ctccctggatcc tggcaatgc tccatcagat gatgtgtatgat gactggagac ttttttggatg 2700
 agatcgaggg agctgtgtatg aacaaatttgc taacaatggg tcctttaaa agaatttaccc 2760
 tttatgacta ccaagccatg tggatggcc acaaggaaaag cagcgatggc gcccattggcc 2820
 tcctggatcc cagaaatttga aacagaccctt ggagccctt gataactgaaat atccagcattt 2880
 cgtctctgag cgcaccatca aggagactac agggaaatattt gcttggatgaaatc actgctccaa 2940

gtcctttgtc atccagcaaa tcccaagcag caacctgttc atgggtgg tggacagcaa 3000
 ctgcctctgt gaatctgtgg cccccatcac catggcaccc attgaaaatca ggtataatga 3060
 atcccctaag tgtgaacgtc taaaggccca gaagatcaga aggcgcccag aatcttgta 3120
 tggcttccat cctgaggaga atgcaaggga gtgtgggggt gcgccgagtc tccaagccca 3180
 gacagtccctc cttctgctcc ctctgcttt gatgctcttc tcaagggtgac actgactgag 3240
 atgttcttctt actgactgag atgttcttctt ggcatgctaa atcatggata aactgtgaac 3300
 caaaaatatgg tgcaaacatac gagacatgaa tatagtccaa ccatcagcat ctcatcatga 3360
 ttttaaactg tgcgtgatataa aactcttataa agatatgttg aaaaaaagtt atctatcatc 3420
 ttttacttt gccagtcatg caaatgtgag tttgccacat gataatcacc cttcatcaga 3480
 aatgggaccg caagtggtag gcagtgtccc ttctgcttga aacctattga aaccaattta 3540
 aaactgtgta ctttttaat aaagtatatt aaaatcataa aaaaaaaaaa aaaaaaaaaa 3598

<210> 45
<211> 27
<212> DNA
<213> Homo sapiens

<400> 45
ccatcctaatac acgactcaact atagggc

27

<210> 46
<211> 23
<212> DNA
<213> Homo sapiens

<400> 46
actcaactataa gggctcgagc ggc

23

<210> 47
<211> 1036
<212> DNA
<213> Homo sapiens

<400> 47
ctgtgagtgc agctgttaggc attcagatga aacttgaatt tttccaaagg aagttcttgg 60
ctgccagcag acagtgtgct tccctggatg gcaaatgctc catcagctgt gatgatgaga 120
ctggagactt ttttggtagt atcgaggagg ctgtgatgaa caaattgcta acaatggct 180
cctttaaaag aattaccctt tatgactacc aagccatgtg tagagccaaac aaggaaagca 240
gcgatggcgc ccattggcctc ctggatccca gaaattgaaa cagaccctgg agccttgg 300
tactgaatat ccagcattcg tctctgagcg caccatcaag gagactacag ggaatattgc 360
ttgtgaagac tgctccaagt cctttgtcat ccagcaaattc ccaagcagca acctgttcat 420
ggtgtgggtg gacagcaact gcctctgtga atctgtggcc cccatcacca tggcacccat 480
tgaaatcagg tataatgaat cccttaagtg tgaacgtcta aaggcccaga agatcagaag 540
gcgcccagaa tcttgcatac gcttccatcc tgaggagaat gcaaggggagt gtgggggtgc 600
gccgagtctc caagcccaga cagtccttcct tctgctccct ctgctttga tgctttctc 660

aaggtgacac tgactgagat gttctttac tgactgagat gttctttgg catgctaaat 720
catggataaa ctgtgaacca aaatatggtg caacatacga gacatgaata tagtccaacc 780
atcagcatct catcatgatt ttaaaactgtg cgtgatataa actcttaaag atatgttgac 840
aaaaagttat ctatcatctt ttactttgc cagtcatgca aatgtgagtt tgccacatga 900
taatcacccct tcatacagaaa tgggaccgca agtggtaggc agtgtccctt ctgcttggaaa 960
cctattgaaa ccaatttaaa actgtgtact ttttaataa agtatattaa aatcataaaaa 1020
aaaaaaaaaaaaaaa aaaaaaa 1036

<210> 48
<211> 26
<212> DNA
<213> Homo sapiens

<400> 48
ctagaggcca tgatccgctt cctcac

26

<210> 49
<211> 20
<212> DNA
<213> Homo sapiens

<400> 49
ccccacgaac aagctgcttc

20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/23519

A. CLASSIFICATION F SUBJECT MATTER
 IPC 7 C12N15/12 C07K14/705 C07K14/47 C07K16/18 C07K16/28
 C12Q1/68 A61K38/17 G01N33/68 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, STRAND, MEDLINE, BIOSIS, SCISEARCH, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA190607, 21 January 1997 (1997-01-21) HILLIER, L. ET AL.: "zq44e03.rl Stratagene hNT neuron, Homosapiens cDNA clone IMAGE: 632572 5' similar to TR:G179762 G179762 Calcium Channel Alpha-2B subunit; mRNA sequence" XP002136760 see the whole document: 97,6% identity in 413bp overlap with SEQ ID No. 3; 96,8% identity in 340bp overlap with SEQ ID No. 43; 97,6% identity in 413bp overlap with SEQ ID No. 44</p> <p>----</p> <p style="text-align: center;">-/--</p>	1,2,22, 23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

21 July 2000

24.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Alt, G

INTERNATIONAL SEARCH REPORT

Final Application No

US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! AC Z44942, 6 November 1994 (1994-11-06) AUFFRAY, C. ET AL.: "Homo sapiens partial cDNA sequence; clone c-2dd03" XP002136761 see the whole document: 99,7% identity in 340 bp overlap with SEQ ID No. 3; 100% identity in 17bp overlap with SEQ ID No. 11 ---	1,2,22, 23
X	DATABASE EMBL 'Online! AC R20288, 23 April 1995 (1995-04-23) HILLIER, L. ET AL.: "yg20f03.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:32708 5', mRNA sequence" XP002136762 see the whole document: 97,6% identity in 340 bp overlap with SEQ ID No. 3 ---	1,2
X	DATABASE EMBL 'Online! AC AA459684, 13 June 1997 (1997-06-13) HILLIER, L. ET AL.: "zx49d08.s1 Soares testis NHT Homo sapiens cDNA clone 759567 3' EST" XP002136763 see whole document: 100% identity in 304bp overlap with SEQ ID No. 3 ---	1,2
X	WO 95 04822 A (SALK INST BIOTECH IND) 16 February 1995 (1995-02-16) see SEQ ID No. 31: 34,4% identity in 540 aa overlap with SEQ ID No. 5; 29,1% identity in 1122aa overlap with SEQ ID No. 6; ---	8
X	DATABASE EMBL 'Online! ACAC005343, 4 August 1998 (1998-08-04) MUZNY, D. ET AL.: "Homo sapiens chromosome 12p13.3 BAC RPCI 11-21K20 (Roswell Park Cancer Institute Human BAC Library) complete sequence" XP002143146 see the whole document: 98,5% identity in 1847 bp overlap with SEQ ID No. 4, 15, 16; ---	1,2,22, 23
X	DATABASE EMBL 'Online! AC AA719773, 7 January 1998 (1998-01-07) HILLIER, L. ET AL.: "zh38g01.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 414384 3'" XP002143147 see the whole document: 98,4% identity in 436 bp overlap with SEQ ID NO. 4 ---	1,2,22, 23

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! AC AA001473, 20 July 1996 (1996-07-20) HILLIER, L. ET AL.: "ze45d04.r1 Soares retina N2b4Hr Homo sapiens cDNA clone 361927 5'" XP002143148 see the whole document: 97,8% identity in 489bp overlap with SEQ ID NO. 4, 15, 16 ---	1,2,22, 23
X	WO 98 11131 A (CHEN AI RU SUN ;FRANCO RODRIGO (US); AMERICAN HOME PROD (US); SHUE) 19 March 1998 (1998-03-19) see SEQ ID NO.4: 29,0% identity in 1129aa overlap with SEQ ID No. 6 ---	8
X	DATABASE EMBL 'Online! AC Z75742, 9 July 1996 (1996-07-09) WILKINSON; J.: "Human DNA sequence from cosmid LUCA10 on chromosome 3p21.3 contains ESTs" XP002143149 see the whole document: 82,8% identity in 87bp overlap with SEQ ID No. 33 ---	23
A	DATABASE EMBL 'Online! AC AB011130, 10 April 1998 (1998-04-10) OHARA, O. ET AL.: "Homo sapiens mRNA for KIAA0558 protein, partial cds." XP002143150 see the whole document; 100% identity in 1145aa overlap with SEQ ID No. 2 ---	22-26,34
Y	GEE N S ET AL: "THE NOVEL ANTICONVULSANT DRUG, GABAPENTIN (NEURONTIN), BINDS TO THEALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5768-5776, XP002022221 ISSN: 0021-9258 cited in the application see the whole document ---	34
	-/-	

INTERNATIONAL SEARCH REPORT

Final Application No

US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BROWN J P ET AL: "CLONING AND DELETION MUTAGENESIS OF THE ALPHA 2 DELTA CALCIUM CHANNEL SUBUNIT FROM PORCINE CEREBRAL CORTEX" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 39, 1998, pages 25458-25465, XP000887190 ISSN: 0021-9258 see the paragraph bridging pages 25461-25462 ---	34
P,X	KLUGBAUER, N. ET AL.: "Molecular diversity of the calcium channel alpha 2 delta subunit" NEUROSCIENCE, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 684-691, XP000886459 see Figure 1; 89,4% identity in 1902bp overlap with SEQ ID 3; 94,0% identity in 251bp overlap with SEQ ID No. 14; 94,8% identity in 561 bp overlap with SEQ ID NO. 40; 96,0% identity in 273bp overlap with SEQ ID No. 41; 88,0% identity in 1494bp of SEQ ID NO. 43; 88,1% identity in 1494bp overlap with SEQ ID NO. 44; 57,1% identity in 2962bp overlap with SEQ ID No. 4; 65,6% identity in 1454bp overlap with SEQ ID NO. 15; 65,6% identity in 1454bp overlap with SEQ ID No. 16; ---	1,2,4, 6-10,22, 23
E	WO 00 12711 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); CORLEY NEIL C (US); REDDY R) 9 March 2000 (2000-03-09) see SEQ ID No. 28: 98,1% identity in SEQ ID No. 28: 1276bp overlap with SEQ ID 3; 89,5% identity in 516bp overlap with SEQ ID No. 40; 98,0% identity in 1276bp overlap with SEQ ID No. 43; 98,1% identity in 1276bp overlap with SEQ ID No. 44; 67,0% identity in 1268bp overlap SEQ ID NO. 4 and SEQ ID No. 28; 67,0% identity in 1268bp overlap with SEQ ID No. 15; 67,0% identity in 1268bp overlap with SEQ ID No. 16; ---	1,2,8, 22,23

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WILLIAMS, M.E. ET AL.: "Structure and functional expression of alpha 1, alpha2, and beta subunits of a novel human neuronal calcium channel subtype" NEURON, vol. 8, January 1992 (1992-01), pages 71-84, XP000886416 see Figure 3; last paragraph, second column, page 84</p> <p>-----</p>	1
A	<p>WALKER, D. AND DE WAARD, M.: "Subunit interaction sites in voltage-dependent Ca²⁺ channels: role in channel function" TRENDS IN NEUROSCIENCES, vol. 21, no. 4, 1998, XP000887176 cited in the application see the whole document</p> <p>-----</p>	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/23519

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 19, 20, 31-33
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

R mark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta C protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 3; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 5; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta C"; claims 22-26 as far as they relate to SEQ ID Nos. 11, 14, 40, 41, 43, 44, 47-49; claims 34 as far as it is related to accession nos. from AU022914.1 to AI051759.1 and SEQ ID Nos. 3, 5, 9-14, 36-41, 43, 44, 47

2. Claims: 1-26 (all partially), 27-30, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta D protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 4; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 6; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta D"; claims 22-26 as far as they relate to SEQ ID Nos. 15, 16, 21-24; claim 34 as far as it is related to accession nos. from T70594.1 to AA001473.1 and SEQ ID Nos. 4, 6, 15, 16, 18-24, 42, 45, 46, 48, 49.

3. Claims: 22-26, 34

subject-matter related to calcium channel alpha 2 delta B protein: claims 22-26 as far as they relate to SEQ ID Nos. 31-35; claim 34 as far as it relates to accession no. AF040709.1 and accession nos. from T80372.1 to Z84492.1 as well as SEQ ID Nos. 1, 2, 7, 8, 25-35.

4. Claim : 34 (partially)

method of using polynucleotides sequences to identify the binding potential of polynucleotide sequences to gabapentin: claim 34 as far as it is related to accession nos. not mentioned before

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 33 directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 19, 20, 31, 32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 19, 20, 31-33

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/23519

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9504822	A 16-02-1995	US 5874236 A		23-02-1999
		AU 3390499 A		19-08-1999
		AU 707793 B		22-07-1999
		AU 7632294 A		28-02-1995
		EP 0716695 A		19-06-1996
		GB 2284814 A, B		21-06-1995
		JP 9509041 T		16-09-1997
WO 9811131	A 19-03-1998	US 6040436 A		21-03-2000
		AU 4343097 A		02-04-1998
WO 0012711	A 09-03-2000	AU 6137699 A		21-03-2000

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)